1-heterocyclyl-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-one derivatives and their use as pde9a modulators
Abstract
This invention relates to novel 1,6-disubstituted pyrazolopyrimidinones, of formula (i), hc is a heterocyclyl mono-, bi- or tricyclic, whose ring members are carbon atoms and at least 1, preferably 1 , 2 or 3 heteroatoms which are selected from the group of nitrogen, oxygen and sulfur. Said heterocyclyl group is in the form of -S (O) r - r is 0, 1 or 2, and is or comprises 1 non-aromatic monocyclic ring, saturated or partially unsaturated, which comprises at least one heteroatom as a member of cycle and 'said heterocyclyl group is bound to the scaffold by said 1 non-aromatic monocyclic ring, saturated or partially unsaturated, which comprises at least one heteroatom as a ring member. According to one aspect of the invention, the novel compounds are used to manufacture drugs, particularly drugs for treating disease states involving deficits in perception, concentration, learning or memory. The new compounds are also used to make drugs to treat Alzheimer's disease.

Term
No projected expiry on record.
- Priority
- Filed
- Granted
- Today
29 claims: 10 independent, 19 dependent
- 1CLAIMS REVENDICATIONS 1. Compound of general formula I 1. Compose de formule I generale 5 or 5 où Hc est un groupe héterocyclyle mono-, bl- ou tri-cyclique dont les éléments de cycle sont des atomes de carbone et au moins ؛ Hc is a mono-, b1- or tri-cyclic heterocyclyl group whose ring elements are carbon atoms and at least ؛ 1 heteroatom, preferably 1, 2 or 3 heteroatoms chosen from the group comprising nitrogen, oxygen and sulfur atoms, 1 hetéroatome, de préférence 1, 2 ou 3 hétéroatomes choisis dans le groupe comprenant les atomes d'azote, d'oxygéné et de soufre, 10 which is in the form -S (O) r-, where r is equal to 0, 1 or 2, and 10 qui est sous la forme -S(O)r-, où r est égal à 0, 1 ou 2, et -ledit groupe hetérocyclyle est ou contient 1 cycle ؛ monocyclique non aromatique, sature ou partiellement insaturé contenant au moins 1 hetéroatome en tant qu'élément de cycle, et -said heterocyclyl group is or contains 1 ring ؛ non-aromatic, saturated or partially unsaturated monocyclic containing at least 1 heteroatom as a ring member, and -ledit groupe hétérocyclyle est lié à la structure 15 principale par 1'intermédiaire dudit 1 cycle monocyclique non ; -said heterocyclyl group is linked to the main structure through said non-monocyclic 1 ring; aromatic, saturated or partially unsaturated containing at least 1 heteroatom as a ring member; aromatique, sature ou partiellement insaturé contenant au moins 1 hetéroatome en tant qu'élément de cycle ; R2 est choisi dans le groupe comprenant :R2 is chosen from the group comprising: C1 to C6 alkyl, C alkenyl2 to Ce, C 2 to C 8 alkynyl, (C 1 to C ؛ alkyl) - s-, (C 1 to 6 alkyl) - s- (alkyl un alkyle en Cl à Ce, un alcényle en c2 à Ce, un alcynyle en 20 Cz à Cg, un (alkyl en Cl à c؛)-s-, un (alkyl en Cl à 6ح)-s-(alkyle MA MY 32201Β1 32201Β1 382 382 POl-2363-ff (C1 to C3) -, a C3 to C7 cycloalkyl, a (C3 to C1 cycloalkyl) (C1 to C8 alkyl) -, a (C3 to C1cycloalkyl) - (C1 to C1s) alkenyl Cg) -, (C3 to C1 cycloalkyl) - (C1 to C8 alkynyl) -, C3 to C1 heterocycloalkyl, (C3 to C1 heterocycloalkyl) 5 (C1 to Cg alkyl) -, (heterocycloalkyl) C 3 to C) - (2 ء to C 8 alkenyl) -, a (C 3 to C 6 heterocycloalkyl) - (C to C 8 alkynyl) -, an aryl, an aryl- (C 1 to C 8 alkyl) -, a aryl- (Cz to جء alkenyl) -, aryl- (C 1 -C 8 alkynyl) -, heteroaryl, heteroaryl- (C 1 -C 8 alkyl) -, heteroaryl- (C 1 -C 6 alkenyl) POl-2363-ff en Cl à C3)-, un cycloalkyle en C3 à C7, un (cycloalkyl en C3 à Cl)(alkyle en Cl à Cg)-, un (cycloalkyl en C3 à Cl)-(alcényle en Cj à Cg)-, un (cycloalkyl en C3 à Cl)-(alcynyle en Cz à Cg)-, un hétérocycloalkyle en C3 à Cl, un (hétérocycloalkyl en C3 à Cl)5 (alkyle en Cl à Cg)-, un (hétérocycloalkyl en C3 à c,)-(alcényle en 2ء à Cg)-, un (hétérocycloalkyl en C3 à Cl)-(alcynyle en Cz à Cg)-, un aryle, un aryl-(alkyle en Cl à Cg)-, un aryl-(alcényle en Cz à جء)-, un aryl-(alcynyle en Cz à Cg)-, un hétéroaryle, un hetéroaryl-(alkyle en Cl à Cg)-, un hetéroaryl-(alcényle en Cz à 10 C ؛) - and heteroaryl- (C 8 -C 6 alkynyl) -, the above-mentioned elements possibly being optionally substituted with one or more substituents selected independently of each other from the group consisting of fluorine, chlorine, bromine, iodine, an oxo, HO-, NC-, CN-, 10 C؛)- et un héteroaryl-(alcynyle en Cz à Cg)-, les éléments mentionnés ci-dessus pouvant être facultativement substitués avec un ou plusieurs substituants choisis indépendamment les uns des autres dans le groupe constitué par le fluor, le chlore, le brome, l'iode, un oxo, HO-, NC-, CN-, 15 F3C-, HFzC-, FHC-, F3C-CH2-, F3C-0-, HFzC-0-, HO- (C1 to 15 F3C-, HFzC-, FHC-, F3C-CH2-, F3C-0-, HFzC-0-, un HO-(alkyle en Cl à Cg) -, R -0- (C1 to Cg alkyl) -, Rl -s- (C1 to Cg alkyl) -, C1 to C8 alkyl, Cz to Cg alkenyl, Cz alkynyl to C8, a C3 to C1 cycloalkyl, a (C3 to C1 cycloalkyl) - (C1 to C8 alkyl) -, a (C3 to ¢ 7 cycloalkyl) -O-, a (C3 to C1 cycloalkyl) 20 (C1 to C8 alkyl) -O-, aryl, aryl- (C1 to C8 alkyl) -, heteroaryl, heteroaryl- (C1 to C8 alkyl) -, heteroaryl-0-, heteroaryl- (C1 to C8 alkyl) -O-, a nitrogen-linked pyridin-2-one, nitrogen-linked pyridin-2-one- (C 1 -C 8 alkyl), nitrogen-linked pyridin-2-one- (C 1 -C 8 alkyl) -o-, a Cg)-, un R -0-(alkyle en Cl à Cg)-, un Rl -s-(alkyle en Cl à Cg)-, un alkyle en Cl à Cg, un alcényle en Cz à Cg, un alcynyle en Cz à Cg, un cycloalkyle en C3 à Cl, un (cycloalkyl en C3 à Cl)-(alkyle en Cl à Cg)-, un (cycloalkyl en C3 à ¢7)-0-, un (cycloalkyl en C3 à Cl)20 (alkyl en Cl à Cg)-O-, un aryle, un aryl-(alkyle en Cl à Cg)-, un hétéroaryle, un hetéroaryl-(alkyle en Cl à Cg)-, un hétéroaryl-0-, un héteroaryl-(alkyl en Cl à Cg)-O-, une pyridine-2-one liée par !'azote, une pyridine-2-one-(alkyle en Cl à Cg)- liée par l'azote, une pyridine-2-one-(alkyle en C] à Cg) -o- liée par l'azote, un 25 C3 to C1 heterocycloalkyl, a (C3 to C1 heterocycloalkyl) (C1 to C8 alkyl) -, a (C3 to ¢ 7 heterocycloalkyl) -O- with heterocyclo-C3 to C7 alkyl linked to o through l 'intermediate one of its ring c atoms, a (C3-Cl heterocycloalkyl) (C1-C8 alkyl) -O- with the C3-Cl heterocycloalkyl bonded to 25 hétérocycloalkyle en C3 à Cl, un (hétérocycloalkyl en C3 à Cl)(alkyle en Cl à Cg)-, un (hétérocycloalkyl en C3 à ¢7)-0- avec l'héterocyclo-alkyle en C3 à C7 lié à o par l'intermédiaire de l'un de ses atomes c de cycle, un (hétérocycloalkyl en C3 à Cl)(alkyl en Cl à Cg)-O- avec l'hetérocycloalkyle en C3 à Cl lié à 30 C1 to C8 alkyl through one of its ring atoms, (Ri () zN-, R٠N- (C1 to C8 alkyl) -, RO-, r! ° -S-, r! ٥CO-, R O-CO-, R٥N-CO-, un (r1٥) zN-CO- (C1-C8 alkyl) -, R١٠CO- (Ri) N-, un r! ٠-CO- ( rO) N- (C1-C8 alkyl) -, R) ٥-CO-O-, R O-COO-, un R o-co-o- (C1-C8 alkyl) -, R O-CO- R٥) N-, one R 0-CO35 R ٥) N- (C1 to Cg alkyl) -, one R ٥) zN-CO-O- (C1 to Cg alkyl), one (RJ ζΝ-CO- R ٥) N- (C1-C8 alkyl) -, r1٠-S٥2- (r1) N-, one R ^ -SOzR ٥) N- (C1-C8 alkyl) -, un (R ^ ٥) zN-SOz- (R ^ ٠) N- (C1 to 30 !'alkyle en Cl à Cg par !'intermédiaire de l'un de ses atomes c de cycle, (Ri٠)zN-, un R٠N-(alkyle en Cl à Cg)-, RO-, r!°-S-, r!٥CO-, R O-CO-, R٥N-CO-, un (r1٥)zN-CO-(alkyle en c, à Cg)-, R١٠CO-(Ri) N-, un r!٠-CO- (rO)N- (alkyle en Cl à Cg)-, R)٥-CO-O-, R O-COO-, un R o-co-o-(alkyle en Cl à Cg)-, R O-CO- R٥)N-, un R 0-CO35 R ٥)N-(alkyle en Cl à Cg)-, un R ٥)zN-CO-O-(alkyle en Cl à Cg), un (RJ ζΝ-CO- R ٥) N- (alkyle en Cl à Cg)-, r1٠-S٥2-(r1)N-, un R^-SOzR ٥)N-(alkyle en Cl à Cg)-, un (R^٥)zN-SOz-(R^٠) N-(alkyle en Cl à MA MY 32201Bl 32201Bl 383 POl-2363-ff 383 POl-2363-ff 6 ة) -, (Ri٠)2N-SO2-, a (R3٠) 2N-SO2- (C1-C8 alkyl) - and / or a ؛ (C1 to C8 alkyl) -S٥2-, إ whereby any of the C3 to C8 cycloalkyl, C3 to C3 heterocycloalkyl groups7, aryl, heteroaryl, pyridine-2- ١ 6ة)-, (Ri٠)2N-SO2-, un ( R3٠ ) 2N-SO2- ( alkyle en Cl à Cg)- et/ou un ؛ (alkyl en Cl à Cg)-S٥2-, إ moyennant quoi !'un quelconque des groupes cycloalkyle en C3 à C,, hetérocycloalkyle en C3 à c7, aryle, hétéroaryle, pyridine-2- ١ 5 one bound by nitrogen and (R3٥) 2N-CO- (C1-C8 alkyl) - mentioned above may be optionally substituted with one or more substituents independently selected from each other from the group consisting of fluorine, chlorine, bromine, HO-, NC-, O2NOT-, 5 one liée par l'azote et ( R3٥ ) 2N-CO- ( alkyle en Cl à Cg)- mentionnés ci-dessus peut être facultativement substitué avec un ou plusieurs substituants choisis indépendamment les uns des autres dans le groupe constitue par le fluor, le chlore, le brome, HO-, NC-, O2N-, F3C-, HF2C_, FHC-, F3C-CH2-, F3C-0-, HF2C-O-, un hétérocycloalkyle F3C-, HF2C_, FHC-, F3C-CH2-, F3C-0-, HF2CO-, a heterocycloalkyl 10 in C3 to C ,, a R3٥-O- (C1-C8 alkyl) -, an R3٠-S- (C1 to C8 alkyl) -, C1 to C8 alkyl, R٥N-, R ٥ N- (C] to C8 alkyl) -, 10 en C3 à C,, un R3٥-O-(alkyle en Cl à Cg)-, un R3٠-S-(alkyle en Cl à Cg)-, un alkyle en Cl à Cg, R٥N-, un R ٥ N-(alkyle en C] à Cg)-, R-O-, R'٠-S-, r1٥-CO-, R3٥O-CO-, R٥)2N-CO-, un R ٥)2N-CO-(alkyle en Cl à Cg)-, R-CO-(R'٥)N-, un R-CO- R٥)N-(alkyle en Cl à Cg)-, RO-, R'٠-S-, r1٥-CO-, R3٥O-CO-, R٥)2N-CO-, one R ٥)2N-CO- (C1-C8 alkyl) -, R-CO- (R'٥) N-, one R-CO- R٥) N- (C1-C8 alkyl) -, Ri-CO-0-, R'٠o-co-o-, a RO-CO-O- (C] to Cg alkyl) -, RO-CO15 (R3٥) N-, a RO-CO- (R) N- (C1-C8 alkyl) -, a R٥)2N-CO-O-, Ri-CO-0-, R'٠o-co-o-, un RO-CO-O-(alkyle en C] à Cg)-, RO-CO15 (R3٥)N-, un RO-CO- (R) N- (alkyle en Cl à Cg)-, un R٥)2N-CO-O-, R٥)2N-CO- R٠) N-, (R3٥) 2N-SO2- (r1٥) N-, un (R3٥) 2N-CO-O- (C1-C8 alkyl) -, a (R3٥) 2N-CO- R ٥) N- (C1-C8 alkyl) -, R3٥-SO2- (R3٥) N-, a R٥)2N-CO- R٠)N-, (R3٥)2N-SO2-(r1٥)N-, un (R3٥)2N-CO-O-(alkyle en Cl à Cg)-, un (R3٥)2N-CO- R ٥)N-(alkyle en Cl à Cg)-, R3٥-SO2-(R3٥)N-, un R3٥-SO2- (R) N- (C1-C8 alkyl) -, one R ٥)2N-SO2- R ٥) N- (ن alkyl R3٥-SO2- (R)N- (alkyle en Cl à Cg)-, un R ٥)2N-SO2- R ٥)N- (alkyle en ن Cl to Cg) -, R٥)2N-SO2-, a (R3٥)2N-SO2- (C1 to C8 alkyl) - and / or a Cl à Cg)-, R٥)2N-SO2-, un (R3٥)2N-SO2-(alkyle en Cl à Cg)- et/ou un 20 (C1 to C8 alkyl) -so2- ;20 (alkyl en Cl à Cg)-so2- ;R2 independently of any other R2 is chosen from the group comprising: R2 indépendamment de tout autre R2 est choisi dans le groupe comprenant : H-, fluorine, NC-, F3C-, HF2C-, FHC-, F3C-CH2-, carboxy, C 1 to C 8 alkyl, C alkenyl2 to Cg, a C-alkynyl2 at Cg, ٠ H-, le fluor, NC-, F3C-, HF2C-, FHC-, F3C-CH2-, un carboxy, un alkyle en Cl à Cg, un alcényle en c2 à Cg, un alcynyle en C2 à Cg, ٠ 25 a (C1 to C8 alkyl) -S-, a (C1 to C8 alkyl) -S- (C1 to C8 alkyl) 25 un (alkyl en Cl à Cg)-S-, un (alkyl en Cl à Cg)-S-(alkyle en Cl à C3) -, preferably (C 1 to C 8 alkyl) -s- (C 1 alkyl)2 to C3) -, ؛ C3-C- cycloalkyl;C3-C-cycloalkyl C3)-, de préférence un (alkyl en C] à Cg)-s-(alkyle en c2 à C3)-, ؛ un cycloalkyle en C3 à C-,, un (cycloalkyle en C3 à c - (alkyle en C;à Cg)-, un ( cycloalkyle en C3 à c,)-( alcényle en c2 à Cg)-, un (cycloalkyle en C3 à C7)-(alcynyle en c2 à Cg)-, un VS;to Cg) -, a (C 3 to c cycloalkyl) - (C alkenyl2 to Cg) -, a (C 3 to C 7 cycloalkyl) - (C alkynyl)2 to Cg) -, a 30 C 3 -C heterocycloalkyl ,, a (C 3 -C heterocycloalkyl) (C 1 -C 8 alkyl) -, a (C 3 -C 7 heterocycloalkyl) - (ί c alkenyl2 to Cg) -, a (C 3 -C heterocycloalkyl) - (C-alkynyl2 to Cg) -, aryl, aryl- (C 1 -C 8 alkyl) -, aryl- (C alkenyl)2 to Cg) -, an aryl- (C-alkynyl2 to Cg) -, a heteroaryl, a 30 hétérocycloalkyle en C3 à c,, un (hétérocycloalkyl en C3 à c,)(alkyle en Cl à Cg) -, un (hétérocycloalkyl en C3 à C7)-(alcényle en ί c2 à Cg)-, un (hétérocycloalkyl en C3 à c,)- (alcynyle en c2 à Cg)-, un aryle, un aryl-(alkyle en Cl à Cg)-, un aryl-(alcényle en c2 à Cg)-, un aryl-(alcynyle en c2 à Cg)-, un hétéroaryle, un 35 heteroaryl- (C1-C8 alkyl) -, heteroaryl- (C-alkenyl)2 to Cg) -, heteroaryl- (C-alkynyl2 to Cg) -, an R3° -O- (C 2 -C 1 alkyl) -, R٥) N-, ROCO-, R) 2N-CO-, R'٥-CO-R٠) N-, R٠ ؛ -CO-, (R3٠) 2N- 35 hétéroaryl- (alkyle en Cl à Cg)-, un hétéroaryl- (alcényle en c2 à Cg)-, un hétéroaryl- (alcynyle en c2 à Cg)-, un R3°-O-(alkyle en c2 à Cl)-, R٥)N-, ROCO-, R)2N-CO-, R’٥-CO-R٠)N-, R٠؛-CO-, (R3٠)2N- MA 32201 Bl MA 32201 Bl 384 إ POl-2363-ff إ CO-R٠) N-, R٥ ؛ -O-CO- (R'٠) N-, r1-SO2- (R) ٥) N-, un (C1 to Cg alkyl) ' s٥2- and an oxo, ي which elements mentioned above may be optionally substituted with one or more substituents 384 إ POl-2363-ff إ CO-R٠)N-, R٥؛-O-CO-(R'٠)N-, r1-SO2-(R)٥)N-, un (alkyl en Cl à Cg)’ s٥2- et un oxo, ي les éléments mentionnés ci-dessus pouvant être facultativement substitués avec un ou plusieurs substituants 5 chosen independently of each other from the group constituted by: 5 choisis indépendamment les uns des autres dans le groupe constitue par : fluorine, chlorine, bromine, NC-, OZN-, F3C-, HC-, FH2C-, F3C-CH2-, HO- (C1 to C8 alkyl) -, (C1 to C8 alkyl) -O-, (C1 to C8 alkyl) - O- (C1 to C8 alkyl) -, C1 to C8 alkyl, le fluor, le chlore, le brome, NC-, OZN-, F3C-, HC-, FH2C-, F3C-CH2-, un HO-(alkyle en Cl à Cg)-, un (alkyle en Cl à Cg)-O-, un (alkyl en Cl à Cg) -O- (alkyle en Cl à Cg)-, un alkyle en Cl à Cg, 10 R٥N-, a (R٠ ؛) zN- (C1 to Ca alkyl) - and (R2 (٠ ؛ N-CO-, and in the case where R2 is linked to a nitrogen which is a cycle element of Hc, this r2 must be independent of any other R2 : H-, F3C-CH2-, HF2C-CH2-, C1-C8 alkyl, C2-C8 alkenyl, C-alkynyl2 to C8, a (C1 to C8 alkyl) -S- (C1 to C8 alkyl) 10 R٥N-, un (R٠؛)zN-(alkyle en Cl à Ca)- et (R2(٠؛N-CO-, et dans le cas où R2 est lié à un azote qui est un élément de cycle de Hc, cet r2 doit être indépendamment de tout autre R2 : H-, F3C-CH2-, HF2C-CH2-, un alkyle en Cl à Cg, un alcényle en C2 à Cg, un alcynyle en c2 à Cg, un (alkyl en Cl à Cg)-S-(alkyle en Cl à 15 C3) -, C3 to c cycloalkyl, (C3 to ccycloalkyl) (C1 to C8 alkyl) -, (C3 to ccycloalkyl) - (Cc alkenyl2 to Cg) -, (C 3 to C cycloalkyl) - (C 2 to C 6 alkynyl) -, C 3 to C heterocycloalkyl, (C 3 to C heterocycloalkyl) (C 1 to C 8 alkyl) -, a (C 3 -C 1 heterocycloalkyl) - (C-alkenyl) 15 C3)-, un cycloalkyle en C3 à c,, un (cycloalkyle en C3 à c,)(alkyle en Cl à Cg)-, un (cycloalkyle en C3 à c,)-(alcényle en c2 à Cg)-, un (cycloalkyle en C3 à c,)-(alcynyle en C2 à Cg)-, un héterocycloalkyle en C3 à c,, un (hétérocycloalkyl en C3 à c,)(alkyle en Cl à Cg)-, un (hétérocycloalkyl en C3 à Cl)-(alcényle en 20 C2 to Cg) -, (C3 to C1 heterocycloalkyl) - (C2 to Cg alkynyl) -, aryl, aryl- (C1 to C8 alkyl) -, heteroaryl, heteroaryl- (C1 to C8 alkyl) Cg) -, R٠ ؛ -O- (C1 to Cl alkyl) -, RO-CO-, R٠) 2N-CO-, R٥ ؛ -CO-, R٠ ؛ -SO2- or (C1 to Cg alkyl ) -S٥2-, the elements mentioned above can be 20 C2 à Cg)-, un (hétérocycloalkyl en C3 à Cl)-(alcynyle en C2 à Cg)-, un aryle, un aryl-(alkyle en Cl à Cg)-, un heteroaryle, un hétéroaryl-(alkyle en Cl à Cg)-, un R٠؛-O-(alkyle en Cl à Cl)-, RO-CO-, R٠)2N-CO-, R٥؛-CO-, R٠؛-SO2- ou un (alkyl en Cl à Cg)-S٥2-, les éléments mentionnés ci-dessus pouvant être 25 optionally substituted with one or more substituents selected independently of one another from the group consisting of: 25 facultativement substitués avec un ou plusieurs substituants choisis indépendamment les uns des autres dans le groupe constitue par : fluorine, HO-, NC-, OzN-, FC-, HF2C-, FHC-, F3C-CH2-, HO (C1 to C8 alkyl) -, R٠ ؛ -O- (C1 to C8 alkyl) -, alkyl C1 le fluor, HO-, NC-, OzN-, FC-, HF2C-, FHC-, F3C-CH2-, un HO(alkyle en Cl à Cg)-, un R٠؛-O-(alkyle en Cl à Cg)-, un alkyle en Cl 30 to Cg, R٠ ؛ -O-, R٠> 2N-, one (R٠ ؛) sN- (C1 to Cl alkyl) - and (r! ٥) 2N-CO-;30 à Cg, R٠؛-O-, R٠>2N-, un (R٠؛)sN-(alkyle en Cl à Cl)- et (r!٥)2N-CO- ;r3 est choisi dans le groupe comprenant : r3 is chosen from the group comprising: H-, hydroxy and rI -O-;H-, un hydroxy et rI -0- ;r4 and r5 are independently selected from one another from the group consisting of H-, fluorine, F3C-, HFZC-, FHC- and alkyl in r4 et r5 sont choisis indépendamment !'un de !'autre dans le groupe comprenant H-, le fluor, F3C-, HFZC-, FHC- et un alkyle en 35 Cl to Cl, لماه r4 and Rs together with the carbon atom to which they are bonded form a 3-6 membered cycloalkyl group. 35 Cl à Cl, لماه r4 et Rs ensemble avec !'atome de carbone auquel ils sont lies forment un groupe cycloalkyle de 3 à 6 chaînons. 32201Β1 32201Β1 385 385 POl-2363-ff les éléments carbocyclique formé, indépendamment les mentionnés ci-dessus, y peuvent être substitués uns des autres avec compris le cycle facultativement et un ou plusieurs substituants choisis dans le qroupe constitue par : POl-2363-ff the carbocyclic elements formed, independently of those mentioned above, may be substituted with each other with the ring optionally included and one or more substituents selected from the group consisting of: fluorine, HO-, NC-, 0 ؛ N-, FC, HFgC-, FHC-, F3C-CH2-, HO (C1 to C8 alkyl) -, CH3-0- (C1 to C8 alkyl) -, C1 to C8 alkyl, (C1 to C8 alkyl) -O- and (C1 to CgN-C0- alkyl);le fluor, HO-, NC-, 0؛N-, FC, HFgC-, FHC-, F3C-CH2-, un HO(alkyle en Cl à Cg)-, un CH3-0-(alkyle en Cl à Cg)-, un alkyle en Cl à Cg, un (alkyle en Cl à Cg)-O- et un (alkyl en Cl à CgN-C0- ;R independently of any other r1٥ is chosen from the group comprising: R indépendamment de tout autre r1٥ est choisi dans le groupe comprenant : 10 H- (but not in the case where it is part of a group selected from RO CO-, R “-S٠2- or R٠ ؛ -CO-), F3C-CH2-, alkyl 10 H- (mais pas dans le cas où il fait partie d'un groupe choisi parmi RO CO-, R“-S٠2- ou R٠؛-CO-), F3C-CH2-, un alkyle en C1 to Cg, a C alkenyl2 to C8, C3 to C1 cycloalkyl, (C3 to C7 cycloalkyl) - (C1 to C3 alkyl) -, C3 to C7 heterocycloalkyl, (C3 to Cheterocycloalkyl,) - (C1 to Cg) -, Cl à Cg, un alcényle en c2 à Cg, un cycloalkyle en C3 à Cl, un (cycloalkyle en C3 à C7)-(alkyle en Cl à C3)-, un hetérocycloalkyle en C3 à C7, un (hetérocycloalkyl en C3 à c,)- (alkyle en Cl à Cg)-, 15 an aryl, an aryl- (C1 to C1) -, a heteroaryl and a heteroaryl- (C1 to C3 alkyl) -, and in the case where two groups r! ٥ are both linked to the same atom of nitrogen, they can form together with said nitrogen atom a 3 to 7 membered heterocycloalkyl ring, and 15 un aryle, un aryl-(alkyle en Cl à Cl)-, un héteroaryle et un hetéroaryl-(alkyle en Cl à C3)-, et dans le cas où deux groupes r!٥ sont lies tous les deux au meme atome d'azote, ils peuvent former ensemble avec ledit atome d'azote un cycle hetérocycloalkyle de 3 à 7 chaînons, et 20 in which one of the -CH - groups of the heterocycloalkyl ring form can be replaced by -0-, -s-, -NH-, a -Nycloalkyl (C3-C8) -, a -N (((C3-Cg cycloalkyl) - (C1 to C alkyl) - or an N (C1 to C- alkyl), preferably, and in particular preferably in the case of (R4٥)2N-CO-, these two r! ٥ together with 20 dans lequel un des groupes -CH - du cycle hetérocycloalkyle forme peut être remplace par -0-, -s-, -NH-, un -Nycloalkyle en C3 à Cg)-, un -N( (cycloalkyl en C3 à Cg)-(alkyle en Cl à c )- ou un N(alkyle en Cl à c-, de préférence, et en particulier de préférence dans le cas de (R4٥)2N-CO-, ces deux r!٥ ensemble avec 25 said nitrogen atom are linked to form a group selected from the group consisting of piperidinyl, piperazinyl, pyrrolidinyl, morpholinyl and thiomorpholinyl, and the above mentioned elements may be optionally substituted with one or more independently selected substituents each other in the group constituted by: 25 ledit atome d'azote sont lies pour former un groupe choisi dans le groupe comprenant le piperidinyle, le piperazinyle, le pyrrolidinyle, le morpholinyle et le thiomorpholinyle, et les éléments mentionnés ci-dessus peuvent être 30 facuitativement substitués avec un ou plusieurs substituants choisis indépendamment îes uns des autres dans le groupe constitue par : fluorine, chlorine, bromine, HO-, NC-, Ο ؛ Ν-, F3C-, HF2C-, FHC, F3C-CH2-, HO- (C1-C8 alkyl) -, CH3-0- (C1-alkyl) le fluor, le chlore, le brome, HO-, NC-, Ο؛Ν-, F3C-, HF2C-, FHC, F3C-CH2-, un HO-(alkyle en c à Cg)-, un CH3-0-(alkyle en Cl 35 to C8) -, C1 to C8 alkyl and (C1 to C8 alkyl) -O-;35 à Cg)-, un alkyle en Cl à Cg et un (alkyle en Cl à Cg)-O- ;x independently of any y: X = 0, 1, 2, 3 or 4, preferably X = 0, 1 or 2, preferably X = 0 or 1, and more preferably X = 0;x indépendamment de tout y : X = 0, 1, 2, 3 ou 4, de préférence X = 0, 1 ou 2, de préférence X = 0 ou 1, et de manière davantage préférée X = 0 ;32201Bl 32201Bl 386 386 PO1-2363-ff y regardless of any X: y = 0 or 1, more preferably y = 0;POl-2363-ff y indépendamment de tout X : y = 0 ou 1, de manière davantage préférée y = 0 ;and! 'one of its pharmaceutically acceptable salts, provided that for each applicable embodiment et !'un de ses sels pharmaceutiquement acceptables, à condition que pour chaque mode de réalisation applicable 5 of formula I of the invention, if Hc is an oxetanyl which is bonded through the carbon atom located next to the oxygenate of the oxetanyl, there is no substituent bonded to said carbon atom. carbon through a -CH? - group. 5 de formule I de !'invention, si Hc est un oxetanyle qui est lié par l'intermédiaire de l'atome de carbone se trouvant à côté de l'oxygéné de !'oxetanyle, il n'y ait aucun substituant lié audit atome de carbone par !'intermédiaire d'un groupe -CH?-.
- 55 and in the case where R2 is linked to a nitrogen which is a cycle element of Hc, this R2 must be independent of any other R2 :H-, (C1-C8 alkyl) -CO-, (C1-C8 alkyl) -O-CO-, C1-C8 alkyl, phenylco-, phenyl-o-co_, ( C1 to C8 alkyl)2N-CO-;5 et dans le cas où R2 est lié à un azote qui est un élément de cycle de Hc, ce R2 doit être indépendamment de tout autre R2 : H-, un (alkyle en Cl à Cg)-CO-, un (alkyle en Cl à Cg)-O-CO-, un alkyle en Cl à Cg, un phenylco-, un phényl-o-co_, un (alkyle en Cl à Cg)2N-CO- ;10 the elements mentioned above being optionally substituted, independently of each other, with one or more fluorine substituents;10 les éléments mentionnés ci-dessus pouvant être facultativement substitués, indépendamment les uns des autres, avec un ou plusieurs substituants fluors ;R3 est choisi dans le groupe comprenant : R3 is chosen from the group comprising: H-, hydroxy and (C1-C8 alkyl) -O-, whereby H-, un hydroxy et un (alkyle en Cl à Cg)-O-, moyennant quoi 15 the (C1-C8 alkyl) -O- group can be optionally substituted with one or more fluorine, chlorine, bromine and HO-;15 le qroupe (alkyle en Cl à Cg)-O- peut être facultativement substitue avec un ou plusieurs fluors, chlores, bromes et HO- ;r4 and R3 are independently selected from the group consisting of H-, fluorine and methyl;preferably, R4 and R ؛ are H;r4 et R3 sont choisis indépendamment !'un de 1'autre dans le groupe comprenant H-, le fluor et le méthyle ;de préférence, R4 et R؛ sont H ;20 r} ٥ independently of any other R'٥ is selected from the group consisting of C1 to C8 alkyl, phenyl and pyridyl, and in the case where r! ٥ is a substituent of a nitrogen atom, r} ٥ is selected from the group consisting of H, C1 to C alkyl 20 r}٥ indépendamment de tout autre R'٥ est choisi dans le groupe comprenant un alkyle en Cl à Cg, un phényle et un pyridyle, et dans le cas où r!٥ est un substituant d'un atome d'azote, r}٥ est choisi dans le groupe comprenant H, un alkyle en Cl à C
- 66, a phenyl and a pyridyl, 6, un phényle et un pyridyle, 25 the elements mentioned above possibly being optionally substituted with one or more substituents selected from the group comprising:25 les éléments mentionnés ci-dessus pouvant être facultativement substitués avec un ou plusieurs substituants choisis dans le groupe comprenant : fluorine, FjC-, HF ؛ C-, FHC-, FCCH-, a Η-Ο- (C1 le fluor, FjC-, HF؛C-, FHC-, FCCH-, un Η-Ο-(alkyle en Cl 35 and one of its pharmaceutically acceptable salts. 35 et l'un de ses sels pharmaceutiquement acceptables. 5. A compound according to claim 1, wherein 5. Composé selon la revendication 1, dans lequel Hc est choisi dans le groupe comprenant un tetrahydropyranyle, un tétrahydrofuranyle, un pipéridinyle, un Hc is selected from the group consisting of tetrahydropyranyl, tetrahydrofuranyl, piperidinyl, MA MY 32201Β1 32201Β1 395 395 POl-2363-ff pyrrolidinyl and piperazinyl, whereby preferably tetrahydropyranyl is 3- or tetrahydropyranyl, tetrahydrofuranyl is 3-tetrahydrofuranyl and piperidinyl is 3- or 4-piperidinyl;more preferably Hc is POl-2363-ff pyrrolidinyle et un pipérazinyle, moyennant quoi de préférence le tétrahydropyranyle est le 3- ou tétrahydropyranyle, le tetrahydrofuranyle est le 3-tetrahydrofuranyle et le piperidinyle est le 3- ou 4-piperidinyle ;de manière davantage préférée Hc est 5 tetrahydropyranyl, tetrahydrofuranyl, piperidinyl, pyrrolidinyl, and among these, preferably 3- and 4tetrahydropyranyl, 3- and 4-piperidinyl and 3-pyrrolidinyl;5 un tétrahydropyranyle, un tetrahydrofuranyle, un piperidinyle, un pyrrolidinyle, et parmi ceux-ci, de préférence le 3- et 4tétrahydropyranyle, le 3- et 4-pipéridinyle et le 3-pyrrolidinyle ;r! est choisi dans le groupe comprenant : r! is chosen from the group comprising: le phenyle, le 2-, 3- et 4-pyridyle, le pyrimidinyle, le phenyl, 2-, 3- and 4-pyridyl, pyrimidinyl, 10 pyrazolyl, thiazolyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentylmethyl, ethyl, propyl, 1- and 2-buty! e, 1-, 2- and 3-penty ! e, tetrahydrofuranyl and tetrahydro-pyranyl, which groups may be optionally substituted with one or more substituents selected independently of each other from the group consisting of fluorine, chlorine, bromine, iodine, oxo, HO-, NC-, un (C1 to C alkyl6) -o-, C 1 -C 8 alkyl, C 6 -C cycloalkyl, (C 8 -C cycloalkyl) -O-, (C 8 -C cycloalkyl) - (C 1 -C 8 alkyl) - O-, CFgO-, CFg-, a 10 pyrazolyle, le thiazolyle, le cyclopropyle, le cyclobutyle, le cyclopentyle, le cyclohexyle, le cycloheptyle, le cyclopentylmethyle, 1'éthyle, le propyle, le 1- et 2-buty!e, le 1-, 2- et 3-penty!e, le tetrahydrofuranyle et le tétrahydro-pyranyle, ces groupes pouvant être facultativement substitués avec un 15 ou plusieurs substituants choisis indépendamment les uns des autres dans le groupe constitué par le fluor, le chlore, le brome, !'iode, un oxo, HO-, NC-, un (alkyle en Cl à c6)-o-, un alkyle en Cl à Cg, un cycloalkyle en Cg à c,, un (cycloalkyl en Cg à Cl)-O-, un (cycloalkyl en Cg à C,)-(alkyle en Cl à Cg)-O-, CFgO-, CFg-, un 20 C 1-8 heterocycloalkyl, (C1-C12 heterocycloalkyl) (C1-C8 alkyl) -, HO- (C1-C alkyl) -, oxadiazolyl, oxazolyl, isoxazolyl, triazolyl, thiazolyl , a pyrrolyl, a furanyl, a pyrazolyl, a pyridyl, a pyridazinyl, a pyrimidinyl, a (R4٥) 2N-CO- (C1-C8 alkyl) -, 20 hétérocycloalkyle en Cg à Cl, un (héterocycloalkyl en Cg à Cl)(alkyle en Cl à Cg)-, un HO-(alkyle en Cl à c؛)-, un oxadiazolyle, un oxazolyle, un isoxazolyle, un triazolyle, un thiazolyle, un pyrrolyle, un furanyle, un pyrazolyle, un pyridyle, un pyridazinyle, un pyrimidinyle, un ( R4٥ ) 2N-CO-(alkyle en Cl à Cg)-, 25 (R2 (٠ ؛ N-CO- and / or a phenyl, whereby the oxadiazolyl, oxazolyl, isoxazolyl, triazolyl, thiazolyl, pyrrolyl, furanyl, pyrazolyl, pyridyl, pyridazinyl, pyrimidinyl and phenyl groups mentioned above may be optionally substituted with 25 (R2(٠؛N-CO- et/ou un phenyle, moyennant quoi les groupes oxadiazolyle, oxazolyle, isoxazolyle, triazolyle, thiazolyle, pyrrolyle, furanyle, pyrazolyle, pyridyle, pyridazinyle, pyrimidinyle et phényle mentionnés ci-dessus peuvent être facultativement substitués avec 30 one or more substituents selected independently of each other from the group consisting of fluorine, CHg-, CFg-, CH3O-, CFgO-, HNCO-, NC-, morpholinyl and / or benzyl-o-;30 un ou plusieurs substituants choisis indépendamment les uns des autres dans le groupe constitué par le fluor, CHg-, CFg-, CH3O-, CFgO-, HNCO-, NC-, un morpholinyle et/ou un benzyl-o- ;Rz independently of any other Rz potential is selected from the group consisting of H- and C1 to C8 alkyl, Rz indépendamment de tout autre Rz potentiel est choisi dans le groupe comprenant H- et un alkyle en Cl à Cg, 35 and in the case where Rz is linked to a nitrogen which is a cycle element of Hc, this Rz must be independent of any other Rz : 35 et dans le cas où Rz est lié à un azote qui est un élément de cycle de Hc, ce Rz doit être indépendamment de tout autre Rz : H-, (C1-C8 alkyl) -CO-, (C1-C8 alkyl) -O-CO-, a H-, un (alkyle en Cl à Cg)-CO-, un (alkyle en Cl à Cg)-O-CO-, un 32201Β1 32201Β1 396 396 POl-2363-ff C1-C8 alkyl, phenyl-CO-, phenyl-O-CO-, (C1-C8alkyl-CO-), the above-mentioned elements being optionally substituted, independently of each other. others, with one or more fluorine substituents;POl-2363-ff alkyle en Cl à Cg, un phenyl-CO-, un phényl-0-CO-, un (alkyle en Cl à CgN-CO-, les éléments mentionnés ci-dessus pouvant être facultativement substitués, indépendamment les uns des autres, avec un ou plusieurs substituants fluors ;R3 est choisi dans le groupe comprenant : R3 is chosen from the group comprising: H-, hydroxyl and (C1-C6 alkyl) whereby the (C1-C8-alkyl) -O- group may be optionally substituted with one or more fluorine, chlorine, bromine and HO-;H-, un hydroxyle et un (alkyle en Cl à moyennant quoi le groupe (alkyle en Cl à Cg) -O- peut être facultativement substitue avec un ou plusieurs fluors, chlores, bromes et HO- ;R4 and Rs are independently selected from the group consisting of H-, fluorine and methyl;preferably, R4 and r5 are both H;R4 et Rs sont choisis indépendamment l'un de !'autre dans le groupe comprenant H-, le fluor et le méthyle ;de préférence, R4 et r5 sont tous les deux H ;Rio independently of any other r! ٥ is selected from the group consisting of H, C1-C8 alkyl, phenyl and pyridyl, the above-mentioned elements possibly being optionally substituted with one or more substituents selected independently of each other in the group constituted by: Rio indépendamment de tout autre r!٥ est choisi dans le groupe comprenant H, un alkyle en Cl à Cg, un phényle et un pyridyle, les éléments mentionnés ci-dessus pouvant être facultativement substitués avec un ou plusieurs substituants choisis indépendamment les uns des autres dans le groupe constitue par : fluorine, F3C-, HF2C-, FHC-, F3C-CH2-, CH3-0- (C1 to C8 alkyl) -, C1 to C8 alkyl and (C1 to C8 alkyl) -O-;le fluor, F3C-, HF2C-, FHC-, F3C-CH2-, un CH3-0-(alkyle en Cl à Cg)-, un alkyle en Cl à Cg et un (alkyle en Cl à Cg)-O- ;X independently of each other X = 0, 1, 2, 3 or 4, preferably X = 0, 1 or 2, preferably X = 0 or 1, and more preferably X = 0;X indépendamment de chaque autre X = 0, 1, 2, 3 ou 4, de préférence X = 0, 1 ou 2, de préférence X = 0 ou 1, et de manière davantage préférée X = 0 ;y independently of each other y = 0 or 1, more preferably y = 0;y indépendamment de chaque autre y = 0 ou 1, de manière davantage préférée y = 0 ;le phényle, le 2-, 3- et 4-pyridyle, le cyclopropyle, le cyclobutyle, le cyclopentyle, le cyclohexyle, 1'éthyle, le 1- et phenyl, 2-, 3- and 4-pyridyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, ethyl, 1- and ΜΑ 32201Β1 i 397 POl-2363-ff ب ΜΑ 32201Β1 i 397 POl-2363-ff ب 2-propy! E, 1- and 2-butyl, 1-, 2- and 3-penty! E, tetrahydrofuranyl and tetrahydropyranyl, which groups may be optionally substituted with one or more substituents independently selected from one of the following groups. 2-propy!e, le 1- et 2-butyle, le 1-, 2- et 3-penty!e, le tétrahydrofuranyle et le tétrahydropyranyle, ces groupes pouvant être facultativement substitués avec un ou plusieurs substituants choisis indépendamment les uns des 5 others in the group consisting of fluorine, chlorine, bromine, iodine, oxo, NC-, (alkyl C 1 to C 8) -O-, alkyl C 1 to 6 ح, CF3O-, CF3-, oxadiazolyl, triazolyl, pyrazolyl, furanyl, pyridyl and / or phenyl, whereby oxadiazolyl, triazolyl, pyrazolyl, furanyl, pyridyl and phenyl mentioned above may be optionally substituted with one or more substituents selected independently of each other from the group consisting of fluorine, CH-, CHO-, HNCO- and / or NC-;5 autres dans le groupe constitue par le fluor, le chlore, le brome, l'iode, un oxo, NC-, un (alkyle en دح à Cg)-O-, un alkyle en Cl à 6ح, CF3O-, CF3-, un oxadiazolyle, un triazolyle, un pyrazolyle, un furanyle, un pyridyle et/ou un phényle, moyennant quoi les groupes oxadiazolyle, triazolyle, 10 pyrazolyle, furanyle, pyridyle et phényle mentionnés ci-dessus peuvent être facultativement substitués avec un ou plusieurs substituants choisis indépendamment les uns des autres dans le groupe constitué par le fluor, CH-, CHO-, HNCO- et/ou NC- ;R2 independently of any other R2 is selected from the group consisting of H- and C1-C8 alkyl, and in the case where R2 is linked to a nitrogen which is a cycle element of Hc, this R2 must be independent of any other R2 : H-, (C1 to C-CO alkyl), (C1 to C8 alkyl) -O-CO-, C1 to C8 alkyl, phenyl-co-, phenyl-0-CO-, a (C1 R2 indépendamment de tout autre R2 est choisi dans le groupe 15 comprenant H- et un alkyle en Cl à Cg, et dans le cas où R2 est lié à un azote qui est un élément de cycle de Hc, ce R2 doit être indépendamment de tout autre R2 : H-, un (alkyle en Cl à C-CO-, un (alkyle en Cl à Cg)-O-CO-, un alkyle en Cl à Cg, un phenyl-co-, un phényl-0-CO-, un (alkyle en Cl 20 to CgN-CO-, the above-mentioned elements being optionally substituted, independently of each other, with one or more fluorine substituents;20 à CgN-CO-, les éléments mentionnés ci-dessus pouvant être facultativement substitués, indépendamment les uns des autres, avec un ou plusieurs substituants fluors ;R3 est choisi dans le groupe comprenant : R3 is chosen from the group comprising: 25 H-, hydroxy and (C1-C8 alkyl) -O-, whereby the (C1-C8 alkyl) -O- group may be optionally substituted with one or more fluorine, chlorine, bromine and HO-;25 H-, un hydroxy et un (alkyle en Cl à Cg)-O-, moyennant quoi le groupe (alkyle en Cl à Cg)-O- peut être facultativement substitué avec un ou plusieurs fluors, chlores, bromes et HO- ;R and R ؛ are independently selected from the group consisting of H-, fluorine and methyl;preferably, R R et R؛ sont choisis indépendamment !'un de !'autre dans le groupe comprenant H-, le fluor et le méthyle ;de préférence, R 30 and R ؛ are both H;30 et R؛ sont tous les deux H ;X independently of all y: X = 0, 1, 2, 3 or 4, preferably χ = 0, 1 or 2, preferably X = 0 or 1, and more preferably X = 0;X indépendamment de tout y : X = 0, 1, 2, 3 ou 4, de préférence χ=0, 1 ou 2, de préférence X = 0 ou 1, et de manière davantage préférée X = 0 ;y independently of any X: y = 0 or 1, so y indépendamment de tout X : y = 0 ou 1, de manière 35 more preferred y = 0;35 davantage préférée y = 0 ;and! a pharmaceutically acceptable salt thereof. et !'un de ses sels pharmaceutiquement acceptables.
- 1010 oxadiazolyl, triazolyl, pyrazolyl, furanyl, pyridyl and / or phenyl, whereby the oxadiazolyl, triazolyl, pyrazolyl, furanyl, pyridyl and phenyl groups mentioned above may be optionally substituted with one or more ؛ 10 oxadiazolyle, un triazolyle, un pyrazolyle, un furanyle, un pyridyle et/ou un phenyle, moyennant quoi les groupes oxadiazolyle, triazolyle, pyrazolyle, furanyle, pyridyle et phenyle mentionnés ci-dessus peuvent être facultativement substitués avec un ou plusieurs ؛ 15 substituents selected independently of each other from the إ group consisting of fluorine, CH-, CHO-, HNCO- and / or NC-; إ 15 substituants choisis indépendamment les uns des autres dans le إ groupe constitué par le fluor, CH-, CHO-, HNCO- et/ou NC- ; إ Rz independently of any other R2 is selected from the group consisting of H- and C1-C6 alkyl, إ the above-mentioned C1-C8 alkyl group (s) إ Rz indépendamment de tout autre R2 est choisi dans le groupe · comprenant H- et un alkyle en Cl à C6, إ le ou les groupes alkyles en Cl à Cg mentionnés ci-dessus إ 20 may be optionally substituted, independently of each ؛ others, with one or more fluorine substituents; إ 20 pouvant être facultativement substitués, indépendamment les uns ؛ des autres, avec un ou plusieurs substituants fluors ; إ R3 est choisi dans le groupe comprenant :إ R3 is chosen from the group comprising: إ H-, hydroxy and (C1-C8 alkyl) -O-, whereby إ the (C1-C8 alkyl) -O- group may optionally be H-, un hydroxy et un (alkyle en Cl à Cg)-O-, moyennant quoi إ le groupe (alkyle en Cl à Cg)-O- peut être facultativement 25 substitutes with one or more fluorine, chlorine, bromine and HO-;25 substitue avec un ou plusieurs fluors, chlores, bromes et HO- ;r4 and R5 are independently selected from one another from the group consisting of H-, fluorine and methyl, preferably r4 and R5 are both H;r4 et R5 sont choisis indépendamment !'un de !'autre dans le groupe comprenant H-, le fluor et le méthyle, de préférence r4 et R5 sont tous les deux H ;X independently of all y: X = 0, 1, 2, 3 or 4, preferably X = 0, 1 or 2, preferably X = 0 or 1, and most preferably X = 0;X indépendamment de tout y : X = 0, 1, 2, 3 ou 4, de 30 préférence X = 0, 1 ou 2, de préférence X = 0 ou 1, et de manière préférée entre toutes X = 0 ;y independently of any X: y = 0 or 1, most preferably y = 0;y indépendamment de tout X : y = 0 ou 1, de manière préférée entre toutes y = 0 ;and! a pharmaceutically acceptable salt thereof. et !'un de ses sels pharmaceutiguement acceptables. 35 10. A compound according to claim 1, wherein 35 10. Compose selon la revendication 1, dans lequel Hc est choisi dans le groupe comprenant un tétrahydropyranyle et un tetrahydrofuranyle, de préférence le 3ou 4-tetrahydropyranyle et le 3-tetra-hydrofuranyle ;Hc is selected from the group comprising a tetrahydropyranyl and a tetrahydrofuranyl, preferably 3 or 4-tetrahydropyranyl and 3-tetra-hydrofuranyl;1 ٦ΐΖ1١ 1 ٦ΐΖ1١ 401 POl-2363-ff 401 POl-2363-ff R est choisi dans le groupe comprenant : R is chosen from the group comprising: le phényle, le 2-, 3- et 4-pyridyle, le cyclo-propyle, le cyclobutyle, le cyclopentyle, le cyclo-hexyle, le cycloheptyle, le cyclopentylméthyle, 1'éthyle, le propyle, le 1- et 2-butyle, le 1-, phenyl, 2-, 3- and 4-pyridyl, cyclo-propyl, cyclobutyl, cyclopentyl, cyclo-hexyl, cycloheptyl, cyclopentylmethyl, ethyl, propyl, 1- and 2-butyl , 1-, 2- and 3-pentyl, tetrahydrofuranyl and tetrahydro-pyranyl, which groups may be optionally substituted with one or more substituents selected independently of each other from the group consisting of NC-, (C1-C؛ alkyl) - O-, C1 to C8 alkyl, CF3O-, CF3- and halogen, the halogen being preferably chosen from fluorine, chlorine and bromine, 2- et 3-pentyle, le tétrahydrofuranyle et le tétrahydro-pyranyle, ces groupes pouvant être facultativement substitués avec un ou plusieurs substituants choisis indépendamment les uns des autres dans le groupe constitue par NC-, un (alkyle en Cl à C؛)-O-, un alkyle en Cl à Cg, CF3O-, CF3- et un halogène, !'halogène étant choisi de préférence parmi le fluor, le chlore et le brome, R2 independently of any other R2 is selected from the group consisting of H- and C1-C8 alkyl, the C1-C8 alkyl group (s) mentioned above being optionally substituted, independently of each other, with one or more fluorine substituents;R2 indépendamment de tout autre R2 est choisi dans le groupe comprenant H- et un alkyle en Cl à Cg, le ou les groupes alkyles en Cl à Cg mentionnés ci-dessus pouvant être facultativement substitués, indépendamment les uns des autres, avec un ou plusieurs substituants fluors ;R3 est choisi dans le groupe comprenant : R3 is chosen from the group comprising: H-, hydroxy and (C1-C8 alkyl) -O-, whereby the (C1-C8 alkyl) -O- group may be optionally substituted with one or more fluorine, chlorine, bromine and HO-;H-, un hydroxy et un (alkyle en Cl à Cg)-O-, moyennant quoi le groupe (alkyle en Cl à Cg)-O- peut être facultativement substitue avec un ou plusieurs fluors, chlores, bromes et HO- ;R4 and Rs are independently selected from the group consisting of H-, fluorine and methyl, preferably R4 and R5 are both H;R4 et Rs sont choisis indépendamment !'un de l'autre dans le groupe comprenant H-, le fluor et le méthyle, de préférence R4 et R5 sont tous les deux H ;X independently of all y: x = 0, 1, 2, 3 or 4, preferably X = 0, 1 or 2, preferably X = 0 or 1, and most preferably x = 0;X indépendamment de tout y: x=0, 1, 2, 3 ou 4, de préférence X = 0, 1 ou 2, de préférence X = 0 ou 1, et de manière préférée entre toutes x=0 ;y independently of any x: y = 0 or 1, most preferably y = 0;y indépendamment de tout x : y = 0 ou 1, de manière préférée entre toutes y = 0 ;and! one of its pharmaceutically acceptable salts. إ et !'un de ses sels pharmaceutiquement acceptables. إ
- 1515 heteroaryl, heteroaryl- (C1-C8 alkyl) -, R2٥-O- (C1-C3 alkyl) -, R 0-0-, R٥)2N-CO-, R٠-CO- or a (C1 to 15 hetéroaryle, un hétéroaryl- (alkyle en Cl à Cg)-, un R2٥-O-(alkyle en Cl à C3)-, R 0-0-, R٥)2N-CO-, R٠-CO- ou un (alkyl en Cl à Cg) -S٥2-, the elements mentioned above being able to be optionally substituted, independently of each other, Cg)-S٥2-, les éléments mentionnés ci-dessus pouvant être facultativement substitués, indépendamment les uns des autres, 20 with one or more substituents selected from the group consisting of fluorine and C1 to C8 alkyl; 20 avec un ou plusieurs substituants choisis dans le qroupe constitué par le fluor et un alkyle en Cl à Cg ; R3 est choisi dans le groupe comprenant :R3 is chosen from the group comprising: independently of any other R3 : H-, hydroxy and (C1 to C8 alkyl) -O-, whereby the (C1 to C8 alkyl) group indépendamment de tout autre R3 : H-, un hydroxy et un (alkyle en Cl à Cg)-O-, moyennant quoi le groupe (alkyle en Cl à 25 Cg) -O- can be optionally substituted with one or more fluorine, chlorine, bromine and HO-;25 Cg)-O- peut être facultativement substitue avec un ou plusieurs fluors, chlores, bromes et HO- ;R4 and R5 are independently selected from the group consisting of H-, fluorine and methyl;preferably, independently of one another, are chosen from the group R4 et R5 sont choisis indépendamment l'un de !'autre dans le groupe comprenant H-, le fluor et le méthyle ;de préférence, indépendamment !'un de !'autre, sont choisis dans le groupe 30 comprising H and fluorine, and more preferably R4 and R3 are both H;30 comprenant H et le fluor, et de manière davantage préférée R4 et R3 sont tous les deux H ;R2٠ independently of any other R20 is selected from the group consisting of C1 to C8 alkyl, C3 to C1 cycloalkyl, aryl and heteroaryl, R2٠ indépendamment de tout autre R20 est choisi dans le groupe comprenant un alkyle en Cl à Cg, un cycloalkyle en C3 à Cl, un aryle et un hetéroaryle, 35 the elements mentioned above possibly being optionally substituted independently of each other with one or more substituents selected from the group consisting of: 35 les éléments mentionnés ci-dessus pouvant être facultativement substitués indépendamment les uns des autres avec un ou plusieurs substituants choisis dans le groupe constitue par : t t ΜΑ 32201Β1 ΜΑ 32201Β1 414 POl-2363-ff إ اً fluorine, F3C-, HF2C-, FHC-, F3C-CH2-, CH3-0- (C1 to C8 alkyl) -, C1 to C8 alkyl and (C1 to C8 alkyl to Cg) -O-;414 POl-2363-ff إ اً le fluor, F3C-, HF2C-, FHC-, F3C-CH2-, un CH3-0-(alkyle en Cl à Cg)—, un alkyle en Cl à Cg et un (alkyle en Cl à Cg)-O- ;X = 0, 1, 2, 3 or 4, preferably X = 0, 1 or 2, preferably X = 0 or 1, and most preferably X = 0;X = 0, 1, 2, 3 ou 4, de préférence X = 0, 1 ou 2, de préférence X = 0 ou 1, et de manière préférée entre toutes X = 0 ;5 y = 0 or 1, and most preferably y = 0;5 y = 0 ou 1, et de manière préférée entre toutes y = 0 ;and a pharmaceutically acceptable salt or solvate thereof, provided that if Hc is an oxetanyl which is linked via, et l'un de ses sels ou solvates pharmaceutiquement acceptables, à condition que si Hc est un oxetanyle qui est lié par l'intermédiaire de , 10 with the carbon atom lying next to the oxygen of the oxetanyl, there is no substituent attached to said carbon atom through a -CH - spacer. 10 l'atome de carbone se trouvant à côté de 1'oxygène de !'oxetanyle, il n'y ait aucun substituant lié audit atome de carbone par 1' intermédiaire d'un espaceur -CH - . 15. A compound according to claim 13, wherein 15. Composé selon la revendication 13, dans lequel Hc est choisi dans le groupe comprenant un Hc is chosen from the group comprising a 15 tetrahydropyranyl, tetrahydrofuranyl, piperidinyl and pyrrolidinyl;15 tetrahydropyranyle, un tetrahydrofuranyle, un pipéridinyle et un pyrrolidinyle ;and et R2 independently of any other R2 is selected from the group consisting of H- and C1-C8 alkyl, R2 indépendamment de tout autre R2 est choisi dans le groupe comprenant H- et un alkyle en Cl à Cg, 20 and in the case where R2 is linked to a nitrogen which is a cycle element of Hc, this R2 must be independent of any other R2 : 20 et dans le cas où R2 est lié à un azote qui est un élément de cycle de Hc, ce R2 doit être indépendamment de tout autre R2 : H-, (C1 to C8 alkyl) -CO-, (C1 to C8 alkyl) -O-CO-, C1 to C8 alkyl, phenyl-C0-, phenyl-o-c٥-, a (C1 to CgN-C0- alkyl, H-, un (alkyle en Cl à Cg)-CO-, un (alkyle en Cl à Cg)-O-CO-, un alkyle en Cl à Cg, un phényl-C0-, un phényl-o-c٥-, un (alkyle en Cl à CgN-C0-, 25 the elements mentioned above being optionally substituted, independently of each other, with one or more fluorine substituents;25 les éléments mentionnés ci-dessus pouvant être facultativement substitués, indépendamment les uns des autres, avec un ou plusieurs substituants fluors ;and et R4 and Rs are H R4 et Rs sont H 30 and 30 et R'٠ independently of any other r! ٥ is selected from the group consisting of C1-C8 alkyl, phenyl and pyridyl, ب the above-mentioned elements being optionally substituted independently of each other with;R'٠ indépendamment de tout autre r!٥ est choisi dans le groupe comprenant un alkyle en Cl à Cg, un phényle et un pyridyle, ب les éléments mentionnés ci-dessus pouvant être facultativement substitués indépendamment les uns des autres avec ;35 one or more substituents chosen from the group consisting of: 35 un ou plusieurs substituants choisis dans le groupe constitue par : fluorine, F3C-, HF2C-, FHC-, F3C-CH2-, CH3-0- (C1-6 alkyl) le fluor, F3C-, HF2C-, FHC-, F3C-CH2-, un CH3-0-(alkyle en Cl ? to C8) -, C1 to C8 alkyl and (C1 to C8 alkyl) -O_. à Cg)-, un alkyle en Cl à Cg et un (alkyle en Cl à Cg)-O_.
- 20Use of a compound according to claims 1 to 18, 20. Utilisation d'un compose selon les revendications 1 à 18, 10 for the manufacture of a medicament for the treatment of a disease which is accessible by inhibiting PDE9. 10 pour la fabrication d'un médicament destine au traitement d'une maladie qui est accessible par !'inhibition de PDE9.
- 23
- 27A method of treating a condition as defined in any one of claims 19 to 25 in a patient, 27. Procédé de traitement d'une affection telle que définie dans l'une quelconque des revendications 19 à 25 chez un patient, 25 comprising the administration to said patient of an amount ؛ therapeutically active of a compound according to any one of claims 1 to 18. 25 comprenant !'administration audit patient d'une quantité ؛ thérapeutiquement active d'un composé selon l'une quelconque des revendications là 18.
- 2930 of Alzheimer's disease. 30 de la maladie d'Alzheimer.
Independent claims10
4,000 paragraphs in 158 sections, as filed
ABSTRACT
NEW COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS
The invention relates to novel 1,6-disubsti.tu pyrazolo-pyrimidinones, wherein i.) The nitrogen atom of the pyrazolo group which is next to the pyrimidino group is bonded to a non-aromatic organic heterocycle containing at least a ring heteroatom selected from O, N and s, and ii.) a second substituent is bonded to the c atom lying between the two nitrogen atoms of the pyrimidinone ring through an optionally substituted methylene bridge. According to one aspect of the invention, the novel compounds are useful for the manufacture of medicaments, in particular medicaments for the treatment of conditions relating to deficits in perception, concentration, learning or memory. The novel compounds are also useful for the manufacture of medicaments for the treatment of Alzheimer's disease.
<img file="MA32201B1_D0001.tif" />
MA 32201 Bl
32Μ
ï آ ؛ .- 3 ن ؛ 3 2 -.1 (Pt
٠١. WR W
~ 4-'3, 4-DjRYRlMHi] tJBRIVKS DE 1-HETER٠CYCIiYI, -1,5-DIHY [1RO-PYRAZOL٠ \ '. ٦١9 (٢ - ؛ _ MODUTATEt-JRS DE يازا ITlLlSATlCiNS as ٠LE٠L ONEJETR3
the ا.ي? لل ؛ لى- ؛ ٢ onoerne de ؛) The present lu vent'ion 0-.:11 e ؛ -٦fts; p isyrarolopyrimidi nones 1,6-disubstituted, in the group azet atom pyrazolo which is at ed '! ا. . ة .que:, or ;؛ u ؛ pyrimi.dj.no group is linked to an org hetecycle
. ؛ ؛؛؛ '1 ؛. · .P. ؛: - e de uyc i fi ohrdn ؛) kingiiatlc etoatoi containing at least one l ؛؛ ، N and- S, and ii.) A second substituent is linked to the afcuiC t: being ؛. found between .both (nitrogen atoms of the pyrimidine ring pe. nt oubol 1 tue الاج '11 éd.iairfc' of a methylene bridge f acu 11 a ؛ f: ertï ؛ .u ؛ ' i. ؛ 'in one aspect (the invention, new compounds,'; (. 'ni. ut ؛ ·؟' ١: ta. manufacture of medicaments, in particular riiédicap.iert; ٦ pou dest linked to . 1-1 treatment of ailments concerning .ci te detes ,! ..'- '.' .. '(' option, concentration, learning or memory os es. (؛ boa,. ؛ we water compounds are, also useful for la. ؛: ؛ - 1 : 0 i l. ؛; ',' oedieamen٢s intended for the treatment of the disease of receded of ؛ 1-1? Es aspects of the present invention frown us ١٦; 'fl' 10.0 'compoats and their use lion' for p (. odul! o ؛؛ y--eta.fi on of ؛ '؛ p
;, |, Ίθ1, '- η „Ί (: - Γ
ΕΝΤΙ0Ν! ٠'Cp GTJHTE_ DE 1
O! : -s .: '؛ Inhibition of pho s ptod ie .s t. é r ، ase 9 A (PDEdA) is a '!.; -.-' 'SO I eo ؛ current on which is based the search for ؛؛ -. 'oncepf' ، geese allowing access to the treatment of salary defcric ors ef, ؛ i (t ؛ h٠. '؛! due to CNS disorders, such as A ؛؛ mgio tive ؛ 'disease
, any other neurodegenerative process of the د hoop or to the compounds of the present invention follow ('e concept.':! ؛ - us, ؛؛ ،
The O sph O diest é t'a se 9Α fold is a member of the grand loti.
U ؛؛ '؛' of enzymes modulate the.s؟ .51 é r a. his . These type ؛ O h c- sp fl O die ;؛ do
Scrape cyclic d 'adenosine monopli ospha t. cyclical e! G'-lei ؛؛ ي ؛ درن .aura '! bot ؛ liu ((IMFci. Ces ؛.) ne monopbosphate cy! ؛. ؛ 0'f f'-d '-guano 1 .... of ؛ ί٠3 -' ؛ - ίΐο ؛ -sa go ns .ΐ ؛ -: ١i ·. GMPc) leaves the seconds me> AMPc);) cyclic 1: ؛ - ': Si-duc n. gold.; entered the caiicades of t ra '؛ -1 YES. , 1 therefore a role ؛ '؛ - ؛.! ,؟ O. ؛ '؛؛؛ between, ؛ reactivated ؛ - ؛؛. ؛ cellular. Each of, e ؛؛؛؛: ؛ sIg
sac -. (؛. ؛ ١٦١a.is not excluded !, vement. .1,1 protein t, s kinases ؛ P .r O té'ine 1.11-1,0), and. the ..? ؛؛؛ life by UPc is. called protein k lilac ؛ 0.1-
protein fi sa ssc ؛ activated ta. ' cGMP is. call؟ ؛ kl nas protein of ؛؛. ؛ - ؛.: f '؛؛ ii leu ؛؛ (UC). !, es ΡΚΛ (and- fl G activated are capable
؛ :: e '؛'. A ؛ cffecf ؛؛ onosphorylate a number of proteins
32201Β1
POl-2363-ff أ إ
cellular (eg ion channels, G protein-coupled receptors, structural proteins, transcription factors). In this way, it is possible for the إ second messengers cAMP and cGMP to regulate a wide variety of ، physiological processes in a wide variety of organs. However, ؛ cyclic nucleotides are also able to act ؛ directly on effector molecules. So, it is known, for example, that cGMP is able to act directly on ؛ channels ionic and therefore influence the concentration of ions in the cell (described in: Wei et al., Prog. Neurobiol., 1998, 56, 3764). Phosphodiesterases (PDEs) are a regulatory mechanism for regulating the activity of cAMP and cGMP and therefore the corresponding physiological processes. PDEs hydrolyze cyclic monophosphates to give the inactive monophosphates AMP and GMP. Currently, 11 families of PDEs have been defined based on the sequence homology of the corresponding f genes. Individual PDE genes within a ل family are differentiated by letters (eg, PDEIA and PDEIB). ؛
If there are also different splice variants in a gene, then إ this is indicated by an additional number after the ؛ letters (for example, PDEIAI). I
Human PDE9A was cloned and sequenced in 1998.
The amino acid identity with other PDEs does not exceed 34% 1 ؛ (PDA) and is never less than 28% (PDE5A). With a Michaelis-Menten constant (Km) of 170 nanomoles, PDE9A إ exhibits a high affinity for cGMP. In addition, PDE9A is selective for cGMP (Km for cAMP = 230 micromoles). The PDE9A ؛ does not have a cGMP binding domain, suggesting that the activity of the enzyme is not regulated by cGMP. Western blot analysis has shown that ΡΟΕ9Α is expressed in humans, inter alia, in testes, brain, small intestine, skeletal muscle, heart, lung, thymus, and lung. missed. The highest expression occurs in the brain, small intestine, kidneys, prostate, colon and spleen (Fisher et al., J. Biol. Chem., 1998, 273 (25), ؛
15559-15564; Wanq et al., Gene, 2003, 314, 15-27). The gene for
Human PDE9A is located on chromosome 21q22.3 and consists of 21 exons. 4 alternative splice variants of PDE9A have been
<img file="MA32201B1_D0002.tif" />
32201BI
Identified POl-2363-ff (Guipponi et al., Hum. Genet., 1998, 103, 386-392). Classical PDE inhibitors do not inhibit human PDE9A. إ
Therefore, 1'ΙΒΜΧ, dipyridamole, SKF94120, rolipram إ and vinpocetine do not inhibit the isolated enzyme at concentrations up to 100 micromoles. An IC of إ micromoles was obtained with zaprinast (Fisher et al., J. إ
Biol. Chem., 1998, 273 (25), 15559-15564). ئ
Murine PDE9A was cloned and sequenced in 1998 by ؛
Soderling et al. (j. Biol. Chem., 1998, 273 (19), 15553-15558). ؛
This exhibits, like the human form, a high affinity for cGMP with a Km of 70 nanomoles. Particularly high expression was found in the kidneys, brain, lungs and liver of mice. Murine PDE9A is also not inhibited by 1'ΙΒΜΧ at concentrations below 200 ؛ micromoles; the Co with zaprinast is 29 micromoles (Soderling et al., j. Biol. Chem., 1998, 273 (19), 15553-15558). إ
PDE9A has been found to be highly expressed in certain regions of the rat brain. These include the olfactory bulb, the hippocampus, the cortex, the basal nuclei and the anterior basal brain (Andreeva et al., J. Neurosci., 2001, 21 (22), 9068-9076). إ
In particular, the hippocampus, cortex and basal anterior brain play an important role in learning processes ؛ and memorization. As previously mentioned, the PDE9A is ؛ distinguished by the fact that it has a particularly high affinity for cGMP. PDE9A is therefore active even at low physiological concentrations, unlike PDE2A (Km = 10 micromoles; Martins et al., J. Biol. Chem.,
1982, 257, 1973-1979), PDE5A (Km = 4 micromoles; Francis et al., J. Biol. Chem., 1980, 255, 620-626), PDE6A (Km = 17 micromoles; Gillespie and Beavo, j. Biol. Chem., 1988, 263 (17),
8133-8141) and PDEllA (Km = 0.52 micromole; Fawcett et al.,
Proc. Nat. Acad. Sci., 2000, 97 (7), 3702-3707). Unlike PDE2A (Murashima et al., Biochemistry, 1990, 29, 5285-5292), the catalytic activity of PDE9A is not increased by cGMP because it does not have a GAF domain ( X
CGMP through which PDE activity is allosterically increased) (Beavo et al., Current Opinion in Cell Biology, <
MY
32201Β1
POl-2363-ff
2000, 12, 174-179). PDE9A inhibitors may therefore cause an increase in the baseline concentration of cGMP.
This paper shows that PDE9A participates in specific physiological processes in a characteristic and unique way, which makes the role of PDE9A particular to all other PDE families.
WO 04 099 210 describes 6-substituted arylmethyl pyrazolo-pyrimidinones which are PDE9A inhibitors. The compounds do not contain a non-pyrazolopyrimidine heterocyclic moiety.
The aromatic document in position
WO 04 096 811 describes heterocyclic bicycles inhibitors of PDE9 for the treatment of diabetes, in particular type 1 diabetes and type 2 diabetes, hyperglycemia, dyslipidemia, poor glucose tolerance, syndrome. metabolic and / or cardiovascular disease.
Other prior art documents relate to chemically similar nucleoside derivatives. For example, the document
WO 02 057 425 describes nucleoside derivatives inhibitors of RNA-dependent RNA polymerase of viruses, document wo 01 060 315 describes nucleoside derivatives for the treatment of hepatitis C, document EP 679 657 describes compounds serving as analoques ribonucleoside or US 2002 058 635 discloses L-nucleoside purine compounds in which the purine rings and the sugar are all either modified or functionalized or both. For example, the sugar must thus have at least one esterified OH group.
WO 06 084 281 describes E1 activating enzyme inhibitors which contain a sulfonamide moiety.
WO 05 051 944 describes oxetane-containing nucleosides for the treatment of disorders associated with nucleoside analogues, such as disorders involving cell proliferation and infection.
WO 9840384 describes pyrazolo-pyrimidinones which inhibit PDE1, 2 and 5 and which can be used to treat cardiovascular and cerebrovascular disorders and disorders of the urogenital system. The documents CH 396 924,
MY
32201Β1
POl-2363-ff
CH 396 925, CH 396 926, CH 396 927, DE 1,147,234, DE 1,149,013,
GB 937 726 describe pyrazolopyrimidinones which have the effect of dilating the coronaries and which can be used to treat disturbances in myocardial blood flow. US 3,732,225 describes pyrazolopyrimidinones which have an anti-inflammatory effect and a blood sugar lowering effect. DE 2 408 906 describes styryl-pyrazolopyrimidinones which can be used as antimicrobial and anti-inflammatory agents to treat, for example, edema.
OBJECT OF THE INVENTION
The previously cited prior art clearly shows that modifications of the substitution profile of pyrazolopyrimidinones lead to interesting changes concerning the biological activity, respectively changes of affinities with respect to the various target enzymes.
Therefore, it is an object of the present invention to provide compounds which efficiently modulate PDE9A for the purpose of drug development, particularly for diseases the treatment of which is accessible through modulation of PDE9A.
Another object of the present invention is to provide compounds which are useful for the preparation of a medicament for the treatment of CNS disorders.
Another object of the present invention is to provide compounds which exhibit a better side effect profile compared to the compounds of the prior art.
Another object of the present invention is to provide compounds which exhibit a selectively favorable profile for inhibition of PDE9A over other members of the PDE families and which, as a result, may prove to be advantageous over to compounds of the prior art.
Another object is to provide such a medicament not only for treating but also for preventing or modifying the corresponding disease.
DETAILED DESCRIPTION OF THE PRESENT INVENTION
MY
32201Bl
POl-2363-ff
The compounds of the present invention are characterized by the general formula I:
<img file="MA32201B1_D0003.tif" />
with the following definitions (substituents may be printed in bold for ease of reading).
The Hc substituent is defined by the following Hc definitions, the sign i describing the order of preference which is increasing from Hc to a more preferred substituent (i.e., Hc), and so on:
: ب
Hc is a mono-, bi- or tri-cyclic heterocyclyl group whose ring elements are carbon atoms and at least
1 heteroatom, preferably 1, 2 or 3 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms, which is in the form -s (O) ؛ -, where r is equal to 0, 1 or 2, and
-said heterocyclyl group is or contains 1 non-aromatic, saturated or partially unsaturated monocyclic ring containing at least 1 heteroatom as a ring element, and
- Said heterocyclyl group is linked to the main structure by the intermediary of said 1 non-aromatic, saturated or partially unsaturated monocyclic ring containing at least 1 heteroatom as a ring element.
Hc:
Hc is a heterocyclyl group possessing any of the formulas 1.1, 1.2 and 1.3:
MY
32201Β1
POl-2363-ff
؛ 1.1 Formula
*
<img file="MA32201B1_D0004.tif" />
η = 1, 2, 3;
χΐ, X<sup>2</sup>, X<sup>2</sup>, independently of each other, are CH, CHR<sup>2</sup>, CHR<sup>3</sup>, C (r2) 2, CRR<sup>3</sup>, o, NH, NR2 or s (o) r or r = 0, 1, 2, whereby at least one of χ١ X<sup>2</sup>, X<sup>3</sup> is 0, NH, NR<sup>2</sup> or s (o) r;
#: means that the ring is not aromatic, while 10 for n = 1, a bond inside the ring system can optionally be a double bond, and for n = 2 or n = 3, a bond or two Bonds within the ring system can / can optionally be (a) a double bond or double bonds, thereby replacing hydrogen atoms linked to ring elements. In each case, preferably a cc double bond. From cyclic is saturated.
The symbol * represents the nitrogen point of the pyrazolo ring of formula I.
the double bond is preferably the attachment system of the atom
<img file="MA32201B1_D0005.tif" />
MY
32201Β1
POl-2363-ff
Formula 1.2:
<img file="MA32201B1_D0006.tif" />
A is the ring system of formula 1.1;
B is a 3, 4, 5 or 6-membered second ring system which is ringed to A and which, in addition to the two atoms and a bond that it shares with A, is only composed of carbon atoms and may be saturated, partially saturated or aromatic; the R substituents<sup>2</sup> and / or R<sup>3</sup> independently of each other and independently of X and y can be on cycle A or cycle B. ح
The two ring atoms which are shared by the two ring systems A and B can both be c atoms, can both be N atoms, or one can be a ؛ atom. c and the other may be an N atom. Two c atoms or a c atom and an N atom are preferred, and two c atoms are more preferred. إ
The shared bond can be a single bond or a double ؛ binding. ؛
<img file="MA32201B1_D0007.tif" />
<img file="MA32201B1_D0008.tif" />
32201Β1
POl-2363-ff ا
Formula 1.3: إ
<img file="MA32201B1_D0009.tif" />
A is the ring system of formula 1.1;
It is a 3, 4, 5 or 6 membered second ring system which is spiro-fused to A and which, in addition to the atom which it shares with A, is only composed of carbon atoms and can be saturated or partially saturated; the R substituents<sup>2</sup> and / or R<sup>3</sup>
<td colspan="2">independently one of 1 can be on cycle ٠</td><td colspan="2">'other and independently of A or ring c;</td><td>X and y</td>
<td>Hc is</td><td>a group</td><td>heterocyclyl</td><td>chosen in</td><td>the group</td>
<td>including:</td><td></td><td></td><td></td><td></td>
<td>r? * El</td><td> ٥&٠</td><td>fl</td><td>0 II Γ٢ — Q ٠0</td><td></td>
<td> ٠٥</td><td>ة.</td><td> ٠٥</td><td>د ؛.</td><td>'مم.</td>
<td> ٥'</td><td> ٥.</td><td> ١٠؛.</td><td>٠ حح.</td><td> ٥.</td>
<td>دد</td><td>lr</td><td>سمح.</td><td>دد</td><td>د ؛.</td>
<td> ٥.</td><td>. O</td><td> ٠٥</td><td> ٠٥</td><td> ٠٥</td>
32201BI
POl-2363-ff
<td> ٠'</td><td>لآ</td><td> ٥</td><td> ٥</td><td> ٥</td>
<td> ٠٥</td><td> ٥</td><td> ٥</td><td> °٥</td><td>م</td>
<td> ٥</td><td> ۶/٠١١ ٥</td><td> .¢</td><td>at</td><td> ۶/٠١١ ٥</td>
<td>U</td><td></td><td>٠Ü</td><td> ٥'</td><td></td>
<td> 00</td><td>2 لا 0 ا (لض ١ خ</td><td>2 or ا (تز 0</td><td> 07</td><td> 07</td>
<td>it</td><td>οά</td><td>œ</td><td> 07</td><td> 07</td>
<td> 07</td><td>فيلالابج * X = 0, s or N</td><td>ج ١ وحي ٠ ١٩ با ١ X = 0, s or N</td><td>'this<sup>1</sup>· X = 0, s or N</td><td></td>
p = 1, 2, 3, p = 1, 2, 3, ρ = 1, 2, 3, ؛ or 5 4 or 5 4 or 5 ؛ q = 1, 2 or 3 q = 1, 2 or 3 q = 1, 2 or 3 ؛
Hc: إ:
Hc is the heterocyclyl group of formula 1.1 as إ defined above for H. إ
Hc<sup>5</sup> : إ
Hc is the heterocyclyl group of formula 1.2 as defined above for Hc ؛.
Hc؟ :;
<img file="MA32201B1_D0010.tif" />
32291Β1
POl-2363-ff
Hc is the heterocyclyl group of formula 1.3 as defined above for Hc.
Hc ٥:
Hc is a non-aromatic saturated monocyclic heterocyclic group containing 4 to 8 ring atoms, preferably 5, 6 or ring atoms, whereby said ring atoms are carbon atoms and 1, 2 or 3 heteroatoms, preferably 1 heteroatom , the heteroatom (s) being chosen (s) from oxygenated, nitrogen and sulfur, the sulfur being in the form -s (o) ٢-, where r is equal to 0, 1 or 2, preferably r is equal to 0, and preferably said heterocyclic group is linked to the main structure through a ring carbon atom which is not directly linked to said ring heteroatom.
Hc د:
Hc is hydropyranyl, pyrrolidinyl selected from the group consisting of tetraun tetrahydrofuranyl, piperidinyl, piperazinyl, preferably is 3- or 4-tetrahydropyranyl, tetrahydrofuranyl is 3-tetrahydrofuranyl and piperidinyl or 3- or 4- is piperidinyl.
Hc<sup>s</sup> :
and tetrahydropyranyl
Hc is selected from the group comprising a tetrahydropyranyl, a tetrahydrofuranyl, a piperidinyl and a pyrrolidinyl, preferably the tetrahydro-pyranyl is 3- or
4-tetrahydropyranyl, tetrahydrofuranyl is 3tetrahydrofuranyl and piperidinyl is 3- or 4-piperidinyl.
Hc:
Hc is selected from the group consisting of piperidinyl and pyrrolidinyl, preferably 3- or 4-piperidinyl and pyrrolidinyl.
Hc:
Hc is selected from the group comprising a tetrahydropyranyl and a tetrahydrofuranyl, preferably 3- or 4tetrahydropyranyl and 3-tetrahydro-furanyl.
The substituent r! is defined by the following definitions r! 'M, respectively rI, the sign j describing the order of preference which is increasing from Ri٥-1 towards
<img file="MA32201B1_D0011.tif" />
MY
32201Β1
POl-2363-ff more preferred definitions, like R '2, and so on ا until r! · !, then r!<sup>2</sup> And so on.
r2. c. 1 j إ
R is chosen from the group comprising:
C1 to C8 alkyl, c alkenyl<sub>2</sub> to Cg, an alkynyl in
2 ء to C8, a (C1 to C؛ alkyl) - s-, a (C1 to C8 alkyl) -s- (C1 to C3 alkyl) -, a C3 to C7 cycloalkyl, a (C3 to C7 cycloalkyl) c,) (C1 to C6 alkyl) -, a (C3 to c cycloalkyl,) - (c alkenyl<sub>2</sub> to Cg) -, a (C 3 to C cycloalkyl) - (C C to C 6 alkynyl) -, a C 3 to C 7 heterocycloalkyl, a (C 3 to C 7 heterocycloalkyl) (C 1 to C 8 alkyl) -, a ( C3 to C heterocycloalkyl,) - (C ؛ to C 8 alkenyl) -, a (C3 to C7 heterocycloalkyl) - (C2 to Cs alkynyl) -, ؛ aryl, aryl- (C 1 -C 8 alkyl) -, aryl- (C alkenyl)<sub>z</sub> to Cg) -, an aryl- (C-alkynyl<sub>2</sub> to Cg) -, heteroaryl, heteroaryl- (C 1 to C 8 alkyl) -, heteroaryl- (C ؛ to C 8 alkenyl) - and heteroaryl- (C alkynyl)<sub>2</sub> to Cg) -, the elements mentioned above possibly being optionally substituted with one or more substituents chosen independently of each other from the group consisting of fluorine, chlorine, bromine, iodine, an oxo, HO-, NC-, ON, ؛
F3C-, HFC, FHC-, FgC-CH-, F3C-0-, HFCO-, HO- (C1 to ؛ alkyl
Cg) -, r “-O- (C1 to C8 alkyl) -, R١٥-S- (C1 to C8 alkyl) -, إ C1 to C8 alkyl, C alkenyl<sub>2</sub> to Cg, a c-alkynyl<sub>2</sub> to C8, a C3 to C7 cycloalkyl, a (C3 to C7 cycloalkyl) - (C1 to C8 alkyl) -, a (C3 to 67 cycloalkyl) -O-, a (C3 to c cycloalkyl,) ( C1 to C8 alkyl -O-, aryl, aryl- (C1 to C8 alkyl) -, heteroaryl, heteroaryl- (C1 to C8 alkyl) -, heteroaryl-0-, heteroaryl- ( C1 to C8 alkyl) -O-, nitrogen-linked pyridine-2-οηε, nitrogen-linked pyridine-2-٠ne_ (C1 to C8 alkyl), ؛ a pyridin-2-one- (C1 to C؛ alkyl) - o- linked by nitrogen, a ; C3 to C7 heterocycloalkyl, a (C3 to C7 heterocycloalkyl) - إ (C1 to C8 alkyl) -, a (C3 to ¢ 7 heterocycloalkyl) -0- with ؛ ' C3 to C7 heterocycloalkyl linked to 0 through one of its ring c atoms, a (C3 to C7 heterocycloalkyl) - (C1 to C8 alkyl) -O- with C3 to heterocycloalkyl to C7 bound to C1 to C8 alkyl through one of its ring atoms, ٢
R٥) N, un (r1٥)<sub>2</sub>N- (C1 to C8 alkyl) -, R -O-, R٥ ؛ -S-, R٥-CO-,
RO-CO-, R٥)<sub>2</sub>N-CO-, un (r1٥)<sub>2</sub>N-CO- (C1-C8 alkyl) -, R٠ ؛ -CO-
<img file="MA32201B1_D0012.tif" />
MA 32201 Bl
POl-2363-ff
R٠) N-, a r! ٥-CO- R ٥) N- (C1-C؛ alkyl) -, r1٥-CO-O-, RO-CO-0-,
<td></td><td>a RO-CO-0- (alkyl in</td><td>Cl to</td><td>Cg) -,</td><td>RO-CO- R ٥) N-</td><td>, a R O-CO- R٥)</td><td>NOT-</td>
<td></td><td>(C1 to C8 alkyl) -,</td><td>a</td><td>R٥)</td><td>N-CO-O- (alkyl ؛</td><td>in ٢٩ to ٩١,</td><td>a</td>
<td></td><td>(Rl) ζΝ-CO- (Rl٥) N- (alkyl</td><td>in</td><td>Cl to</td><td>Cg) -, rI-SOz- (</td><td colspan="2">Ri٥) N-, one R “-S٠2-</td>
<td> 5</td><td>(R1) N- (C1 to C alkyl</td><td>Cg) -</td><td>, a</td><td>(٥ ؛ 2N-SO2- (R (٠ ^ R)</td><td>؛ N- (C1-alkyl</td><td>at</td>
<td></td><td>Cg) -, R٠) 2N-SOz-, a</td><td>(R)</td><td>? N — SQ?</td><td>- (C-alkyl)</td><td>to Cg) - and / or</td><td>a</td>
(C1-C8 alkyl) -SO2-, whereby any of the C 1-8 cycloalkyl groups<sub>3 </sub>to C ,, C 3 -C 1 heterocycloalkyl, aryl, heteroaryl, nitrogen-linked pyridin-210 one and (r1٥) 2N-CO- (C 1 -C - alkyl) - mentioned above can be optionally substituted with a or more substituents selected independently of each other from the group consisting of fluorine, chlorine, bromine, HO-, NC-, Ο2Ν-, F3C-, HF2C-, FHC-, FC-CH-, F<sub>3</sub>CO-, HFzC-Ο-, a heterocycloalkyl in c<sub>3</sub> to Cl, r1٥-O- (C1 to C8 alkyl) -, R) ٠-S- (C1 to C8 alkyl) -, C1 to C8 alkyl, (rOJzN-, (R) ٠) 2N- (C1 to C8 alkyl) -, R٠-O-, R٠ ؛ -S-, RÎ٥-CO-, ROCO-, R٠N-CO-, un (R ^ N-CO- (C1 to C8 alkyl) -, r! ٥-CO- R٥) N-, un R٥ ؛ -CO- R ٥) N- (C1-C8 alkyl) -, Ri٥-CO-O-, RO-CO-0-, un R٦٠O- CO-O- (C1 to C8 alkyl) -, RO-CO20 (r! ٥) N-, one Ri٥O-CO-R٥) N- (C1 to C8 alkyl) -, one R٥) zN-CO-O -, (RJ٥) zN-C0- R٥) N-, (R ^ ٥) 2N-SO2- (R ^ ٥) N-, un (R) ؛ (٥N-CO-O- (C1-C8 alkyl) -, un R ٥) ζΝ-CO- R ٥) N- (C1-C8 alkyl) -, r1٥-SO<sub>2</sub>- (R1٥) N-, un R١٥-SOz_ R ٥) N- (C1 to Cg alkyl) -, un R٥) zN-SO2- (r1) N- (C1 to Cg alkyl) -, R٥) zN-SO2-, (r1٥) 2N-SO2- (C1 to C8 alkyl) - and / or (C] to C8 alkyl) -SO2_;
rI.0.2 ؛
R1 is chosen from the group comprising:
C1-C8 alkyl, C-cycloalkyl<sub>3</sub> to Cl, a (cycloalkyl in c<sub>3</sub> to c,) - (C1 to c- alkyl, c heterocycloalkyl<sub>3</sub> to Cl, a (heterocycloalkyl in c<sub>3</sub> to Cl) - (C1 to C8 alkyl) -, an aryl, an aryl- (C1 to C8 alkyl) -, a heteroaryl and a heteroaryl- (C1 to C8 alkyl) -, the elements mentioned above possibly be optionally substituted with one or more substituents selected independently of each other from the group consisting of fluorine, chlorine, bromine, iodine, oxo, HO-, NC-, Ο2Ν-, F<sub>3</sub>C-, HFzC-, FHC-, F<sub>3</sub>C-CH-, F<sub>3</sub>CO-, HF2C-0-, r! ٠-O- (C1 to C8 alkyl) -, C1 to C8 alkyl, Cz to C8 alkenyl, alkynyl
<img file="MA32201B1_D0013.tif" />
MY
32201Bl
POl-2363-ff in c<sub>2</sub> to Cs, a cycloalkyl in c<sub>3</sub> to Cl, (C3 to C4 cycloalkyl) (C1 to C8 alkyl) -, aryl, aryl- (C1 to C8 alkyl) -, heteroaryl, heteroaryl- (C1 to C8 alkyl) -, nitrogen-linked pyridin-2one, pyridin-2-one- (C1-C8 alkyl) - linked>.
by nitrogen, a heterocycloalkyl in c<sub>3</sub> to Cl, a (heterocycloalkyl in c<sub>3</sub> to Cl) - (C1 to C8 alkyl) -, a tetrahydrofuranyl-O-, a tetrahydropyranyl-O-, a piperidinyl-O- where the piperidinyl is bonded to O through one of its ring C atoms , a pyrrolidinyl-O- where the pyrrolidinyl is linked to O through one of its ring C atoms, (^ ٥)<sub>2</sub>Ν-, un (RN (C1-C8 alkyl) -, RO-, (R N-CO-, un R ٥) zN-CO- (C1-C8 alkyl) -, R1-CO- R٥) N- , r1٥-CO- (R٥ ؛) N- (C1-C8 alkyl) -, ROCO-O- and / or r! ٥O-CO- (r! ٥) N-, whereby any of the groups cycloalkyl in c<sub>3</sub> \ to C1, heterocycloalkyl in c<sub>3</sub> to Cl, aryl, hetereroaryl, nitrogen linked pyridin-2one, tetrahydrofuranyl, tetrahydropyranyl, piperidinyl, pyrrolidinyl, R N-CO- (C1-C8 alkyl) mentioned above may be optionally substituted with one or more selected substituents. independently of each other in the group consisting of fluorine, chlorine, bromine,
NC-, Μ-- FC, HC-, FHC-, FCH-, F3C-0-, HF2C-0-, heterocycloalkyl in c<sub>3</sub> to Cl, a R'٠-O- (C1 to C8 alkyl) -, a ؛ C1 to C8 alkyl, r10-O-, r! ٠-CO-, ROCO-, a benzyl-O- and / or
R٥) 2N-CO-, whereby piperidinyl or pyrrolidinyl is preferably substituted with R-CO-;
rI.0.3 ٠ r} is chosen from the group comprising:
phenyl, 2-, 3- and 4-pyridyl, pyrimidinyl, pyrazolyl, thiazolyl, cyclo-propyl, cyclobutyl, إ cyclopentyl, cyclo-hexyl, cycloheptyl, ز cyclopentylmethyl, ethyl , propyl, 1- and 2-bùtyl, 1-,؟
2- and 3-penty! E, tetrahydrofuranyl and tetrahydro-pyranyl, إ which groups may be optionally substituted with one or more substituents independently selected from one of '؛ others in the group consisting of fluorine, chlorine, bromine, ٠! 'iodine, oxo, HO-, NC-, (C 1 to C 8 alkyl) -O-, C 1 to C 8 alkyl, cycloalkyl in c<sub>3</sub> to Cl, a (C-cycloalkyl<sub>3</sub> to Cl) -O-, a (C-cycloalkyl<sub>3</sub> to Cl) - (C1 to C alkyl<sub>3</sub>) -O-, CFO, CF<sub>3</sub>-, a
<img file="MA32201B1_D0014.tif" />
MA 32201 Bl
POl-2363-ff heterocycloalkyl in c<sub>3</sub> to Cl, a (C heterocycloalkyl<sub>3</sub> to c,) - ؛ (C1 to C8 alkyl) -, HO- (C1 to C8 alkyl) -, oxadiazolyl, إ oxazolyl, isoxazolyl, triazolyl, thiazolyl, pyrrolyl, furanyl, pyrazolyl, pyridyl, . ؛ pyridazinyl, pyrimidinyl, (R N-C0- (C1-C8 alkyl) -, (rIn-CO- and / or phenyl, ؛ whereby the oxadiazolyl, oxazolyl, ؛ isoxazolyl, triazolyl, thiazolyl, pyrrolyl, furanyl, \ pyrazolyl, pyridyl, pyridazinyl, pyrimidinyl and phenyl ، mentioned above can be optionally substituted with ؛ one or more substituents selected independently of each other from the group consisting of fluorine, CH-, CF<sub>3</sub>-, CH<sub>3</sub>O_,
CF<sub>3</sub>0-, H2NC0-, NC-, morpholinyl and / or benzyl-o-.
Rl.0.4 ؛
R) is chosen from the group comprising:
phenyl, 2-, 3- and 4-pyridyl, cyclo-propyl, cyclobutyl, cyclopentyl, cyclo-hexyl, ethyl, 1- and
2-propyl, 1- and 2-buty! E, 1-, 2- and 3-penty! E, ا tetrahydrofuranyl and tetrahydropyranyl, إ which groups may be optionally substituted with one or more substituents independently selected from each other. others in the group consisting of fluorine, chlorine, bromine, iodine, oxo, NC-, (C1 to C8 alkyl) -O-, C1 to C8 alkyl, CFO, CF<sub>3</sub>-, oxadiazolyl, triazolyl, pyrazolyl, furanyl, pyridyl and / or phenyl, whereby the oxadiazolyl, triazolyl, pyrazolyl, furanyl, pyridyl and phenyl groups mentioned above may be optionally substituted with one or more substituents selected independently of each other from the group consisting of fluorine, CH-, CHO-, HNCO- and / or NC-.
Rl-1:
R) is chosen from the group comprising:
C1 to C8 alkyl, C2 to C8 alkenyl, C2 to Cg alkynyl, (C1 to C8 alkyl) -S-, (C1 to C8 alkyl) -S- (C1 to C8 alkyl) -, a cycloalkyl in c<sub>3</sub> to c ,, a (cycloalkyl in c<sub>3</sub> to C,) - ي (C1 to C8 alkyl) -, un (C cycloalkyl)<sub>3</sub> to Cl) - (C2 to ؛ alkenyl
Cg) -, a (C-cycloalkyl<sub>3</sub> to C,) - (C alkynyl<sub>2</sub> to Cg) -, a ؛ heterocycloalkyl in c<sub>3</sub> to Cl, a (C heterocycloalkyl<sub>3</sub> to Cl) - ؛
<img file="MA32201B1_D0015.tif" />
<img file="MA32201B1_D0016.tif" />
32201Β1
POl-2363-ff (C1-C6 alkyl) -, (C-C heterocycloalkyl) - (C-C-alkenyl) -, (C-C-C heterocycloalkyl) - (C-C-alkynyl) - , aryl, aryl- (C1-C6 alkyl) -, heteroaryl and heteroaryl- (C1 to C6 alkyl) -, the above mentioned elements being optionally substituted independently of each other with one or more substituents selected from the group consisting of fluorine, chlorine, bromine, HO-, NC-, OjN-, F3C-, HF2C-, FHC-, F3C-CH2-, F3C-0-, HF2C-0-, HO- (C1 to C6 alkyl) -, R -O10 (C1 to C6 alkyl) -, R -s- (C1 to C8 alkyl) -, C 1 -C 6 alkyl, C 3 -C cycloalkyl,, (C 3 -C cycloalkyl) - (C 1 -C 6 alkyl) -, (C 3 -C cycloalkyl) -O-, (C 3 -cycloalkyl to C7) - (C1 to C6 alkyl) -O-, aryl, aryl- (C1 to C8 alkyl) -, heteroaryl, heteroaryl- (C1 to C6 alkyl) -, heteroaryl15 0-, a heteroaryl- (C1 to c alkyl<sub>6</sub>) -o-, C3 to C1 heterocycloalkyl, (C3 to C1 heterocycloalkyl) - (C1 to C؛ alkyl) -, (C3 to C1 heterocycloalkyl) -O- with C3 to C1 heterocycloalkyl linked to O through one of its ring atoms, a (C 3 -C heterocycloalkyl) - (C 1 -C 8 alkyl) -O- with
C3 to C1 heterocycloalkyl bonded to C1 to C8 alkyl through one of its ring atoms, (R<sup>1٠</sup>)<sub>2</sub>N-, un (R ^ ٥) zN- (C1-C8 alkyl) -, R٥ ؛ -O-, RS-, r! ٥-CO-, RO-CO-,
R٥N-CO-, a (r1٥) 2N-C0- (C1-C8 alkyl) -, r1٥-CO- (r1٥) N-, a R٠ ؛ -CO- (R١٥) N- (C1-C8 alkyl) -, r! ٥-CO-O-, RO-CO-0-, a RO-CO25 0- (C1 to C8 alkyl) -, R O-CO- (r “) N-, a RO-CO- R ٥) N- (alkyl in
Cl to Cg) -, a (Rj٥) 2N-CO-O- (C1 to Cg alkyl), a R٥N-CO- R٥) N (C1 to Cg alkyl) -, Ri٥-S٠2- R٥) N-, one R٠ ؛ -S٠2- (r1٠) N- (C1 to C8 alkyl) -, one (R ^ ٥) 2N-SO2- (R ^ ٥) N- (C1 to C8 alkyl) -, R٥) 2N- SO2-, a
R "NSO 2 (C1-C8 alkyl) - and (C1-C8 alkyl) -SO2-, whereby any of the above-mentioned C3-C1 cycloalkyl, C3-C1 heterocycloalkyl, aryl, heteroaryl groups can be optionally substituted with HO-, NC-, Ο2Ν-, F3C-, HF<sub>2</sub>C-, FHC-, F3C-CH2-, F3C-0-, HF2C-0-, HO- (C1 to
<td></td><td>Cg)</td><td>-, R٥-O- (C1 to</td><td>- (6 ح</td><td>S- (alkyl-٥ ؛ un R, '</td><td>in</td><td>Cl to Cg),</td>
<td> 35</td><td>a</td><td>C1 to C8 alkyl, (r1٥) 2Ν-,</td><td>a</td><td>R ٠) 2 لال- (alkyl en</td><td>Cl to</td><td>Cg) -, r! ٠-</td>
<td></td><td> 0-</td><td>, Ri٥-S-, r! ٥-co-, RO-CO-,</td><td>(Ri٥)</td><td>2N٠ ؛ 2N-CO-, un (r1٥</td><td>-CO-</td><td>(alkyl in</td>
<td></td><td>Cl</td><td>to Cg) -, rJ٠-CO- (r “) N-, un r! ٥</td><td>-CO-</td><td>- (R ^ ٥) N- (alkyl in</td><td>ة ت ٢</td><td>Cg) -, R<sup>10</sup>-</td>
<td></td><td>م ٢</td><td>-0-, R ^ ٥O-CO-O-, a RO-CO-O-</td><td colspan="2">(C1 to C8 alkyl) -,</td><td>r! ٥o-</td><td>-CO- (س) N-</td>
<img file="MA32201B1_D0017.tif" />
32201Bl
POl-2363-ff un Ri ؛ o-C٥- (R٤٥) N- (C1 to Cg alkyl) -, (RJzN-CO-O-, R٥N-C0R٥) N-, (R ^ N-SOz- R٥) N-, a (R) 2N-CO-O- (C1-C6 alkyl) -, a (Ri٥) 2N-CO- (RÎ٠) N- (C1-C6 alkyl) -, R “-SOz- R٥ ) N-, R ^ ٠-SOz (Rl) N- (C1-C6 alkyl) -, R٠NSO2- R٥) N- (C1-C6 alkyl)
Ce) -, R٠) 2N-SO<sub>2</sub>-, (R2 (٠ ؛ N-SO2- (C1 to C6 alkyl) - or (C to C8 alkyl) -S02-٠
Ri-2:
R<sup>2</sup> is chosen from the group comprising:
C1 to C8 alkyl, C3 to C7 cycloalkyl, (C3 to C4 cycloalkyl) - (C1 to C3 alkyl) -, C to C1 heterocycloalkyl, aryl and heteroaryl, the elements mentioned above may be optionally substituted independently of each other with one or more substituents selected from the group consisting of fluorine, chlorine, bromine, HO-, NC-, Ο2Ν-, FC-, HF2C-, FHC-,
F3C-CH2-, F3C-0-, HF2C-0-, HO- (C1 to C8 alkyl) -, r! ٥-O (C1 to C8 alkyl) -, C1 to C8 alkyl, C3 to C8 cycloalkyl, (C3 to Ccycloalkyl) - (C1 to C8 alkyl) -, aryl, aryl- (C1 to C8 alkyl) -, heteroaryl, heteroaryl- (C1 to C8 alkyl) C1 to Cg) -, a C3 to C7 heterocycloalkyl, a (C3 to C7 heterocycloalkyl) - (C1 to C8 alkyl) -, a tetrahydrofuranyl-O-, a tetrahydro-pyranyl-O-, a piperidinyl-O- where piperidinyl is linked to O through one of its ring c atoms, a pyrrolidinyl-O- where pyrrolidinyl is linked to O through one of its ring c atoms cycle, (r1٠)<sub>2</sub>N-, un (r1٥)<sub>2</sub>N (C1-C8 alkyl) -, r! ٠-O-, (r1 °)<sub>2</sub>N-C0-, un (RJ 2N-CO- (alkyl en
Cl to Cg) -, R٠ ؛ -CO- (R٠ ؛) N-, un r} ٥-CO- R ٠) N- (C1 to Cg alkyl) -, ROCO-O- and RO-CO- (r1٥ )NOT- ;
whereby any of the C3-C7 cycloalkyl, C3-C7 heterocycloalkyl, aryl, heteroaryl, tetrahydrofuranyl, tetrahydro-pyranyl, piperidinyl, pyrrolidinyl groups mentioned above may be optionally substituted with NC-, Ο2Ν-, F3C- , HF ؛ C_, FHC-, F3C-CH2-, F3C-0-,
HF2C-0-, un R) ٥-O- (C1 to c alkyl<sub>6</sub>) -, C1 to C8 alkyl, R٠ ؛ -O-,
R -CO-, R ^ ٥O-CO- or (r1٥)<sub>2</sub>N-CO-, whereby piperidinyl or pyrrolidinyl is preferably substituted with R) ٥-CO-.
R لا:
r 'is chosen from the group comprising:
ΜΑ 32201Β1 أ POl-2363-ff phenyl, 2-, 3- and 4-pyridyl, pyrimidinyl, pyrazolyl, thiazolyl, cyclo-propyl, cyclobutyl, cyclopentyl, cyclo-hexyl, cycloheptyl, cyclopentylmethyl, ethyl, propyl, 1- and 2-butyl, 1-,
2- and 3-penty! E, tetrahydrofuranyl and tetrahydro-pyranyl, which groups may be optionally substituted with one or more substituents selected from the group consisting of HO-, NC-, a (C1 to C alkyl, - o-, C1 to C alkyl, (C3 to C cycloalkyl) - o-, (C3 to C7 cycloalkyl) - (C1 to C7) alkyl
C1 to ¢ 3) -0-, CF3O-, CF3-, fluorine, chlorine, bromine, C3 to C heterocycloalkyl, and (C3 to C7 heterocycloalkyl) (C1 to C alkyl) -.
Ri<sup>4</sup> :
R) is chosen from the group comprising:
phenyl, 2-, 3- and 4-pyridyl, cyclo-propyl, cyclobutyl, cyclopentyl, cyclo-hexyl, cycloheptyl, cyclopentylmethyl, ethyl, propyl, 1- and 2-butyl , 1-, 2- and 3-penty! e, tetrahydrofuranyl and tetrahydro-pyranyl, which groups may be optionally substituted with one or more substituents selected from the group consisting of NC-, (C1-C8 alkyl) -O-, C1 to C8 alkyl, CF3O-, CF3- and halogen, (the halogen being preferably chosen from the group comprising fluorine, chlorine and bromine).
The optional substituent R<sup>2</sup> is defined by the definitions
R<sup>2</sup>٠٥'k following, respectively R<sup>2</sup>'k, the sign k describing the order of preference which is increasing from r2-0٠i towards the more preferred definitions (like R<sup>2</sup>’<sup>2</sup>) And so on.
r2.0.1 ؛
R<sup>2</sup> independently of any other R<sup>2</sup> is chosen from the group comprising:
H-, fluorine, NC-, F3C-, HFzC-, FH<sub>2</sub>C-, F3C-CH2-, carboxy-, C1-C8 alkyl, c-alkenyl<sub>2</sub> to Cg, a c-alkynyl<sub>2</sub> to c<sub>6</sub>, a (C1 to C8 alkyl) -S-, a (C1 to C8 alkyl) -s- (C1 to C3 alkyl) -, preferably a (C1 to C8 alkyl) -s- (Cz alkyl) to c-, C3-C7 cycloalkyl, (C3-C7 cycloalkyl) - (C1-C8 alkyl) -, (C3-c cycloalkyl) - (C-alkenyl<sub>2</sub> to Cg) -, a (C 3 to C 7 cycloalkyl) - (C alkynyl)<sub>2</sub> to Cg) -, a C3 to C7 heterocycloalkyl, a (C3 to C heterocycloalkyl,) -
<img file="MA32201B1_D0018.tif" />
<img file="MA32201B1_D0019.tif" />
32291Bl
POl-2363-ff إ (C1 to C؛ alkyl) -, un (C3 to c heterocycloalkyl) - (ا c alkenyl<sub>2</sub> to Cg) -, a (C 3 to C 6 heterocycloalkyl) - (C 2 to C 6 alkynyl) -, ٢ an aryl, an aryl- (C 1 to C 8 alkyl) -, an aryl- (C alkenyl<sub>2</sub> at
Cg) -, aryl- (C to C alkynyl) -, heteroaryl, heteroaryl- (C 1 to C 8 alkyl) -, heteroaryl- (C alkenyl)<sub>2</sub> to ٢
Cg) -, heteroaryl- (C-alkynyl<sub>2</sub> to Cg) -, R -0- (C-alkyl<sub>2</sub> at
C3) -, (R) zN-, ROCO-, (r1)<sub>2</sub>N-C0-, r! ٥-CO- (R) n-, r<sup>3</sup>٥-co-, R٥)<sub>2</sub>NOT- ;
CO- R٥) N-, R٠-O-C٥- (r “) N-, R<sup>3</sup>٥-SO<sub>2</sub>- (r1٥) N-, un (C1 to C8 alkyl) so<sub>2</sub>- and an oxo, إ the elements mentioned above possibly being optionally substituted with one or more substituents chosen independently of each other from the group consisting of ٠ by:
fluorine, chlorine, bromine, NC-, ON, F3C-, HFC, FH<sub>2</sub>VS_,
F3C-CH2-, HO- (C1 to C8 alkyl) -, (C1 to C8 alkyl) -O-, (C1 to C8 alkyl) -o- (C1 to C8 alkyl) -, C] to C8 alkyl,
R٥)<sub>2</sub>N-, one R٥) N- (C1-C3 alkyl) - and R٥)<sub>2</sub>N-CO-, and in the case where r2 is linked to a nitrogen which is a ring element of Hc, this r2 must be independent of any other R<sup>2</sup> :
H-, F3C-CH2-, HF<sub>2</sub>C-CH<sub>2</sub>-, C 1 to C 8 alkyl, C alkenyl<sub>2</sub> at
Cg, a c-alkynyl<sub>2</sub> to C8, (C1 to C8 alkyl) -S- (C1 to C3 alkyl) -, C3 to C1 cycloalkyl, (C3 to C1 cycloalkyl) (C1 to C8 alkyl) -, (cycloalkyl C3 to Cl) - (C alkenyl<sub>2</sub> to Cg) -, a (C 3 to C 1 cycloalkyl) - (C 6 alkynyl)<sub>2</sub> to Cg) -, C3 to C1 heterocycloalkyl, (C3 to C1 heterocycloalkyl) (C1 to C8 alkyl) -, (C3 to C1 heterocycloalkyl) - (C<sub>2</sub> to Cg) -, a (C 3 -C 1 heterocycloalkyl) - (C-alkynyl)<sub>2</sub> to Cg) -, an aryl, an aryl- (C1 to C8 alkyl) -, a heteroaryl, a heteroaryl- (C1 to C8 alkyl) -, an R1 -0- (C1 to C3 alkyl) -, ؛
R o co-, R٥)<sub>2</sub>N-C0-, r1٥-CO-, rJ٠-SO<sub>2</sub>- or a (C1 to C8 alkyl) -so<sub>2</sub>-, إ the elements mentioned above possibly being optionally substituted with one or more substituents ؛ chosen independently of each other from the group consisting إ by: ؛ fluorine, HO-, NC-, ON, F3C-, HF<sub>2</sub>C_, FHC-, F3C-CH-, an HO (C1 to C8 alkyl) -, an R<sup>3</sup>٥-O- (C1 to C8 alkyl) -, C1 to C8 alkyl, R٥)<sub>2</sub>N-, a (R<sup>3</sup>٥) 2N- (C1-C3 alkyl) - and (R<sup>3</sup>٥) 2N-CO-.
R<sup>2</sup>'
<img file="MA32201B1_D0020.tif" />
<img file="MA32201B1_D0021.tif" />
32201Β1
POl-2363-ff
R<sup>z</sup> independently of any other R<sup>z</sup> is chosen from the group comprising:
H-, fluorine, NC-, F3C-, HC-, FHC-, F3C-CH2-, carboxy-, C1 to C alkyl (preferably C2 to C6 alkyl), C2 to C6 alkenyl vs<sub>6</sub>, a C2 to C6 alkynyl, a (C1 to C8 alkyl) S-, a (C1 to د 6 alkyl ح- s- (C1 to C3 alkyl) -, a C3 to C1 cycloalkyl, a (C3 cycloalkyl) to c؟) - (C1 to Ce alkyl) -, a
<td>(C3 cycloalkyl</td><td>to Cl)</td><td> -(</td><td>alkenyl</td><td>in C2 to Ce)</td><td>-, a (</td><td colspan="2">cycloalkyl</td><td>in</td>
<td>C3 to Cl) - (alkynyl</td><td>in Cz</td><td>at</td><td>This) -, a</td><td>heterocycl</td><td>oalkyl</td><td>in</td><td>C3 to Cl,</td><td>a</td>
<td>(heterocycloalkyl</td><td>in</td><td>vs<sub>3</sub></td><td>to Cl)</td><td>- (alkyl</td><td>in C</td><td>at</td><td>This)-,</td><td>a</td>
<td>(heterocycloalkyl</td><td>in</td><td>C3</td><td>to Cl) -</td><td>- (alkenyl</td><td>in 2 ح ٢</td><td>at</td><td>This)-,</td><td>a</td>
<td>(heterocycloalkyl</td><td>in C3</td><td>at</td><td colspan="2">Cl) - (Cz alkynyl</td><td>to This) -</td><td>, a</td><td>L aryle.</td><td>a</td>
aryl- (C1 to C6 alkyl) -, heteroaryl, heteroaryl- (C1 to C6 alkyl) -, R) ٥-O- (C alkyl<sub>2</sub> to C3) -, R٥) zN-, R٠o-co-, (r! ٠) 2N-CO-, r1٠-CO_ R٥) N-, R١٥-CO-, R٥N-CO- R٥) N-, rI-SOz (r1٥) N- and (C1-C6 alkyl) -SC> 2-, the above-mentioned elements being optionally substituted independently of each other with one or more substituents selected from the group consisting of:
fluorine, chlorine, bromine, NC-, OsN-, F3C-, HC-, FHC-,
F3C-CH2 ', HO- (C1 to C؛ alkyl) -, (C1 to C؛ alkyl) - o (C1 to C6 alkyl) -, C1 to C6 alkyl, (RJ2N-, R٠N (C1 to C3 alkyl) - and R ؛ (٥N-CO-, and in the case where r2 is bonded to nitrogen which is a إ ring element of Hc, this R<sup>z</sup> must be independent of any other r2: H-, F3C- إ
CH-, HF2C-CH2-, C1-C6 alkyl, C-alkenyl<sub>2</sub> to Ce, C 1 -C 6 alkynyl, (C 1 -C 6 alkyl) -s- (C 1 -C 3 alkyl) -, إ C 3 -C 1 cycloalkyl, (C 3 -C 1 cycloalkyl) - (C 1 -C alkyl)
Cl to Ce) -, a (C3 to Cl cycloalkyl) - (C2 to Ce alkenyl) -, a ؛ (C 3 -C cycloalkyl) - (C-alkynyl)<sub>2</sub> to Ce) -, إ C3-C1 heterocycloalkyl, (C3-C1 heterocycloalkyl) - إ (C1-C6 alkyl) -, (C3-C1 heterocycloalkyl) - (alkenyl in:
C2 to C6) -, (C 3 to C heterocycloalkyl) - (C 2 to C 6 alkynyl) -, aryl, aryl- (C 1 to C 6 alkyl) -, heteroaryl, heteroaryl- (C 1 to C 6 alkyl) Ce) -, a R'٠-O- (C1 to C3 alkyl) -,
R٠ ؛ o-co-, R٥) zN ~ CO-, R٠ ؛ -CO-, r! ٥-SO2- or a (C1 to CJ-alkyl-SO ؛ -,
<img file="MA32201B1_D0022.tif" />
ΜΑ 32201Β1 d 21 POl-2363-ff ه أ ؛ the above mentioned elements possibly being إ optionally substituted independently of each other with إ one or more substituents selected from the group consisting of ؛ fluorine, HO-, NC-, Ο2Ν-, F3C-, HFC, FHC-, F3C-CH2-, HO- إ (C1 to C6 alkyl) -, rI -0- (C1 to C alk alkyl ) -, C1 to C6 alkyl, RO-, (R N-, (RJN C1 to C3alkyl) - and (R) 2N-C0-. إ r2٠2: إ
R<sup>2</sup> independently of any other R<sup>2</sup> is chosen from the group comprising: ؛
H-, fluorine, F3C-, HFgC-, FHzC-, F3C-CH9-, C1 to alkyl
Ce (preferably C2 to C alkyl, (Ri٥) zN-CO- and R<sup>2</sup>° -CO- ؛
R٥) N-, ٢ the above mentioned elements possibly being ، optionally substituted with one or more substituents;
chosen from the group consisting of fluorine, chlorine and bromine,
NC-, Ο2Ν-, F3C-, HFzC-, FHC-, F3C-CH-, HO- (C1-C6 alkyl) -, (C1-C6 alkyl) -O- (C1-C6 alkyl) ) -, C1 to C C alkyl, (r1 °)<sub>2</sub>N-, a (Ri ؛ (٥N- (C1 to C3 alkyl) - and (rIr-CO-, and in the case where R<sup>2</sup> is linked to a nitrogen which is a cycle element of Hc, this R<sup>2</sup> must be independent of any other R<sup>2</sup> :
H-, F3C-CH2-, HF2C-CH2-, C1-C6 alkyl, C3-Cl cycloalkyl, (C3-Cl cycloalkyl) - (C1-C6 alkyl) -, C3-heterocycloalkyl to Cl, a (C3 to Cl heterocycloalkyl) (C1 to 0 ة alkyl) -, an aryl, an aryl- (C1 to C6 alkyl) -, a heteroaryl, a heteroaryl- (C1 to C6 alkyl) -, a R٠ ؛ -O- (C1 to Cj alkyl) -, RO CO-, R٠N-CO-, r! ٥-CO_ or a (C] alkyl to CsSOz-, the above mentioned elements being optionally substituted independently of each other with one or more substituents selected from the group consisting of fluorine, HO-, NC-, OzN-, F3C-, HFzC-, FHC-, F3C-CH2 -, HO (C1 to Ce alkyl) -, r1٥-O- (C1 to Ce alkyl) -, C1 to Ce alkyl, Ri٥-O-, (r! ٠)<sub>2</sub>N-, R ٥N- (C1-C3 alkyl) - and (Ri) zN-CO-.
R<sup>2</sup> ق:
R<sup>2</sup> independently of any other R<sup>2</sup> is chosen from the group comprising:
MY
32201Bl
POl-2363-ff
H-, fluorine, F3C-, HF ؛ C٠, FHC-, F3C-CH2-, C1 to إ alkyl
Ce (preferably C2-C6 alkyl), (R N-CO- and R -CO- ؛ (Ri٥) N-, ٢ the above-mentioned elements possibly being ؛ optionally substituted independently of each other with a or more substituents selected from the group consisting of fluorine, chlorine, bromine and C1 to C8 alkyl, and in the case where R<sup>2</sup> is linked to a nitrogen which is a cycle element of Hc, this R<sup>2</sup> must be independent of any other R<sup>2</sup> :
H-, F3C-CH2-, HF<sub>2</sub>C-CH<sub>2</sub>-, C1 to C8 alkyl, C3 to C1 cycloalkyl, (C3 to C1 cycloalkyl) - (C1 to C8 alkyl) -, C3 to C1 heterocycloalkyl, (C3 to C1 heterocycloalkyl) ( C1 to C alkyl) -, aryl, aryl- (C1 to C8 alkyl) -, ؛ heteroaryl, heteroaryl- (C1 to C؛ alkyl) -, r} ٥-O- (C1 to C3 alkyl) -, RO-CO-, (r1٥) 2N-CO-, r! ٥-CO- or a (C1 to ؛ alkyl
Cg) -SO2-, which substituents may be optionally substituted, independently of each other, with one or more substituents selected from the group consisting of fluorine and ؛ C1 to C8 alkyl. إ
R<sup>2</sup>.، : ؛
R<sup>2</sup> independently of any other R<sup>2</sup> is chosen from the group خ comprising:
H- and C1 to C8 alkyl (preferably C2 to ؛ alkyl
Cg), and in the case where R<sup>2</sup> is bound to a nitrogen which is a cycle element of Hc, then R<sup>2</sup> must be independent of any other l
R<sup>2</sup> : H-, C1 to C8 alkyl, RO-CO-, (R ^ N-CO-, R١٥-CO-, phenylco- and phenyl-0-CO-, the above-mentioned elements may optionally be substituted, independently of each other, with one or more substituents selected from the group consisting of fluorine and C1 to C8 alkyl.
R<sup>2</sup> :
R<sup>2</sup> independently of any other R<sup>2</sup> is chosen from the group ؛ comprising H- and C1 to C8 alkyl, and in the case where R<sup>2</sup> is linked to a nitrogen which is an element ؛ cycle of Hc, this R<sup>2</sup> must be independent of any other R<sup>2</sup> : إ
<img file="MA32201B1_D0023.tif" />
MA 32201 Bl
POl-2363-ff
H-, (C1 to C6 alkyl) -CO-, (C1 to C6 alkyl) -O-CO-, C1 to C8 alkyl, phenyl-00-, phenyl-0-CO-, a (C1 to C8 alkyl)<sub>2</sub>N-CO 2, the above mentioned elements being optionally substituted, independently of each other, with one or more fluorine substituents.
The optional substituent R<sup>3</sup> is defined by the definitions R<sup>3</sup>'ئ following, the sign 1 describing!' Order of preference, which increases (from R<sup>3</sup>ل) to signify increased preference (i.e. R<sup>3</sup>'<sup>2</sup>) And so on.
R<sup>3</sup>-<sup>3</sup> :
R<sup>3</sup> is selected from the group consisting of H-, hydroxy and r1٥-o.
r<sup>3</sup>'<sup>2</sup> :
R<sup>3</sup> is selected from the group consisting of H-, hydroxyl and (C1-C8 alkyl) -O-, whereby the (C1-C8 alkyl) -O- group may be optionally substituted with one or more fluorines, chlorines, bromines and HO-.
r3.3:
R<sup>3</sup> is H.
R substituents<sup>4</sup> and R<sup>s</sup> are defined by the definitions R<sup>4</sup>''<sup>3</sup>'' following, the sign m describing the order of preference, which increases (from R ،<sup>5</sup>/ ؛ '!) To mean!' Increased preference (i.e. R<sup>4</sup>/<sup>2</sup>';) And so on.
ل-ةس -.
R<sup>4</sup> and R<sup>5</sup> are independently selected from one another from the group consisting of H-, fluorine, FiC-, HFC, FHC- and alkyl in.
) زتك ٢ ة جء
R<sup>4</sup> and R<sup>5</sup> together with the carbon atom to which they are attached form a 3- to 6-membered cycloalkyl group, the above-mentioned elements, including the carbocyclic ring formed, may be optionally and independently substituted with one or more substituents chosen in the group constituted by:
fluorine, HO-, NC-, O<sub>2</sub>N-, F<sub>3</sub>C-, HF<sub>2</sub>C_, FHC-, F<sub>3</sub>C-CH<sub>2</sub>-, HO (C1 to C8 alkyl) -, CHO- (C1 to C8 alkyl) -, C1 to C8 alkyl, (C1 to C8 alkyl) -O- and (C1 to C8 alkyl) Cg)<sub>2</sub>N-CO_.
<img file="MA32201B1_D0024.tif" />
<img file="MA32201B1_D0025.tif" />
32201BI
POl-2363-ff r4 / 5.2 ٠ r 'and R<sup>5</sup> are independently selected from the group consisting of H-, fluorine and methyl.
r4 / 5.3 d
R tR are H-.
The substituent rI is defined by the following definitions r1٥ ', respectively r “', the sign n describing the order of preference. Preference increases from 1<sup>ط</sup>ام to r1٥'٥ '<sup>۶ </sup>more preferred, and so on until
Rio٠٠٠i:
r! ٥ independently of any other R) ٠ is chosen from the group comprising:
H- (but not in the case where it is part of a group selected from R 0-0-, r1٥-SO2- or r1٥-CO-), F3C-CH2-, alkyl in
Cl to c<sub>6</sub>, C 2 to C alkenyl, C 3 to C cycloalkyl, (C 3 to C cycloalkyl) - (C 1 to C 1 alkyl) -, C heterocycloalkyl<sub>3</sub> to Cl, a (C3 to C1 heterocycloalkyl) - (C1 to C؛ alkyl) -, an aryl, an aryl- (C1 to C3 alkyl) -, a heteroaryl and a heteroaryl- (C1 to C3 alkyl) -, and in the case where two groups r! ٥ are both linked to the same nitrogen atom, they can together with said nitrogen atom form a 3 to 7 membered heterocycloalkyl ring, and in which one of the groups - CH- of the heterocycloalkyl ring formed can be replaced by -O-, -s-, -NH-, a -N (C3 to cycloalkyl
C ؛) -, a -N ((C 3 -C cycloalkyl- (C 1 -C alkyl) - or an N (C 1 -C ، alkyl) -, preferably, and particularly preferably in the case of ( r1٥) 2N-CO-, these two R'٥ together with said nitrogen atom are linked to form a group selected from the group consisting of piperidinyl, piperazinyl, pyrrolidinyl, morpholinyl and thiomorpholinyl, and the elements mentioned above may be optionally substituted with one or more substituents selected independently of each other from the group constitutes
<td>by :</td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>fluorine, chlorine,</td><td>bromine, HO-</td><td>, NC-,</td><td>Ο2Ν-, FaC-,</td><td>HFzC-,</td>
<td>FHC-,</td><td>F3C-CH2-, HO- (alkyl</td><td>in Cl to Cg)</td><td>-, a</td><td>CH3-0- (alkyl</td><td>in Cl</td>
<td>- (؟ to C</td><td>, C1 to C8 alkyl and</td><td>an (alkyl</td><td>in Cl</td><td>to 06) -0-.</td><td></td>
<img file="MA32201B1_D0026.tif" />
MY
32201Β1
POl-2363-ff
ت 10.0.2 ^
R independently of any other r! ٥ is selected from the group comprising H- (but not in the case where it is part of a group selected from RO-CO-, r} ٥-SO2- or r “-CO-1 , C1 to C alkyl<sub>6</sub>, C3 to C1 cycloalkyl, (C3 to C3 cycloalkyl) (C1 to C3 alkyl) -, aryl and heteroaryl, and in the case where two R groups are both bonded to the same atom of nitrogen, they can form together with said nitrogen atom a 3 to 7 membered heterocycloalkyl ring, and in which one of the -CH - groups of the heterocycloalkyl ring formed can be replaced by -O-, -NH-, a -N ( C3 to Cg cycloalkyl) -, a -Ncycloalkyl (C 3 to C ؛) - (C 1 to C 4 alkyl)) - or a -N (C 1 to C alkyl -, and preferably, and in particular preferably in the case of (R) 2Ν-0 -, these two R together with said nitrogen atom are linked to form a group chosen from the group comprising piperidinyl, piperazinyl, pyrrolidinyl, morpholinyl and thiomorpholinyl, and the elements mentioned above may be optionally substituted with one or more substituents selected independently of each other from the group consisting of:
<td></td><td>fluorine, NC-, F3C-</td><td>, HFzC-,</td><td>FHC-,</td><td>F3C-CH2-,</td><td>a CH3-0- (alkyl</td>
<td> 25</td><td>C1 to C ؛) -, alkyl</td><td>Cl to Cg</td><td>and one (</td><td>alkyl in</td><td>Cl to Cg) -O_.</td>
<td></td><td>r10.0.3.</td><td></td><td></td><td></td><td></td>
<td></td><td>r! ٥ independently</td><td>of all</td><td>other</td><td>r! ٠ is</td><td>chosen in the</td>
<td></td><td>group including:</td><td></td><td></td><td></td><td></td>
<td></td><td>H- (but not in</td><td>the case</td><td>where he</td><td colspan="2">is part of a group</td>
<td> 30</td><td>chosen from RO-CO-, r! ٥-</td><td>so<sub>2</sub>- or</td><td>r10-co-)</td><td colspan="2">, C1 to C8 alkyl,</td>
C3 to C4 cycloalkyl, aryl and heteroaryl, preferably aryl is phenyl and further, heteroaryl is preferably selected from the group consisting of oxadiazolyl, oxazolyl, isoxazolyl, triazolyl, thiazolyl, pyrrolyl, furanyl, pyrazolyl, pyridyl, pyridazinyl and pyrimidinyl;
the elements mentioned above being optionally substituted with one or more substituents
MY
32201Β1
POl-2363-ff إ chosen independently of each other from the group constituted by:
fluorine, F<sub>3</sub>C-, HF2C-, FHzC-, F3C-CH2-, CH3-0- (C1 to C8 alkyl) -, C1 to C6 alkyl and (C1 to COalkyl).
r1O٠O.4 ٠
R) ٥ independently of any other r! ٥ is selected from the group consisting of C1 to C alkyl<sub>6</sub>, phenyl and pyridyl, and in the case where r1٥ is a substituent of a nitrogen atom, rO is selected from the group consisting of H, C1 to C4 alkyl<sub>6</sub>, a ; phenyl and pyridyl;
the above-mentioned elements possibly being optionally substituted with one or more substituents ٢ selected independently of each other from the group consisting of ؛ by: أ fluorine, F3C-, HC-, FHC-, F3C-CH2-, a CH3-0- (C 1 to C 8 alkyl) -, a C 1 to C 8 alkyl and a (C 1 to C 8 alkyl) -O_.
rIO.O.5 ؛ r! ٥ independently of any other r1٥ is selected from the group consisting of methyl, ethyl and tert-butyl, and in the case where r “is a substituent of a nitrogen atom, R is selected from the group comprising H, methyl, ethyl and tert-butyl;
it being possible for the above mentioned elements to be إ optionally substituted independently of each other with flu one or more fluorines. ؛ rIO.1.
R١٥ independently of any other R١٥ is selected from the group consisting of H- (but not in the case where it is part of a group selected from R) ٠o-co-, rI-SOz- or r} ٥-CO_), F3C -CH2-, C] -C 8 alkyl, C2-C8 alkenyl, C3-C7 cycloalkyl, (C3-C-cycloalkyl) - (C1-C3 alkyl) -, aryl, aryl- (C1 to C3 alkyl) -, a heteroaryl and a heteroaryl- (C] to C3 alkyl) -, and in the case where two R١٠ groups are both linked to the same nitrogen atom, they can form together with said nitrogen atom a 3 to 7 membered heterocycloalkyl ring, and in which one of the -CH- groups of the heterocycloalkyl ring formed can be replaced by -0-, -s-, -NH-, a - N (C3 to cycloalkyl
<img file="MA32201B1_D0027.tif" />
<img file="MA32201B1_D0028.tif" />
32201Β1
POl-2363-ff
Cg) -, a -NUcycloalkyl (C3 to C6) - (C1 to C alk alkyl)) - or an N (C calkyl) -, preferably, and in particular preferably in the case of ( R) ζΝ-CO-, these two groups r “together with said nitrogen atom are linked to form a group selected from piperidinyl, piperazinyl, pyrrolidinyl, morpholinyl and thiomorpholinyl, and the elements mentioned above may be optionally substituted independently of each other with one or more substituents selected from the group consisting of:
fluorine, chlorine, bromine, HO-, NC-, Ο2Ν-, F3C-, HF2C-,
FHC-, F3C-CH2-, HO- (C1 to C8 alkyl) -, CH3-0- (C1 to C- alkyl, C1 to C8 alkyl and (C1 to C؛ alkyl) - o-.
Rio.2:
r! ٥ independently of any other r! ٥ is selected from the group consisting of C1-C8 alkyl, C1-C12 cycloalkyl, aryl and heteroaryl, and in the case where two R١٥ groups are both linked to the same nitrogen atom, they can form together with said nitrogen atom a 3 to 7 membered heterocycloalkyl ring, and in which one of the -CH- groups of the heterocycloalkyl ring formed can be replaced by -O-, -NH-, a -N (C3 to c ؛ cycloalkyl) -, a -NUcycloalkyl (C3 to C6) - (C1 to C،alkyl)) - or a -N (C1 to C6alkyl -, preferably, and in particular preferably in the case of (r! ٥) 2N- CO-, these two Rs together with said nitrogen are linked to form a group chosen from piperidinyl, piperazinyl, pyrrolidinyl, morpholinyl and thiomorpholinyl, and the elements mentioned above may be optionally substituted independently of each other with one or more substituents selected from the group consisting of:
fluorine, NC-, F3C-, HF ؛ C_, FHC-, F3C-CH2-, CH3-0- (C1 to C8 alkyl) -, C1 to C8 alkyl and (C1 to C8 alkyl) -O-٠ r10-3 r1٥ independently of any other R is selected from the group consisting of C1-C8 alkyl, C3-C7 cycloalkyl, aryl and heteroaryl.
<img file="MA32201B1_D0029.tif" />
MY
32201Β1
PO1-2363-ff the elements mentioned above being optionally substituted independently of each other with?
one or more substituents selected from the group consisting of: إ fluorine, FjC-, HC-, FHC-, FCCH-, CH3-0- (C1 to C alkyl) -, C1 to C8 alkyl and a (C1 to C8 alkyl) -O-.
Rio .4: إ
Ri٥ independently of any other r! ٥ is selected from the group consisting of C1-C8 alkyl, phenyl and pyridyl, the above-mentioned elements possibly being optionally substituted independently of each other with one or more substituents selected from the group formed by: ؛ fluorine, F3C-, HFzC-, FHC-, F3C-CH2-, CH3-0- (C1 to C8 alkyl) -, C1 to C8 alkyl and (C1 to C8 alkyl) -O_.
X = 0, 1, 2, 3 or 4, preferably x = 0, 1 or 2, and more preferably X = 0, 1, or better still X = 0; if it is not specified otherwise in the context;
y = 0 or 1, preferably y = 0, if not specified otherwise in the context;
provided that for each applicable embodiment of formula I of the invention - such as, for example, embodiments comprising Hc and Hc if Hc is an oxetanyl which is bonded through the carbon atom located thereto. side of the oxygenated oxetanyl, there is no substituent linked to said carbon atom by
1'intermediate a spacer -CH ؛ -.
The values of x and y are independent of each other.
The symbols i, j, k, 1, m, n in R ؛ 'j, R<sup>2</sup>'k etc. are subscripts, each representing a whole number: 1, 2, 3, etc. so that each Rid, R<sup>z</sup>'k etc. represents an individual embodiment and characterizes corresponding substituents for which rIJ, R<sup>2</sup>'k etc. are the definitions.
Therefore, given the definitions given above, a generic genus of compounds of formula I is fully characterized by the term (Hc ± R ؛ '؛ R<sup>2</sup>'k R<sup>2</sup>-ن R4 / 5.m Rio.) If an individual number is given for each letter i, j, k, 1, m and n, whereby - if not otherwise indicated in a specific context - for each of these embodiments (Hc ؛
<img file="MA32201B1_D0030.tif" />
!MY
32201Bl
POl-2363-ff
Rj <sub>R</sub>2.k r3.i <sub>R</sub>4 / 5٠m Rio.), X must be equal to 0, 1, 2, 3 or 4, preferably X = 0, 1 or 2 and y must be equal to 0 or 1, and on the condition that for each mode of Applicable embodiment of formula I of the invention, if Hc is an oxetanyl which is bonded through the carbon atom located next to the oxygenate of the oxetanyl, there is no substituent bonded to said carbon atom through a -CH ؛ - spacer.
In other words, each embodiment (Hc ؛ R د '؛ R<sup>2</sup>'k r3.i RII / sm r1٥-) represents a genus or fully characterized subset agent of general formula I, i.e. a generic genus of compounds which belong to the present invention
Such an embodiment defines the variables Hc, R ؛, R<sup>2</sup>, R<sup>3</sup>, r4, r<sup>5</sup> and, where appropriate R٠ ؛, of formula I and - if not otherwise indicated in a specific context - X should be 0, 1, 2, 3 or 4, preferably 0, 1 or 2 , and y must be 0 or 1, and with the proviso that for each applicable embodiment of formula I of the invention, if Hc is an oxetanyl which is linked through the carbon atom present next to the oxygenated oxetanyl, there is no substituent linked to said carbon atom through a -CH- spacer.
In a first general aspect! of the present invention, the compound or compounds of the present invention is (are) defined by the following embodiment according to general formula I characterized by:
H٠1r-1٠CUr2٠O٠1r3.1r4 / 5.1r1O.O.1 with
X independently of tct y: X = 0, 1, 2, 3 or 4 'preferably X = 0, 1 or 2' y independently of any X: y = 0 or 1, and their pharmaceutically acceptable salts and / or their solvates and / or their tautomers etc. ; provided that if Hc is an oxetanyl which is bonded through the carbon atom lying next to the oxygenate of the oxetanyl, there is no substituent bonded to said carbon atom by
1'intermediate a spacer -CH ؛ -.
<img file="MA32201B1_D0031.tif" />
MA 32201 Bl
إ
POl-2363-ff
From what has been mentioned above, this means that the first aspect of the present invention relates to compounds of general formula I
<img file="MA32201B1_D0032.tif" />
32201Β1
<img file="MA32201B1_D0033.tif" />
<td>Hc</td><td>is</td><td>Phone</td><td>than</td><td>defined</td><td>by Hc<sup>3</sup> ;</td>
<td></td><td>is</td><td>Phone</td><td>than</td><td>defined</td><td>by Riii;</td>
<td>r2</td><td>is</td><td>Phone</td><td>than</td><td>defined</td><td>by r2'٥٠i;</td>
<td>R<sup>3</sup></td><td>is</td><td>Phone</td><td>than</td><td>defined</td><td>by R<sup>3</sup>'! ;</td>
<td>R</td><td>and R</td><td colspan="3">ام are such that</td><td>defined by</td>
<td>Rio</td><td>is</td><td>Phone</td><td>than</td><td>defined</td><td>; '· ٥. by R</td>
<td> 10</td><td>x independently</td><td>of</td><td>everything there</td><td>: X is equal to 0, 1, 2, 3 or 4,</td>
<td></td><td>preferably χ = 0, 1</td><td>or</td><td> 2 ;</td><td></td>
<td></td><td>y independently</td><td>of</td><td>all X:</td><td>y = 0 or 1;</td>
and their pharmaceutically acceptable salts and / or their solvates and / or their tautomers, etc. ;
provided that if Hc is an oxetanyl which is linked through the carbon atom lying adjacent to the oxetanyl oxygen, there is no substituent linked to said carbon atom through the intermediary. a -CH- spacer.
Therefore, this first aspect of the invention is defined as a compound of general formula I
<img file="MA32201B1_D0034.tif" />
/
<img file="MA32201B1_D0035.tif" />
32201Β1
POl-2363-ff
Hc is a mono-, bi- or tri-cyclic heterocyclyl group, the ring elements of which are carbon atoms and at least 1 heteroatom, preferably 1, 2 or 3 heteroatoms selected from the group comprising nitrogen atoms, d 'oxygen and sulfur, which is in the form -S (O) ٢-, where r is 0, 1 or 2, and
-said heterocyclyl group is or contains 1 non-aromatic, saturated or partially unsaturated monocyclic ring, containing at least 1 heteroatom as a ring element, and
said heterocyclyl group is linked to the main structure through said non-aromatic, saturated or partially unsaturated 1 monocyclic ring containing at least 1 heteroatom as a ring member;
R ؛ is chosen from the group comprising:
C1 to C8 alkyl, c alkenyl<sub>2</sub> to Cg, a 15c alkynyl<sub>2</sub> to C8, a (C1 to C8 alkyl) -S-, a (C1 to C8 alkyl) -s- (C1 to C8 alkyl) -, a C3 to C1 cycloalkyl, a (C3 to C1 cycloalkyl) (C1-C8 alkyl) -, a (C3-C1 cycloalkyl) - (C-alkenyl<sub>2</sub> to Cg) -, a (C 3 to C 1 cycloalkyl) - (C alkynyl)<sub>2</sub> to C 8) -, C3 to C1 heterocycloalkyl, (C3 to C1 heterocycloalkyl) 20 (C1 to C8 alkyl) -, (C3 to C1 heterocycloalkyl) - (C1 to C18 heterocycloalkyl)
<td>vs<sub>2</sub></td><td>to Cg) -,</td><td>a (heterocycloalkyl</td><td>in</td><td>C3</td><td colspan="2">to Cl) - (C-alkynyl<sub>2</sub> at</td><td>Cg)</td><td> -,</td>
<td>a</td><td>aryl.</td><td>aryl- (C-alkyl</td><td>1 to</td><td>Cg:</td><td>) -, an aryl-</td><td>(alkenyl in</td><td>C2</td><td>at</td>
<td>Cg)</td><td>-, a</td><td>aryl- (alkynyl en</td><td>vs<sub>2</sub></td><td>at</td><td>Cg) -, a</td><td>heteroaryl.</td><td></td><td>a</td>
<td colspan="2">heteroaryl</td><td>- (C1 to C8 alkyl).</td><td colspan="2">-f one</td><td>heteroaryl- ا</td><td>(alkenyl in</td><td>VS</td><td>at</td>
<td>Cg)</td><td>- and one</td><td>heteroaryl- (alkynyl</td><td>in</td><td>vs<sub>2</sub></td><td>to Cg) -,</td><td></td><td></td><td></td>
<td></td><td>the</td><td colspan="2">items mentioned</td><td></td><td>above</td><td>can</td><td colspan="2">to be</td>
optionally substituted with one or more substituents selected independently of each other from the group consisting of fluorine, chlorine, bromine, iodine, oxo, HO-, NC-, O<sub>2</sub>NOT-,
F3C-, HF<sub>2</sub>C_, FHC-, F3C-CH2-, F3C-0-, HF2C-0-, HO- (C1 to
Cg) -, r! ٥-O- (C1 to C6 alkyl> -, r! ٥-S- (C1 to C8 alkyl) -, C1 to C8 alkyl, C2 to C8 alkenyl, a c-alkynyl<sub>2</sub> to C 8, a C3 to c cycloalkyl ,, a (C3 to c cycloalkyl) - (C1 to C8 alkyl) -, a (C3 to c cycloalkyl) - o-, a (C3 to c cycloalkyl ,) 35 (C1 to C8 alkyl) -O-, aryl, aryl- (C1 to C8 alkyl) -, heteroaryl, heteroaryl- (C1 to C8 alkyl) -, heteroaryl-O-, heteroaryl- (C1-C8 alkyl) -O-, nitrogen-linked pyridin-2-one, nitrogen-linked pyridin-2-one- (C1-C8 alkyl).
<img file="MA32201B1_D0036.tif" />
MA 32201 BI
POl-2363-ff pyridin-2-one- (C1 to C alkyl) - o- linked by nitrogen, C to C 1 heterocycloalkyl, (C 3 to C heterocycloalkyl) (C 1 to C alkyl) Cg) -, a (C 3 -C heterocycloalkyl) - o- with C 3 -C 1 heterocycloalkyl linked to 0 through one of its ring c atoms, a (C 3 -C heterocycloalkyl) - (C1 to C alkyl) - o- with C3 to C1 heterocycloalkyl linked to C1 to C8 alkyl through one of its ring atoms, (r! ٠)<sub>2</sub>N-, un (RJ٠) zN- (C1-C8 alkyl) -, r! ٥-O-, r] ٥-S-, R٥ ؛ -CO-, r! ٥O-CO_, (R<sup>10</sup>)<sub>2</sub>N-CO-, one R ٥)<sub>2</sub>N-CO- (C1 to C8 alkyl) -, R٠ ؛ -CO10 (Ri٠) N-, one Ri -CO- (R) N- (C1 to C8 alkyl) -, R٥ ؛ -CQ-O-, ROCO-O-, RO-CO-O- (C1-C8 alkyl) -, R0-C0- R٥) N-, R٠O-CO- (R) ٠) N (C1-C8 alkyl) -, an R ٥)<sub>2</sub>N-CO-O- (C1-C8 alkyl), un (R٥ ؛) ζΝ-CO- (R ^ ٥) N- (C1-C8 alkyl) -, r! ٥-SO<sub>2</sub>-R٥) N-, a rW-S0<sub>2</sub>R ٥) N- (C1 to C8 alkyl) -, un (R ^ ٥) 2N-SO2- (R ^ ٥) N- (C] to alkyl
Cg) -, R٥) 2N-SO2-, a (R ^ N-SO ؛-( C1 to C8 alkyl) - and / or a (C1 to C8 alkyl) -so<sub>2</sub>-, whereby any of the C3-C1 cycloalkyl, C3-C1 heterocycloalkyl, aryl, heteroaryl, nitrogen-linked pyridin-2one and R N-CO- (C1-C8 alkyl) groups - mentioned above Above may be optionally substituted with one or more substituents independently selected from the group consisting of fluorine, chlorine, bromine, HO-, NC-, ON, F3C-, HFzC-, FHC-, F3C- CH2-, F3C-0-, HF2C-0-, a C3 to Cl heterocycloalkyl, a rI-Ο- (C1 to C8 alkyl) -, an R٥ ؛ -S- (C1 to
Cg) -, C1 to C8 alkyl, (rI N-, R٠) 2N- (C1 to Cg alkyl) -,
R٠ ؛ -O-, r “-S-, r! ٥-CO-, R 0-00-, (r1٥)<sub>2</sub>N-CO-, un (r ')<sub>2</sub>N-CO- (C1-C8 alkyl) -, r1٥-CO- R٥) N-, un r0-CO- (r} ٥) N- (C1-C8 alkyl) -, R٠ ؛ -CO-O- , R٠ ؛ o-c٥-o-, a Ri O-CO-O- (C1 to Cg alkyl) -, ROCOR٥) N-, a RO-CO- R٥) N- (C1 to Cg alkyl) -, a (R<sub>2</sub>(٥ ؛ N-CO-O-,
R٥) 2N-CO- R٠) N-, (r1٥) 2N-SO2- (R} ٥) N-, un (R ^ N-CO-O- (C1-C8 alkyl) -, un (r1٠)<sub>2</sub>N-CO- (R1٥) N- (C1-C8 alkyl) -, R ^ -SOz- R٠) N-, un r1-SO<sub>2</sub>- R ٠) N- (C1 to C8 alkyl) -, un R ٥) 2N-S٥2- (Ri٥) N- (C1 to C8 alkyl) -, (R<sub>2</sub>(٥ ؛ N-SO2-, un R ٥)<sub>2</sub>N-SO2- (C1 to C8 alkyl) - and / or (C1 to C8 alkyl) -SO2-;
R<sup>2</sup> independently of any other R<sup>2</sup> is chosen from the group comprising:
H-, fluorine, NC-, F3C-, HFzC-, FHC-, F3C-CH2-, carboxy, C 1 to C alkyl<sub>6</sub>, C2-C8 alkenyl, C-alkynyl<sub>2</sub> to c<sub>6</sub>, /
<img file="MA32201B1_D0037.tif" />
32201Β1
POl-2363-ff (C1 to C8 alkyl) -S-, (C1 to C8 alkyl) -s- (C1 to C8 alkyl)
C3) -, preferably a (C1 to C8 alkyl) -s- (C alkyl)<sub>2</sub> to C3) -, ؛ C3 to C1 cycloalkyl, (C3 to C1 cycloalkyl) - (C1 to C1)
C1 to C8) -, a (C3 to C1 cycloalkyl) - (C to C8 alkenyl) -, a 5 (C3 to C1 cycloalkyl) - (calkynyl<sub>2</sub> to Cg) -, a C3 to C1 heterocycloalkyl, a (C3 to C1 heterocycloalkyl) (C1 to C8 alkyl) -, a (C3 to C1 heterocycloalkyl) - (C to Cg alkenyl) -, a (heterocycloalkyl C3 to Cl) - (C alkynyl<sub>2</sub> to Cg) -, aryl, aryl- (C 1 -C 8 alkyl) -, aryl- (C alkenyl<sub>2</sub> at
Cg) -, an aryl- (C-alkynyl<sub>2</sub> to Cg) -, heteroaryl, heteroaryl- (C1 to C8 alkyl) -, heteroaryl- (C alkenyl)<sub>2</sub> to Cg) -, a heteroaryl- (C-alkynyl<sub>2</sub> to Cg) -, R -o- (C-alkyl<sub>2</sub> at إ c<sub>3</sub>) -, R٥)<sub>2</sub>N-, R<sup>4</sup>٥O-CO-, R٥) 2N-CO-, r1٥-CO- R٥) N-, R1-CO-, (R<sup>3</sup>٥) 2N- ؛ co- R٠) N-, r1٥-O-CO- (r1٥) N-, r1٥-SO<sub>2</sub>- R٥) N-, (C1-C8alkyl) 15-30., - and oxo, the above-mentioned elements possibly being optionally substituted with one or more substituents independently selected from the group consisting of ( by :
fluorine, chlorine, bromine, NC-, ON, F3C-, HF<sub>2</sub>C_, FH<sub>2</sub>C_, إ
F3C-CH-, HO- (C1 to C8 alkyl) -, (C1 to C8 alkyl) -O-, ن (C1 to C8 alkyl) -O- (C1 to C8 alkyl) -, a C1 to C8 alkyl, (r! ٠)<sub>2</sub>N-, a (R N- (C1 to C3 alkyl) - and (R<sup>4</sup>٥)<sub>2</sub>N-CO-, and in the case where R<sup>2</sup> is linked to a nitrogen which is a cycle element of Hc, this R<sup>2</sup> must be independent of any other R<sup>2</sup> :
H-, F3C-CH-, HF<sub>2</sub>C-CH<sub>2</sub>-, C 1 to C 8 alkyl, C alkenyl<sub>2</sub> to Cg, a c-alkynyl<sub>2</sub> to C8, a (C] to C8 alkyl) -s- (C1 to C3 alkyl) -, a C3 to C1 cycloalkyl, a (C3 to C1 cycloalkyl) (C1 to C8 alkyl) -, a ( C 3 -C cycloalkyl) - (C-alkenyl<sub>2</sub> at
Cg) -, a (C 3 -C 1 cycloalkyl) - (C-alkynyl<sub>2</sub> to Cg) -, C3 to C1 heterocycloalkyl, (C3 to C1 heterocycloalkyl) (C1 to C8 alkyl) -, (C3 to C1 heterocycloalkyl) - (C<sub>2</sub> to Cg) -, a (C 3 -C heterocycloalkyl) - (C-alkynyl)<sub>2</sub> to Cg) -, aryl, aryl- (C1 to Cg alkyl) -, heteroaryl, ؛ heteroaryl- (C1 to C8 alkyl) -, an rI-Ο- (C] to C3 alkyl) -,
RO-CO-, R٥)<sub>2</sub>N-CO-, r1٥-CO-, r1٥-SO<sub>2</sub>- or a (C1 to C8 alkyl) -so<sub>2</sub>-, the elements mentioned above possibly being optionally substituted with one or more substituents
ΜΑ 32201Β1
POl-2363-ff chosen independently of each other in by:
the group constitutes fluorine, HO-, NC-, 0 ؛ N-, F3C-, HFgC-, FHC-, F3C-CH2-, HO (C1-C8 alkyl) -, R١٠-O- (C1-C8 alkyl) C1 to C) -, C1 to C6 alkyl, r “-O-, (r2٥) 2N-, R٥Ν- (C1 to C3 alkyl) - and (rJ٠) zN-CO-;
r3 is chosen from the group comprising:
H-, hydroxy and R'٠-O-;
R ^ and R<sup>5</sup> are independently selected from one another from the group consisting of H-, fluorine, F3C-, HFzC, FHC- and C1-C8 alkyl,
R<sup>4</sup> and R<sup>5</sup> together with the carbon atom to which attached form a 3- to 6-membered cycloalkyl group.
they are the elements mentioned above, carbocyclic y form, can be substituted independently of each other with including the ring ؛ optionally and إ one or more ؛ substituents selected from the group consisting of: إ fluorine, HO-, NC-, OzN-, F3C-, HFzC-, FHC-, F3C-CH2-, HO- j (C1 to C alkyl) -, a CH3-0- (C1 to C؛ alkyl) -, C1 to C alkyl<sub>6</sub>, (C1 to C8 alkyl) -O- and (C1 to CgN alkyl-CO-; إ
R'٥ independently of any other Rio is chosen from the إ group comprising: ؛
H- (but not in the case where it is part of a group j chosen from R'٠o-co-, R'٠-S٥2- or r1٠-CO_), F3C-CH2-, an alkyl in ا
C1 to C8, C2 to C alkenyl<sub>6</sub>, C3 to C1 cycloalkyl, (C3 to C1 cycloalkyl) - (C1 to C3 alkyl) -, C3 to C1 heterocycloalkyl, (C3 to C1 heterocycloalkyl) - (C1 to C8 alkyl) - , aryl, aryl- (C1-C3 alkyl) -, heteroaryl and heteroaryl- (C1-C1) -, and in the case where two groups r! ٥ are both bonded to the same atom d 'nitrogen, they can form together with said nitrogen atom a 3 to 7 membered heterocycloalkyl ring, and in which one of the -CH1- groups of the heterocycloalkyl ring form may be replaced by -0-, -S-, -NH-, a -N (C3-C6 cycloalkyl) -, a -Ncycloalkyl (C3-C8) - (C1 to C، alkyl)) - or N (C1 to C c alkyl) -, preferably, and in particular preferably in the case of R٥N-CO-, these two r! ٥ together with said atom d nitrogen are linked to form a group selected from the
'ΜΑ 32201Β1
POl-2363-ff group comprising piperidinyl, piperazinyl, pyrrolidinyl, morpholinyl and thiomorpholinyl, ؛ and the elements mentioned above may be optionally substituted with one or more substituents selected independently of each other from the group constitutes
<td>by :</td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>fluorine.</td><td>chlorine,</td><td>bromine, HO-</td><td>, NC-,</td><td>ON, F3C-, HF<sub>2</sub>VS-,</td>
<td>FHC “</td><td>, F3C-CH2-,</td><td>an HO- (alkyl</td><td>in Cl to Cg)</td><td>-, a</td><td>CH3-0- (C1-alkyl</td>
<td>at 6 ح)</td><td>-, an alkyl</td><td>e in Cl to C<sub>6</sub> and</td><td>an (alkyl</td><td>e١٦ Cl</td><td>to Cg) -O-;</td>
X independently of all y: X = 0, 1, 2, 3 or 4, preferably X = 0, 1 or 2, preferably X = 0 or 1, and more preferably X = 0;
y independently of any X: y = 0 or 1, more preferably y = 0;
and a pharmaceutically acceptable salt thereof, provided that for each applicable embodiment of formula I of the invention, if Hc is an oxetanyl which is bonded through the carbon atom adjacent to oxygenate from oxetanyl, there is no substituent attached to said carbon atom through a * -CH ؛ - spacer.
* This means that no substituent contains a CH ؛ - group through which it is linked to oxetanyl.
A second aspect of the invention relates to a compound of general formula I of the first aspect of the invention, in the textual
Hc is a heterocyclyl group having a formula selected from the group of formulas 1.1, 1.2 and 1.3:
Formula 1.1:
<img file="MA32201B1_D0038.tif" />
MA 32201 BI
لآ
POl-2363-ff η = 1, 2, 3;
χΐ, χ2, X<sup>3</sup>, independently of each other, are CH, CHR,
CHR<sup>3</sup>, C (r2) 2, CR2r<sup>3</sup>, O, NH, NR2 or s (o) r where r = 0, 1, 2, whereby at least one of X ', X<sup>2</sup>, X<sup>3</sup> is o, NH, NR<sup>3</sup> or s (o) r;
#: means that the ring is not aromatic, while for n = 1, one bond within the ring system can optionally be a double bond, and for n = 2 or n = 3, one bond or two bonds to! 'inside the ring system can / can optionally be (a) a double bond or double bonds, thereby replacing hydrogen atoms linked to ring elements, whereby said double bond or double bonds are preferably a cc double bond, and more preferably the ring is saturated;
Formula 1.2
A is the ring system of formula 1.1;
B is a 3, 4, 5 or 6 membered second ring system which is linked to A and which, in addition to the two atoms and a bond which can be a single bond or a double bond - which it shares with A , is only composed of carbon atoms and can be saturated, partially saturated or aromatic; the substituents r2 and / or R<sup>3</sup> independently of each other and independently of X and y may be on ring A or ring B; whereby the two ring atoms which are shared by the two ring systems A and B can both be carbon atoms, can both be nitrogen atoms, or one can be a carbon atom and the other can be a nitrogen atom, whereby two carbon atoms or one carbon atom and one atom
MY
32201Β1
Nitrogen POl-2363-ff are preferred and two carbon atoms are more preferred;
POl-2363-ff 'ΜΑ 32201Β1
Formula 1.3:
<img file="MA32201B1_D0039.tif" />
<td>AT</td><td>is</td><td>the system</td><td>cyclic</td><td>formula</td><td> 1.1 ;</td><td></td>
<td>VS</td><td>is</td><td>a second</td><td>system</td><td>cyclic.</td><td>saturated</td><td>or partially</td>
<td>saturated.</td><td>to 3,</td><td>4, 5 or S</td><td>links</td><td colspan="3">which is spiro-fused to A and which.</td>
<td>more</td><td>of</td><td>the atom qu</td><td colspan="2">'he shares with A,</td><td>, is</td><td>only compose</td>
<td>atoms</td><td>of</td><td>carbon and</td><td colspan="2">the R substituents<sup>2</sup></td><td>and or</td><td>R<sup>2</sup> independently</td>
one of the other and independent of X and of y can be on the ring A or the ring c;
R<sup>2</sup> is chosen from the group comprising:
C1 to C6 alkyl, C3 to C4 cycloalkyl, (C3 to C1 cycloalkyl) - (C1 to C3 alkyl) -, C3 to C1 heterocycloalkyl, (C3 to C heterocycloalkyl) - (C1 to C، alkyl) -, aryl, aryl- (C1 to C8 alkyl) -, heteroaryl and heteroaryl- (C1 to C؛ alkyl) -, the above-mentioned elements being optionally substituted with one or more substituents chosen independently of each other from the group consisting of fluorine, chlorine, bromine, iodine, an oxo, HO-, NC-, Ο2Ν-, F3C-, HFzC-, FHC-, F3C-CH2-, F3C-0-, HF2C-0-, an R٠ ؛ -O- (C1 to C؛ alkyl) -, C1 to C8 alkyl, C2 to Cg alkenyl, C2 to Cg alkynyl, C3 to C1 cycloalkyl, (C3 to C1 cycloalkyl) (C1 to Cg alkyl) -, aryl, aryl- (C1-C8 alkyl) -, heteroaryl, heteroaryl- (C1-C8 alkyl) -, nitrogen-linked pyridin-2one, pyridin-2-one- (C1-C8 alkyl) ) - linked by nitrogen, a C3 to Cl heterocycloalkyl, a (C3 to C1 heterocycloalkyl) - (C1 to C8 alkyl) -, a tetrahydrofuranyl-O-, a tetrahydropyranyl-O-, a piperidinyl-o- where the piperidinyl is linked to O through one of its ring atoms c, a pyrrolidinyl-O- where the pyrrolidinyl is linked to o by ، Z
MY
32201Β1
POl-2363-ff
The intermediary of one of its ring atoms, (R N-, a (R<sup>3</sup>٥> 2N (C-C ؛ alkyl) -, R٠ ؛ -O-, R٥) 2N-CO-, un (؛ (١٥Ν-CO- (C-alkyl)
Cl to Cg) -, R<sup>3</sup>٥-CO-R٠) N-, R CO- (R١N- (C1-C8 alkyl) -, ROΟΟ-Ο- and / or ١٠O-CO- (١٠) N-, whereby any of the groups C3-C7 cycloalkyl, C3-C7 heterocycloalkyl, aryl, heteroaryl, nitrogen-linked pyridin-2one, tetrahydrofuranyl, tetrahydropyranyl, piperidinyl, pyrrolidinyl, R N-CO- (C1 to C alkyl) mentioned above may be optionally substituted with one or more substituents selected independently of each other from the group consisting of fluorine, chlorine, bromine,
NC-, Ο2Ν-, FjC-, HC-, FHC-, F3C-CH2-, F3C-0-, HF2C-0-, C 1 -C 6 heterocycloalkyl, RO- (C 1 -C 8 alkyl) - , C1 to C8 alkyl, r! ٥-0-, r1٥-C0-, ROCO-, benzyl-O- and / or (r1٥) 2N-CO-, whereby piperidinyl or pyrrolidinyl is preferably substituted with R-CO-;
R<sup>2</sup> independently of any other R<sup>2</sup> is chosen from the group comprising:
H-, fluorine, F3C-, HFgC-, FHC-, F3C-CH-, C1 to C alkyl<sub>6</sub> (preferably C2-C8 alkyl), R٥) 2N-C0-, R) ٥-CO- (R٥٥) N-, the above-mentioned elements possibly being optionally substituted with one or more substituents independently selected from each other. others in the group made up of:
fluorine, chlorine, bromine and C1 to C8 alkyl, and in the case where R<sup>2</sup> is linked to a nitrogen which is a cycle element of Hc, this R<sup>2</sup> must be independent of any other R<sup>2</sup> :
H-, F3C-CH2-, HF2C-CH2-, C 1 to C 8 alkyl, C 3 to C 7 cycloalkyl, (C 3 to C cycloalkyl) - (C 1 to C 8 alkyl) -, C 3 heterocycloalkyl to C7, a (3 ح to C7 heterocycloalkyl) (C 1 to C 8 alkyl) -, an aryl, an aryl- (C 1 to C 8 alkyl) -, a heteroaryl, a heteroaryl- (C 1 to C 8 alkyl) -, an R-٥-O- (C1 to Cl alkyl) -, RO-CO-, (r1٥) 2N-CO-, r! ٠-CO- or a (C1 to
Cg) -so<sub>2</sub>-, the elements mentioned above possibly being optionally substituted, independently of each other, with one or more substituents selected from the group consisting of fluorine and C1 to C8 alkyl;
MY
32201Β1
POl-2363-ff
R<sup>3</sup> is chosen from the group comprising:
H-, hydroxy and (C1-C8 alkyl) -O-, whereby ؛ the group (C 1 to C alkyl (1- 0- may be optionally substituted with one or more fluorine, chlorine, bromine and HO-; إ r4 and R<sup>5</sup> are chosen independently of each other in the ؛ group comprising H-, fluorine and methyl; إ r! ٥ independently of any other r! ٥ is chosen from the إ group comprising: ؛
H- (but not in the case where it is part of a إ group selected from RO-CO- or rI-CO-), C1 to C8 alkyl, C3 to C7 cycloalkyl, (C3 to C7 cycloalkyl) C7) - (C1 to C3 alkyl) -, an aryl and a heteroaryl, and in the case where two groups r! ٥ are both linked to the same nitrogen atom, they can form together with said nitrogen atom a 3- to 7-membered heterocycloalkyl ring, and in which one of the -CH ؛ - groups of the heterocycloalkyl ring formed can be replaced by -o-, -NH-, a -N (C3 to C؛ cycloalkyl) -, a -N ((C3 to C8 cycloalkyl) - (C1 to C، alkyl)) - or a -N (C1 to C1 alkyl) -, preferably , and in particular preferably in the case of (r1٥) 2N-CO-, these two r5٥ together with said nitrogen atom are linked to form a group selected from the group comprising piperidinyl, piperazinyl, pyrrolidinyl, morpholinyl and thiomorpholinyl, and the elements mentioned above may be optionally substituted with one or more substituents selected independently of each other from the group consisting of:
fluorine, NC-, F3C-, HFgC-, FHC-, F3C-CH2-, CH3-0- (C1 to C8 alkyl) -, C1 to C8 alkyl and (C1 to C8 alkyl) - O-;
x independently of any y: X = 0, 1, 2, 3 or 4, preferably X = 0, 1 or 2, preferably X = 0 or 1, and more preferably X = 0;
y independently of any X: y = 0 or 1, more preferably y = 0;
and! a pharmaceutically acceptable salt thereof.
A third aspect of the invention relates to a compound of general formula I of the first aspect of the invention, in which
<img file="MA32201B1_D0040.tif" />
32201Bl
؛ POl-2363-ff
Hc is a monocyclic, non-aromatic and saturated heterocyclic group containing 4 to 8, preferably 5, 6 or 7 ring atoms, whereby said ring atoms are carbon atoms and 1, 2 or 3 heteroatom (s), of preferably 1 heteroatom, the heteroatom (s) being chosen from oxygenated, nitrogen and sulfur, the sulfur being in the form -or-, where r is equal to 0, or 2, preferably r is equal to 0, and whereby, preferably, said heterocyclic group is linked to the main structure through a ring carbon atom which is not directly linked to said ring heteroatom;
Ri is chosen from the group comprising:
C1 to C8 alkyl, C3 to C1 cycloalkyl, (C3 to C1 cycloalkyl) - (C1 to C3Ialkyl-, C3 to C1 heterocycloalkyl, (C3 to C1 heterocycloalkyl) - (C1 to C3 alkyl) Cl to Cg) -,;
aryl, aryl- (C1-C8 alkyl) -, heteroaryl and إ heteroaryl- (C1-C8 alkyl) -, ؛ the elements mentioned above possibly being إ optionally substituted with one or more substituents ؛ chosen independently of each other from the group consisting of fluorine, chlorine, bromine, iodine, an oxo, HO-, NC-, Ο2Ν-,
F3C-, HFzC-, FHC-, F3C-CH2-, F3C-0-, HF2C-0-, R ؛ ° -O- (C1 to C8 alkyl) -, C1 to C8 alkyl, C1 to C8 alkenyl C2 to Cg, C2 to Cg alkynyl, C3 to ccycloalkyl, (C3 to cc cycloalkyl) (C1 to C8 alkyl) -, aryl, aryl- (C1 to Cg alkyl) -, heteroaryl, heteroaryl- (C1 to C8 alkyl) -, nitrogen linked pyridin-2one, pyridin-2-one- (C1 to C8 alkyl) - nitrogen linked, heterocycloalkyl C 3 to C ?, a (C 3 to C heterocycloalkyl) - (C 1 to C 8 alkyl) -, tetrahydrofuranyl-O-, tetrahydropyranyl-O-, piperidinyl-O- or piperidinyl is linked to O through one of its ring c atoms, a pyrrolidinyl-O- where pyrrolidinyl is linked to O through one of its ring atoms, R٥> 2N-, an RN (C1-C8 alkyl) -, R٥ ؛ -O-, (R٠ ؛) zN-CO-, an R<sup>2</sup>N-CO- (alkyl in
Cl to Cg) -, R٥ ؛ -CO- R٥) N-, un R٠-CO- (R٥ ؛) N- (C1 to Cg alkyl) -, RO35 CO-0- and / or R 1٠O-CO- ( R٠ ؛) N-, whereby any one of C3-Cl cycloalkyl, C3-Cl heterocycloalkyl, aryl, heteroaryl, nitrogen-linked pyridin-2one, tetrahydrofuranyl, tetrahydropyranyl.
؛،
<img file="MA32201B1_D0041.tif" />
32201Bl
POl-2363-ff piperidinyl, pyrrolidinyl, (R<sup>3</sup>٥) 2N-CO- (C1-C8 alkyl) mentioned above may be optionally substituted with one or more substituents selected independently of each other from the group consisting of fluorine, chlorine, bromine,
NC-, ON, FsC-, HF<sub>2</sub>C-, FHC-, F3C-CH2-, F3C-0-, HF<sub>2</sub>CO-, C3 to C7 heterocycloalkyl, RO- (C1 to C8 alkyl) -, C1 to C8 alkyl, R<sup>3</sup>٠-O-, r1-C0-, ROCO-, a benzyl-o- and / or
R)<sub>2</sub>N-CO-, whereby piperidinyl or pyrrolidlnyl is preferably substituted with R-CO-;
r2 independently of any other r2 is selected from the group consisting of H- and C1-C8 alkyl, and in the case where R<sup>2</sup> is linked to a nitrogen which is a cycle element of Hc, this R<sup>2</sup> must be independent of any other R<sup>2</sup> : H-, (C1 to C8 alkyl) -co-, (C1 to C؛ alkyl) - o-co-, C1 to C8 alkyl, phenyl-00-, phenyl-0-CO -, (C1 to C6alkyl-CO-, the elements mentioned above possibly being optionally substituted, independently of each other, with one or more fluorine substituents;
R<sup>3</sup> is chosen from the group comprising:
H-, hydroxy and (C1-C8 alkyl) -O-, whereby the (C1-C8 alkyl) -O- group may be optionally substituted with one or more fluorine, chlorine, bromine and HO-;
R<sup>4</sup> and R<sup>5</sup> are independently selected from the group consisting of H-, fluorine and methyl; preferably they are both H;
R<sup>3</sup>٥ independently of any other R<sup>3</sup>٥ is C1 to C8 alkyl, phenyl and pyridyl, and in the case where r} ٥ is a substituent of a nitrogen atom, r! ٥ is selected from the group consisting of H, C1 to C alkyl C8, phenyl and pyridyl, the above-mentioned elements possibly being optionally substituted with one or more substituents selected independently of each other from the group consisting of:
fluorine, F3C-, HFC, FHC-, F<sub>3</sub>C-CH<sub>2</sub>-, CH3-O- (C1-C8 alkyl) -, C1-C8 alkyl and (C1-C8 alkyl) -O-;
<img file="MA32201B1_D0042.tif" />
32201Β1
POl-2363-ff
X independently of all y: X = 0, 1, 2, 3 or 4, preferably X = 0, 1 or 2, preferably X = 0 or 1, and more preferably X = 0;
y independently of any X: y = 0 or 1, more preferably y = 0;
and a pharmaceutically acceptable salt thereof, provided that if Hc is an oxetanyl which is bonded through the carbon atom adjacent to the oxygen of the oxetanyl, there is no substituent bonded to said carbon atom through a -CH- * group.
* This means that no substituent contains a CH- group through which it is linked to the oxetanyl.
A fourth aspect of the invention relates to a compound of general formula I of the first aspect of the invention, wherein
Hc is selected from the group consisting of tetrahydropyranyl, tetrahydrofuranyl, piperidinyl, pyrrolidinyl and piperazinyl, whereby preferably the tetrahydropyranyl is 3- or 4-tetrahydropyranyl, the tetrahydrofuranyl is 3-tetrahydrofurinyl and is 3-piperazinyl - or 4-piperidinyl; more preferably, Hc is tetrahydropyranyl, tetrahydrofuranyl, piperidinyl, pyrrolidinyl, and among these, preferably 3- and 4tetrahydropyranyl, 3- and 4-piperidinyl and 3-pyrrolidinyl;
R is chosen from the group comprising:
C 1 to C 8 alkyl, C 3 to C 7 cycloalkyl, (C 3 to C 7 cycloalkyl) - (C to C 8 alkyl) -, C 3 to C 7 heterocycloalkyl, (C 3 to C heterocycloalkyl) - (C1 to C8 alkyl) -, aryl, aryl- (C1 to C8 alkyl) -, heteroaryl and heteroaryl- (C1 to C؛ alkyl) -, the elements mentioned above may be optionally substituted with one or more substituents chosen independently of each other from the group consisting of fluorine, chlorine, bromine, iodine, an oxo, HO-, NC-, Ο2Ν-,
F3C-, HF2C-, FHC-, F3C-CH2-, F3C-0-, HF2C-0-, r! ٥-O- (C 1 to C 8 alkyl) -, C 1 to C 8 alkyl, C alkenyl C2 to c<sub>6</sub>, C2-C8 alkynyl, C1-C8 cycloalkyl, (C1-C8 cycloalkyl) (C1-C8alkyl) -, aryl, aryl- (C1-C8alkyl) -,
ئ
<img file="MA32201B1_D0043.tif" />
32201Β1
POl-2363-ff إ
heteroaryl, heteroaryl- (C1-C8 alkyl) -, nitrogen-linked pyridin-2- إ one, nitrogen-linked pyridin-2-one- (C1-C8 alkyl) - nitrogen-linked, a C3 to C1 heterocycloalkyl, a (C3 to C heterocycloalkyl إ) - (C1 to C8 alkyl) -, tetrahydrofuranyl-O-, إ tetrahydropyranyl-O-, piperidinyl-o- where piperidinyl is bonded ér to 0 through one of its ring atoms, an i.
pyrrolidinyl-O- where pyrrolidinyl is linked to 0 by ؛ ! 'intermediate one of its ring atoms c, (r! ٥)<sub>2</sub>N-, un (r1٥)<sub>2</sub>N (C1-C8 alkyl) -, r1٥-O-, R٥) NCO-, un R ٥)<sub>2</sub>N-CO- (إ alkyl
Cl to Cg) -, R-CO- R٥) N-, un R'٠-CO- R ٥) N- (C1 to Cg alkyl) -, R'٥o- إ
CO-Ο- and / or R 0 co- (R٥ ؛) N-, ؛ whereby any of C 3 -C 7 cycloalkyl, C3-C7 heterocycloalkyl, aryl, heteroaryl, nitrogen-linked pyridin-2one, tetrahydrofuryl, tetrahydropyranyl, piperidinyl, pyrrolidinyl, R ٥)<sub>2</sub>N-CO- (C1-C8 alkyl) -:
mentioned above may be optionally substituted with one or more substituents selected independently of each other from the group consisting of fluorine, chlorine, bromine,
NC-, CN-, F3C-, HFC, FHC, F3C-CH2-, F3C-0-, HF<sub>2</sub>CO-, a ؛ C3 to C1 heterocycloalkyl, R'٥-O- (C1 to C8 alkyl) -, C1 to C8 alkyl, R٠ ؛ -O-, R) ٠-CO-, R 0 co-, benzyl- o- and / or
R٥)<sub>2</sub>N-CO-, whereby piperidinyl or pyrrolidinyl is preferably substituted with R-CO-;
R<sup>2</sup> independently of any other R<sup>2</sup> potential is selected from the group consisting of H- and C1-C6 alkyl, and in the case where R<sup>2</sup> is linked to a nitrogen which is a cycle element of Hc, this R<sup>2</sup> must be independent of any other R<sup>2</sup> :
H-, (C1 to C8 alkyl) -co-, (C1 to C8 alkyl) -O-CO-, C1 to C8 alkyl, phenyl-ΟΟ-, phenyl-0-CO-, a (C1 to CgN-CO- alkyl;
the elements mentioned above being optionally substituted, independently of each other, with one or more fluorine substituents;
<td></td><td>R<sup>3</sup> is</td><td>chosen in</td><td>the</td><td>group including:</td><td></td>
<td> 35</td><td>H-, a</td><td>hydroxy and</td><td>a</td><td>(C 1 to C 8 alkyl) -O-,</td><td>averaging</td>
<td></td><td>the group</td><td>(alkyl in</td><td>Cl</td><td>to Cg) —0— can be</td><td>optionally</td>
substitutes with one or more fluorine, chlorine, bromine and HO-;
MA 32201 Bl
POl-2363-ff;
R and R<sup>s</sup> are independently selected from the group consisting of H-, fluorine and methyl; preferably, R and R<sup>5</sup> are both H;
rO independently of any other r1٥ is selected from the group consisting of C1 to C6 alkyl, phenyl and pyridyl, and in the case where r "is a substituent of a nitrogen atom, r! ٥ is selected from the group consisting of: group comprising H, C1 to C alkyl<sub>6</sub>, phenyl and pyridyl, the above-mentioned elements possibly being optionally substituted with one or more substituents إ selected independently of each other from the group consisting of إ by:
fluorine, F3C-, HC-, FHC-, F3C-CH2-, CH3-0- (C1 إ to C ؛ alkyl) -, C1 to C alkyl and (C1 to C8 alkyl) -O -; إ
X independently of all y: X = 0, 1, 2, 3 or 4, of ؛ preferably X = 0, 1 or 2, preferably X = 0 or 1, and so ؛ more preferred X = 0; ;
y independently of any X: y = 0 or 1, more preferably y = 0;
> and! a pharmaceutically acceptable salt thereof.
A fifth aspect of the invention relates to a compound of general formula I of the first aspect of the invention, wherein
Hc is selected from the group consisting of tetrahydropyranyl, tetrahydrofuranyl, piperidinyl, pyrrolidinyl and piperazinyl, whereby preferably the tetrahydropyranyl is 3- or ، -tetrahydropyranyl, the tetrahydrofuranyie is 3-tetrahydrofuranyl and is piperazinyl. - or 4-piperidinyl; more preferably Hc is tetrahydropyranyl, tetrahydrofuranyl, piperidinyl, pyrrolidinyl, and among these, preferably 3- and 4tetrahydropyranyl, 3- and ، -piperidinyl and 3-pyrrolidinyl;
R) is chosen from the group comprising:
phenyl, 2-, 3- and 4-pyridyl, pyrimidinyl, pyrazolyl, thiazolyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, ج cyclopentylmethyl, ethyl, propyl, 1- and 2-buty! E, the 1-,
2- and 3-penty! E, tetrahydrofuranyl and tetrahydro-pyranyl.
<img file="MA32201B1_D0044.tif" />
MY
32201Bl
POl-2363-ff which groups may be optionally substituted with one or more substituents selected independently of each other from the group consisting of fluorine, chlorine, bromine, iodine, oxo, HO-, NC-, un (C1-C8 alkyl) -O-, C1-C8 alkyl
C1 to C8, C3 to C7 cycloalkyl, (C3 to CJO cycloalkyl), (C3 to C7 cycloalkyl) - (C1 to C7alkyl)<sub>3</sub>) -o-, CF3O-, CF3-, a C3 to C7 heterocycloalkyl, a (C3 to C7 heterocycloalkyl) (C1 to C8 alkyl) -, an HO- (C1 to Cg alkyl) -, an oxadiazolyl, an oxazolyl, an isoxazolyl, a triazolyl, a thiazolyl, a pyrrolyl, a furanyl, a pyrazolyl, a pyridyl, a pyridazinyl, a pyrimidinyl, a (R) NCO- (C1 to C8 alkyl) -,
R٠) zN-CO- and / or phenyl, by means of which the oxadiazolyl, oxazolyl, isoxazolyl, triazolyl, thiazolyl, pyrrolyl, furanyl, pyrazolyl, pyridyl, pyridazinyl, pyrimidinyl and phenyl groups mentioned above may be optionally substituted with one or several substituents selected independently of each other from the group consisting of fluorine, CH-, CF3-, CHO-, CF3O-, HNCO-, NC-, morpholinyl and / or benzyl-O_;
R<sup>2</sup> independently of any other R<sup>2</sup> potential is selected from the group consisting of H- and C1-C8 alkyl, and in the case where R<sup>2</sup> is linked to a nitrogen which is a cycle element of Hc, this R<sup>2</sup> must be independent of any other R<sup>2</sup> : H-, (C1 to C8 alkyl) -CO-, (C1 to C8 alkyl) -O-CO-, C1 to C8 alkyl, phenyl-00-, phenyl-0-CO- , (C1-C8 alkyl) ؛ N-CO-, the above mentioned elements being optionally substituted, independently of each other, with one or more fluorine substituents;
R<sup>3</sup> is chosen from the group comprising:
H-, hydroxyl and (C1-C8 alkyl) -O-, whereby the (C1-C8 alkyl) -O- group may be optionally substituted with one or more fluorine, chlorine, bromine and HO-;
r4 and R<sup>5</sup> are independently selected from the group consisting of H-, fluorine and methyl; preferably, r4 and R<sup>s</sup> are both H;
MY
32201Bl
إ
POl-2363-ff
R independently of any other R is selected from the group consisting of H, C1-C8 alkyl, phenyl and pyridyl, the above-mentioned elements possibly being optionally substituted with one or more substituents independently selected from one another from the group. group made up of:
fluorine, F3C-, HF<sub>2</sub>C-, FH ؛ C_, F3C-CH2-, CH3-0- (C1 to C8 alkyl) -, C1 to C8 alkyl and (C1 to C8 alkyl) -O-;
X independently of each other x = 0, 1, 2, 3 or 4, preferably X = 0, 1 or 2, preferably x = 0 or 1, and more preferably X = 0;
y independently of each other y = 0 or 1, more preferably y = 0;
and! a pharmaceutically acceptable salt thereof.
A sixth aspect of the invention relates to a compound of general formula I of the first aspect of the invention, wherein
Hc is pyrrolidinyl and chosen
<td>in the group</td><td>including</td><td>a</td>
<td>tetrahydrofuranyl, a</td><td>piperidinyl.</td><td>a</td>
<td>piperazinyle</td><td>preference</td><td>a</td>
<td>tetrahydrofuranyl, a</td><td>piperidinyl.</td><td>a</td>
<td colspan="2">these, preferably the 3- and</td><td> 4-</td>
tetrahydropyranyl, 3- and 4-piperidinyl and 3-pyrrolidinyl; r 'is chosen from the group comprising:
phenyl, 2-, 3- and 4-pyridyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, ethyl, 1- and 2-propy! e, 1- and 2-butyl, 1 -, 2- and 3-penty! E, tetrahydrofuranyl and tetrahydropyranyl, which groups may be optionally substituted with one or more substituents selected independently of each other from the group consisting of fluorine, chlorine, bromine, iodine, oxo, NC-, (C1 to C8 alkyl) -O-, C1 to C8 alkyl, CF3O-, CF3-, an oxadiazolyl, a triazolyl, a pyrazolyl, a furanyl, a pyridyl and / or a phenyl.
whereby the oxadiazolyl, triazolyl, pyrazolyl, furanyl, pyridyl and phenyl groups mentioned above may be optionally substituted with one or more /
MY;
32201Bl
Substituents selected independently of one another from the group consisting of fluorine, CH-, CHO-, HNCO- and / or NC-;
R<sup>2</sup> independently of any other R<sup>2</sup> is selected from the group consisting of H- and C1-C8 alkyl, and in the case where R<sup>2</sup> is linked to a nitrogen which is a cycle element of Hc, this R<sup>2</sup> must be independent of any other R<sup>2</sup> : H-, (C1 to C8 alkyl) -CO-, (C1 to C8 alkyl) -O-CO-, C1 to C8 alkyl, phenyl-C0-, phenyl-O-CO- , a (C1 to C8 alkyl)<sub>2</sub>N-CO-, the elements mentioned above possibly being optionally substituted, independently of each other, with one or more fluorine substituents;
r3 is chosen from the group comprising:
H-, hydroxy and (C1-C8 alkyl) -O-, whereby the (C1-C8 alkyl) -O- group may be optionally substituted with one or more fluorine, chlorine, bromine and HO-;
r4 and R<sup>s</sup> are selected independently of one another from the group consisting of H-, fluorine and methyl; preferably, r4 and R<sup>s</sup> are both H;
X independently of all y: X = 0, 1, 2, 3 or 4, preferably X = 0, 1 or 2, preferably X = 0 or 1, and more preferably X = 0;
y independently of any X: y = 0 or 1, more preferably y = 0;
and! a pharmaceutically acceptable salt thereof.
A seventh aspect of the invention relates to a compound of general formula I of the first aspect of the invention, wherein
Hc is selected from the group consisting of piperidinyl and pyrrolidinyl, preferably 3- or 4-piperidinyl and pyrrolidinyl;
R<sup>2</sup> is chosen from the group comprising:
phenyl, 2-, 3- and 4-pyridyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, ethyl, 1- and 2-propy! e, 1- and 2-butyl, 1 -, 2- and 3-penty! E, tetrahydrofuranyl and tetrahydropyranyl, these groups possibly being optionally substituted with one or more substituents independently selected from the group consisting of fluorine, chlorine, bromine, iodine, oxo , NC-,
<img file="MA32201B1_D0045.tif" />
Μα 32201Β1
POl-2363-ff إ إ
(C1 to C alkyl) - o-, C1 to C8 alkyl, CF3O-, CF3-, ؛ oxadiazolyl, triazolyl, pyrazolyl, furanyl, pyridyl and / or phenyl, ا whereby the oxadiazolyl, triazolyl, pyrazolyl, furanyl, pyridyl and phenyl groups mentioned above may be optionally substituted with one or more ؛ ' substituents independently selected from the إ group consisting of fluorine, CH-, CHO-, HNCO- and / or NC-; ٣
R ؛ independently of any other r2 is selected from the group إ 'comprising H- and C-C٥ alkyl, and in the case where r2 is bonded to nitrogen which is a ring member of Hc, that r2 should be independent of any other r2:
H-, (C1 to C8 alkyl) -CO-, (C1 to co-co-) alkyl, C1 to C8 alkyl<sub>6</sub>, phenyl-c٠-, phenyl-0-CO-, (C1-C12 alkyl<sub>6</sub>)<sub>2</sub>N-CO-, the elements mentioned above possibly being optionally substituted, independently of each other, with one or more fluorine substituents;
R<sup>3</sup> is chosen from the group comprising: j
H-, hydroxy and (C1 to C8 alkyl) -O-, whereby ، the group (C1 to C؛ alkyl) - o- may be optionally substituted with one or more fluorine, chlorine, bromine and HO- ;
R<sup>4</sup> and R ؛ are independently selected from one another from the group consisting of H-, fluorine and methyl, preferably R<sup>4</sup> and
R<sup>5</sup> are both H; ئ
X independently of all y: X = 0, 1, 2, 3 or 4, preferably X = 0, 1 or 2, preferably X = 0 or 1, and so ؛ more preferred X = o; ؛.
y independently of any X: y = 0 or 1, more preferably y = 0;
and one of its pharmaceutically acceptable salts.
An eighth aspect of the invention relates to a compound of general formula I of the first aspect of the invention, in which
Hc is selected from the group consisting of piperidinyl and pyrrolidinyl, preferably 3- or 4-piperidinyl and 3pyrrolidinyl;
r! is chosen from the group comprising: إ
<img file="MA32201B1_D0046.tif" />
MA 32201 Bl إ POl-2363-ff إ أ
I ا phenyl, 2-, 3- and 4-pyridyl, cyclopropyl, ٠ cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl,؟ cyclopentylmethyl, ethyl, propyl, 1- and 2-buty! e, 1-, إ
2- and 3-penty! E, tetrahydrofuranyl and tetrahydro-pyranyl, ت which groups may be optionally substituted with one or more substituents selected independently of each other from the group consisting of NC-, (C1 to C alkyl co-, إ a c to c alkyl<sub>6</sub>, CFO-, CF3- and a halogen, the halogen being preferably chosen from fluorine, chlorine and bromine,
R<sup>2</sup> independently of any other R<sup>2</sup> is selected from the group consisting of H- and C 1 -C 8 alkyl, ٤ and in the case where R<sup>2</sup> is linked to a nitrogen which is an element élément of the cycle of Hc, this R<sup>2</sup> must be independent of any other R<sup>2</sup> : إ
H-, (C1-C8 alkyl) -CO-, (C1-C8 alkyl) -O-CO-, إ C1-C8 alkyl, phenyl-C0-, phenyl-0-CO- , a (C1 to
the elements mentioned above being optionally substituted, independently of each other, with one or more fluorine substituents;
0 r4 and R ؛ are both H;
X = 0 or 1; y = 0;
and one of its pharmaceutically acceptable salts.
A ninth aspect of the invention relates to a compound of general formula I of the first aspect of the invention, wherein إ
Hc is selected from the group consisting of tetrahydropyranyl and tetrahydrofuranyl, preferably 3 or 4-tetrahydropyranyl and 3-tetra-hydrofuranyl;
r! is chosen from the group comprising:
phenyl, 2-, 3- and 4-pyridyl, cyclo-propyl, cyclobutyl, cyclopentyl, cyclo-hexyl, ethyl, 1- and 2-propyl, 1- and 2- butyl, 1-, 2- and 3-penty! e, tetrahydrofuranyl and tetrahydropyranyl, which groups may be optionally substituted with one or more substituents independently selected from the group consisting of fluorine, chlorine, bromine, iodine, oxo, NC-, (C1 to C8 alkyl) -O-, C1 to C8 alkyl, CF3O-, CF3-,
ΜΑ 32201Β1
POl-2363-ff oxadiazolyl, triazolyl, pyrazolyl, furanyl, pyridyl and / or phenyl, whereby the oxadiazolyl, triazolyl, pyrazolyl, furanyl, pyridyl and phenyl groups mentioned above may be optionally substituted with one or several substituents selected independently of each other from the group consisting of fluorine, CH-, CHO-, HNCO- and / or NC-;
R<sup>2</sup> independently of any other R<sup>2</sup> is selected from the group consisting of H- and C1 to C alkyl, the above mentioned C1 to C alkyl group (s) being optionally substituted, independently of each other, with one or more fluorine substituents;
R<sup>3</sup> is chosen from the group comprising:
H-, hydroxy and (C1-C8 alkyl) -O-, whereby the (C1-C8 alkyl) -O- group may be optionally substituted with one or more fluorine, chlorine, bromine and HO-;
r4 and R<sup>5</sup> are independently selected from one another from the group consisting of H-, fluorine and methyl, preferably R<sup>4</sup> and R<sup>5</sup> are both H;
X independently of all y: X = 0, 1, 2, 3 or 4, preferably X = 0, 1 or 2, preferably x = 0 or 1, and most preferably x = 0;
y independently of any x: y = 0 or 1, most preferably y = 0;
and! a pharmaceutically acceptable salt thereof.
A tenth aspect of the invention relates to a compound of general formula I of the first aspect of the invention, wherein
Hc is selected from the group consisting of tetrahydropyranyl and tetrahydrofuranyl, preferably 3 or 4-tetrahydropyranyl and 3-tetra-hydrofuranyl;
Ri is chosen from the group comprising:
phenyl, 2-, 3- and 4-pyridyl, cyclo-propyl, cyciobutyl, cyclopentyl, cyclo-hexyl, cycloheptyl, cyclopentylmethyl, ethyl, propyl, 1- and 2-buty ! e, 1-, 2- and 3-penty! e, tetrahydrofuranyl and tetrahydro-pyranyl, which groups may be optionally substituted with one or more substituents selected independently of each other from the group consisting of NC-, a (C1 to C alkyl) - o-.
/
MY
32201Β1
POl-2363-ff C1-C8 alkyl, CF3O-, CF3- and halogen, the halogen being;
preferably chosen from fluorine, chlorine and bromine, إ
R<sup>2</sup> independently of any other R<sup>2</sup> is selected from the group إ comprising H- and C1 to C8 alkyl, the C1 to C8 alkyl group (s) mentioned above ؛ which may be optionally substituted, independently of each other, with one or more fluorine substituents;
R<sup>3</sup> is chosen from the group comprising: ؛
H-, hydroxy and (C1-C8 alkyl) -O-, whereby the (C1-C؛ alkyl) - O- group may be optionally substituted with one or more fluorine, chlorine, bromine and HO -; ة r4 and R<sup>3</sup> are independently selected from one another from the group consisting of H-, fluorine and methyl, preferably R '' and R<sup>3</sup> are both H;
X independently of all y: X = 0, 1, 2, 3 or 4, preferably X = 0, 1 or 2, preferably X = 0 or 1, and most preferably X = o;
y independently of any X: y = 0 or 1, most preferably y = 0;
and one of its pharmaceutically acceptable salts. >
An eleventh aspect of the invention relates to a compound of general formula I of the first aspect of the invention, wherein
Hc is selected from the group consisting of اً tetrahydropyranyl and tetrahydrofuranyl, preferably 325 or 4-tetrahydropyranyl and 3-tetra-hydrofuranyl; ؛
R) is chosen from the group comprising:
phenyl, 2-, 3- and 4-pyridyl, cyclo-propyl, ؛ cyclobutyl, cyclopentyl, cyclo-hexyl, cycloheptyl, cyclopentylmethyl, ethyl, propyl, 1- and 2-butyl, 1-,
2- and 3-penty! E, tetrahydrofuranyl and tetrahydro-pyranyl, which groups may be optionally substituted with one or more substituents independently selected from ؛ others in the group consisting of NC-, (C1 to C8 alkyl) -O-, C1 to C8 alkyl, CF3O-, CF3- and halogen, the halogen being preferably chosen from fluorine, chlorine and bromine,
R '' and R<sup>5</sup> are both H; ؛ x = 0;
Z
MA 32201 BI
POl-2363-ff and a pharmaceutically acceptable salt thereof.
A twelfth aspect of the invention relates to a compound of general formula I:
<img file="MA32201B1_D0047.tif" />
or
Hc is a mono-, bi- or tri-cyclic heterocyclyl group إ whose ring elements are carbon atoms and at least 1 heteroatom, preferably 1, 2 or 3 heteroatoms chosen from the group comprising nitrogen atoms, oxygen and sulfur, which is in the form -S (O) r-, where r is 0, 1 or 2, and
-said heterocyclyl group is or contains 1 non-aromatic, saturated or partially unsaturated monocyclic ring containing at least 1 heteroatom as a ring element, and
-said heterocyclyl group is linked to the main structure via said non-aromatic, saturated or partially unsaturated 1 ring monocyclic containing at least 1 heteroatom as a ring element;
rI is selected from the group consisting of: إ C1 to C8 alkyl, 2 ح to C 8 alkenyl, C alkynyl<sub>2</sub> to Cg, a (C1 to c alkyl<sub>6</sub>) -s-, (C1 to C8 alkyl) -s- (C1 to C3 alkyl) -, C3 to C1 cycloalkyl, (C3 to C1 cycloalkyl) -;
(C1 to C8 alkyl) -, (C3 to C1 cycloalkyl) - (C2 to C8 alkenyl) -, (C3 to C1 cycloalkyl) - (Cz to C8 alkynyl) -, C3 to heterocycloalkyl Cl, un (C3-Cl heterocycloalkyl) - I (C1-C8 alkyl) -, (C3-Cl heterocycloalkyl) - (C1-C8 alkenyl)
C2 to Cg) -, a (C3 to C1 heterocycloalkyl) - (C2 to Cg alkynyl) -, an aryl, an aryl- (C1 to Cg alkyl) -, a heteroaryl and a ؛ heteroaryl- (C1 to C8 alkyl) -,
اي
MY
32201Β1
POl-2363-ff which elements mentioned above may be إ optionally substituted independently of each other with one or more substituents selected from the group consisting of ؛ fluorine, chlorine, bromine, HO-, NC-, 0 ؛ Ν-, F3C-, HFzC-, FHC-, ؛
F3C-CH2-, F3C-0-, HF2C-0-, HO- (C1 to C8 alkyl) -, R -0- إ (C1 to C8 alkyl) -, R١٥-S- (C1 to C8 alkyl) C1 to Cg) -, C 1 to C 8 alkyl, C 3 to C cycloalkyl, (C 3 to C cycloalkyl) - (C 1 to C 8 alkyl) -, (C 3 to C cycloalkyl, ) -o-, a (C3 to cycloalkyl
C,) - (C1 to C8 alkyl) -O-, aryl, aryl- (C1 to C8 alkyl) -, heteroaryl, heteroaryl- (C1 to C8 alkyl) -, heteroaryl0-, a heteroaryl- (C1 to C8 alkyl) -O-, a C3 to C1 heterocycloalkyl, a (C3 to C1 heterocycloalkyl) - (C1 to C8 alkyl) -, a (C3 to C heterocycloalkyl) - 0 - with C to C heterocycloalkyl, linked to 0 via one of its ring atoms, ئ a (C3 to C1 heterocycloalkyl) - (C1 to C8 a! Kyl) -O- with the C3 to C7 heterocycloalkyl linked to the C1 to C8 alkyl through one of its atoms ring c, (r1٥) 2N-, un (R) ٥) 2N- (C1-C8 alkyl) -, R٠ ؛ -O-, R٠ ؛ -S-, r1٥-CO-, RO-CO-,
R٥) 2N-C0-, un R ٥) 2N-CO- (C1-C8 alkyl) -, R<sup>3</sup>٥-CO- R٥) N-, a
R<sup>3</sup>٠-CO- (r1٠) N- (C1 to C8 alkyl) -, rI-CO-0-, r o-co-o-, un r! ٥O-CO0- (C1 to C8 alkyl) -, r1٥O -CO- (r1٥) N-, a R٥ ؛ O-CO- (r1٥) N- (C1 to Cg alkyl) -, an R ٥) 2N-CO-O- (C1 to Cg alkyl), a R٥ ) 2N-C0- R٥) N- j.
(C1 to C8 alkyl) -, R<sup>3</sup>٠-SO2_ R٥) N-, un r1٥-SO2- R٥) N- (C1 ؛-Cg alkyl) -, un (R<sup>3</sup>٠) 2N-SO2- (R<sup>3</sup>٠) N- (C1-C8 alkyl) -, (R ^ N-SO ؛ -, a
R ٥) 2N-SO2- (C1-C8 alkyl) - and (C1-C8 alkyl) -SÜ2-, whereby any of the C3 ؛ cycloalkyl groups to C1, C3 to C1 heterocycloalkyl, aryl, heteroaryl mentioned above may be optionally substituted, preferably independently of each other with HO-, NC-, Ο2Ν-, F3C-, HF2C-,
FHC-, F3C-CH2-, F3C-0-, HF2C-0-, HO- (C1 to C8 alkyl) -, r! ٥0- (C1 to C8 alkyl) -, R'٥-S - (C1 to C8 alkyl) -, C1 to C8 alkyl, R٥N-, one (Rl N- (C1 to C8 alkyl) -, r! ٥-O-, r! ٥-S-, r1٠- CO_, R O-CO-, R٥) 2N-C0-, un (r1n-C0- (C1 to C8 alkyl) -,
Rj٥-co- R٥) N-, a r! ٥-CO- R ٥) N- (C1-C8 alkyl) -, rI-CO-0-, RO35 CO-O-, a RO-CO-O- (C1 to C8 alkyl) -, R O-CO- (R٥ ؛) N-, a ROCO- (R<sup>3</sup>٥) N- (C1-C8 alkyl) -, (r1٠)<sub>2</sub>N-CO-O-, R٥) 2N-CO-R٥) N-, ؛
R٥NSO2- R٥) N-, un (Ri٥) zN-CO-O- (C1-C8 alkyl) -, un R٥) zN- ؛
CO- R ٥) N- (C1-C8 alkyl) -, r1٥-SO2_ R٠) N-, un R<sup>3</sup>٠-SO2_ (R<sup>3</sup>٥) N- ؛ '
ΜΑ 32201Β1
POl-2363-ff (C1 to C8 alkyl) -, un (R ^ ٥) 2N-SO2- (R) ٠) N- (C1 to Cg alkyl) -,
R٥N-SO2-, (R) ٠) 2N-SO2- (C1 to C8 alkyl) - or (C1 to C8 alkyl) -SO2-; :
r2 independently of any other r2 is chosen from the group comprising: إ
H-, fluorine, NC-, F3C-, HF2C-, FH ؛ C-, F3C-CH2-, carboxy, C 1 to C 8 alkyl (preferably C 2 to C 8 alkyl), إ alkenyl C2 to C8 alkynyl, C2 to Cg alkynyl, (C1 to C8 alkyl) S-, (C1 to Cg alkyl) -s- (C1 to C3 alkyl) -, cycloalkyl
C3 to C ,, one (C3 to C1 cycloalkyl) - (C1 to C8 alkyl) -, one (C3 to C1 cycloalkyl) - (C2 to C8 alkenyl) -, one (C3 to C8 cycloalkyl) - (C2 to C8 alkynyl) -, C3 to C1 heterocycloalkyl, (C3 to C1 heterocycloalkyl) - (C1 to C8 alkyl) -, (C3 to C1 heterocycloalkyl) - (C2 to Cg alkenyl ) -, (C3 to C18 heterocycloalkyl) - (C2 to C8 alkynyl) -, aryl, aryl- (C1 to C8 alkyl) -, heteroaryl, heteroaryl- (C1 to Cg alkyl) - , an R) ٠-O- (C<sub>2</sub> to C3) -, (r! ٠)<sub>2</sub>N-, RO-CO-,
R٥) 2N-CO-, r1٥-CO- (r1٥) N-, r1٥-CO-, (r1) 2N-CO- R٥) N-, r٠ ؛ -s٥2_ (Ri٠) N- and a (C1 to alkyl) Cg) -SO2_, the elements mentioned above possibly being optionally substituted independently of each other with إ one or more substituents selected from the group consisting of: إ fluorine, chlorine, bromine, NC-, CN-, F3C -, HC-, FHC-,
F3C-CH2-, HO- (C1 to C8 alkyl) -, (C1 to C، alkyl) - o25 (C1 to C8 alkyl) -, C1 to C8 alkyl, R٥N-, R٥N- إ (C1-C3 alkyl) - and R٠) 2N-CO-, إ and in the case where r2 is bonded to a nitrogen which is a ring element of Hc, this r2 must be independently of any other r2:
H-, F3C-CH2-, HF2C-CH2-, C1 to C8 alkyl, C ؛ alkenyl to إ
C8, C2 to C6 alkynyl, (C1 to 0 alkyl) - S- (C1 to ؛ alkyl
C3) -, C3-C1 cycloalkyl, (C3-C1 cycloalkyl) (C1-C8 alkyl) -, (C3-C1 cycloalkyl) - (C2-Cg alkenyl) -, (C1-C8cycloalkyl) - C3 to C7) - (C2 to C8 alkynyl) -, C3 to C1 heterocycloalkyl, (C3 to C1 heterocycloalkyl) (C1 to C8 alkyl) -, (C3 to C1 heterocycloalkyl) - (alkenyl in c<sub>2</sub> to Cg) -, a (C 3 to C 6 heterocycloalkyl) - (C 2 to C 6 alkynyl) -, an aryl, an aryl- (C 1 to C 8 alkyl) -, a heteroaryl, a
ΜΑ 32201Β1
POl-2363-ff heteroaryl- (C1-C8 alkyl) -, an R<sup>3</sup>٠-O- (C1-C3 alkyl) -, R<sup>3</sup>٥o-co-, (R1) 2N-CO-, R٠ ؛ -C٥-, R<sup>3</sup>٥-SO2- or a (C1-C8 alkyl) -so<sub>2</sub>-, the elements mentioned above being able to be optionally substituted independently of each other with one or more substituents chosen from the group consisting of:
fluorine, HO-, NC-, ON, F3C-, HF<sub>2</sub>C_, FHC-, F3C-CH-, HO (C1 to C8 alkyl) -, r! ٥-O- (C1 to C8 alkyl) -, C1 to C8 alkyl, rI-Ο-, ( R) zN-, one R ٥)<sub>2</sub>Ν- (C1 to C1 alkyl) - and (R<sup>3</sup>٥)<sub>2</sub>N-CO-;
r3 is independently selected from the group consisting of H-, hydroxy and R'٥-O-;
R<sup>4</sup> and R<sup>s</sup> are independently selected from one another from the group consisting of H-, fluorine, F3C-, HF<sub>2</sub>C-, FHC- and ع to C-3 alkyl,
R<sup>4</sup> and R<sup>5</sup> together with the additional carbon atom they are linked to form a 3- to 6-membered cycloalkyl group.
the above-mentioned elements, carbocyclic y form, may be substituted independently of each other with optionally including the ring and one or more substituents selected from the group consisting of:
fluorine, HO-, NC-, 0<sub>2</sub>N-, F3C-, HF<sub>2</sub>C_, FHC-, F3C-CH-, HO (C1 to C8 alkyl) -, CH3-0- (C1 to C8 alkyl) -, C1 to C8 alkyl, (C1 to C8 alkyl) -O- and one (C1 to C8 alkyl)<sub>2</sub>N-CO-;
r} ٥ independently of any other r! ٥ is chosen from the group comprising:
H- (but not in the case where it is part of a group selected from RO-CO-, r ”-SO<sub>2</sub>- or R٠ ؛ -CO-1, F3C-CH-, C1 to C alkyl<sub>6</sub>, an alkenyl in 0<sub>2</sub> to C8, a C3 to C7 cycloalkyl, a (C3 to C- cycloalkyl) - (C1 to C3 alkyl) -, an aryl, an aryl (C1 to C3 alkyl) -, a heteroaryl and a heteroaryl- (C1 to C alkyl) -, and in the case where two groups r! ٥ are both bonded to the same nitrogen atom, they can together with said nitrogen atom form a 3 to 7 membered heterocycloalkyl ring, and in which one of the groups -CH<sub>2</sub>- of the heterocycloalkyl ring formed can be replaced by -0-, -s-, -NH-, a -N (C3 to Cg cycloalkyl) -, a -N ((C3 to Cg cycloalkyl) - (C1 to Cg alkyl) c) - or an N (C1 to C، alkyl) -, preferably, and in particular of
<img file="MA32201B1_D0048.tif" />
ΜΑ 32201Β1 ؛
٠^
POl-2363-ff preferably in the case of (R N-CO-, these two groups r1٥ together with said nitrogen atom are linked to form a group selected from piperidinyl, piperazinyl, pyrrolidinyl, morpholinyl and thiomorpholinyl , and the elements mentioned above can be optionally substituted independently of each other with one or more substituents selected from the group consisting of fluorine, chlorine, bromine, HO-, NC-, 0<sub>2</sub>N-, F3C-, HF ؛ C-, FHC-,
F3C-CH2-, HO- (C1-C8 alkyl) -, CH-O- (C1-C8 alkyl) -, C1-C8 alkyl and (C1-C8 alkyl) -O-;
x independently of any other X = 0, 1, 2, 3 or 4, preferably X = 0, 1 or 2, preferably X = 0 or 1, and more preferably X = 0;
y independently of any other y = 0 or 1, and more preferably y = 0;
and a pharmaceutically acceptable salt or solvate thereof, provided that if Hc is an oxetanyl which is bonded through the 20 carbon atom lying adjacent to the oxygenate of the oxetanyl, it does not. there is no substituent attached to said carbon atom by
The intermediary of a -CH- spacer.
A thirteenth aspect of the invention relates to a compound of general formula I of the twelfth aspect of the invention, wherein
Hc is a heterocyclyl group having a formula selected from the group of formulas 1.1, 1.2 and 1.3:
Formula 1.1:
*
<img file="MA32201B1_D0049.tif" />
where n = 1, 2, 3;
MY
32201Β1
POl-2363-ff χΐ X<sup>2</sup>, X<sup>2</sup>, independently of each other, are CH, CHR<sup>2</sup>, CHR<sup>2</sup>, C (R<sup>2</sup>) 2, CRR, o, NH, NR<sup>2</sup> or s (o) r where r = 0, 1, 2, whereby at least one of χΐ, X<sup>2</sup>, X<sup>2</sup> is o, NH, NR<sup>2</sup> or S (O) r;
#: means that the ring is not aromatic, whereas 5 for n = 1, one bond within the ring system can optionally be a double bond, and for n = 2 or n = 3, one bond or two bonds inside the ring system. the interior of the ring system can / can optionally be (a) a double bond or double bonds, thereby replacing hydrogen atoms linked to ring elements, whereby said double bond or double bonds are preferably a cc double bond, and more preferably the ring is saturated;
Formula 1.2:
<img file="MA32201B1_D0050.tif" />
A is the ring system of formula 1.1;
B is a 3, 4, 5 or 6 membered second ring system which is annealed to A and which, in addition to the two atoms and a bond which may be a single bond or a double bond - which it shares with A, is only composed of carbon atoms and can be saturated, partially saturated, or aromatic; the R substituents<sup>2</sup> and / or R<sup>2</sup> independently of each other and independently of X and y may be on ring A or ring B; whereby the two ring atoms which are shared by the two ring systems A and B can both be carbon atoms, can both be nitrogen atoms, or one can be a carbon atom and! other can be a nitrogen atom, whereby two carbon atoms or one carbon atom and one atom
<img file="MA32201B1_D0051.tif" />
32291B1 of nitrogen are preferred and two carbon atoms are more preferred;
Formula 1.3:
POl-2363-ff
Θ ©
<td></td><td>AT</td><td>is</td><td>the system</td><td>cyclic</td><td>of formula 1.1;</td><td></td>
<td></td><td>vs</td><td>is</td><td>a second</td><td>system</td><td colspan="2">cyclic, saturated or partially</td>
<td></td><td>saturated.</td><td>to 3,</td><td>4, 5 or 6</td><td>links</td><td>which is spiro-fuses to A</td><td>and who تم</td>
<td> 10</td><td>more</td><td>of</td><td>! 'atom qu</td><td colspan="2">'he shares with A, is only</td><td>compound</td>
of carbon atoms and the substituents R<sup>2</sup> and / or R<sup>3</sup> independently of each other and independently of X and y may be on ring A or ring c;
r! is chosen from the group comprising:
C1 to C8 alkyl, C3 to C1 cycloalkyl, (C3 to C1 cycloalkyl) - (C] to c) alkyl, C3 to C1 heterocycloalkyl, aryl and heteroaryl, the elements mentioned above above which may be optionally substituted independently of each other with one or more substituents selected from the group consisting of fluorine, chlorine, bromine, HO-, NC-, O<sub>2</sub>N-, F3C-, HF<sub>2</sub>C_, FHC-, F3C-CH2-, F3C-0-, HF<sub>2</sub>CO-, HO- (C1 to C8 alkyl) -, rJ٥-O (C1 to C؛ alkyl) -, C1 to C8 alkyl, C3 to C1 cycloalkyl, (C3 to C4 cycloalkyl) Cl) - (C1 to C8 alkyl) -, aryl, aryl- (C1 to C8 alkyl) -, heteroaryl, heteroaryl- (C1 to C8 alkyl) -, C3 to C1 heterocycloalkyl, (C 3 to C heterocycloalkyl) - (C 1 to C 8 alkyl) -, tetrahydrofuranyl-O-, tetrahydro-pyranyl-O-, piperidinyl-O- where the piperidinyl is linked to O via! one of its ring C atoms, a pyrrolidinylO- where the pyrrolidinyl is linked to 0 through one of its ring atoms, (r! ٠)<sub>2</sub>N-, one R٠)<sub>2</sub>NOT-
<img file="MA32201B1_D0052.tif" />
ΜΑ 32201Β1
POl-2363-ff (C1-C8 alkyl) -, R٥ ؛ -O-, R ؛ (٥N-CO-, un R ؛ (٥Ν-0- (alkyl)
Cl to Cg) -, r1-C0- (r! ٥) N-, un R٥ ؛ -CO- (R٥ ؛) N- (C1 to Cg alkyl) -, RO CO-Ο- and R O-CO- R٠) N-;
whereby any of the C 3 -C 5 cycloalkyl, C 3 -C heterocycloalkyl, aryl, heteroaryl, tetrahydrofuranyl, tetrahydro-pyranyl, piperidinyl, pyrrolidinyl groups mentioned above may be optionally substituted, preferably independently of the above. each other with NC-, (N, F3C-, HC-, FHC-, F3C-CH2-, F3C-0-, HF2C-0-, a R٥ ؛ -O10 (C] -C8 alkyl) -, a C1 to C8 alkyl, r1٥-O-, R٠ ؛ -CO-, RO-CO or (R JNCO-, whereby piperidinyl or pyrrolidinyl is preferably substituted with R٥ ؛ -CO-;
R<sup>2</sup> independently of any other R<sup>2</sup> is chosen from the group comprising:
H-, fluorine, FjC-, HFzC-, FHC-, F3C-CH2-, C1 to alkyl
C8 (preferably C<sub>2</sub> to Cg), R٥) 2N-CO-, r1٠-CO- R٥) N-, the above-mentioned elements being optionally substituted independently of each other with one or more substituents selected from the group consisting of:
fluorine, chlorine, bromine and C1 to C8 alkyl, and in the case where R<sup>2</sup> is linked to a nitrogen which is a cycle element of Hc, this R<sup>2</sup> must be independent of any other R<sup>2</sup> : H-, F3C-CH2-, HF2C-CH2-, C 1 -C 8 alkyl, C 3 -C cycloalkyl ,, (C 3 -C cycloalkyl) - (C 1 -C 8 alkyl) -, heterocycloalkyl C3 to C ,, a (C 3 to C heterocycloalkyl) (C 1 to C 8 alkyl) -, an aryl, an aryl- (C 1 to C 8 alkyl) -, a heteroaryl, a heteroaryl- (C 1 to C 8 alkyl) ) -, R٥ ؛ -O- (C1 to C alkyl) -, R O-CO-, R٠N-CO-, R٥ ؛ -CO- or (C1 to CgSOz- alkyl, the elements mentioned above which can be optionally substituted, independently of each other, with one or more substituents selected from the group consisting of fluorine and C 1 to C 8 alkyl;
R<sup>3</sup> independently of any other R<sup>3</sup> is chosen from the group comprising:
H-, hydroxy and (C1-C8 alkyl) -O-, whereby the (C1-C8 alkyl) -O- group may optionally be
<img file="MA32201B1_D0053.tif" />
ΜΑ 32201Β1
POl-2363-ff substituted with one or more fluorine, chlorine, bromine and HO-; preferably, R<sup>3</sup> is H;
r4 and R<sup>3</sup> are independently selected from the group consisting of H-, fluorine and methyl; preferably,
Regardless of each other, are H or fluorine, and more preferably R<sup>4</sup> and R ؛ are both H;
R٥ ؛ independently of any other R<sup>w</sup> is chosen from the group comprising:
C1 to C alkyl, C1 to C4 cycloalkyl, aryl and heteroaryl, and in the case where two R) ٥ groups are both bonded to the same nitrogen atom, they can together form with said nitrogen atom is a 3- to 7-membered heterocycloalkyl ring, and wherein one of the -CH- groups of the heterocycloalkyl ring may be replaced by -O-, -NH-, a -N (C-cycloalkyl<sub>3</sub> at Ce) -, a -Ncycloalkyl in c<sub>3</sub> to C8) - (C1 to C، alkyl)) - or a -N (C1 to CJ alkyl-, preferably, and in particular preferably in the case of R٥N-CO-, these two r! ٠ together with said nitrogen atom are linked to form a group selected from piperidinyl, piperazinyl, pyrrolidinyl, morpholinyl and thiomorpholinyl, and the above mentioned elements may be optionally substituted independently of each other with one or more selected substituents in the group constituted by:
fluorine, NC-, F<sub>3</sub>C-, HFzC-, FHC-, FCCH-, CHO- (C1-C8 alkyl) -, C1-C8 alkyl and (C1-C8 alkyl) -O-;
X independently of any other x = 0, 1, 2, 3 or 4, preferably X = 0, 1 or 2, preferably X = 0 or 1, and more preferably X = 0;
y independently of any other y = 0 or 1, and more preferably y = 0;
and! one of its pharmaceutically acceptable salts or solvates.
A fourteenth aspect of the invention relates to a compound of general formula I of the twelfth aspect of the invention, wherein
Hc is a heterocyclyl group chosen from the group comprising:
MA 32291 Bl
POl-2363-ff
<td>٠ € ï</td><td> ٥&٠</td><td>* F</td><td>0 II Γ٢—0 لآ ٠</td><td></td>
<td> ٠٥</td><td> ٥.</td><td> ٠٥</td><td>ه.</td><td> ٥</td>
<td> .۵</td><td> ٥•</td><td>مه.</td><td> ٥٠٠.</td><td>،، قيم</td>
<td>Q</td><td> ٥٠•</td><td>مه.</td><td>ه.</td><td>ه.</td>
<td> ٥.</td><td> ٥.</td><td>ه</td><td> ٠٥</td><td> ٠٥</td>
<td> ٥'</td><td>لا</td><td>دثم.</td><td> ٠.</td><td>اثم '</td>
<td> ٥.</td><td>اثم '</td><td> ٠.</td><td>هثم.</td><td>٠ مم.</td>
<td>زغ '</td><td>۶/٠١١ ي</td><td>اثم '</td><td>دع-</td><td>۶/٥١١ دثم.</td>
<td>Cf</td><td>نمم ه</td><td>مم لا</td><td> ٥</td><td> ٠٥</td>
<td>مع</td><td>2 لا ٠ ا (لد ٧ ح</td><td>هظلآئ 2 1 or (تبح</td><td colspan="2">OQ, CQ</td>
O
ثم
POl-2363-ff
<img file="MA32201B1_D0054.tif" />
Ο
<img file="MA32201B1_D0055.tif" />
<img file="MA32201B1_D0056.tif" />
<img file="MA32201B1_D0057.tif" />
X = 0, s or NX = 0, s or NX = 0, s or N p = 1, 2, 3, p = 1, 2, 3, p = 1, 2, 3, or 5 or 5 or 5 q = 1, 2 or 3 q = 1, 2 or 3 q = i, 2 or 3
R ؛ is chosen from the group comprising:
C1 to C8 alkyl, C3 to C1 cycloalkyl, (C3 to C1 cycloalkyl) - (C1 to C1) -, C3 to C1 heterocycloalkyl, aryl and heteroaryl, the elements mentioned above above may be optionally substituted independently of each other with one or more substituents selected from the group consisting of fluorine, chlorine, bromine, HO-, NC-, Ο2Ν-, F3C-, HF2C-, FHC-,
F3C-CH2-, F3C-0-, HF2C-0-, HO- (C1 to C8 alkyl) -, R٥ ؛ -O (C1 to C8 alkyl) -, C1 to C8 alkyl, cycloalkyl C3 to C1, (C3 to C1 cycloalkyl) - (C1 to C8 alkyl) -, aryl, aryl- (C1 to C8 alkyl) -, heteroaryl, heteroaryl- (C1 to Cg alkyl) ) -, a C3 to C1 heterocycloalkyl, a (C3 to C1 heterocycloalkyl) - (C1 to C8 alkyl) -, a tetrahydrofuranyl-O-, a tetrahydro-pyranyl-O-, a piperidinyl-O- where the piperidinyl is linked to 0 through one of its ring c atoms, a pyrrolidinyl-O- where the pyrrolidinyl is linked to O through one of its ring c atoms ring, R٥) 2N-, a R٥) 2N (C] -C8 alkyl) -, RO-, R٥N-CO-, a R٥N-CO- (C1-C8 alkyl) -, R٥ ؛ -CO- R٥) N-, R٥ ؛ -CO- R ٥) N- (C1-C8 alkyl) -, ROCO-0- and RO-CO- R٠) N-;
whereby any of the C 3 -C cycloalkyl, C 3 -C heterocycloalkyl, aryl, heteroaryl, tetrahydrofuranyl, tetrahydro-pyranyl, piperidinyl, pyrrolidinyl groups mentioned above can be optionally substituted, preferably independently of any of the above. others with
ل
MA 32201 Bl .65 إ POl-2363-ff إ NC-, OzN-, FjC-, HF<sub>2</sub>C-, FHC-, F3C-CH2-, F3C-0-, HF<sub>2</sub>CO-, R٥-O ق (C1 to Cg alkyl) -, C1 to Cg alkyl, H٥-O-, R'٥-CO-, R O-CO or (r! ٥) 2N-CO—, by means of which piperidinyl or pyrrolidinyl is preferably substituted with r4٠-CO_;
R<sup>2</sup> independently of any other R<sup>2</sup> is chosen from the group ؛ including:
H-, fluorine, F3C-, HFC-, FHC-, F3C-CH2-, C1 to C8 alkyl (preferably C1 to C8 alkyl)<sub>2</sub> to Cg), (R N-CO-, r4٠-CO- R٥) N-, the above-mentioned elements being optionally substituted independently of each other with one or more substituents selected from the group consisting of: fluorine , chlorine, bromine and C1 to C8 alkyl, and in the case where R<sup>2</sup> is bound to a nitrogen mistletoe which is a cycle element of Hc, this R<sup>2</sup> must be independent of any other R<sup>2</sup> : 15 H-, F3C-CH2-, HF<sub>2</sub>C-CH<sub>2</sub>-, C1 to C8 alkyl, C3 to C1 cycloalkyl, (C3 to C1 cycloalkyl) - (C1 to C8 alkyl) -, C3 to C1 heterocycloalkyl, (C3 to C1 heterocycloalkyl) ( C1 to C8 alkyl) -, aryl, aryl- (C1 to C8 alkyl) -, heteroaryl, heteroaryl- (C1 to C8 alkyl) -, R<sup>3</sup>٥-O_ (C1 to C3 alkyl) -, R O-CO-, (R<sub>2</sub>(٠ ؛ N-CO-, r! ٥-CO- or a (C1 to
Cg) -so<sub>2</sub>-, the elements mentioned above possibly being optionally substituted, independently of each other, with one or more substituents selected from the group consisting of fluorine and C1 to C8 alkyl;
R<sup>3</sup> independently of any other R<sup>3</sup> is chosen from the group comprising:
H-, hydroxyl and (C1-C8 alkyl) -O-, whereby the (C1-C؛ alkyl) - o- group may be optionally substituted with one or more fluorine, chlorine, bromine and HO-;
r4 and R<sup>3</sup> are selected independently of each other from the group consisting of H-, fluorine and methyl; preferably, independently of one another, are selected from the group consisting of H and fluorine, and more preferably R<sup>4</sup> and
R<sup>5</sup> are H;
R٥ ؛ independently of any other rI is chosen from the group comprising:
MY
32201BI
POl-2363-ff C1-C8 alkyl, C3-C8 cycloalkyl, aryl and heteroaryl, the above-mentioned elements being optionally substituted independently of each other with one or more substituents selected from the group consisting of :
fluorine, F3C-, HC-, FHC-, F3C-CH2-, CH3-0- (C1 to C8 alkyl) -, C1 to C8 alkyl and (C1 to C8 alkyl) -O-;
X independently of any other X = 0, 1, 2, 3 or 4, preferably X = 0, 1 or 2, preferably X = 0 or 1, and more preferably X = 0;
y independently of any other y = 0 or 1, and more preferably y = 0;
and a pharmaceutically acceptable salt or solvate thereof, provided that if Hc is an oxetanyl which is linked through the carbon atom lying adjacent to the oxygenate of the oxetanyl, there is no has no substituent bonded to said carbon atom through a -CH- spacer.
A fifteenth aspect of the invention relates to a compound of the thirteenth aspect of the invention, wherein
Hc is selected from the group consisting of tetrahydropyranyl, tetrahydrofuranyl, piperidinyl and pyrrolidinyl;
and
R<sup>2</sup> independently of any other R<sup>2</sup> is selected from the group consisting of H- and C1-C8 alkyl, and in the case where R<sup>2</sup> is linked to a nitrogen which is a cycle element of Hc, this R<sup>2</sup> must be independent of any other R<sup>2</sup> :
H-, (C1 to C؛ alkyl) - co-, (C1 to C8 alkyl) -O-CO-, C1 to C8 alkyl, phenyl-C0-, phenyl-0-CO- , (C1-C8 alkyl) zN-C0-, the above-mentioned elements being optionally substituted, independently of each other, with one or more fluorine substituents; and
R<sup>4</sup> and R<sup>s</sup> are H and
ΜΑ 32201Β1
POl-2363-ff ت
independently of any other ١٥ is selected from the group consisting of C 1 -C 6 alkyl, phenyl and pyridyl, the above-mentioned elements being optionally substituted independently of each other with one or more substituents selected from the group consisting of by :
fluorine, F3C-, HC-, FHC-, F3C-CH2-, CH3-0- (C1 to C8 alkyl) -, C1 to C8 alkyl and (C1 to C8 alkyl) -O-.
A sixteenth aspect of the invention relates to a compound of the fifteenth aspect of the invention, wherein
١ is chosen from the group comprising:
phenyl, 2-, 3- and ، -pyridyl, pyrimidinyl, pyrazolyl, thiazolyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentylmethyl, ethyl, propyl, 1 - and 2-buty! e, the 1-,
2- and 3-penty! E, tetrahydrofuranyl and tetrahydro-pyranyl, which groups may be optionally substituted with one or more substituents selected from the group consisting of HO-, NC-, (C1 to C alkyl) - o-, C1 to C8 alkyl, (C3 to C7 cycloalkyl) -O-, (C3 to C7 cycloalkyl) - (C1 to C7) alkyl
Cl to ¢ 3) -0-, CF3O-, CF3-, fluorine, chlorine, bromine, C3 to C7 heterocycloalkyl and (C3 to C1 heterocycloalkyl) (C1 to C8 alkyl) -,
A seventeenth aspect of the invention relates to a compound exhibiting all the characteristics of the sixteenth aspect of the invention, except that is selected from the group comprising:
phenyl, 2-, 3- and 4-pyridyl, cyclo-propyl, cyclobutyl, cyclopentyl, cyclo-hexyl, cycloheptyl, cyclopentylmethyl, ethyl, propyl, 1- and 2-butyl , 1-,
2- and 3-penty! E, tetrahydrofuranyl and tetrahydro-pyranyl, which groups may be optionally substituted with one or more substituents selected from the group consisting of NC-, (C1 to C؛ alkyl) - o-, C1 to C alkyl<sub>6</sub>, CF3O-, CFg- and a halogen, the halogen preferably being chosen from the group comprising fluorine, chlorine and bromine.
A specific aspect of the invention (eighteenth aspect) relates - independently of one another and separable from the other aspects - each of the following compounds and / or, when this
<img file="MA32201B1_D0058.tif" />
<img file="MA32201B1_D0059.tif" />
32201Β1
POl-2363-ff is applicable, each specific stereoisomer thereof and / or ؛ their tautomer and / or! 'one of their pharmaceutically ؛ salts acceptable. Each compound is represented and considered under the ؛ form of the neutral compound without indicating their stereochemistry, if it إ exists. The left column indicates the example from which the compound إ is derived. Specific information regarding stereochemical properties can be found in section ؛ experimental, section “examples of embodiments”. In the case where the final compounds according to said section "exemplary embodiments" are salts, they can be converted neutre into neutral compound (free base or free acid) using conventional أ methods. ج
<td>Example No.</td><td>Structure</td>
<td> 1</td><td></td>
<td> 2</td><td>و</td>
<td> 3</td><td></td>
ΜΑ 32201Β1
69 POl-2363-ff ؛
<td> 4</td><td></td>
<td> 5</td><td>ولا</td>
<td> 6</td><td> :</td>
<td> ٦</td><td></td>
<td> 8</td><td>لآم</td>
MA 32201 BI
POl-2363-ff
<td> 9</td><td></td>
<td> 10</td><td>ج</td>
<td> 11</td><td>ممح</td>
<td> 12</td><td>ؤب-</td>
<td> 13</td><td>ب'رذ</td>
MA 32201 Bl
POl-2363-ff
<td> 14</td><td>جلي</td>
<td> 15</td><td> ٨٦</td>
<td> 16</td><td> .٥٦</td>
<td> 17</td><td></td>
/
<img file="MA32201B1_D0060.tif" />
32291Bl
POl-2363-ff
<td> 18</td><td> -...</td>
<td> 19</td><td>لخلاذكراً '<sup>٢</sup> تمخخ ي ٠</td>
<td> 20</td><td></td>
<td> 21</td><td></td>
<td> 22</td><td>ذي</td>
<img file="MA32201B1_D0061.tif" />
ΜΔ
32201Bl
POl-2363-ff
<td> 23</td><td> ,</td>
<td> 24</td><td> ٦٠٦</td>
<td> 25</td><td> ٠٨.</td>
<td> 26</td><td>حلالم ه ٥٠</td>
MA 32201 BI
POl-2363-ff
<td>اة</td><td>حدت غ ه</td>
<td> 28</td><td>٩ ج</td>
<td> 29</td><td>رب.</td>
<td> 30</td><td>ي</td>
<img file="MA32201B1_D0062.tif" />
ΜΑ 32201Β1
POl-2363-ff
<td> 31</td><td> ٩,</td>
<td> 32</td><td>جذدم</td>
<td> 33</td><td>فتي</td>
<td> 34</td><td>دم '</td>
<img file="MA32201B1_D0063.tif" />
MY
32201Β1
POl-2363-ff
<td> 35</td><td> ١٥</td>
<td> 36</td><td>حدتم</td>
<td>٦ ة</td><td>ذف</td>
<td> 38</td><td>ه ..</td>
MY
32201Β1
POl-2363-ff
<td> 39</td><td> ٠٩.</td>
<td rowspan="2"> 40 40-1</td><td> ·٠٩</td>
<td>مه</td>
<td> 40-2</td><td>ه ب'ء 0 /</td>
<img file="MA32201B1_D0064.tif" />
ΜΑ 32201Β1
POl-2363-ff
<td> 40-3</td><td>Ο دعا ٠٩</td>
<td> 40-4</td><td>٠١٥٦١٠ ό</td>
<td> 40-5</td><td>اتم</td>
<td> 40-6</td><td>١ ثم</td>
MY
32201Β1
POl-2363-ff
<td> 40-7</td><td>رك</td>
<td> 41</td><td></td>
<td> 42</td><td>زد!</td>
<td> 43</td><td>ار ٩</td>
ΜΑ 32201Β1
POl-2363-ff
<td> 44</td><td>. ه ؛ :</td>
<td> 45</td><td></td>
<td> 46 & 131 & 132</td><td>ري</td>
<td> 47</td><td> ۶١</td>
ΜΑ 32201Β1
POl-2363-ff
<td> 48</td><td>-لاع.</td>
<td> 49</td><td>ةش.</td>
<td> 50</td><td>ض</td>
<td> 51</td><td>ر'د</td>
<td> 52</td><td>ذي</td>
MA 32201 Bl
POl-2363-ff
<td> 53</td><td>٦ ى</td>
<td> 54</td><td> ٨-</td>
<td> 55</td><td>أذيم</td>
<td> 56</td><td>مع.</td>
<td> 57 & 58</td><td></td>
ΜΑ 32201Β1
POl-2363-ff
<td>0 ج</td><td></td>
<td> 61 & 62</td><td>ب ؛ ',</td>
<td> 63</td><td>٠ ح ٦ خ</td>
<td> 64</td><td>Ή σ</td>
<td> 65</td><td>هط; ٠σ</td>
MA 32201 Bl
POl-2363-ff
<td> 66</td><td>٠ يأه at</td>
<td>0٦ ا</td><td>٠٠ ر '٠٠</td>
<td> 68</td><td></td>
<td> 69</td><td></td>
<td> 70</td><td> ٩<sub>؛</sub>٠</td>
<img file="MA32201B1_D0065.tif" />
ΜΑ 32201Β1
POl-2363-ff
<td> 71</td><td>٦ ع</td>
<td> 72</td><td>لاذر.</td>
<td> 73</td><td>٤ د</td>
<td> 74 & 132-3 & 132-4</td><td><sub>؛</sub>·'٦</td>
<td> 75</td><td>ذزدج..٢</td>
<img file="MA32201B1_D0066.tif" />
ΜΑ 32201Β1
POl-2363-ff
<img file="MA32201B1_D0067.tif" />
MA 32201Β1
POl-2363-ff
<td> 81</td><td> ١.</td>
<td> 82</td><td>.'ز</td>
<td> 83</td><td>٦ ؛ ي</td>
<td> 84</td><td> ٦؛٠·٠:</td>
<td> 85</td><td>غية</td>
ΜΑ 32201Β1
POl-2363-ff
<td> 86</td><td>أيدو</td>
<td> 87</td><td>أهج</td>
<td> 88</td><td> ٩٩</td>
<td> 89</td><td>هئ</td>
<td> 90</td><td>ذم.</td>
MA 32201 BI
POl-2363-ff
<td> 91</td><td>٠ç٩٦</td>
<td> 92</td><td> ٩٦</td>
<td> 93</td><td>رتيرج</td>
<td> 94</td><td> ٠٩</td>
<td> 95</td><td> ٩</td>
ΜΑ 32201Β1
POl-2363-ff
<td> 96</td><td>لأل ؛</td>
<td> 97</td><td> ٦٦'</td>
<td> 98</td><td>دي H</td>
<td> 99</td><td> ٩١</td>
<td> 100</td><td>ζ٩١</td>
MA 32201 BI
POl-2363-ff
<td> 101</td><td>٦'٦ا.</td>
<td> 102</td><td>٦ ك</td>
<td> 103</td><td>ميلح</td>
<td> 104</td><td> ٩...</td>
<td> 105</td><td> .٠٦•</td>
<img file="MA32201B1_D0068.tif" />
32201Β1
POl-2363-ff
<td> 106</td><td>٦ ت</td>
<td> 108</td><td>حلايل:</td>
<td> 111 & 118</td><td>اب</td>
<td> 112 & 117</td><td>١ ن</td>
<td> 113 & 116</td><td> ٩٠؟</td>
MA 32201 Bl
POl-2363-ff
<td> 114 & 115</td><td> .٩:</td>
<td> 119</td><td>- (؟ يلد</td>
<td> 120</td><td> ٥١١٠٠</td>
<td> 121</td><td>يقج</td>
<td> 122</td><td>؛ 'ذب</td>
ΜΑ 32201Β1
POl-2363-ff
<td> 123</td><td>٦ ع</td>
<td> 124</td><td>.وئي</td>
<td> 125</td><td>عب ه لأ</td>
<td> 126</td><td>. ذر</td>
<td> 127</td><td>CC.</td>
ΜΑ 32201Β1
POl-2363-ff
<td> 128</td><td> ۶٦.</td>
<td> 129</td><td> ٠·:>؟</td>
<td> 130</td><td> '</td>
<td> 132-1</td><td>از</td>
<td> 132-2 & 132-5</td><td>ولية رنم</td>
ΜΑ 32201Β1
POl-2363-ff
<td> 132-6 & 132-9</td><td> ٠٩</td>
<td> 132-7</td><td>ر ٢.</td>
<td> 132-8</td><td>كوهد</td>
<td> 133</td><td>لأليت ١ 0</td>
<td> 134</td><td>٠-ؤح -٦:</td>
MA 32201 Bl
POl-2363-ff
<td> 135</td><td> ١</td>
<td> 136</td><td></td>
<td> 137</td><td>لأتم</td>
<td> 138</td><td>.'ح:</td>
<td> 139</td><td>ن ؛ - ؛، '</td>
MY
322٥1Β1
؛
POl-2363-ff
<td> 140</td><td>ئ. ، ٠</td>
<td> 141</td><td>ذم</td>
<td> 142</td><td>٦ ئئيئ</td>
<td> 143</td><td>h ؛ '</td>
<td> 144</td><td>ا</td>
MY
32291Bl
POl-2363-ff
<td> 145</td><td> ?</td>
<td> 146</td><td></td>
<td> 147</td><td></td>
<td> 147-1</td><td> ٦></td>
<td> 147-2</td><td>٦١ ز</td>
<img file="MA32201B1_D0069.tif" />
ΜΑ 32201Β1
100 POl-2363-ff
<td> 147-3</td><td></td>
<td> 148</td><td>لأتم</td>
<td> 149</td><td></td>
<td> 150</td><td></td>
<td> 151</td><td></td>
<img file="MA32201B1_D0070.tif" />
MA 32201 Bl
101
POl-2363-ff
<td> 152</td><td></td>
<td> 153</td><td>خلادلآب<sup>٠</sup>ύ ο_</td>
<td> 154</td><td></td>
<td> 155</td><td></td>
<td> 156</td><td> :</td>
MY
32201Β1
102 POl-2363-ff
<td> 157</td><td> 1.</td>
<td> 158</td><td>٩ ئ ٠ زم</td>
<td> 159</td><td>ح</td>
<td> 160</td><td>لا</td>
<td> 161</td><td>دلا</td>
'MY
32201Β1
103 POl-2363-ff
<td> 162</td><td>Λ ، ٠</td>
<td> 163</td><td>ب</td>
<td> 164</td><td>ب</td>
<td> 165</td><td> ...</td>
<td> 166</td><td>ي</td>
ΜΑ 32201Β1
104
POl-2363-ff
<td> 167</td><td></td>
<td> 168</td><td> ٦</td>
<td> 169</td><td>ج'٦; '</td>
<td> 170</td><td> :</td>
<img file="MA32201B1_D0071.tif" />
ΜΑ 32201Β1
105
POl-2363-ff
<td> 171</td><td></td>
<td> 172</td><td></td>
<td> 173</td><td>... ر</td>
<td> 174</td><td>ز ؛ .٢٩</td>
<td> 175</td><td> . ٦</td>
MY
32291Bl
106
POl-2363-ff
<td> 176</td><td></td>
<td> 177</td><td>لاير</td>
<td> 178</td><td></td>
<td> 179</td><td></td>
<td> 180</td><td>'٦Ή٦η-ο</td>
<td> 181</td><td>ر</td>
ΜΑ 32201Β1
107 POl-2363-ff
<td> 182</td><td></td>
<td> 183</td><td>..- ري</td>
<td> 184</td><td> ٦.</td>
<td> 185</td><td>'مه</td>
<td> 186</td><td>د ؛ حبي</td>
t% 21٩٦
108
POl-2363-ff
<td> 187</td><td>., لأ /.</td>
<td> 188</td><td></td>
<td> 189</td><td></td>
<td> 190</td><td> ١</td>
<td> 191</td><td> ...</td>
MA 32201 Bl
109
POl-2363-ff
<td> 192</td><td></td>
<td> 193</td><td></td>
<td> 194</td><td>٩ ح</td>
<td> 195</td><td>إ ٦</td>
<td> 196</td><td> .;٦٢;</td>
<img file="MA32201B1_D0072.tif" />
ΜΑ 32201Β1
110
POl-2363-ff
<td> 197</td><td> -٩'</td>
<td> 198</td><td>ع ٦ لادبب<sup>ع</sup>ئ لا</td>
<td> 199</td><td>٩ ا</td>
<td> 200</td><td>٦ ب '</td>
<td> 201</td><td>دغ</td>
MA 32201 Bl
111
POl-2363-ff
<td> 202</td><td>٩ ب</td>
<td> 203</td><td>علادئب ٠ V فع</td>
<td> 204</td><td> ٦</td>
<td> 205</td><td> :</td>
<td> 206</td><td>-٦ ج</td>
ΜΑ 32201Β1
112
POl-2363-ff
<td> 207</td><td> ٨٩</td>
<td> 208</td><td> .٩</td>
<td> 209</td><td>مد 'E -ة لا</td>
<td> 210</td><td>٩ ئ</td>
<td> 211</td><td>٦ ر'٢ '</td>
<img file="MA32201B1_D0073.tif" />
ΜΑ 32201Β1
113
POl-2363-ff
<td> 212</td><td>F</td>
<td> 213</td><td>ق'ش</td>
<td> 214</td><td> ٢٦</td>
<td> 215</td><td></td>
<td> 216</td><td> ...</td>
<img file="MA32201B1_D0074.tif" />
ΜΑ 32201Β1
114
POl-2363-ff
<td> 217</td><td>'' ر</td>
<td> 218</td><td> ٠٩</td>
<td> 219</td><td></td>
<td> 220</td><td> ٦</td>
<td> 221</td><td> :</td>
<img file="MA32201B1_D0075.tif" />
MY
32201Β1
115
POl-2363-ff
<td> 222</td><td> ٩</td>
<td> 223</td><td></td>
<td> 224</td><td></td>
<td> 225</td><td> :٦</td>
<td> 226</td><td>أي ٩</td>
<td> 22٦</td><td> ٦ ٦ ---</td>
ΜΑ 32201Β1
116
POl-2363-ff
<td> 228</td><td></td>
<td> 229</td><td></td>
<td> 230</td><td> ' ٠</td>
<td> 230-1</td><td> ١٠</td>
<td> 230-2</td><td></td>
ΜΑ 32201Β1
117
POl-2363-ff
<td> 230-3</td><td></td>
<td> 230-4</td><td>ؤي.</td>
<td> 231</td><td>زردج-</td>
<td> 232</td><td>لا? بج</td>
<td> 233</td><td>١'ذ ٦</td>
32201Β1
118
POl-2363-ff
<td> 234</td><td></td>
<td> 235</td><td>ه</td>
<td> 236</td><td></td>
<td> 237</td><td> ٦</td>
These 18 main aspects of the invention, their subgroups and certain other aspects of the invention are listed as elements of the following matrix 0 and matrix I, which use the notation (Hc ؛ R ن '؛ R<sup>2</sup>'k R<sup>3</sup>'ل R<sup>4/5</sup>'<sup>m</sup> R٥ ؛ 'f') which is read as defined above, that is to say with the general formula I and the remaining characteristics, such as X and Y, as shown directly below said matrix 0 or matrix I .
<img file="MA32201B1_D0076.tif" />
ΜΑ 32201Β1
119
POl-2363-ff
The matrix 0 and the matrix I present in the right column the embodiments (Hc ؛ R د R<sup>2,</sup>k R<sup>3</sup>ق R<sup>4</sup>/<sup>5</sup>'<sup>1</sup> r1٠٦'٥) of the invention according to general formula I which are preferred, إ independent and separable from each other, that is to say the individual aspects of the invention. The left column provides a reference number for these embodiments. The embodiments or elements are present in an order that ؛ starts from least preferred and ends with the most preferred one, the preferred embodiments إ
1 (-) being increasing with the reference number. This means that the embodiment which is presented by the matrix element in the last row and the last entry of the matrix 0 and ؛ of matrix I is the most preferred embodiment, while embodiments of matrix I are preferred ؛ compared to the embodiments of the matrix 0. ج
Aspects 1 to 18 are the main aspects of ؛ !'invention.
The first embodiment of this matrix 0 represents the first general aspect of the invention. The following embodiments are subsets thereof. '؛
<td>No.</td><td>Embodiment</td>
<td>Μ0-001</td><td>0.1. 1r3. 1r4 / 5. IrIO. ٠. 1r2. ٥ ٠ ل ٦ لححيل</td>
<td>Μ0-002</td><td>fj ٠ 2 rI. 0.2 r2.3 r3.2 r4 / 5.2 R10.0.2</td>
<td>Μ0-003</td><td>r٠2r1.0.2r2.3r3.3r4 / 5.2r10٠0.2</td>
<td>Μ0-004</td><td>Rç3r1.0.2r2.3r3.2r4 / 5.3r10.0.3</td>
<td>Μ0-005</td><td>0.0.3 3 rI .0.2 r2.3 r3.3 r4 / 5.3r1 حلا</td>
<td>Μ0-006</td><td>Hc٦٠٥R٠٥ '^ r2٠0٠1r3٠1r4 / 5.1r1.0.0.1</td>
<td>Μ0-007</td><td>H<sub>vs</sub>7٠٠r1٠0٠2r2.1r3.1r4 / 5.2r10.0.2</td>
<td>Μ0-008</td><td>H<sub>vs</sub>7٠Or1.0.2r2.2r3.2r4 / 5.2r10٠0.2</td>
<td>Μ0-009</td><td>H<sub>٠</sub>7٠0r1٠0.2r2.3r3.2r4 / 5.2r10٠0.2</td>
ΜΑ 32201Β1
120 POl-2363-ff
<td>Μ0-010</td><td>Hc7٠0r1٠٥<sup>٠</sup>2r2٠4r3.2r4 / 5.2r10.0.2</td>
<td>Μ0-011</td><td>ه ٠ G ٠ 5r3 2r4 / 5 ، 3r1٥ ٠ 2r2 ٠ ه 'Rl لع'? Hc</td>
<td>Μ0-012</td><td>Hc? . ٥r! . ٥. 2r2 ٠ 5r3.3r4 / 5.3r1O .0.4</td>
<td>Μ0-013</td><td>H<sub>vs</sub>7.Or1.O.3r2.5r3.2r4 / 5.3r1O.O.4</td>
<td>Μ0-014</td><td>0.4. ٠3r4 / 5.3r1O OrI. 0.3r2.<sup>5</sup>R<sup>3</sup> . ؟ Hc</td>
<td>Μ0-015</td><td>HC? .٥R? .٧.RR2r4 / 3٠3r10.0.3</td>
<td>Μ0-016</td><td>Hc? ٠ 0 r! 0.3r2.5r3.3r4 / 5 ٠ 3r1O .0.5</td>
<td>Μ0-017</td><td>H ^ 7.٥r1'Q * ، r2.5r3.2r4 / 5.3</td>
<td>Μ0-018</td><td>1r1.0٠1r2٠0.1r3٠1r4 / 5.1r10.0.1.؟ Hc</td>
<td>Μ0-019</td><td>0.2. 7. IrI. 0 .2r2.2r3.2r4 / 5.2r1O حلا</td>
<td>Μ0-020</td><td>0.2. 0.2r2.3r3.2r4 / 5.2r1O ٠ IrI. ؟ Hc</td>
<td>Μ0-021</td><td>HC? .R.٥.2r2.R.2r4 / 3.3r10٠٥.4</td>
<td>Μ0-022</td><td>0.4. 3r4 / 5.3r1O ٠ 5r3 ٠ 2r2. ٥. Hc? . IrI</td>
<td>Μ0-023</td><td>٥٠3r2٠5r3.2r4 / 5.3r10.0.4.٠1r1؟ ^ H</td>
<td>Μ0-024</td><td>HC? ٠R٠٥.3r2.R.2r4 / 3r1O.O.5</td>
<td>Μ0-025</td><td>Hc٠؟ IrI.0.3r2.5r3.3r4Z5.3r1O .0.5</td>
<td>Μ0-026</td><td>H .1r1.0.4r2.5r3.2r4 / 5.3</td>
<td>Μ0-027</td><td>H٠7.1r1.0.r.5r3.3r4 / 5.3</td>
<td>Μ0-028</td><td>Hc8r1.ü.1r2.0.1r3.1r4 / 5.1r10.0.1</td>
<td>Μ0-029</td><td>jcr1.O.2r2.3r3.2r4 / 5.2r1O.O.2</td>
<td>Μ0-030</td><td>Jcr1.O.2r2.5r3.2r4 / 5.3r1O.O.4</td>
<td>Μ0-031</td><td>H c 8 rI ٠ ٥ ٠ 2 r2.5 r3.3 r4 / 5.3r10.0.4</td>
<td>Μ0-032</td><td>Hc8r٤٠٥.3r2.5r3.2r4 / 5.3r10.0٠4</td>
<td>Μ0-033</td><td>Hc8r1.O.3r2.5r3.3r4 / 5.3r1O.O.4</td>
<td>Μ0-034</td><td>HcR.٥.3r2.Sr3.2rV5.3r10.0.5</td>
<td>Μ0-035</td><td>Hc8r1.٥.3r2٠5r3.3r4 / 5.3r10.0.5</td>
<td>Μ0-036</td><td><sub>Hc</sub>8<sub>r</sub>1.0.4r2.<sub>5</sub>r3.2r4 / 5.3</td>
ΜΑ 32201Β1
121 POl-2363-ff
<td>Μ0-037</td><td>Rc8r1 ٥ 4r2.5r3.3r4 / 5.3</td>
<td>Μ0-038</td><td>3.1. 9r1. 3.1r2.0 .1r3.1r4 / 5. Iris;<sub>H</sub>VS</td>
<td>Μ0-039</td><td>Jcr1.O.2r2٠3r3.2r4 / 5.2r1O.O.2</td>
<td>Μ0-040</td><td>H<sub>vs</sub>9r1-O-2r2-5r3-2r4 / 5٠3r1O.O, 4</td>
<td>Μ0-041</td><td>r٠9r1.0.2r2.5r3.3r4 / 5.3r10.0.4</td>
<td>Μ0-042</td><td>h 9r1.0.3r2.5r3.2r4 / 5.3r10.0.4</td>
<td>Μ0-043</td><td>H٠9r1٠0-3r2.5r3.3r4 / 5.3r10.٥.4</td>
<td>Μ0-044</td><td>r٥9r1.0.3r2.5r3.2r4 / 5.3r10.0.5</td>
<td>Μ0-045</td><td>r ^ 9r1.0.3r2.5r3.3r4 / 5.3r10.0.5</td>
<td>Μ0-046</td><td>Hc9r1٠0٠4r2.5r3.2r4 / 5.3</td>
<td>Μ0-047</td><td>R 9 ح r! ٠ 0. 4 r2.5 r3.3 r4 / 5.3</td>
<td>Μ0-048</td><td>HC<sup>9</sup>^ -4R<sup>2</sup>-4R3 '<sup>2</sup>R4 /<sup>S</sup>'<sup>2</sup>Rl٥ '<sup>4</sup></td>
<td>Μ0-049</td><td>Hc5r1'4r2٠4r3٠2r4 / 5.3r13.4</td>
<td>ΜΟ-050</td><td>R 9 ح rI. 4 r2 ٠ 4 r3.3 r4 / 5.2 r! 0.4</td>
<td>Μ0-051</td><td>HcRl R2.4r3.3r4Z5.r0.4</td>
<td>Μ0-052</td><td>H<sub>vs</sub>10r1 ٠ Q. 1r2.0.1r3.1r4 / 5. IrIO .0.1</td>
<td>Μ0-053</td><td>R (Or1.O.2r2.3r3.2r4 / 5.2r1O.O.2</td>
<td>Μ0-054</td><td>r٠10r1.0.2r2.5r3.2r4 / 5.3r10.0.4</td>
<td>Μ0-055</td><td>R 10 ح R1. ٥. 2 r2.5 r3.3 R 4 / 5.3 R10.0.4</td>
<td>Μ0-056</td><td>R (10r1.0.3r2.5r3.2r4 / 5.3r10.0.4</td>
<td>Μ0-057</td><td>Rc١10 R 3. ٥. ن r2.5 r3. 3 r 4 / 5.3 rI 0.0.4</td>
<td>Μ0-058</td><td>r <1r1.0.3r2.5r3.2r4 / 5.3r10.0.5</td>
<td>Μ0-059</td><td>R 0 اح rI. 0.3r2.5 r3.3 r4 / 5.3 rI0.0.5</td>
<td>Μ0-060</td><td>R 10 ح rI .0.4 r2.5 r3. 2 r4 / 5.3</td>
<td>Μ0-061</td><td>HcR- ، r2.5rr5.3</td>
<td>Μ0-062</td><td>H ^ 0r1٠4r2.4r3.2r4 / 5.2</td>
<td>Μ0-063</td><td>Hc10r1٠4r2.4r3.2r4 / 5.3</td>
my
32201Β1
122 POl-2363-ff
<td>Μ0-064</td><td><sub>Hc</sub>1٠<sub>R</sub>1٠4r2.4r3.3r4 / 5.2</td>
<td>Μ0-065</td><td>Hc1٥r1-4r2٠5<sub>R</sub>3٠2r4 / 5٠3</td>
<td>Μ0-066</td><td>Hcri-r-r'r '<sup>3</sup>'<sup>3</sup></td>
whereby for each embodiment of matrix 0: ؛
X independently of any other = 1, 2, 3 or 4, preferably إ X = 0; 1 or 2 ; preferably x is 0 or 1, and more preferably X = 0;
y independently of any other y = 0 or 1; and so;
more preferred y = 0, whereby the definitions ؛ specific with the embodiments of the matrix prevail; أ and their pharmaceutically acceptable salts and / or solvates, \ and provided that - for each embodiment of matrix 0 for which this condition is applicable - as for ؛ the embodiments comprising Hc as defined by Hc) or
Hc<sup>3</sup> if Hc is an oxetanyl which is linked through ؛
With the carbon atom lying next to the oxygen of the oxetanyl, there is no substituent attached to said carbon atom through a -CH ؛ - spacer.
It is obvious that if X and / or y = 0, then Hc is not substituted, i.e. the corresponding valences of the ring atoms are saturated with hydrogen.
If R is not sufficiently defined in a 0 matrix, it must be r1٥'٥'4 or r1٥'٥<sup>3</sup>, preferably R5'٠'٠ ؛.
Matrix I
<td>No.</td><td>Embodiment</td>
<td>ΜΙ-001</td><td>HcR-R'R'R ^ 'R «-<sup>3</sup></td>
<td>ΜΙ-002</td><td>Hc R ' <sup>4</sup>R<sup>2</sup> 'Ir<sup>3</sup>'1r<sup>4 / s</sup> 'R ل'ه</td>
<td>ΜΙ-003</td><td>H 2 ح r! . 2 r2.3 r3.2 r4 / 5.2 rI 0.2</td>
<td>ΜΙ-004</td><td>HcR.R.<sup>3</sup>R<sup>3</sup>.R<sup>3</sup>.<sup>2</sup>R<sup>3</sup>.<sup>2</sup></td>
<td>ΜΙ-005</td><td>HcR'Ir<sup>2</sup>'<sup>3</sup>R<sup>3</sup> - 1r<sup>V5</sup> - 1r1٥'1</td>
<img file="MA32201B1_D0077.tif" />
ΜΑ 32201Β1
123 POl-2363-ff
<td>ΜΙ-006</td><td>Hc3r1-2r2-1r3٠r / 5.1r1O.1</td>
<td>ΜΙ-007</td><td>H (٦3r1.2r2.2r3.2r4 / .5.2r10.2</td>
<td>ΜΙ-008</td><td>H (3r1.2r2٠3r3.2r4 / 5٠3r10.3</td>
<td>ΜΙ-009</td><td>H٠3r1 2r2.3r3.3r4 / 5.3r1O. 3</td>
<td>ΜΙ-010</td><td>H٠3r1.2r2.4r3.2r4 / 5.3r10.4</td>
<td>ΜΙ-011</td><td>Hc2R<sup>4</sup>-2r2'5r3.2r4 / 5.3r10.4</td>
<td>ΜΙ-012</td><td>3 ح ير r! . 2 r2.5 r3.3 r4 / 5.3 rI 0.4</td>
<td>ΜΙ-013</td><td>HcR'3r2'R'R / 5'1r1٥'1</td>
<td>ΜΙ-014</td><td>3 ح بر rI. 3 r2.2 r3.2 r4 / 5.2 r! 0.2</td>
<td>ΜΙ-015</td><td>Hc3r1.3r2.3r3.2r4 / 5.3r10.3</td>
<td>ΜΙ-016</td><td>Hc3r1.3r2.4r3.2r4 / 5.3r10.4</td>
<td>ΜΙ-017</td><td>H (3r1.3r2.4r3.3r4 / 5.3r10.4</td>
<td>ΜΙ-018</td><td>Hc3r3-3r2'5r3.2 ^ 4 / 5.3</td>
<td>ΜΙ-019</td><td>Hc3r1'3r2'5r3٠r / 5'3</td>
<td>ΜΙ-020</td><td>Hcr1r'r'r / 5'r ° '<sup>4</sup></td>
<td>ΜΙ-021</td><td>^^ 3r1.4r2.2r3.2r4 / 5.2r1O. 2</td>
<td>ΜΙ-022</td><td>r٠3r1.4r2.3r3.2r4 / 5.3r10.3</td>
<td>ΜΙ-023</td><td>Hc3r1r-R'2r4 / 5٠3r10٠4</td>
<td>ΜΙ-024</td><td>Hc3r3-R'R'r / S-3r1٥٠4</td>
<td>ΜΙ-025</td><td>Hc<sup>3</sup>R3<sup>,4</sup>R<sup>2</sup>'<sup>S</sup>R<sup>3</sup>-<sup>Z</sup>R<sup>4/</sup>3'3</td>
<td>ΜΙ-026</td><td>Hc<sup>3</sup>r1<sup>4</sup>R2-R-3r4 / 5.3</td>
<td>ΜΙ-027</td><td>Hc<sup>4</sup>R<sup>4</sup>-<sup>4</sup>R2-<sup>4</sup>R3-<sup>4</sup>R4 / 5-1r3٥-3</td>
<td>ΜΙ-028</td><td>HC<sup>4</sup>R<sup>4</sup>'2r2'<sup>4</sup>R3-3r «/ 3'1r3٠-3</td>
<td>ΜΙ-029</td><td>HcR.2r2.2r3.2r4 / 5.2r1O.2</td>
<td>ΜΙ-030</td><td>3.3r3.2r4 / 5.3r1O ٠ Hc ، 1r1 · 2r2</td>
<td>ΜΙ-031</td><td>HcR-<sup>2</sup>R2-<sup>4</sup>R<sup>3</sup>-2rV5٠3r10٠4</td>
<td>ΜΙ-032</td><td>HC<sup>4</sup>R<sup>4</sup>- 2r2-Sr3-2r4 / 5.3r1O.4</td>
ΜΑ 32201Β1
124 POl-2363-ff
<td>ΜΙ-033</td><td>HC ^ R<sup>2</sup>'2r2'1r<sup>2</sup>'1r4 / 5.1 ^ 10.1</td>
<td>ΜΙ-034</td><td>HcR.2r2.2r3.2r5.2r1O.2</td>
<td>ΜΙ-035</td><td> 2^2.3^3.2^4/5.3^10.3</td>
<td>ΜΙ-036</td><td>HcR2.2r2.R.2rS.3r10.4</td>
<td>ΜΙ-037</td><td>٠.3R. ؛ HcR2r2.RR</td>
<td>ΜΙ-038</td><td>HcR} .2r2.5r3.2r4 / 5.3r10.4</td>
<td>ΜΙ-039</td><td>Hc4r1٠2r2٠5r3.3r4 / 5.3r10.4</td>
<td>ΜΙ-040</td><td>hr13r2'1r3r / 5٠1r! ٥٠i</td>
<td>ΜΙ-041</td><td>HcR1'R2'Zr3'2r4 / 5'2r10'2</td>
<td>ΜΙ-042</td><td>H ، ٦4r1.3r2.3r3.2r4 / 5.3r10.3</td>
<td>ΜΙ-043</td><td>3.R. ؛, ٥R2.RRHcR</td>
<td>ΜΙ-044</td><td>H c لي Ri ٠ 3 R<sup>2</sup> 4 R<sup>2</sup> 2r4 / 5٠3r10.4</td>
<td>ΜΙ-045</td><td>HcR.R2.R.r5.R٠.٠</td>
<td>ΜΙ-046</td><td>HcR-R-5r3'2r4 / 5'3</td>
<td>ΜΙ-047</td><td>HR3r2'R٠3r5'3</td>
<td>ΜΙ-048</td><td>hr. ، r2-r.ir ، '5.r٠.i</td>
<td>ΜΙ-049</td><td>HR3. ، R2.2r3.2r5.2r1.2</td>
<td>ΜΙ-050</td><td>4r2.3ρ3.2ρ4 / 5.3ρ10.3</td>
<td>ΜΙ-051</td><td>HC<sup>4</sup>R1-<sup>4</sup>R2-4<sub>R</sub>3.2r4 / 5.٩r10.4</td>
<td>ΜΙ-052</td><td>HcR'R٠4r3٠3r4 / 5.3r1O.4</td>
<td>ΜΙ-053</td><td>3'5 / R<sup>2</sup>'2 r4 ج' R<sup>2</sup> لي 'rI لي H c</td>
<td>ΜΙ-054</td><td>3 'ؤ نم R<sup>2</sup>'3 r4 ج' R<sup>2</sup> لي '{r لي H c</td>
<td>ΜΙ-055</td><td>Hc3-3r3-3r2- ^ R3-1r4Z5-1r3٥-1</td>
<td>ΜΙ-056</td><td>HcR.2r2.1r3.1r5.1r1٥.1</td>
<td>ΜΙ-057</td><td><sub>Hc</sub>7.1r1.2r2.<sub>2</sub>r3.2<sub>r</sub>4 / 5.2r10.<sub>2</sub></td>
<td>ΜΙ-058</td><td>Hc'.R.2r2.3r3-2r4 / S.3r1٥.3</td>
<td>ΜΙ-059</td><td>r٠7.1r1.2r2.3r3.3r4 / 5.3r10.3</td>
<img file="MA32201B1_D0078.tif" />
32201Β1
125
POl-2363-ff
<td>ΜΙ-060</td><td>HcR-2r2٠R٠2r4Z5.3r10.4</td>
<td>ΜΙ-061</td><td><sub>Hc</sub>1٠1r3٠? ٠<sub>R</sub>2.4r3.3<sub>r</sub>4 / 5.3r10.4</td>
<td>ΜΙ-062</td><td>r3٠2r4 / 5.3r10.4 ؛ H'R1'2r2٠</td>
<td>ΜΙ-063</td><td> .1^1.2^2.5^3.3^4/5.3^10.4</td>
<td>ΜΙ-064</td><td>Hc? . IrI ٠ 3r2.1r3.1r4 / 5. IrIO. 1</td>
<td>ΜΙ-065</td><td>1r1٠3r2.2r3.2r4 / 5.2r10.2.؟ Hc</td>
<td>ΜΙ-066</td><td>٠1r1٠3r2٠3r3.2r4 / 5.3r10.3؟ Hc</td>
<td>ΜΙ-067</td><td>٠3r2.3r3.3r4 / 5.3r13.3- ^ 1r؟ Hc</td>
<td>ΜΙ-068</td><td>4. 4r3.2r4 / 5.3r1O ٠ IrI. 3r2. ؟ Hc</td>
<td>ΜΙ-069</td><td>٠1r1٠3r2٠4r3٠3r4 / 5.3r10٠4؟ Hc</td>
<td>ΜΙ-070</td><td>Hc, .1r1.3r2.5r3.2r4 / 5.3</td>
<td>ΜΙ-071</td><td>Hc7.1r1.3r2.5r3.3r4 / 5.3</td>
<td>ΜΙ-072</td><td>Hc R- R- R -<sup>3</sup>اب 'R٥-l</td>
<td>ΜΙ-073</td><td>Hc, .1r1.4r2.2r3.2r4 / 5.2r1٠.2</td>
<td>ΜΙ-074</td><td>r1٠4r23r3٠2r4 / 5٠3r10.3؟ ٠؟ Hc</td>
<td>ΜΙ-075</td><td>1r1٠4r2.3r3.3r4 / 5.3r10.3.؟ Hc</td>
<td>ΜΙ-076</td><td>4. IrI. 4r2.4 r3.2r4 / 5.3r1O ٠؟ Hc</td>
<td>ΜΙ-077</td><td>Hc7.1r1.4r2.4r3.3r4Z5.3r1C.4</td>
<td>ΜΙ-078</td><td>٠1r) .4r2٠5r3.2r4 / 5.34؟ Hc</td>
<td>ΜΙ-079</td><td>1r1'4r2-5r3-3r4 / 5٠3 '؟ Hc</td>
<td>ΜΙ-080</td><td>Hc8r1٠2r2.1r3.1r4Z5.1r1O.1</td>
<td>ΜΙ-081</td><td>H<sub>c8</sub>Rl٠2R<sub>2</sub>.2<sub>R</sub>3.2R4 / 5.<sub>2</sub>Rl0.2</td>
<td>ΜΙ-082</td><td>HC ج r! . 2 r2.3 r3.2r4 / 5٠3r10.3</td>
<td>ΜΙ-083</td><td>R 8 ح r! . 2 r2.3 r3.3r4 / 5.3r10.3</td>
<td>ΜΙ-084</td><td>Hc8r1.2r2.4r3.2r4Z5.3r1٠.4</td>
<td>ΜΙ-085</td><td>Hc8r1.2r2.4r3.3r4Z5.3r1Q.4</td>
<td>ΜΙ-086</td><td>Hc8r1.2r2.5r3.2r4Z5.3r10.4</td>
<img file="MA32201B1_D0079.tif" />
<img file="MA32201B1_D0080.tif" />
32201Β1
126
POl-2363-ff
<td>ΜΙ-087</td><td>HC<sup>B</sup>R1-<sup>2</sup>R2 '<sup>S</sup>R<sup>3</sup>-3r4 /<sup>5</sup>^^<sup>0</sup>·<sup>4</sup></td>
<td>MI-088</td><td>HcR-3r<sup>2</sup>'R-'r4 / 5-R٥-3</td>
<td>ΜΙ-089</td><td>HcV '<sup>3</sup>R<sup>2</sup>-<sup>2</sup>R3-<sup>2</sup>R4<sup>/5</sup>'2Rl<sup>0</sup>·<sup>2</sup></td>
<td>ΜΙ-090</td><td>hc8ri-3r2-3r3٠2r4 / 5.3r1o.3</td>
<td>ΜΙ-091</td><td>3 ٠ 8r3.3r4 / 5.3r1O.</td>
<td>ΜΙ-092</td><td>Hc3r1'3r2'4r3.2r4 / 5.3r10.4</td>
<td>ΜΙ-093</td><td>Hc8r1 ت ٠ r2.4r3.3r4 / 5.3r1O. 4</td>
<td>ΜΙ-094</td><td>HcR-<sup>3</sup>R<sup>2</sup>R<sup>3</sup>-2r4 / 5٠3</td>
<td>ΜΙ-095</td><td>HC٠RJ '<sup>3</sup>R<sup>2</sup>'5r3٠3r4 / 5٠3</td>
<td>ΜΙ-096</td><td>Hc8r1. ه r2.1r8 ٠ 1r4 / ٠ ة) r! ل. ٥</td>
<td>ΜΙ-097</td><td>HcBr1.4r2.2r3.2r4 / 5.2r1O.2</td>
<td>ΜΙ-098</td><td>JJ 8 ح r 1.4 r2.3 r3.2 r 4 / 5.3 r 10.3</td>
<td>ΜΙ-099</td><td>r٠8r1.4r2.3r3.3r4 / 5.3r10.3</td>
<td>ΜΙ-100</td><td>R 8 ح rI. 4 r2.4 r3.2 r4 / 5.3r! 0.4</td>
<td>ΜΙ-101</td><td>H c 8 r! 4 r2 - 4 r3 ٠ 3 r4 / 5.3 r! 0'4</td>
<td>ΜΙ-102</td><td>HC<sup>3</sup> R<sup>4</sup> '4 r2'3 r3'2 r4 / 5'3</td>
<td>ΜΙ-103</td><td>Hc8r4-4rZ٠5r3٠3r4 / 5.3</td>
whereby for each embodiment of matrix I:
X independently of any other = 1, 2, 3 or 4, preferably X = 0; 1 or 2 ;
y independently of any other y = 0 or 1;
and their pharmaceutically acceptable salts and / or solvates, and provided that - for each embodiment of matrix 0 for which this condition is applicable - as for the embodiments comprising Hc as defined by Hc<sup>4</sup> or
Hc<sup>3</sup>if Hc is an oxetanyl which is linked via
With the carbon atom lying next to the oxygenate of oxetanyl, there is no substituent attached to said carbon atom through a -CH- spacer.
<img file="MA32201B1_D0081.tif" />
32201Β1
127 POl-2363-ff
It is obvious that if X and / or y = 0, then Hc is not substituted, i.e. the corresponding valences of إ ring atoms are saturated with hydrogen.
In the case where r! ٥ is not sufficiently defined in a ؛ matrix I, it must be r1 ، u.
إ
Additional embodiments according to the invention and subset of aspects 1 to 17 and embodiments of matrix إ and matrix I ؛
Other embodiments are present in the following. Each embodiment is independent and separable, that is to say, it is an individual aspect of the invention.
The embodiments (Hc<sup>5</sup>Ri '، nR<sup>2</sup>'٥'iR<sup>3</sup>'iR'<sup>1</sup>/ MRi٥'٥'i) and (HcrI 'R'٥' R 'r / ^' r “'<sup>3</sup>':') are further mentioned, the remaining characteristics being as indicated for the elements of matrix I.
a) Subset of aspects 1 to 17 and embodiments of matrix 0 or I with respect to R<sup>2</sup> (all) In an individual and independent subset of embodiments of the present invention, its embodiments correspond to each of aspects 1 to 17 and to each of the embodiments of matrix 0 and matrix I, where Hc to ! inside the group HcRJx R] y can be a group defined by the following formula Dl:
0 ، position ** (Dl), where the symbol * is the point of attachment to the pyrazolo group of the general formula L and n = 0, 1, 2 or 3, except that in this subset, for no embodiment , there is an R<sup>2</sup> to the
ΜΑ 32201Β1
128 POl-2363-ff position ** which comprises a group -CH2- qthrough which r2 is linked to said position **.
This subset is called “a.1.1 subset”.
(a.1.2) In an individual and independent subset of embodiments of the present invention, its embodiments correspond to each of aspects 1 to 17 and to each of the embodiments of matrix 0 and matrix I, where Hc inside the group HcR] x [R<sup>3</sup>] y can be a group defined by the following formula Dl:
<img file="MA32201B1_D0082.tif" />
position ** (ذه) where the symbol * is the point of attachment to the pyrazolo group of general formula I and n = 0, 1, 2 or 3, except that in this subset, for no embodiment, there is has an r2 or an R<sup>3</sup> different from H at position **.
This subset is called “a.1.2 subset”.
(a.2.1) In an individual and independent subset of embodiments of the present invention, its embodiments correspond to each of aspects 1 to 17 and to each of the embodiments of matrix 0 and matrix I, where Hc inside the group HcR] x [R<sup>3</sup>] y can be a group defined by the following formula Dl-2:
<img file="MA32201B1_D0083.tif" />
position ** (Dl-2),
MA 32201 Bl
129 POl-2363-ff where the symbol * is the point of attachment to the pyrazolo group of the general formula I and n = 1, 2 or 3, and where z<sup>2</sup> is selected from the group consisting of N, 0 and s (٥) r, with r = 0, 1, 2, and z ؛ is selected from the group consisting of c, N, O and S (O) r, with r = 0, 1, 2, and the finally remaining valences of z<sup>2</sup> or z<sup>2</sup> are saturated by H in all cases or possibly by R<sup>z</sup> or R<sup>2 </sup>as appropriate, except that in this subset, for no embodiment, there is an R<sup>2</sup> at position ** which includes an optionally substituted -CH ؛ - group whereby this R<sup>2</sup> is linked to said position **.
This subset is called “a.2.1 subset”.
(a.2.2) In an individual and independent subset of embodiments of the present invention, its embodiments correspond to each of aspects 1 to 17 and to each of the embodiments of matrix 0 and matrix I, where Hc within the group Hc [R<sup>2</sup>] x R] y can be a group defined by the following formula Dl-2:
<img file="MA32201B1_D0084.tif" />
position ** (Dl-2), where the symbol * is the point of attachment to the pyrazolo group of the general formula I and n = 1, 2 or 3, and where z<sup>2</sup> is selected from the group consisting of N, O and S (O) ٢, with r = 0, 1, 2, and z<sup>2 </sup>is selected from the group consisting of c, N, O and s (o) r, with r = 0, 1, 2, and the finally remaining valences of z<sup>2</sup> or z<sup>2</sup> are saturated by H in all cases or possibly by R<sup>2</sup> or R<sup>2 </sup>as appropriate, except that in this subset, for no embodiment, there is an R<sup>2</sup> or an R<sup>2</sup> different from H at position * ٠.
<img file="MA32201B1_D0085.tif" />
<img file="MA32201B1_D0086.tif" />
32201Β1
130 POl-2363-ff
This subset is called “a.2.2 subset”.
(a.3) In an individual and independent subset of embodiments of the present invention, its embodiments correspond to each of aspects 1 to 17 and to each of the embodiments of matrix 0 and matrix I, where Hc is or may be tetrahydrofuranyia, except that in this subset, for no embodiment, R<sup>2</sup> is a CH group which is bonded alpha to the oxygen atom of the ring.
This subset is called “a.3 subset”.
(a.4) In an individual and independent subset of embodiments of the present invention, its embodiments correspond to each of aspects 1 to 17 and to each of the embodiments of matrix 0 and matrix I, where Hc is or may be tetrahydrofuranyia, except that in this subset, for no embodiment, R<sup>2</sup> is r! ٥-O- (C alkyl<sub>2</sub> to C؟) - containing a -CH group; - through which it is bonded to a c atom of tetrahydrofuranyia, which is in the alpha position with respect to the oxygen atom of the ring.
This subset is called “a.4 subset”.
(a. 5.1) In an individual and independent subset of embodiments of the present invention, its embodiments correspond to each of aspects 1 to 17 and to each of the embodiments of matrix 0 and matrix I, where Hc is or may be tetrahydrofuranyia, except that in this subset, for no embodiment, R<sup>2</sup> is a C 1 -C 6 alkyl group bonded alpha to the ring oxygen atom.
This subset is called “a.5.1 subset”.
(a.5.2) In an individual and independent subset of embodiments of the present invention, its embodiments correspond to each of aspects 1 to 17 and to each of the embodiments of matrix 0 and matrix I, where Hc is or may be tetrahydrofuranyia, except that in this subset, for no embodiment, R<sup>2</sup> is an alkenyl group in c<sub>2</sub> to Cg bound in alpha position with respect to the oxygen atom of the cycle.
This subset is called “a.5.2 subset”.
(a.5.3) In an individual and independent subset of embodiments of the present invention, its embodiments correspond to each of aspects 1 to 17 and to each
د
MY
32201Β1
131
POl-2363-ff of the embodiments of matrix 0 and matrix I, where Hc is or may be tetrahydrofuranyl, except that in this subset, for neither embodiment, R<sup>2</sup> is a C-alkynyl group<sub>2</sub> at
Cg bonded in alpha position with respect to the oxygen atom of the cycle.
This subset is called “a.5.3 subset”. ؛ (a.6) In an individual and independent subset of ؛ embodiments of the present invention, its modes of ؛ embodiments correspond to each of aspects 1 to 17 and to each of the embodiments of matrix 0 and matrix I, where Hc is 10 or may be tetrahydrothiophenyl, except that in this subset, for no embodiment, R<sup>2</sup> is a CH group bonded alpha to the ring sulfur atom. ؛
This subset is called “a.6 subset”.
(a.7) In an individual and independent subset of embodiments of the present invention, its embodiments correspond to each of aspects 1 through 17 and each of the embodiments of matrix 0 and matrix I , where Hc is or may be tetrahydrothiophenyl, except that in this subset إ, for any embodiment, R<sup>2</sup> is R '' - O- (C-alkyl<sub>2</sub> to Cg) - containing a -CH group - whereby it is إ bonded to a c atom of tetrahydrothiophenyl, which is in the ب alpha position with respect to the sulfur atom of the ring. ؛
This subset is called “a.7 subset”.
(a.8) In an individual and independent subset of إ embodiments of the present invention, its embodiments correspond to each of aspects 1 to 17 and to each of the embodiments of matrix 0 and matrix I, where Hc is or may be tetrahydrothiophenyl, except that in this subset, for no embodiment, R<sup>2</sup> is a C 1 to C 8 alkyl group containing a -CH - group by which it is bonded in the alpha position relative to the sulfur atom of the ring.
This subset is called “a.8 subset”.
(a.9) In an individual and independent subset of embodiments of the present invention, its embodiments correspond to each of aspects 1 to 17 and to each of the embodiments of matrix 0 and matrix I, where Hc is or may be tetrahydropyranyl or tetrahydrothiopyranyl, except that in this subset, for no embodiment, R<sup>2</sup>
<img file="MA32201B1_D0087.tif" />
<img file="MA32201B1_D0088.tif" />
32201Β1
132 POl-2363-ff is a CH group bonded in an alpha position with respect to the oxygen atom of the ring or to the sulfur atom respectively.
This subset is called “a.9 subset”.
(a.10) In an individual and independent subset of embodiments of the present invention, its embodiments correspond to each of aspects 1 to 17 and to each of the embodiments of matrix 0 and matrix I, where Hc is or may be tetrahydropyranyl or tetrahydrothiopyranyl, except that in this subset, for no embodiment, R<sup>۶</sup> is a group rI-Ο- (C 1 alkyl<sub>2</sub> to Cg) - containing a -CH group thanks to which it is bonded to a c atom of tetrahydropyranyl or tetrahydrothiopyranyl, said c atom being in the alpha position respectively relative to the oxygen atom of the ring or to the sulfur atom.
This subset is called “a.10 subset”.
(a.11) In an individual and independent subset of embodiments of the present invention, its embodiments correspond to each of aspects 1 to 17 and to each of the embodiments of matrix 0 and matrix I, where Hc is or may be tetrahydropyranyl or tetrahydrothiopyranyl, except that in this subset, for no embodiment, R<sup>2 </sup>is a C1-C8 alkyl group containing a -CH - group by which it is bonded in alpha position respectively with respect to the oxygen atom of the ring or to the sulfur atom.
This subset is called “a.11 subset”.
(a.12) In an individual and independent subset of embodiments of the present invention, its embodiments correspond to each of aspects 1 to 17 and to each of the embodiments of matrix 0 and matrix I, where Hc can be an oxetanyl group, except in this subset, for any embodiment, Hc is an oxetanyl group.
This subset is called “a.12 subset”.
(a.13) In an individual and independent subset of embodiments of the present invention, its embodiments correspond to each of aspects 1 to 17 and to each of the embodiments of matrix 0 and matrix I, where Hc is or may be a cyclic hexanosyl sugar group in which, for all hydroxy groups, hydrogen may be
<img file="MA32201B1_D0089.tif" />
<img file="MA32201B1_D0090.tif" />
32201Β1
133
POl-2363-ff optionally replaced with any other group and / or Hc is or may be a cyclic mono-deoxy or di-deoxy hexanosyl sugar group in which, for all remaining hydroxy groups, hydrogen may be be optionally replaced by any other group, except that in this subset, for no embodiment, R<sup>2</sup> is a CH group bonded alpha to the oxygen atom of the ring.
This subset is called “a.13 subset”.
(a.14) In an individual and independent subset of embodiments of the present invention, its embodiments correspond to each of aspects 1 to 17 and to each of the embodiments of matrix 0 and matrix I, where Hc is or may be a cyclic hexanosyl sugar group in which, for all hydroxy groups, The hydrogen can be optionally replaced by any other group and / or Hc is or can be a cyclic mono-deoxy or di-deoxyhexanosyl sugar group in which, for all remaining hydroxy groups, hydrogen can be be optionally replaced by any other group, except that in this subset, for no embodiment, R<sup>2</sup> is a C1-C6 alkyl group bonded in alpha position to the ring oxygen atom.
This subset is called “a.14 subset”.
(a.15) In an individual and independent subset of embodiments of the present invention, its embodiments correspond to each of aspects 1 to 17 and to each of the embodiments of matrix 0 and matrix I, where Hc is or may be a cyclic hexanosyl sugar group in which, for all hydroxy groups, The hydrogen can be optionally replaced with any other group and / or Hc is or can be a cyclic mono-deoxy or di-deoxyhexanosyl sugar group in which, for all remaining hydroxy groups, hydrogen can be be optionally replaced by any other group, except that in this subset, for no embodiment, R<sup>2</sup> is R٥ ؛ -O-C-alkyl<sub>z</sub> to Cg bound in alpha position with respect to the oxygen atom of the cycle.
This subset is called “a.15 subset”.
(a.16) In an individual and independent subset of embodiments of the present invention, its embodiments
MY
32201Bl
134
POl-2363-ff embodiment correspond to each of aspects 1 to 17 and to each of the embodiments of matrix 0 or I, where R<sup>2</sup> is defined in such a way as to include a group chosen from (r! ٠)<sub>2</sub>N- and (r3٥)<sub>2</sub>NOT- ; C1 to C3 alkyl, except that in this subset, for no embodiment, R<sup>2</sup> is a group (r3٥)<sub>2</sub>N- or (R} ٥)<sub>2</sub>N-C 1 -C 3 alkyl, while all remaining definitions of R<sup>2</sup> remain unchanged.
This subset is called “a.16 subset”.
hl Ous-set of embodiments of matrix 0 or matrix I with respect to R<sup>V5</sup> ؛ (b1) In an Individual and independent subset of embodiments of the present invention, its modes of:
realization correspond to each of the embodiments of matrix 0 or matrix I where r4 / 5 is R<sup>4 / s</sup>·<sup>2</sup>, whereby for the embodiments of this sub-assembly.
r4 / 5.2-2 means that r4 and r5, independently of each other, are H- or fluorine.
This subset is called “b1 subset”. ي
c) Subset of embodiments of matrix I with respect to r “(c.1) In an individual and independent subset of embodiments of the present invention, each embodiment selected in the present invention is discussed. qroup of the matrix I where r} ٥ is defined by r3٥ '<sup>2</sup>, r1٥'3 or r1٥'4: for the embodiments of this subset, each of the definitions R'٥ '<sup>2</sup>, r1٥'3 and r1٥'4 is extended so that r1٥ can also be H in the case where this r! ٥ is bonded to a nitrogen atom.
This subset is called “0.1 subset”.
It will be obvious that the subsets as defined in
a.) and b.) in this section “additional embodiments إ according to the invention / subset of aspects 1 to 17 and embodiments of matrix 0 and matrix I” correspond to the embodiments of aspects 1 to 17 and respectively of matrix 0 and matrix I, whereby the scope of the specific definitions is changed. In the event that these modifications are limitations, it can be considered that the
MY
32201Β1
135
POl-2363-ff new definitions include conditions. Therefore, these embodiments are considered to be only "subsets" of Aspects 1 through 17 and embodiments of Matrix 0 and Matrix I, respectively.
It is considered that each embodiment of formula I <sup>؛</sup> general defined by aspects 1 to 18 and! 'any of the elements of the matrix 0 and of the matrix I or gue each embodiment defined by the subsets a.), b.) or c.) here- ؛ above is an independent and separable aspect of the invention, ie an individual aspect of the invention.
TERMS AND DEFINITIONS USED
The terms which are not specifically defined in this document will be assigned the definitions which would be given to them by those skilled in the art in the light of the description and the context. Examples include ؛ substituents or atoms specific ones that are present with their 1 or 2 letter code, such as H for hydrogen, N for nitrogen, c for carbon, 0 for oxygen, s for sulfur and the like. Optionally, but not necessarily, the letter is followed by a hyphen to indicate a connection. As used in the memo, unless otherwise noted, the following terms have the meanings indicated and the following conventions are adhered to.
In the groups, radicals or moieties defined below, the number of carbon atoms is often specified after the group, for example C1-C6 alkyl.<sub>6</sub> is an alkyl group or an alkyl radical containing 1 to 6 carbon atoms. In general, for groups comprising two or more subgroups, the last group named is the point of attachment of the radical, for example the term "thioalkyl" refers to a monovalent radical of formula HS-alkyl-. If the term of a substituent begins or ends with a minus sign or a hyphen, i.e. -, this sign indicates the point of attachment, as in the previously mentioned HS-alkyl- example. wherein "alkyl" is attached to the group of which HS-alkyl- is a substituent. Unless otherwise specified below, the conventional definitions of terms are checked and the classical valences of atoms
MY
32201Β1
136
Stable POl-2363-ff are assumed and obtained in all formulas and groups.
In general, "all tautomeric forms and all isomeric forms and all forms", whether they are individual geometric isomers or optical isomers or racemic or non-racemic forms of isomers, of a chemical or d structure. A compound is expected, unless the specific stereochemistry or isomeric form is specifically indicated in the compound name or structure. ح ؛
The term "substitutes", as used explicitly or implicitly in this document, means that a or ؛ several hydrogens on the designated atom are replaced by an element from the indicated group of substituents, provided that the normal valence of the desired atom is not exceeded. In the case where a substituent is linked via a double bond, for example an oxo substituent, this substituent replaces ؛ two hydrogen atoms on the desiqne atom. The substitution should give a stable compound. The term "stable" in this context preferably refers to a compound which, from a pharmaceutical point of view, is sufficiently chemically and physically stable for use as an active pharmaceutical ingredient of a. pharmaceutical composition.
If a substituent is not defined, it is hydrogen. The term "optionally substituted" means that the corresponding group is either substituted or unsubstituted. Therefore, whenever this term is used, the unsubstituted variation is a more pronounced aspect of the invention, i.e., these optional substituents are preferably not present.
The term "pharmaceutically acceptable" is used 1 herein to refer to compounds, substances, compositions and / or dosage forms which are, within the framework of sound medical judgment, suitable for use in contact. with tissues of humans and animals without toxicity, irritation, excessive allergic response or without causing any other problem or complication, proportionate to a reasonable benefit / risk ratio.
<img file="MA32201B1_D0091.tif" />
ΜΑ 32201Β1
137 POl-2363-ff
As used in the present document, the expression "pharmaceutically acceptable salt (s)" refers to derivatives of the compounds described, the parent compound being modified by the preparation of one of its acid or base salts. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues, such as amines; alkali or organic salts of acidic residues, such as carboxylic acids; and the like. Pharmaceutically acceptable salts include conventional non-toxic salts or quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. For example, its conventional non-toxic salts include those derived from inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, sulfamic acid, phosphoric acid, nitric acid and the like; and salts prepared from organic acids such as acetic acid, propionic acid, succinic acid, glycolic acid, stearic acid, lactic acid, malic acid,
Tartaric acid, citric acid, ascorbic acid, pamoic acid, maleic acid, hydroxymaleic acid, phenylacetic acid, glutamic acid, benzoic acid, salicylic acid, sulfanilic acid, 2-acetoxybenzolic acid, fumaric acid, toluenesulfonic acid, methanesulfonic acid, ethane disulfonic acid, oxalic acid, isothionic acid and the like. As the compounds of the present invention can contain both acidic and basic groups, these compounds can therefore also be present in the form of internal salts.
Pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or free base form of these compounds with a stoichiometric amount of a suitable base or acid in water or in an organic solvent, or in a mixture of the two; in general, non-aqueous media, such as
MY
32201Β1
138 POl-2363-ff
Ether, ethyl acetate, ethanol, isopropanol or acetonitrile are preferred.
"Prodrugs" are considered to be compounds which release in vivo an active parent drug of the present invention when that prodrug is administered by a mammalian subject. Prodrugs according to the present invention are prepared by modifying functional groups present on the compound in such a way that these modifications are converted back to the original functional groups under physiological conditions. Prodrugs include compounds of the present invention in which a hydroxy, amino or sulfhydryl group is bonded to any group which, when the prodrug of the present invention is administered to a mammalian subject, is retransformed to release said hydroxyl, amino or group. sulfhydryl. Examples of prodrugs include, but are not limited to, the acetate, formate and benzoate derivatives of the alcohol and amine groups of the compounds of the present invention.
"Metabolites" are considered to be derivatives of the compounds of the present invention which form in vivo. Active metabolites are metabolites that cause a pharmacological effect. It will be understood that the metabolites of the compounds of the present invention are also a subject of the present invention, in particular the active metabolites.
Some of the compounds can form "solvates". For the purposes of the invention, the term "solvate" refers to the forms of compounds which form, in the solid or liquid state, a coordination complex with the solvent molecules. Hydrates are a specific form of solvate in which coordination takes place with water. According to the present invention, the term is preferably used for solid solvates, such as amorphous solvates or, more preferably, crystalline solvates.
“Main structure”: the main structure of the compounds according to the present invention is represented by the following central structure, the numbering of which is indicated in bold:
<img file="MA32201B1_D0092.tif" />
MY
32201Β1
139
POl-2363-ff
<img file="MA32201B1_D0093.tif" />
It will be obvious to those skilled in the art that this main structure can be described by its “enol” tautomeric form.
<img file="MA32201B1_D0094.tif" />
In the context of the present invention, the two i structural representations of the main structure must ؛ be considered as the subject of the present invention, even if ؛ only one of the two representations is presented. It is believed that for the majority of compounds, under ambient conditions and also under conditions which are the conditions suitable for a pharmaceutical composition containing said compounds, the balance of tautomeric forms lies on the side of the pyrazolopyrimidin-4-one representation. Therefore, all embodiments are presented as derivatives of pyrazolopyrimidin-4-one or, more specifically, as derivatives of pyrazolo [3,4-d] pyrimidin-4-one ؛ ٠ “Bond”: if in a chemical formula of a ring system or a defined group a substituent is directly bonded to an atom or group, such as “RyR” in the formula below, this means that the substituent is only bonded to the corresponding atom. However, if from another ؛ substituent, like "RxR", a bond is not specifically:
linked to an atom of the ring system but traced towards the center of the ring or group, this means that this substituent
L
<img file="MA32201B1_D0095.tif" />
32201Bl
40 ل POl-2363-ff "RxR" can be attached to any valid atom of the ring system / group, unless otherwise specified.
<img file="MA32201B1_D0096.tif" />
The symbol "-" for a link (= minus sign) or the ؛ symbol "- *" (= minus sign followed by an asterisk) represents the bond by which a substituent is linked to the corresponding remaining part of the main molecule / structure. In the event that the minus sign does not seem to be sufficiently clear, an asterisk is added to the link symbol "-" in order to ؛ ' determining the point of attachment of said connection to the part;
corresponding principal of the principal molecule / structure.
In general, bonding to one of the heterocycloalkyl groups, ؛ heterocyclyl or heteroaryl as defined herein can be effected through a C atom or optionally) an N atom.
The term "aryl" used herein indicates a phenyl, biphenyl, indanyl, indenyl, 1,2,3,420 tetrahydronaphthyl or naphthyl group, preferably it indicates a ، phenyl or naphthyl group, and more preferably a إ phenyl group. . This definition applies for the use of the term "aryl" in any context within the present description in the absence of another definition.
the term "C1 to Cn alkyl" indicates a saturated, branched or unbranched hydrocarbon group containing 1 to n atoms ؛
C, n being a number chosen from the group comprising 2, 3, 4, 5,
6, 7, 8, 9 and 10, preferably in the group comprising 2, 3, 4, ؛ ' and 6, and more preferably in the group comprising إ
2, 3 and 4. Examples of such groups include methyl, [
Ethyl, n-propyl, iso-propyl, butyl, iso-butyl, sec-butyl, tert-butyl, n-pentyl, iso-pentyl, neopentyl, tert -pentyl, n-hexyl, iso-hexyl, etc. As the context will show, such a C to C alkyl group can be optionally substituted. ؛
ΜΑ 32201Β1
141
POl-2363-ff
This definition applies for the use of the term "alkyl" in any reasonable context within the present description in the absence of another definition.
When the term "C 1 to C alkyl" is used in the middle of two other groups / substituents, as for example in "(C 1 to C cycloalkyl (C 1 to C alkyl"), this means the moiety "alkyl Cl to Cn "forms a bridge between said two other groups. In the present example, it forms a bridge between the cycloalkyl C1 to Cn and the oxygenate, as in" cyclopropyl-methyl-oxy- ". It is obvious that in such a case the term "C1 to Cn alkyl" has the meaning of a "C1 to Cn alkylene" spacer, such as methylene, ethylene, etc. Groups which are bridged by "C1 to Cn alkyl" can be linked to the "C1 to Cn alkyl" group at any position of the latter. Preferably, the right group is located at the right distal end of the alkyl group and the left group is located at the left distal end of the alkyl group. This applies in the same way for the other substituents.
The term "alkenyl in c<sub>2</sub> to Cn ”indicates a branched or unbranched hydrocarbon group containing 2 to n c atoms and at least one c = c group (i.e., a carbon-carbon double bond), n preferably taking a value selected from the group comprising 3, 4, 5, 6, 7 and 8, and more preferably 3, 4, 5 or 6, or better still 3 or 4. Examples of such groups include ethenyl,! -Propenyl, 2-propenyl, iso-propenyl,! -Butenyl, 2-butenyl, 3 -butenyl, 2-methyl! -L. -propenyl, 1-pentenyl, 2-pentenyl, 3pentenyl, 4-pentenyl, 3-methyl-2-butenyl, 1-hexenyl, 2-hexenyl! e, 3-hexenyl! e , 4-hexenyl, 5-hexenyl etc.
As the context will show, such a c-alkenyl group<sub>2</sub> to Cn can be optionally substituted.
This definition applies for the use of the term "alkenyl" in any reasonable context within the present description in the absence of another definition, if there is no other definition.
When the term "alkenyl in c<sub>2</sub> to Cn ”is used in the middle of two other groups / substituents, the same definition as that given in the case of the C1 to Cn alkyl group applies.
<img file="MA32201B1_D0097.tif" />
32201Bl
142 POl-2363-ff
The term "C-alkynyl<sub>2</sub> to Cn ”indicates a branched or unbranched hydrocarbon group containing 2 to n c atoms and at least one CsC group (that is to say, a carbon-carbon triple bond), n preferably taking a value selected from the group comprising 3 , 4, 5, 6, 7 and 8, and more preferably 3, 4, 5 or 6, or better still 3 or 4. Examples of such groups include ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-pentynyl, 2pentynyl, 3-pentynyl, 4 -pentynyl, l-hexynyl,
2-hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl etc. As the context will show, such a C 1 to C 1 alkynyl group can be optionally substituted.
This definition applies for the use of the term "alkynyl" in any reasonable context within the present description in the absence of another definition.
When the term "alkynyl in c<sub>2</sub> to Cn ”is used in the middle of two other groups / substituents, the same definition as that given in the case of the C1 to Cn alkyl group applies.
The term "C3-Cn cycloalkyl" indicates a saturated monocyclic group containing 3 n ring c atoms, n is preferably taken as 4 to 8 (= 4, 5, 6, 7 or 8), and more preferably 4 to 7, or better still, this C3 to Cn cycloalkyl is 5 or 6 membered. Examples of such groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, etc. This definition applies for "cycloalkyl" in any reasonable context within the present description in the absence of another definition.
The term "halogen" indicates an atom chosen from F, Cl, Br and I.
The term "heteroaryl" used in the present specification indicates an aromatic heterocyclic system, mono- or bi-cyclic, which contains in the ring system itself, in addition to at least one atom c, one or more heteroatoms chosen from N , 0 and / or S. A monocyclic system preferably consists of 5 to 6 ring elements, a bicyclic system preferably consists of 8 to 10 ring elements. Preferred heteroaryls contain up to 3 heteroatoms, and more preferably up to 2 heteroatoms, or more preferably 1 heteroatom. Heteroatom
MY
32201Β1
143 Preferred POl-2363-ff is N. Examples of such fragments are إ benzimidazolyl, benzisoxazolyl, benzo [1,4] -oxazinyl, benzoxazol-onyl, benzofuranyl, benzoisothiazolyl, 1-benzodioxolyl, benzo-thiadiazolyl, benzothiazolyl, benzothienyl, benzoxadiazolyl, benzoxazolyl, chromanyl, chromenyl, chromonyl, cinnolinyl, 2,3di-hydrobenzo [1,4] dioxinyl, 2,3-dihydrobenzofuranyl, 3,4dihydrobenzo [1,4] oxazinyl, 2,3-dihydro-indolyl, 1,3dihydroisobenzofuranyl, 2,3-di-hydroisoindolyl, 6,710 dihydropyrrolizinyl, di-hydroquinolin-2-onyl, dihydroquinolin-4-onyl, furanyl, imidazo [l, 2-a] pyrazinyl, l 'imidazo [1,2-a] pyridyl,!' imidazolyl, imidazopyridyl, ؛ imidazo [4,5-d] thiazolyl, indazolyl, indolizinyl, indolyl, isobenzofuranyl, isobenzothienyl, إ isochromanyl, isochromenyl, isoindoyl, iso-quino ! in-2_ onyl,! 'isoquinolinyl, isothiazolyl, isoxazolyl, the ; naphthyridinyl, 1,2,4-oxadiazoyl, 1,3,4-oxadiazoyl,
1.2.5- oxadiazoyl, oxazolo-pyridyl,! 'Oxazolyl, 2-oxo-2,3dihydro-benzimidazolyl, 2-oxo-2,3-dihydroindolyl, إ 1-oxoindanyl, phthalazinyl, pteridinyl, purinyl, 'pyrazinyl, pyrazolo [1,5-a] pyridyl, pyrazolo [!, 5a] pyrimidinyl, pyrazolyl, pyridazinyl, pyridopyrimidinyl, pyridyl (pyridinyl), pyridyl-Noxyde, pyrimidinyl, pyrimidopyrimidinyl, pyrrolopyridyl, pyrrolo-pyrimidinyl, pyrrolyl, quinazolinyl, quinolin4-onyl, quinolinyl, quinoxalinyl, 1,2,3,4- ٤ tetrahydroquinolinyle, 1,2,3,4-tetrahydro-isoquinolinyl, ؛ ' tetrazolyl, 1,2,4-thiadiazûlyl, 1,3,4-thiadiazolyl,
1.2.5- thiadiazol.yle, thiazolyl, thieno [2,3-d] imidazolyl, thieno [3,2-5] pyrrolyl, thieno [3,2-b] thiophenyl, thienyl, triazinyl or triazolyl.
Preferred heteroaryl groups are furanyl,
Isoxazolyl, pyrazolyl, pyridyl, pyrimidinyl, thienyl and thiazolyl.
More preferred heteroaryl groups are ٠
Oxadiazolyl, triazolyl, pyrazolyl, furanyl and pyridyl, pyrazolyl and pyridyl are more preferred.
<img file="MA32201B1_D0098.tif" />
32201Bl
144
POl-2363-ff
The definition of pyrazole includes the IH-, 3Η- and
4H-pyrazo! E. Preferably, pyrazolyl indicates 1H-pyrazolyl.
The definition of imidazole includes the IH-, 2Η- and
Himidazole. A preferred definition of imidazolyl is IH5 imidazolyl.
The definition of triazole includes the isomers IH-, 3Η- and
4Η- [1,2,4] -triazole as well as 1H-, 2Η- and 4H- [1,2,4] -triazoles. The definition of triazolyl therefore includes 1H- [1,2,4] -triazol-1-yl, -3-yl and -5-yl, 3H- [1,2,4] -triazol-3-yl and -5 -yl, 4Η- [1,2,4] 10-triazol-3-yl, -4-yl and -5-yl, 1H- [1,2,3] -triazol-1-yl, -4-yl and -5-yl, 2Η- [1,2,3] _triazol-2-y! E, -4-yl and -5-yl as well as
4H- [1,2,3] -triazol-4-yl and -5-yl.
The term tetrazole includes the isomers 1H-, 2Η- and 5Ηtetrazole. The definition of tetrazolyl therefore includes ΙΗ-tetrazol-1-yl and -5-yl, 2H-tetrazol-2-yl and -5-yl and 5H-tetrazol-5-yl.
The definition of indole includes the IH- and 3Ηindole isomers. The term indolyl preferably indicates ΙΗ-indol-1-yl.
The term isoindole includes the 1H- and 2H-isoindole isomers. This definition applies for "heteroaryl" in any reasonable context within the present description in the absence of another definition.
The term "nitrogen-linked pyridin-2-one" used herein indicates:
<img file="MA32201B1_D0099.tif" />
The term "heterocycloalkyl" in the context of the present invention denotes a 3 to 8 membered, preferably 5, 6 or 7 membered saturated ring system or a 5 to 12 membered saturated bicyclic system, which contains 1, 2 , 3 or 4 heteroatoms chosen from N, O and / or s. 1, 2 or 3 heteroatoms are preferred.
MA 32201 Bl
145 POl-2363-ff
ا
إ
The preferred number of carbon atoms is 3 to 7 with 1, 2, or 4 heteroatoms selected from N, 0 and / or s. These إ heterocycloalkyl groups are indicated as C 1 to C 6 heterocycloalkyl. إ
Preferably, the saturated heterocycloalkyl rings contain 5, 6 or 7 ring atoms, of which 1 or 2 are heteroatoms and the others are c atoms.
When heterocycloalkyl substituents in c<sub>3</sub> to c, are mentioned, their preferred embodiments are 5, 6 or 7 membered rings, and more preferably ر monocycles. They contain 1, 2, 3 or 4 heteroatoms chosen from N, 0 and / or s, preferably 1 or 2 heteroatoms of this type, and more preferably 1 heteroatom of this type.
Preferred examples of heterocycloalkyl include morpholinyl, piperidinyl, piperazinyl, thiomorpholinyl, oxathianyl, dithianyl, dioxanyl, pyrrolidinyl, tetrahydrofuranyie, dioxolanyl, oxathiolanyl, imidazolidinyl, tetra-hydropyranyyl, tiperazinopolinidylidyl, homiperazinopolinidyl, iperazinopolinididyl, iperazinopolinididyl, iperazinopolinidylidyl, iperazinopolinidylidyl, iperazinopinylidyl homothiomorpholinyl, azetidinyl, 1,320 diazacyclohexanyl or pyrazolidinyl.
This definition applies for "heterocycio-alkyl" in رل any reasonable context within this:
description in the absence of another specific definition.
The term "heterocyclyl" is used specifically to define the Hc group in formula I and formulas derived therefrom. Therefore, this term will be used independently of the definition of the term "heterocycloalkyl". However, the definitions given to "heterocycloalkyl" should be included in the definition of the term "heterocyclyl". Hc is a إ group which is or which includes at least one non-aromatic ί heterocycloalkyl group which is bonded to structure ؛ main. ;
In the context of the present invention and as used herein, specifically in the context of Hc, the term "heterocyclyl" refers to a non-aromatic monocyclic, bicyclic or tricyclic system, the ring elements being carbon atoms. carbon and at least one, preferably one to three heteroatoms chosen from the group
٦،
MA 32201 Bl إ
146 إ POl-2363-ff إ ί comprising! 'Nitrogen,!' Oxygen or! E sulfur, the sulfur being ٤ part of the group -S (O) r- where r is equal to 0, 1 or 2. Such a system أ cyclic can additionally be spawning. Such ring systems will also be referred to as heteromonocyclic, heterobicyclic or heterotricyclic in the present context.
This heterocyclyl group may be saturated or partially \ unsaturated, whereby in systems containing more than one ؛ ring systems, at least one of them is not aromatic.
This at least one non-aromatic ring system comprises said at least one heteroatom. ب:
This heterocyclyl group can be related to the main structure in several ways. If no particular binding arrangement إ is specified, then all possible arrangements ؛ are being considered. For example, the term "tetrahydropyranyl" includes 2-, 3- or tetrahydropyranyl and the like. When there are several ring systems, the bond to the main structure is effected through at least one ring atom of the non-aromatic ring system comprising at least one heteroatom. Preferably, this heterocyclyl group is linked to the main structure through a nitrogen atom or one of the saturated carbon atoms belonging to said ring system. More preferably, it is linked to the main structure through a carbon atom of the non-aromatic heterocyclic system.
This heterocyclyl group can be fused, respectively ringed, with a cycloalkyl, with another heterocyclic group, with an aromatic ring system, such as phenyl, or can be part of a spirocyclic system. In a fused or ringed system, the two ring systems share a bond between two atoms of adjacent rings. In the spiro variation, the two ring systems have one ring atom in common. إ
Monoheterocyclic systems belonging to this definition are non-aromatic monocyclic systems in which at least one carbon atom, preferably one to three ؛ carbon atoms have been replaced by a heteroatom, such as إ nitrogen, oxygen or sulfur, with sulfur being part of the group
-s (o) r or r is equal to 0, 1 or 2, and preferably comprise 4 to ring atoms. In this context, heterocyclic cycles'
٦ΐΖ1١
147 Saturated or at least partially unsaturated 5, 6 or 7 membered POl-2363-ff are preferred.
The heterobicyclic systems belonging to this definition are bicyclic systems in which at least one carbon atom, preferably one to three carbon atoms, has been replaced by a heteroatom, such as a nitrogen, an oxygen or a sulfur, the sulfur making part of the group -S (O) ؛ where r is 0, 1 or 2; the ring system contains at least one non-aromatic ring comprising said at least one heteroatom, and the bicyclic system preferably contains 7 to 12 ring atoms. In this context, saturated or at least partially unsaturated 8, 9 or 10 membered heterocyclic rings are preferred.
Heterotricyclic systems belonging to this definition are tricyclic systems of ringed unicycles, in which at least one carbon atom, preferably one to three carbon atoms, has been replaced by a heteroatom, such as nitrogen, oxygen or sulfur. , the sulfur being part of the group -S (O) r where r is equal to 0, 1 or 2; the ring system contains at least one non-aromatic ring comprising said at least one heteroatom, and the tricyclic system preferably contains 7 to 14 ring atoms.
The expression "spirocyclic system" mentioned in this definition preferably indicates 5 to 10 membered spirocyclic rings which may optionally contain 1, 2 or 3 heteroatoms selected from oxygen, sulfur and nitrogen. These systems can be optionally annealed to an aromatic ring system, such as phenyl.
The order of preference of the heterocyclic ring systems is as follows: Monocyclic systems are preferred over bicyclic systems, which are preferred over tricyclic systems.
Examples of heterocyclic Hc groups according to the present invention are the following groups:
<img file="MA32201B1_D0100.tif" />
ΜΑ 32201Β1
148
POl-2363-ff
<td>ه. هد</td><td>ة. ه.</td><td>مم ٠٠٠.</td><td>ة ٠. ٠٠٠.</td><td>ة ٠. ذي.</td>
<td>Q</td><td> °٠٠.</td><td> °٠٠.</td><td>ة ٠.</td><td>د ٠.</td>
<td>ه.</td><td>ه.</td><td>.-Ô</td><td>ة.</td><td>ة.</td>
<td> ٠.</td><td>لا</td><td>ه.</td><td> ٠.</td><td> ٠-</td>
<td> ٠.</td><td>دح.</td><td> ٠.</td><td> ٠٠.</td><td>٠ ج.</td>
<td>ع.</td><td>ي-</td><td>دغ.</td><td> ٠٠</td><td> ٠</td>
<td> ٠٠</td><td>تمم</td><td>دج</td><td>مم.</td><td>ممد</td>
<td> .٠٥</td><td>2 1 or (للجح ١ ح</td><td>2 لا 1٠ (لت ٩</td><td colspan="2">OQ OQ</td>
Ο
٠٠۵٠٥. coccr
ΜΑ 32201Β1
149
POl-2363-ff
<img file="MA32201B1_D0101.tif" />
<img file="MA32201B1_D0102.tif" />
<img file="MA32201B1_D0103.tif" />
X = O, S or N p = 1, 2, 3, or 5 q = 1, 2 or 3
X = 0, S or N p = 1, 2, 3, or 5 q = 1, 2 or 3
بر
X = 0, s or N p = 1, 2, 3, or 5 q = 1, 2 or 3 where - * represents the bond through which said group is bonded to the nitrogen atom of the structure main, whose number is 1.
The above definition applies for "heterocyclyl" in any reasonable context within the present description in the absence of another definition.
The term "oxo" indicates an oxygen atom as a substituent which is linked by a double bond, preferably linked to a c atom. When an oxo is used as a substituent, the οχο replaces two hydrogen atoms of the corresponding atom of the unsubstituted compound.
The following schemes illustrate a process for preparing the compounds of the present invention by way of example.
MY
32201Β1
150
POl-2363-ff
Diagram 1 ه -: رفي<sup>٠,</sup>س ١ ب R * heat Η<sub>2</sub>Ν ٦٠
<img file="MA32201B1_D0104.tif" />
activation reagent with
بأ ٦ آ
؟ R<sup>3</sup>]
R * ت
Scheme 1: in a first step, 2-ethoxy-methylene5 malononitrile is condensed with monosubstituted hydrazines by heating in a suitable solvent, such as ethanol, in the presence of a base (for example, triethylamine) to form 5 -amino-1H-pyrazole-4-carbonitriles. These compounds are converted, in a second step, into corresponding amides, for example by treating an ethanolic solution with ammonia (25% in water) and hydrogen peroxide (35% in water). . In a third step, heating with carboxylic esters in basic condition (eg sodium hydride in ethanol) or carboxylic acids with an activating reagent (eg polyphosphoric acid) gives pyrazolo [3 , 4-d] pyrimidin-4-ones as end products [see, eg, A. Miyashita et al., Heterocycles 1990, 31, 1309ff].
Schemes 2 and 3 illustrate alternative methods for preparing the final compounds: in these exemplary preparation methods, amides of 5-amino-! H-pyrazole-4- acid.
<img file="MA32201B1_D0105.tif" />
MA 32201 Bl
151 Carboxylic POl-2363-ff are condensed, in a first step, with a suitable ester derivative, then in a second step, an alkylation is carried out with suitable electrophiles.
<img file="MA32201B1_D0106.tif" />
<img file="MA32201B1_D0107.tif" />
32201Β1
152 POl-2363-ff
Diagram 3
<img file="MA32201B1_D0108.tif" />
RR LC
<img file="MA32201B1_D0109.tif" />
X = O, NH, NR2, S, SOduSO٠2 Ri: R2 QU R3
LG = Br-, Cl-, I-, CH<sub>3</sub>-SO<sub>2</sub>-O٦ p-taluenesulfanyln = 1.2
Scheme 4 illustrates alternative methods for preparing the final compounds ؛ in the preparation methods given as an example, amides of 5-amino-1H-pyrazole-4-carboxylic acid are condensed, in a first step, with ester derivatives of the acid (2-bromo-phenyl) - acetic then, in a second step, the bromine atom is replaced by an aromatic or heteroaromatic residue, for example using the reaction conditions of Suzuki or Ullmann.
MY
32291Β1
153 POl-2363-ff
Diagram 4
<img file="MA32201B1_D0110.tif" />
<img file="MA32201B1_D0111.tif" />
Ullmann
RÎS-H
Cul / Ν-Ν'-dimethylethylenediamine CS2CO3 / DMF 12O ° C
<img file="MA32201B1_D0112.tif" />
with
R ؟؟ = optionally substituted
<img file="MA32201B1_D0113.tif" />
<img file="MA32201B1_D0114.tif" />
R؟ = aryl, heteroaryl
CH, O, N
Scheme 5 illustrates alternative methods for preparing 5 final compounds: in the exemplary preparation method, amides of 5-amino-1H-pyrazole-4-carboxylic acid are condensed, in a first step, with ester derivatives of (2-cyano-phenyl> -acetic acid then, in a second step, the nitrile group is converted into a 5-membered heteroaromatic group.
Diagram 5
<img file="MA32201B1_D0115.tif" />
ΜΑ 32201Β1
154
POl-2363-ff '5 „4
<img file="MA32201B1_D0116.tif" />
<img file="MA32201B1_D0117.tif" />
Z
<img file="MA32201B1_D0118.tif" />
with
, [لاب ٠ ، RR ly] z = o, NH
Other alternative methods for preparing pyrazolo [3,4-d] pyrimidin-4-ones are known in the art and can also be used to synthesize the compounds of the invention (see, for example: p. Schmidt et al. ai., Helvetica Chimica Acta 1962, 189, 162Off.).
The monosubstituted hydrazine derivatives, which are used in step 1 of scheme 1, can be prepared either by nucleophilic displacement on the corresponding mesylate derivative (scheme 6), or by reduction of the hydrazone intermediate as indicated on the diagram. Scheme 7 [see, e.g., Jw Timberlake et al., "Chemistry of Hydrazo-, Azo-, and Azoxy Groups"; Patais, Ed.; 1975, chapter 4; sc Hunq et al., Journal of orqanic Chemistry 1981, 46, 5413-5414].
Diagram 6
ر
<img file="MA32201B1_D0119.tif" />
32201Β1
155 POl-2363-ff
<img file="MA32201B1_D0120.tif" />
X = O, NH, NR2, S, SO or s٥2
R ** = R٦OUB?
n = 1.2
Diagram 7
<img file="MA32201B1_D0121.tif" />
X = 0, NH, NR2, S, SO or s٠2 n = 1.2
Further information can also be found in document wo 04 099 210 (in particular page 9, last paragraph up to page 14, line 8, incorporated by reference).
The compounds of the invention exhibit a valid range of pharmacological effects which could not have been predicted. In particular, they are characterized by the inhibition of PDE9A.
Preferably, the compounds according to the present invention exhibit a high selectivity profile for inhibiting or modulating specific members within the PDE9 family or other PDE families, with a marked preference (selectivity) for inhibition of PDE9. PDE9A.
<img file="MA32201B1_D0122.tif" />
MY
32201Β1
156 POl-2363-ff
The compounds of the present invention are believed to exhibit a favorable safety profile.
TREATMENT METHOD
The present invention relates to compounds which are believed to be effective and selective inhibitors of 9Α phosphodiesterase and which can be used in drug development. These medicaments will preferably be used for the treatment of diseases in which inhibition of PDE9 may develop a therapeutic, prophylactic or disease modifying effect. Preferably, the drugs will be used to improve perception, concentration, cognition, learning or memory, such as those found, in particular, in the following conditions / diseases / syndromes: mild cognitive impairment, age-associated learning and memory impairment, age-associated memory loss, vascular dementia, head trauma, stroke, dementia producing after a cerebrovascular accident (post-stroke dementia), post-traumatic dementia, general disturbances of concentration, concentration disorders in children with learning and memorization problems, Alzheimer's disease, Lewy body dementia, dementia with degeneration of the frontal lobes, in particular Pick's syndrome, Parkinson's disease, progressive nuclear palsy, dementia with corticobasal degeneration, amyotrophic lateral sclerosis (ALS), Huntington's disease, multiple sclerosis, thalamic degeneration, Jacob Creutzfeld30 dementia, HIV-related dementia, schizophrenia with dementia, or Korsakoff's psychosis.
Another aspect of the present invention relates to the treatment of a disease which is accessible by modulation of PDE9A, in particular sleep disorders such as insomnia or narcolepsy, bipolar disorder, metabolic syndrome, obesity, diabetes mellitus, especially type 1 or type 2 diabetes, hyperglycemia, dyslipidemia, poor glucose tolerance or disease of the testes,
<img file="MA32201B1_D0123.tif" />
<img file="MA32201B1_D0124.tif" />
32201Β1
157
POl-2363-ff brain, small intestine, skeletal muscle, heart, lung, thymus or spleen.
Therefore, the medical aspect of the present invention can be summarized by the fact that it is believed that a compound according to any of the embodiments of the invention present herein is used as a medicament. document, in particular that of formula I, as defined by each of aspects 1 to 17, each of the elements / embodiments of matrix 0 or of matrix I, or a compound selected from the group of exemplary final compounds (see aspect 18 or the chapter of exemplary embodiments).
Such a medicament is preferably intended for the treatment of CNS disease.
In an alternative use, the medicament is for the treatment of CNS disease, the treatment of which is accessible by inhibiting PDE9.
In an alternative use, the medicament is for the treatment of a disease which is accessible by inhibiting
PDE9.
In an alternative use, the medicament is for the treatment, amelioration and / or prevention of a cognitive disorder related to perception, concentration, cognition, learning or memory.
In an alternative use, the medicament is for the treatment, amelioration and / or prevention of a cognitive impairment related to age-associated learning and memory impairment, memory loss associated with age. age, vascular dementia, head trauma, stroke, dementia occurring after stroke (post-stroke dementia), post-traumatic dementia, general concentration disturbances, concentration disturbances in children with learning and memorization problems, Alzheimer's disease, Lewy body dementia , dementia with degeneration of the frontal lobes, in particular Pick's syndrome, Parkinson's disease, progressive nuclear palsy, dementia with degeneration
<img file="MA32201B1_D0125.tif" />
MY
32201Β1
158
POl-2363-ff corticobasal, amyotrophic lateral sclerosis (ALS), Huntington's disease, multiple sclerosis, thalamic degeneration, Creutzfeld-Jacob dementia, HIV-related dementia, schizophrenia with dementia or Korsakoff's psychosis.
In an alternative use, the medicament is for the treatment of Alzheimer's disease.
In an alternative use, the medicament is for the treatment of sleep disorders, bipolar disorder, metabolic syndrome, obesity, diabetes mellitus, hyperglycemia, dyslipidemia, poor tolerance to alcohol. glucose or disease of the testes, brain, small intestine, skeletal muscle, heart, lung, thymus or spleen.
PHARMACEUTICAL COMPOSITIONS
The medicaments for administration comprise a compound according to the present invention in a therapeutically effective amount. By "therapeutically effective amount" it is meant that if the drug is used in the appropriate dosage regimen suited to the disease of the patient, the amount of said compound of formula (I) will be sufficient to effectively treat, prevent or slow progression. of the corresponding disease or, moreover, to improve the state of health of a patient suffering from such a disease. It may happen that the "therapeutically effective amount" in one monotherapy is different from the "therapeutically effective amount" in a combination therapy with another drug.
The dose range of compounds of general formula (I) applicable per day is usually 0.1 mg to 5000 mg, preferably 0.1 mg to 1000 mg, preferably 2 mg to 500 mg, and more preferably from 5 mg to 250 mg, and most preferably from 10 mg to 100 mg. A dosage unit (for example, a tablet) preferably contains between 2 mg and 250 mg, and particularly preferably between 10 mg and 100 mg of the compounds according to the invention.
The actual pharmaceutically effective amount or therapeutic dosage will of course depend on known factors of
<img file="MA32201B1_D0126.tif" />
ΜΑ 32201Β1
159 POl-2363-ff إ! 'Those skilled in the art, such as the patient's age, weight, sex or other condition, route of administration, severity of disease and ؛ equivalent.
The compounds according to the invention can be administered orally, parenterally (intravenously, intramuscularly, etc.), intranasally, sublingually, intrathecally, topically or rectally or by inhalation. Preparations suitable for administering the compounds according to the present invention include, for example, patches, tablets, capsules, pills, granules, ؛ dragees, powders, tablets, suppositories, liquid preparations such as solutions, suspensions, emulsions, drops, syrups, elixirs, or gaseous preparations such as aerosols, sprays and the like. The content of the pharmaceutically active compound (s) should be in the range from 0.05% to 90% by weight, preferably from 0.1% to 50% by weight of the composition as a whole. Suitable tablets can be obtained, for example, by mixing the active substance (s) with known excipients, for example inert diluents such as calcium carbonate, calcium phosphate or lactose, disintegrants such as starch. but or alqinic acid, binders such as starch or gelatin, lubricants such as magnesium stearate or talc and / or agents for delaying release, such as carboxymethylcellulose, cellulose acetate phthalate or polyvinyl acetate. The tablets can also have several layers.
Therefore, coated tablets can be prepared by coating cores produced in the same manner as tablets with substances normally used for coating tablets, for example collidone or shellac, acacia, talc, etc. titanium dioxide or a sugar. To achieve delayed release or to avoid incompatibilities, the core can also be made up of a number of layers.
Similarly, the tablet coating may be composed of a number of layers to achieve delayed release, optionally by means of the above-mentioned excipients for tablets.
<img file="MA32201B1_D0127.tif" />
<img file="MA32201B1_D0128.tif" />
32201Β1
160
POl-2363-ff
Syrups or elixirs containing the active substances or their combinations according to the invention may additionally contain a sweetener, such as saccharin, cyclamate, glycerol or a sugar, and a flavor enhancer, for example an aroma such as vanillin. or an orange extract. They can also contain suspension adjuvants or thickeners, such as sodium carboxymethylcellulose, wetting agents such as, for example, the products of condensation between fatty alcohols and ethylene oxide, or preservatives such as p10 hydroxybenzoates.
Solutions are prepared in the usual manner, for example with the addition of isotonic agents, preservatives such as p-hydroxy-benzoates, or stabilizers such as the alkali metal salts of ethylenediaminetetraacetic acid, optionally using emulsifiers. and / or dispersants, while if water is used as a diluent, for example, organic solvents can optionally be used as solubilizing agents or as a ؛ dissolution, and the solutions can be transferred to vials or ampoules for injection or bottles for infusion.
Capsules containing one or more active substances or combinations of active substances can be prepared, for example, by mixing the active substances with inert carriers, such as lactose or sorbitol, and filling them into gelatin capsules. إ
Appropriate suppositories can be prepared, by ؛ for example, by mixing with supports suitable for this application, such as neutral fats or polyethylene glycol or their derivatives.
Excipients which may be used include, for example, water, pharmaceutically acceptable organic solvents, such as paraffins (eg, petroleum fractions), vegetable oils (eg, peanut or sesame oil). , mono- or poly-functional alcohols (for example, ethanol or glycerol), carriers such as, for example, natural mineral powders (for example, kaolins, clays, talc, chalk), synthetic mineral powders
<img file="MA32201B1_D0129.tif" />
<img file="MA32201B1_D0130.tif" />
32201Β1
161
POl-2363-ff (for example, highly dispersed silicic acid and silicates), sugars (for example, cane sugar, lactose ؛ and glucose), emulsifiers (for example, lignin, إ waste liquors containing bisulfite, methylcellulose, starch and polyvinylpyrrolidone) and lubricants (for example, magnesium stearate, talc, stearic acid, and sodium lauryl sulfate). ؛
For oral use, the tablets may of course contain, in addition to the specified carriers, such additives as sodium citrate, calcium carbonate and dicalcium phosphate, with various additional substances such as starch, preferably potato starch, gelatin and the like. Lubricants, such as magnesium stearate, sodium lauryl sulfate, and talc, can؟ also be used to produce the tablets. In the case of aqueous suspensions, the active substances can be combined with flavor enhancers or colorings in addition to the excipients mentioned above.
The dose of the compounds according to the invention is naturally extremely dependent on the method of administration and on the condition to be treated. When administered by inhalation, the compounds of formula (I) are characterized by high therapeutic activity, even at doses of the order of a microgram. إ
The compounds of formula (I) can also be used effectively in amounts greater than one microgram. The dose اً can then be of the order of a gram, for example. إ
COMBINATION WITH OTHER ACTIVE SUBSTANCES
In another aspect, the present invention relates to the pharmaceutical formulas mentioned above as such, which being characterized in that they contain a compound according to the present invention.
In another aspect, the present invention relates to a combination of each of the compounds of the present invention, preferably at least one compound according to the present invention with another compound selected from the group comprising, for example, beta-secretase inhibitors; gammasecretase inhibitors; gamma-secretase modulators; inhibitors
<img file="MA32201B1_D0131.tif" />
MA 32201 Bl
؛ 162 POl-2363-ff
إ amyloid aggregation, such as for example alzhemed; ٦ neuroprotective and / or disease modifying substances acting l directly or indirectly; antioxidants, such as, for example, vitamin E, ginko biloba or ginkolide; substances ؛ anti-inflammatory drugs, such as cox inhibitors, ٠
NSAIDs possessing in addition or exclusively lowering properties \
Αβ; HMG-CoA reductase inhibitors, such as statins; acetylcholine esterase inhibitors, such as donepezil, ؛ rivastigmine, tacrine, galantamine; NMDA receptor antagonists, such as, for example, memantine; agonists ؛ the 1ΆΜΡΑ receptor; positive modulators of the 1ΆΜΡΑ receptor, AMPkines - 'receptor reuptake inhibitors monoamine; substances modulating the concentration or release of neurotransmitters; substances inducing the secretion of a growth hormone, such as ibutamorene mesylate and capromorelin; CB-1 receptor antagonists or reverse agonists; antibiotics such as minocycline or rifampicin; PDE1, PDE2 inhibitors,
PDE4, PDE5 and / or PDEIO, inverse agonists of the GABAA receptor;
GABAA receptor antagonists; nicotinic receptor agonists or partial agonists; nicotinic alpha4beta2 receptor agonists or partial agonists; alpha7 receptor agonists or partial agonists;
nicotinic; histamine Η3 receptor antagonists;
agonists or partial agonists of the 5-ΗΤ4 receptor; 5-ΗΤ6 receptor antagonists; the antagonists of ؛
Alpha2 adrenoreceptor, calcium channel blockers; positive muscarinic M1 receptor agonists or modulators; muscarinic in2 receptor antagonists; Μ4 muscarinic receptor antagonists; positive modulators of the metabotropic glutamate receptor; metabotropic glutamate receptor 2 antagonists, and other substances which modulate receptors or enzymes in such a way that the efficacy and / or safety of the compounds according to the invention is increased and / or the side effects are increased. unwanted are reduced.
The present invention further relates to pharmaceutical compositions containing one or more active substances,
<img file="MA32201B1_D0132.tif" />
MY
32291Β1
163
POl-2363-ff preferably an active substance which is selected from the compounds of the present invention and / or the corresponding salts, thus
<td>one or</td><td>several active substances.</td><td>of</td><td>preference</td><td>a</td>
<td colspan="2">active substance chosen from alzhemed.</td><td>the</td><td>Vitamin E,</td><td>the</td>
<td>5 ginkolide.</td><td>doneepezil, rivastigmine</td><td> •</td><td>tacrine.</td><td>the</td>
<td>galantamine.</td><td>memantine, mesylate</td><td>of</td><td>ibutamorene.</td><td>the</td>
capromoreline, minocycline and / or rifampicin, optionally with one or more inert carriers and / or diluents.
The compounds according to the invention can also be
Used in combination with immunotherapies, such as active immunization with Abeta or parts thereof, or passive immunization with antibodies or antibody fragments or humanized anti-Abeta nanobodies, to treat the diseases and conditions mentioned above.
The combinations according to the present invention can be provided simultaneously in one and the same dosage form, i.e. in the form of a combination preparation, for example the two components can be incorporated in a tablet, for example in different layers of said tablet. The combination can also be provided separately, in the form of a free combination, i.e. the compounds of the present invention are provided in dosage form and one or more of the combination partners mentioned above. above are supplied in an alternate dosage form. These two dosage forms may be equivalent dosage forms, for example a co-administration of two tablets, one containing a therapeutically effective amount of the compound of the present invention and the other containing a therapeutically effective amount of the combination partner mentioned above. -above. It is also possible to combine different forms of administration, if desired. All types of suitable administration forms can be provided.
The compounds according to the invention, or! 'One of their physiologically acceptable salts, in combination with another active substance can be used simultaneously or at staggered times, but at particularly close times. If administered simultaneously, the two active substances
<img file="MA32201B1_D0133.tif" />
ΜΑ 32201Β1 '164 POl-2363-ff are given together to the patient; if they are administered to ؛ shifted hours, the two active substances are given to the patients successively in a period which is less than or equal to 12 hours, in particular less than or equal to 6 hours.
Dosage or administration forms are not limited, all suitable dosage forms can be used within the scope of the present invention. For example, the إ dosage forms can be chosen from solid preparations, such as patches, tablets, capsules, pills, granules, dragees, powders, tablets, اً suppositories, liquid preparations such as solutions, suspensions, emulsions, drops, syrups, elixirs, or gaseous preparations such as aerosols, sprays and the like.
Dosage forms are advantageously formulated in dosage units, each dosage unit being tailored to provide a single dosage of each active component present. The ; ingredients are chosen according to the route of administration اً and the galenic form.
The dose of the combination partners mentioned above ؛ suitably represents 1/5 of the lowest normally recommended dose up to 1/1 of the normally recommended dose.
Dosage forms are administered to patients, for example, 1, 2, 3 or 4 times per day depending on the nature of the formulation. In the case of delayed or sustained release formulations or other pharmaceutical formulations, the same can be applied in a different way (eg once a week or a month etc.). Preferably, the compounds of the invention are administered three times or less than three times per ؛ day, and more preferably once or twice a day.
EXAMPLES
ر
PHARMACEUTICAL COMPOSITIONS
The following pharmaceutical formulas can illustrate the present invention without limiting its scope.
<img file="MA32201B1_D0134.tif" />
ΜΑ 32201Β1
165 POl-2363-ff
Certain examples of formulas will now be described, in which the term “active substance” indicates one or more compounds according to the invention, including their salts. In the case of the above-mentioned combinations with one or more other active substances, the term "active substance" also includes the additional active substances.
Example A
Cnpries containing 100 mg of active substance
Composition:
tablet contains:
<td>active substance</td><td>100.0 mg</td>
<td>lactose</td><td>8 0.0 mg</td>
<td>corn starch</td><td>34.0 mg</td>
<td>polyvinylpyrrolidone</td><td>4.0 mg</td>
<td>magnesium stearate</td><td>2.0 mg</td>
<td></td><td>220.0 mg</td>
Diameter: 10mm, biplanar, faceted on both sides and with a notch on one side.
Example B
Tablets containing 150 mg of active substance
Composition:
tablet contains:
<td>active substance</td><td>150.0 mg</td>
<td>lactose powder</td><td>89.0 mg</td>
<td>corn starch</td><td>40.0 mg</td>
<td>colloidal silica</td><td>10.0 mg</td>
<td>polyvinylpyrrolidone</td><td>10.0 mg</td>
<td>magnesium stearate</td><td>1.0 mg</td>
<td></td><td>300.0 mg</td>
Diameter: 10 mm, flat.
MA 32201 BI
156 POl-2363-ff
Example c
Hard gelatin capsules containing 150 mg of active substance capsule contains:
<td>active substance</td><td>150.0 mg</td>
<td>corn starch (dry)</td><td>about 80.0 mg</td>
<td>lactose (powder)</td><td>about 87.0 mg</td>
<td>magnesium stearate</td><td>3.0 mg</td>
<td></td><td>about 320.0 mg</td>
Capsule shell: size 1 hard gelatin capsule. ؛ إ
Example D ؛ '
Suppositories containing 150 mg of active substance ا suppository contains: ؛ '
<td>active substance</td><td>150.0 mg</td>
<td>polyethylene glycol 1500</td><td>550.0 mg</td>
<td>polyethylene glycol 6000</td><td>460.0 mg</td>
<td>sorbitan monostearate polyoxyethylene</td><td>840.0 mg</td>
<td></td><td>2000.0 mg</td>
Example E
Ampoules containing 10 mg of active substance
Composition:
<td>active substance</td><td>10.0 mg</td>
<td>hydrochloric acid 0.01 N</td><td>٩. S</td>
<td>twice distilled water</td><td>up to 2.0 ml</td>
Example F
Ampoule containing 50 mg of active substance
Composition:
<td>active substance</td><td>50.0 mg</td>
<td>hydrochloric acid 0.01 N</td><td>qs</td>
<img file="MA32201B1_D0135.tif" />
MY
32291Bl
167
POl-2363-ff
<td>twice distilled water</td><td>up to 10.0 ml</td>
The preparation of the above mentioned formulas can be carried out according to standard procedures.
BIOLOGICAL TEST
The in vitro effect of the compounds of the invention can be shown with the following biological tests.
Protocol of the test with the PDE9A2
The assay for the enzymatic activity of PDE9A2 was performed by means of a proximity scintillation assay (SPA), in general! according to manufacturer's protocol (Amersham Biosciences, product number: TRKQ 7100).
As the source of the enzyme, a lysate of SF9 cells expressing human PDE9A2 (PBS with 1% Triton Χ-100 supplemented with protease inhibitors was used, the cell debris having been removed by centrifugation at 13,000 revolutions / minute for 30 minutes). The total amount of protein included in the assay varies depending on the infection and production efficiency of the SF9 cells and is in the range of 0.1 ng to 100 ng.
In general, the test conditions were as follows:
- total volume of the test: 40 microliters
- amount of protein: 0.1 ng to 50 ng
- substrate concentration (cGMP): 20 nanomoles; ~ 1 mCi / 1
- incubation time: 60 minutes at room temperature
- final DMSO concentration: 0.2% to 1%.
The assays were performed in a 384-well format. The assay reagents along with the enzyme and substrate were diluted in assay buffer. The assay buffer contained 50 mM Tris, 8.3 mM Mgl, 1.7 mM EGTA, 0.1% BSA, 0.05% Tween 20; the pH test buffer was adjusted to 7.5. The reaction was stopped using an excess of PDE9 specific inhibitor (eg, the compounds described in WO 04 099 210).
Determination of% inhibition
Μα 32201Β1
168 POl-2363-ff
The activity of the positive control (minus the negative control = background noise) is set at 100% and the activity in the presence of the test compound is expressed relative to these 100%.
Under these conditions, greater than 100% inhibition is possible due to the nature of the variation of the positive control in the assay. However, in this case, the% inhibition reported was adjusted to 100%. ;
إ إ!
إ Determination of the IC<sub>50</sub> إ The IC can be calculated with GraphPadPrism or another إ ؛ appropriate software, setting the positive control to 100 and the negative control to 0. To calculate the CI, we must select and ؛ test dilutions of the compounds to be tested (substrates) by following ١ the previously mentioned protocol.
Data
In the following,% inhibition data will show that compounds according to the present invention are suitable for inhibiting PDE9 and provide useful pharmacological properties. The examples do not represent a limitation. The table also shows the values of CI (,. The values are presented in a nanomolar range (nM), i.e. in the range from 1 nanomole to 100 nanomoles or in the range from 101 nanomoles to 1200 nanomoles. . The specific value of the IC is found in said plate. The number of the example refers to the final examples set forth in the section "Examples of embodiments" (see also aspect 18 of the invention). ن
All data is measured according to the procedure described in this document. ؛
<td>Example No.</td><td>% inhibition of PDE9A2 (at a concentration of 10 micromoles)</td><td>CI in the plate [nanomole (nM)]</td>
<td> 1</td><td> 100</td><td>1 to 100</td>
<td> 2</td><td> 99</td><td>1 to 100</td>
<td> 3</td><td> 99</td><td>1 to 100</td>
<img file="MA32201B1_D0136.tif" />
ΜΑ 32201Β1
169 POl-2363-ff
<td> 4</td><td> 98</td><td>1 to 100</td>
<td> 5</td><td> 99</td><td>1 to 100</td>
<td> 6</td><td> 98</td><td>1 to 100</td>
<td> 7</td><td> 98</td><td>1 to 100</td>
<td> 8</td><td> 100</td><td>1 to 100</td>
<td> 9</td><td> 99</td><td>1 to 100</td>
<td> 10</td><td> 98</td><td>1 to 100</td>
<td> 11</td><td> 98</td><td>1 to 100</td>
<td> 12</td><td> 97</td><td>1 to 100</td>
<img file="MA32201B1_D0137.tif" />
Μα 32201Β1
170 ئ POl-2363-ff
<td>Example No.</td><td>% inhibition of PDE9A2 (at a concentration of 10 micromoles)</td><td>Co in the beach [nanomole (nM)]</td>
<td> 13</td><td> 90</td><td>101 to 1,200</td>
<td> 14</td><td> 96</td><td>101 to 1,200</td>
<td> 15</td><td> 92</td><td>101 to 1,200</td>
<td> 16</td><td> 86</td><td>101 to 1,200</td>
<td> 17</td><td> 100</td><td>1 to 100</td>
<td> 18</td><td> 99</td><td>1 to 100</td>
<td> 19</td><td> 99</td><td>1 to 100</td>
<td> 20</td><td> 98</td><td>1 to 100</td>
<td> 21</td><td> 97</td><td>101 to 1,200</td>
<td> 22</td><td> 98</td><td>1 to 100</td>
<td> 23</td><td> 99</td><td>1 to 100</td>
<td> 24</td><td> 86</td><td>101 to 1,200</td>
<td> 25</td><td> 96</td><td>1 to 100</td>
<td> 26</td><td> 91</td><td>101 to 1,200</td>
<td> 21</td><td> 99</td><td>1 to 100</td>
<td> 28</td><td> 98</td><td>1 to 100</td>
<td> 29</td><td> 96</td><td>1 to 100</td>
<td> 30</td><td> 100</td><td>1 to 100</td>
<td> 31</td><td> 98</td><td>1 to 100</td>
<td> 32</td><td> 100</td><td>1 to 100</td>
<td> 33</td><td> 97</td><td>1 to 100</td>
<td> 34</td><td> 93</td><td>101 to 1,200</td>
<td> 35</td><td> 100</td><td>101 to 1,200</td>
<td> 36</td><td> 100</td><td>1 to 100</td>
<td> 37</td><td> 97</td><td>1 to 100</td>
<td> 38</td><td> 99</td><td>1 to 100</td>
<img file="MA32201B1_D0138.tif" />
ΜΑ 32201Β1
171 POl-2363-ff
<td>Example No.</td><td>% inhibition of PDE9A2 (at a concentration of 10 micromoles)</td><td>Co in the beach [nanomole (nM)]</td>
<td> 39</td><td> 99</td><td>1 to 100</td>
<td> 40</td><td> 99</td><td>1 to 100</td>
<td> 40-1</td><td> 100</td><td>1 to 100</td>
<td> 40-2</td><td> 100</td><td>1 to 100</td>
<td> 40-3</td><td> 100</td><td>101 to 1,200</td>
<td> 40-4</td><td> 92</td><td>101 to 1,200</td>
<td> 40-5</td><td> 98</td><td>1 to 100</td>
<td> 40-6</td><td>الأ</td><td>1 to 100</td>
<td> 40-7</td><td> 95</td><td>101 to 1,200</td>
<td> 41</td><td> 92</td><td>101 to 1,200</td>
<td> 42</td><td> 92</td><td>101 to 1,200</td>
<td> 43</td><td> 98</td><td>1 to 100</td>
<td> 44</td><td> 99</td><td>1 to 100</td>
<td> 45</td><td> 98</td><td>1 to 100</td>
<td> 46</td><td> 100</td><td>1 to 100</td>
<td> 47</td><td> 97</td><td>1 to 100</td>
<td> 48</td><td> 96</td><td>1 to 100</td>
<td> 49</td><td> 98</td><td>1 to 100</td>
<td> 50</td><td> 97</td><td>1 to 100</td>
<td> 51</td><td> 96</td><td>1 to 100</td>
<td> 52</td><td> 100</td><td>1 to 100</td>
<td> 53</td><td> 99</td><td>1 to 100</td>
<td> 54</td><td>الأ</td><td>1 to 100</td>
<td> 55</td><td>الأ</td><td>1 to 100</td>
<td> 56</td><td> 95</td><td>1 to 100</td>
<td> 51</td><td> 100</td><td>1 to 100</td>
<img file="MA32201B1_D0139.tif" />
ΜΑ 32201Β1
172
POl-2363-ff
<td>Example No.</td><td>% inhibition of PDE9A2 (at a concentration of 10 micromoles)</td><td>CI in range [nanomole (nM) j</td>
<td> 58</td><td> 96</td><td>1 to 100</td>
<td> 60</td><td> 97</td><td>1 to 100</td>
<td> 61</td><td> 97</td><td>1 to 100</td>
<td> 62</td><td> 95</td><td>1 to 100</td>
<td> 63</td><td> 92</td><td>101 to 1,200</td>
<td> 64</td><td> 97</td><td>1 to 100</td>
<td> 65</td><td> 97</td><td>1 to 100</td>
<td> 66</td><td> 91</td><td>101 to 1,200</td>
<td> 67</td><td> 95</td><td>101 to 1,200</td>
<td> 68</td><td> 97</td><td>1 to 100</td>
<td> 69</td><td> 99</td><td>1 to 100</td>
<td> 70</td><td> 99</td><td>1 to 100</td>
<td> 71</td><td> 99</td><td>1 to 100</td>
<td> 12</td><td> 91</td><td>101 to 1,200</td>
<td> 12</td><td> 97</td><td>1 to 100</td>
<td> 74</td><td> 95</td><td>1 to 100</td>
<td>لآ ٦</td><td> 98</td><td>1 to 100</td>
<td> 16</td><td> 98</td><td>1 to 100</td>
<td> 11</td><td> 89</td><td>101 to 1,200</td>
<td> 78</td><td> 99</td><td>101 to 1,200</td>
<td> 79</td><td> 99</td><td>1 to 100</td>
<td> 80</td><td> 94</td><td>1 to 100</td>
<td> 81</td><td> 78</td><td>101 to 1,200</td>
<td> 82</td><td> 100</td><td>1 to 100</td>
<td> 83</td><td> 96</td><td>1 to 100</td>
<td> 84</td><td> 97</td><td>1 to 100</td>
<img file="MA32201B1_D0140.tif" />
MA 32201 Bl
173 POl-2363-ff
<td>Example No.</td><td>% inhibition of PDE9A2 (at a concentration of 10 micromoles)</td><td>CI in range [nanomole (nM))</td>
<td> 85</td><td> 99</td><td>1 to 100</td>
<td> 86</td><td> 95</td><td>101 to 1,200</td>
<td> 87</td><td> 86</td><td>101 to 1,200</td>
<td> 88</td><td> 96</td><td>1 to 100</td>
<td> 89</td><td> 95</td><td>101 to 1,200</td>
<td> 90</td><td> 100</td><td>1 to 100</td>
<td> 91</td><td> 99</td><td>1 to 100</td>
<td> 92</td><td> 98</td><td>1 to 100</td>
<td> 93</td><td>الأ</td><td>1 to 100</td>
<td> 94</td><td> 96</td><td>101 to 1,200</td>
<td> 95</td><td> 98</td><td>1 to 100</td>
<td> 96</td><td> 99</td><td>1 to 100</td>
<td> 97</td><td> 98</td><td>1 to 100</td>
<td> 98</td><td> 97</td><td>1 to 100</td>
<td> 99</td><td> 96</td><td>1 to 100</td>
<td> 100</td><td> 93</td><td>101 to 1,200</td>
<td> 101</td><td> 98</td><td>1 to 100</td>
<td> 102</td><td> 100</td><td>1 to 100</td>
<td> 103</td><td> 99</td><td>1 to 100</td>
<td> 104</td><td> 95</td><td>101 to 1,200</td>
<td> 105</td><td> 84</td><td>101 to 1,200</td>
<td> 106</td><td> 87</td><td>101 to 1,200</td>
<td> 108</td><td> 89</td><td>101 to 1,200</td>
<td> 111</td><td> 88</td><td>101 to 1,200</td>
<td> 112</td><td>الأ</td><td>1 to 100</td>
<td> 113</td><td> 92</td><td>101 to 1,200</td>
ثم
MA 32201 Bl
174 POl-2363-ff
<td>Example No.</td><td>% inhibition of PDE9A2 (at a concentration of 10 micromoles)</td><td>Co in the beach [nanomole (nM)]</td>
<td> 114</td><td> 89</td><td>101 to 1,200</td>
<td> 115</td><td> 92</td><td>101 to 1,200</td>
<td> 116</td><td> 93</td><td>101 to 1,200</td>
<td> 117</td><td>الأ</td><td>1 to 100</td>
<td> 118</td><td> 89</td><td>101 to 1,200</td>
<td> 119</td><td> 95</td><td>1 to 100</td>
<td> 120</td><td> 95</td><td>1 to 100</td>
<td> 121</td><td> 94</td><td>101 to 1,200</td>
<td> 122</td><td> 85</td><td>101 to 1,200</td>
<td> 123</td><td> 91</td><td>101 to 1,200</td>
<td> 124</td><td> 95</td><td>101 to 1,200</td>
<td> 125</td><td> 95</td><td>1 to 100</td>
<td> 126</td><td> 98</td><td>1 to 100</td>
<td> 127</td><td> 97</td><td>1 to 100</td>
<td> 128</td><td> 99</td><td>1 to 100</td>
<td> 129</td><td> 99</td><td>1 to 100</td>
<td> 130</td><td> 99</td><td>1 to 100</td>
<td> 131</td><td> 97</td><td>1 to 100</td>
<td> 132</td><td> 90</td><td>101 to 1,200</td>
<td> 132-1</td><td> 97</td><td>1 to 100</td>
<td> 132-2</td><td> 100</td><td>1 to 100</td>
<td> 132-3</td><td> 89</td><td>101 to 1,200</td>
<td> 132-4</td><td> 98</td><td>1 to 100</td>
<td> 132-5</td><td> 100</td><td>1 to 100</td>
<td> 132-6</td><td> 99</td><td>1 to 100</td>
<td> 132-7</td><td> 94</td><td>1 to 100</td>
Μα 32201Β1
175 POl-2363-ff
<td>Example No.</td><td>% inhibition of PDE9A2 (at a concentration of 10 micromoles)</td><td>CI in range [nanomole (nM)]</td>
<td> 132-8</td><td> 94</td><td>101 to 1,200</td>
<td> 132-9</td><td> 95</td><td>101 to 1,200</td>
<td> 133</td><td> 98</td><td>1 to 100</td>
<td> 134</td><td> 99</td><td>1 to 100</td>
<td> 135</td><td> 98</td><td>1 to 100</td>
<td> 136</td><td> 100</td><td>1 to 100</td>
<td> 137</td><td> 99</td><td>1 to 100</td>
<td> 138</td><td> 100</td><td>1 to 100</td>
<td> 139</td><td> 99</td><td>1 to 100</td>
<td> 140</td><td> 100</td><td>1 to 100</td>
<td> 141</td><td> 99</td><td>1 to 100</td>
<td> 142</td><td> 98</td><td>1 to 100</td>
<td> 143</td><td> 100</td><td>1 to 100</td>
<td> 144</td><td> 100</td><td>1 to 100</td>
<td> 145</td><td> 84</td><td>101 to 1,200</td>
<td> 146</td><td> 91</td><td>101 to 1,200</td>
<td> 147</td><td> 99</td><td>1 to 100</td>
<td> 147-1</td><td> 86</td><td>101 to 1,200</td>
<td> 147-2</td><td> 87</td><td>101 to 1,200</td>
<td> 147-3</td><td> 95</td><td>1 to 100</td>
<td> 148</td><td> 86</td><td>101 to 1,200</td>
<td> 149</td><td> 95</td><td>101 to 1,200</td>
<td> 150</td><td> 90</td><td>101 to 1,200</td>
<td> 151</td><td> 92</td><td>101 to 1,200</td>
<td> 152</td><td> 93</td><td>101 to 1,200</td>
<td> 153</td><td> 90</td><td>101 to 1,200</td>
<img file="MA32201B1_D0141.tif" />
ΜΑ 32201Β1
176 POl-2363-ff
<td>Example No.</td><td>% inhibition of PDE9A2 (at a concentration of 10 micromoles)</td><td>CIso in the beach [nanomole (nM)]</td>
<td> 154</td><td> 100</td><td>1 to 100</td>
<td> 155</td><td> 100</td><td>1 to 100</td>
<td> 156</td><td> 99</td><td>1 to 100</td>
<td> 157</td><td>٦ لأ</td><td>1 to 100</td>
<td> 158</td><td>الأ</td><td>1 to 100</td>
<td> 159</td><td> 100</td><td>1 to 100</td>
<td> 160</td><td> 96</td><td>1 to 100</td>
<td> 161</td><td> 95</td><td>101 to 1,200</td>
<td> 162</td><td> 98</td><td>1 to 100</td>
<td> 163</td><td>٦ لأ</td><td>101 to 1,200</td>
<td> 164</td><td> 98</td><td>101 to 1,200</td>
<td> 165</td><td> 99</td><td>101 to 1,200</td>
<td> 166</td><td> 92</td><td>101 to 1,200</td>
<td> 167</td><td> 93</td><td>101 to 1,200</td>
<td> 168</td><td> 90</td><td>101 to 1,200</td>
<td> 169</td><td> 86</td><td>101 to 1,200</td>
<td> 170</td><td> 15</td><td>101 to 1,200</td>
<td> 171</td><td> 100</td><td>101 to 1,200</td>
<td> 172</td><td> 100</td><td>1 to 100</td>
<td> 173</td><td> 86</td><td>101 to 1,200</td>
<td> 174</td><td> 89</td><td>101 to 1,200</td>
<td> 175</td><td> 88</td><td>101 to 1,200</td>
<td> 176</td><td> 85</td><td>101 to 1,200</td>
<td> 177</td><td> 93</td><td>101 to 1,200</td>
<td> 178</td><td> 92</td><td>101 to 1,200</td>
<td> 179</td><td> 91</td><td>101 to 1,200</td>
<img file="MA32201B1_D0142.tif" />
32201BI
177 POl-2363-ff
<td>Example No.</td><td>% inhibition of PDE9A2 (at a concentration of 10 micromoles)</td><td>Co in the beach [nanomole (nM)]</td>
<td> 180</td><td> 96</td><td>101 to 1,200</td>
<td> 181</td><td> 96</td><td>1 to 100</td>
<td> 182</td><td> 100</td><td>1 to 100</td>
<td> 183</td><td> 99</td><td>1 to 100</td>
<td> 184</td><td> 97</td><td>1 to 100</td>
<td> 185</td><td> 100</td><td>1 to 100</td>
<td> 186</td><td> 97</td><td>1 to 100</td>
<td> 187</td><td> 96</td><td>1 to 100</td>
<td> 188</td><td> 96</td><td>1 to 100</td>
<td> 189</td><td> 90</td><td>101 to 1,200</td>
<td> 190</td><td> 82</td><td>101 to 1,200</td>
<td> 191</td><td> 92</td><td>101 to 1,200</td>
<td> 192</td><td> 100</td><td>101 to 1,200</td>
<td> 193</td><td> 99</td><td>101 to 1,200</td>
<td> 194</td><td> 97</td><td>101 to 1,200</td>
<td> 195</td><td> 88</td><td>101 to 1,200</td>
<td> 196</td><td> 91</td><td>101 to 1,200</td>
<td> 197</td><td> 91</td><td>101 to 1,200</td>
<td> 198</td><td> 100</td><td>101 to 1,200</td>
<td> 199</td><td> 88</td><td>101 to 1,200</td>
<td> 200</td><td> 91</td><td>101 to 1,200</td>
<td> 201</td><td> 85</td><td>101 to 1,200</td>
<td> 202</td><td> 83</td><td>101 to 1,200</td>
<td> 203</td><td> 84</td><td>101 to 1,200</td>
<td> 204</td><td> 87</td><td>101 to 1,200</td>
<td> 205</td><td> 100</td><td>1 to 100</td>
<img file="MA32201B1_D0143.tif" />
32201Bl
178
POl-2363-ff
<td>Example No.</td><td>% inhibition of PDE9A2 (at a concentration of 10 micromoles)</td><td>CI in range [nanomole (nM)]</td>
<td> 206</td><td> 82</td><td>101 to 1,200</td>
<td> 207</td><td> 100</td><td>1 to 100</td>
<td> 208</td><td> 100</td><td>101 to 1,200</td>
<td> 209</td><td> 89</td><td>101 to 1,200</td>
<td> 210</td><td> 97</td><td>1 to 100</td>
<td> 211</td><td> 99</td><td>1 to 100</td>
<td> 212</td><td> 92</td><td>101 to 1,200</td>
<td> 213</td><td> 86</td><td>101 to 1,200</td>
<td> 214</td><td> 98</td><td>1 to 100</td>
<td> 215</td><td> 93</td><td>101 to 1,200</td>
<td> 216</td><td> 96</td><td>1 to 100</td>
<td> 217</td><td> 97</td><td>101 to 1,200</td>
<td> 218</td><td> 88</td><td>101 to 1,200</td>
<td> 219</td><td> 100</td><td>1 to 100</td>
<td> 220</td><td> 100</td><td>1 to 100</td>
<td> 221</td><td> 100</td><td>1 to 100</td>
<td> 222</td><td> 100</td><td>1 to 100</td>
<td> 223</td><td> 100</td><td>1 to 100</td>
<td> 224</td><td> 100</td><td>1 to 100</td>
<td> 225</td><td> 100</td><td>1 to 100</td>
<td> 226</td><td> 100</td><td>1 to 100</td>
<td> 227</td><td> 100</td><td>1 to 100</td>
<td> 228</td><td> 100</td><td>1 to 100</td>
<td> 229</td><td> 99</td><td>1 to 100</td>
<td> 230</td><td> 100</td><td>1 to 100</td>
<td> 230-1</td><td> 98</td><td>1 to 100</td>
<img file="MA32201B1_D0144.tif" />
MA 32201 Bl
179
POl-2363-ff
<td>Example No.</td><td>% inhibition of PDE9A2 (at a concentration of 10 micromoles)</td><td>CI50 in range [nanomole (nM)]</td>
<td> 230-2</td><td> 100</td><td>1 to 100</td>
<td> 230-3</td><td> 99</td><td>1 to 100</td>
<td> 230-4</td><td> 98</td><td>101 to 1,200</td>
<td> 231</td><td> 95</td><td>1 to 100</td>
<td> 232</td><td> 99</td><td>1 to 100</td>
<td> 233</td><td> 100</td><td>1 to 100</td>
<td> 234</td><td> 100</td><td>1 to 100</td>
<td> 235</td><td> 98</td><td>101 to 1,200</td>
<td> 236</td><td> 93</td><td>101 to 1,200</td>
<td>الآة</td><td> 89</td><td>101 to 1,200</td>
Effect in vivo
The in vivo effect of the compounds of the present invention can be tested in the test for recognition of new objects according to the procedure of Prickaerts et al. (Neuroscience, 2002, 113, 351361).
For further information regarding bioassays of compounds of the present invention, see also
Neuropharmacology, 2008, 55, 908-918.
Chemical preparation
Abbreviations:
<td></td><td>APCI</td><td>chemical ionization under atmospheric pressure</td>
<td> 15</td><td>DAD</td><td>iodine array detector</td>
<td></td><td>DMSO</td><td>dimethylsulfoxide</td>
<td></td><td>ESI</td><td>electrospray ionization (in MS)</td>
<td></td><td>Exp.</td><td>example</td>
<td></td><td>Pf.</td><td>Fusion point</td>
<td> 20</td><td>h</td><td>hour (s)</td>
<td></td><td>HPLC</td><td>high performance liquid chromatography</td>
HPLC-MS high performance liquid chromatography coupled with detection by mass spectrometry
GC-MS gas chromatography with detection by mass spectrometry
<img file="MA32201B1_D0145.tif" />
MA 32291 Bl
180 POl-2363-ff
CLPM medium pressure liquid chromatography ml milliliter μΐ microliter min minute
MS racem mass spectrometry. racemic
TA ambient temperature Tr retention time (in HPLC)
Rf retention factor (in TLC)
TBTU 2- (1H-Benzotriazol-1-yl) 1,1,3,3-tetramethyluronium tetrafluoroborate
TFA trifluoroacetic acid
TLC thin layer chromatography l
CL-SM methods إ اً
Method A ٠
Instrument: ThermoFinnigan HPLC / MS. DAD Surveyor for HPLC, LCQduo ion trap; column: Sunryse MS-C18, 5 µm,
4.6 X 100 mm; eluent A: water and 20 mM ammonium formate; eluent ؛
B: acetonitrile + 20 mM ammonium formate; gradient: A / B (95: 5) for 1 min, then change to Α / Β (5: 95) in 7 min for 1.5 min; flow rate: 0.85 ml / min; uv detection: 254 nm;
ionization source: ESI.
أ
Method 1
SM Device Type: Waters Micromass ZQ; HPLC device type: Waters Alliance 2695, Waters 2996 iodine strip detector; column: Varian Microsorb 100 C18, 30 X 4.6 mm, 3.0 µm; eluent A: water + 0.13% TFA, eluent B: acetonitrile; gradient: 0.0 min 5% B * 0.18 min 5% B * 2.0 min 98% B 2.2 ي min 98% B 2.3 ؤ min 5% B 2.5 ي min 5% B; 'flow rate: 3.5 ml / min; uv detection: 210-380 nm.
Method 2 ؛
SM Device Type: Waters Micromass ZQ; Device type
HPLC: Waters Alliance 2695, Waters Iodine Bar Detector
ΜΑ 32201Β1] 81 POl-2363-ff ؛
2996 ; column: Merck Chromolith Performance RP18e, 100 X 1 mm;
eluent A: water ٠ 0.13% TFA, eluent B: acetonitrile; ٦ ؛ gradient: 0.0 min 5% B — 0.2 min 5 أ BA 1.6 min 98% B 1.9 ي min 98% B * 2.0 min 5% B _ »2.2 min 5% B; ن flow rate: 3.5 ml / min; uv detection: 210-380 nm.
إ
ID Method
Instrument: ThermoFinnigan HPLC-MS. DAD Surveyor for HPLC,
Quadrupole MSQ; column: Sunryse SM-C18, 5 µm, 4.6 X 100 mm; إ eluent A: 90% water t 10% acetonitrile t ammonium formate ٢ mM; eluent B: acetonitrile 90% t 10% water ؛ 10 mM ammonium formate; gradient: A (100) for 1 min, then change to B (100) in 7 min for 1 min; flow rate: 1.2 ml / min; detection
UV: 254 nm; ionization source: APCI. إ
Method ΙΕ l
Instrument: ThermoFinnigan HPLC-MS. DAD Surveyor for HPLC,
Quadrupole MSQ; column: Symmetry C8, 5 µm, 3 X 150 mm; eluent A: 90% water 10 ؛ % acetonitrile + 10 mM ammonium formate; eluent B: acetonitrile 90% t 10% HO ا 10 mM ammonium formate; gradient: A (100) for 1.5 min, then change to B (100) in 10 min for 1.5 min; flow rate: 1.2 ml / min; uv detection:
254 nm; ionization source: APCI.
Method 1Ε fusion
Instrument: ThermoFinnigan HPLC-MS. DAD Surveyor for HPLC,
Quadrupole MSQ; column: Synergi Fusion-RP80A, 4 pm,
4.60 X 100 mm; eluent A: 90% water t 10% acetonitrile + ؛ 10 mM ammonium formate; eluent B: acetonitrile 90% + 10% ؛ of HO ؛ 10 mM ammonium formate; gradient: A (100%) for 1.5 min, then change to B (100%) in 10 min for 1.5 min; flow rate:], 2 ml / min; uv detection: 254 nm; ionization source:
APCI. إ
Method 1Ε hydro
Instrument: ThermoFinnigan HPLC-MS. DAD Surveyor for HPLC,
Quadrupole MSQ; column: Synergi Hydro-RP80A, 4 µm.
<img file="MA32201B1_D0146.tif" />
32201Bl
182
POl-2363-ff
4.60 X 100 mm; eluent A: 90% water + 10% acetonitrile + 10 mM ammonium formate; eluent B: acetonitrile 90% t 10% ؛ 10 mM HO + ammonium formate; gradient: A (100%) during
1.5 min, then change to B (100%) in 10 min for 1.5 min;
ل flow rate: 1.2 ml / min; uv detection: 254 nm; ionization source:
إ APCI.
Method 2F
Instrument: ThermoFinnigan HPLC-MS. DAD Surveyor for HPLC,
<td>trap</td><td>finnigan ions</td><td colspan="2">LCQduo;</td><td>column</td><td>: Symmetry-ci8,</td><td>5 µm.</td>
<td colspan="2">3 X 150 mm; eluent A:</td><td> 95</td><td>% water</td><td> + 5%</td><td>acetonitrile +</td><td>acid</td>
<td>formic</td><td>0.1%; eluting</td><td>B;</td><td colspan="3">acetonitrile 95% + 5% water t</td><td>acid</td>
<td>formic</td><td colspan="2">0.1%; gradient</td><td>: Α / Β</td><td> (95/5)</td><td>for 1.5 min.</td><td>then</td>
change to A / B (5/95) in 10 min for 1.5 min; flow rate: 1 ml / min;
uv detection: 254 nm; ionization source: ESI.
2L method
Instrument: ThermoFinnigan HPLC-MS. DAD Surveyor for HPLC, Finnigan LCQduo ion trap;
column: Symmetry Shield, 5 µm, 4.6 X 150 mm; eluent A:
% water + 10% acetonitrile + 0.1% formic acid; eluent B: 90% acetonitrile + 10% water + 0.1% formic acid; flow rate: 0.85 ml / min; uv detection: 254 nm; ionization source: ESI.
Grad C8 acid method
Instrument: Waters HPLC-SM. DAD Alliance 2695 for HPLC, Quadrupole ZQ; column: xterra MS-C8, 3.5 µm, 4.6 X 50 mm; eluent A: water + 0.1% TFA + 10% acetonitrile; eluent B: acetonitrile; gradient: A / B (80:20), then change to A / B
90 : 10 ؛) in 3.25 min for 0.75 min; flow rate: 1.3 ml / min;
uv detection: 254 nm; ionization source: ESI.
Grad C18 acid method
Instrument: Waters HPLC-SM. DAD Alliance 2695 for HPLC, Quadrupole ZQ; column: Sunfire SM-C18, 3.5 µm, 4.6 X 50 mm; eluent A: water t 0.1% TFA + 10% acetonitrile; eluent B: acetonitrile; gradient: A / B (80:20), then change to A / B
<img file="MA32201B1_D0147.tif" />
ΜΑ 32201Β1
183 POl-2363-ff (10:90) in 3.25 min for 0.75 min; flow rate: 1.3 ml / min;
uv detection: 254 nm; ionization source: ESI.
Grad 90 method 10 C8 acid
Instrument: Waters HPLC-SM. DAD Alliance 2695 for HPLC,
Quadrupole ZQ; column: xterra MS-C8, 3.5 µm, 4.6 X 50 mm; eluent A: water 0.1 ا% TFA t 10% acetonitrile; eluent B: acetonitrile; gradient: A (100 ¾), then change to A / B (10: 90) in 3.25 min for 0.75 min; flow rate: 1.3 ml / min; uv detection:
254 nm; ionization source: ESI.
Grad method 90 10 C18 acid
Instrument: Waters HPLC-SM. DAD Alliance 2695 for HPLC, Quadrupole ZQ; column: xterra SM-C18, 3.5 µm, 4.6 x 50 mm;
eluent A: water p 0.1% TFA t 10% acetonitrile; eluent B: acetonitrile; gradient: A (100), then change to Α / Β (10: 90) in 3.25 min for 0.75 min; flow rate: 1.3 ml / min; uv detection:
254 nm; ionization source: ESI.
Grad Method C8 NH COOH
Instrument: Waters HPLC-SM. DAD Alliance 2695 for HPLC, Quadrupole ZQ. Column: xterra MS-C8, 3.5 µm, 4.6 x 50 mm; eluent A: water ٠ 5 mM ammonium formate + 10% acetonitrile; eluent B: acetonitrile; gradient: At 100%, then change to A / B (10:90) in 3.25 min for 0.75 min; flow rate: 1.3 ml / min;
uv detection: 254 nm; ionization source: ESI.
Chiral HPLC methods
Instrument: Agilent 1100. Column: Chiralpak AS-Η Daicel, 4.6 µm, 4.6 X 250 mm;
<td>Method</td><td>chiral</td><td></td><td> 1</td><td>: eluent:</td><td>hexane / ethanol</td><td> 97/3</td>
<td>isocratic);</td><td>debit :</td><td> 1,</td><td> 0</td><td colspan="2">ml / min; uv detection: 254 nm.</td><td></td>
<td>Method</td><td>chiral</td><td></td><td> 2</td><td>eluting:</td><td>hexane / ethanol</td><td> 98/2</td>
<td>isocratic);</td><td>debit :</td><td> 1,</td><td> 0</td><td colspan="2">ml / min; uv detection: 254 nm.</td><td></td>
<td>Method</td><td>chiral</td><td></td><td> 3</td><td>: eluent:</td><td>hexane / ethanol</td><td> 80/20</td>
<td>isocratic);</td><td>debit :</td><td> 1,</td><td> 0</td><td colspan="2">ml / min; uv detection: 254 nm.</td><td></td>
CG / SM methods
MA 32201 Bl
184 POl-2363-ff
Method 3Α إ
Instrument: CG / SM Finnigan. Trace GC, Quadrupole MSQ.
Column: DB-5MS, 25m X 0.25mm X 0.25 µm; carrier gas: helium, constant flow rate at 1 ml / min; oven program: 50 ° c (maintained for 1 minute), at 100 ٥c at 10 "c / minute, at 200 'c at 20 ٥c / minute, at 300" c at 30 "c / rainute for elution, detection: Quadrupole trace MSQ. ؛
Ionization source: IE scan range: 50 to 450 U. j
اً
Method 3Α.1
Instrument: CG / SM Finnigan Thermo Scientific. Trace GC Ultra, monoQuadrupole DSQ II. Column: DB-5MS IU, mx 0.25 mm X 0.25 µm; carrier gas: helium, constant flow rate at 1 ml / min; oven program: 50 ° c (maintained 1 minute), at 100 ٥c at 10 "C / minute, at 200" c at 20 "c / minute, at 300" c at 30 "c / minute for elution , detection: monoQuadrupole trace DSQ. >
Microwave heating: ؛
Type of microwave appliance:
- Discover® CEM instruments, equipped with 10 ml and 35 ml containers; '
- Type of microwave appliance: Biotage Initiator Sixty.
إ
General comments concerning the presentation of structures
Some compounds contain one or more chiral centers. The structure presented will not necessarily show all the possible stereochemical realizations of the compound, but only one. However, in such a case, a term like ؛ "Cis racemic mixture" is placed next to the structure to indicate other stereochemical options.
An example is given below for structural formula shown is:
! 'Example 7D. The
MA 32291 Bl
185
POl-2363-ff
<img file="MA32201B1_D0148.tif" />
Racemic mixture Cis
The term "cis racemic mixture" adds indicates the second stereochemical option:
<img file="MA32201B1_D0149.tif" />
This principle also applies to the other structures presented.
Synthesis
In the following, the preparation of examples of compounds of the present invention is described. When the process for the preparation of a specific compound has not been described in the literature, those skilled in the art will find a description of similar procedures in these descriptions which he can in principle follow. It is mentioned in some places that the examples can be prepared by analogy with another example. If reference is to be made to such an "analogous process", the reaction conditions are about the same, although the molar ratios of reactants and educts have to be adjusted. It will also be evident that the starting compounds in a described process can be chemically modified to achieve the same results, i.e. if in an ester condensation reaction the alcoholic component is a leaving group and not the subject of the product, this alcoholic component can be altered without significantly altering the procedure.
<img file="MA32201B1_D0150.tif" />
MY
32201Β1
186
POl-2363-ff
Starting compounds
Example IA 5
<img file="MA32201B1_D0151.tif" />
A solution of 70 g (201 mmol) of carbethoxymethylene triphenylphosphorane in 300 ml of diethyl ether was cooled to 0 ° C and 25 g (198 mmol) of 1,1,1-trifluorobutanone was added. The solution was warmed to room temperature and stirred overnight. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure (700 mbar and 40 ° C. bath temperature). The residue was purified by vacuum distillation (170 mbar and 130 c bath temperature, main fraction: 95-96 ٠C). 29 g (75%) of the product was obtained as a colorless oil.
HPLC-MS (method 1): Rr: 1.77 minutes.
MS (ESI pos): m / z = 196 (MtH) *.
Example 1ΑΑ
ض
400 mg (10.0 mmol) of hydride hydride (60% in mineral oil) was suspended in 10 ml of THF and cooled to 4 ٠c. While stirring, a solution of 1.3 ml (8.99 mmol) of trimethylphosphono acetate in 10 ml of THF was added. The mixture was left under stirring for 1 hour at the same temperature. Then, a solution of 4,4-difluoro-cyclohexanone in 10 ml of THF was added at 0 ° C. The mixture was left at
L
<img file="MA32201B1_D0152.tif" />
32201Β1
187
POl-2363-ff warm to room temperature and stir for 14 hours. THF and water were added and the THF was evaporated The remainder was diluted with ethyl acetate, washed with water and saturated sodium hydrogencarbonate solution, then evaporated to give 1 , 49 g (95%) of the product.
MS (El): m / z = 190 (M) ٠
The following Examples IB, IC, ID, ΙΕ, 2Α, 2Β, 2C and 2D show how the following racemic acids, i.e. 3-trifluoromethyl-pentanoic acid and 3 'trifluoromethyl-butyric acid, can be transferred to both enantiomeric forms of the free acid. Resolution can be accomplished by separation of the diastereomeric intermediates. The two pure enantiomeric forms of the free acid will be called respectively enantiomer A and enantiomer B. The corresponding diastereomeric intermediates will be called diastereomer A and diastereomer B respectively.
The same principle can be applied for the enantiomeric resolution of other racemic mixtures, if necessary.
Example IB
Diasteoisomer A
A solution of 3-trifluoromethyl-pentanolgue acid (8 g,
47 mmol), TBTU (16.6 g, 52 mmol) and diisopropylethylamine (24.1 ml, 141 mmol) in dimethylformamide (80 ml) was stirred at 20 ٠c for 1 hour, then the (5) - ( -) - 1-Phenylethylamine (10 g, 82 mmol) was added and the mixture was stirred for 16 hours at 20 ° C. The solvent was removed and dichloromethane (200 mL) was added. The resulting mixture was washed with 10% citric acid in water (200ml), 20% K2CO3 in water (100ml) and dried over sodium sulfate. Evaporation of the solvent gave a crude solid which was mixed with methanol (10 mL).
<img file="MA32201B1_D0153.tif" />
32201Β1
188
POl-2363-ff and filter through a buffer of activated basic alumina. The separation of the diastereoisomers was obtained by flash chromatography on Si٥2 eluting with a mixture of cyclohexane / ethyl acetate 85/15.
4 5 g (35.8%) of the title compound was obtained as a white solid.
Rf: 0.25 (cyclohexane / ethyl acetate 85/15, staining with nc> 4 basic).
HPLC-MS (IE hydro method): Tr: 9.35 minutes.
MS (APCI pos): m / z = 274 (M + H) ٠.
Chiral HPLC (chiral method 1): Tr: 5.58 minutes ed:
> 99 %.
Example IC 15
0 ززب
Diasteoisomer B
4.4 g (34.2%) of a white solid was obtained as a second product by flash chromatography of Example 1B.
Rf: 0.20 (cyclohexane / ethyl acetate 85/15, staining with basic KMnO4).
HPLC-MS (IE hydro method): Tr: 9.33 minutes.
MS (APCI pos): m / z = 274 (MtH) ؛.
Chiral HPLC (chiral method 1): Tr: 6.18 minutes ed:
> 99 %.
Example ID
3-Trifluoromethyl-pentanoic acid, enantiomer A
189
POl-2363-ff
<img file="MA32201B1_D0154.tif" />
<img file="MA32201B1_D0155.tif" />
OH
Enantiomer A
A solution of Example IB (4.6 g, 17 mmol) in dioxane (15 ml) was treated with H<sub>2</sub>SO<sub>4</sub> at 70% in water (25 ml) and left at reflux for 16 hours. The mixture was cooled, made basic to pH 14 with 32% NaOH in water, diluted with water (50 mL) and extracted with dichloromethane (2 x 200 mL). The resulting solution was acidified to pH 1 with 9N HCl, extracted with dichloromethane (3 X 500 mL) and the combined organic phases were dried. Evaporation of the solvent gave 2.47 g (86.3%) of a brown oil.
Rf: 0.66 (dichloromethane / methanol 9/1, staining with bromocresol green).
Chiral HPLC (chiral method 1): Tr 5.58 minutes ee:
.فأ 99 <
ده
<img file="MA32201B1_D0156.tif" />
32201Β1
190
POl-2363-ff
Example ΙΕ
3-Trifluoromethyl-pentanoic acid, B enantiomer
<img file="MA32201B1_D0157.tif" />
enantiomer B
By analogy with the preparation of Example ID, the title compound was obtained using Example IC as a starting compound.
Efficiency: 80.3%
Rf: 0.66 (dichloromethane / methanol 9/1, staining with bromocresol green).
Chiral HPLC (chiral method 1): Tr: 5.08 minutes ee:
> 99 %.
Example 2Α
4,4, Trifluoro-N - ((R) -2-hydr0xy-1-phenyl-ethyl) -3-methyl20 butyramide diastereoisomer A
<img file="MA32201B1_D0158.tif" />
OH
A solution of 3- (trifluoromethyl) butyric acid (10 g, 64 mmol) in dimethylformamide (100 ml) was treated with N- (3-dimethylamino-propyl) -N'-ethylcarbodiimide hydrochloride (14, 7 g, 77 mmol), 4-dimethyl-amino pyridine (11 g, 89.7 mmol) and (R) - (-) - phenylglycinoL (9.9 g, 70.5 mmol). The mixture was stirred at 20٠c for 16 hours, then concentrated to reduce the volume and treated with 10% citric acid in water (300ml). The mixture was extracted with ethyl ether.
MA 32201 Bl
191
POl-2363-ff (2 X 200 ml) and the separated organic phase was washed with
10% HO (150 ml) and brine (150 ml). The organic phase was dried and evaporated to give 13.1 g of crude white solid.
The separation of the diastereomers was carried out by flash chromatography on SiOj eluting with a mixture of ethyl acetate / hexane 6/4.
5.32 g (30.2%) of the title compound was obtained as a white solid.
Rf: 0.23 (ethyl acetate / hexane 6/4).
HPLC-MS (1Ε hydro): Tr: 6.97 minutes.
MS (APCI pos): m / z = 276 (MtH) *.
Example 2Β
4,4,4-Trifluoro-N - ((R) -2-hydr0xy-1-phenyl-ethyl) -3-methylbutyramide, diastereoisomer B
<img file="MA32201B1_D0159.tif" />
3.08 g (17.5%) of a white solid were obtained as a second product by flash chromatography of Example 2Α.
Rf: 0.16 (ethyl acetate / hexane 6/4).
HPLC-MS (1Ε hydro): Tr: 6.92 minutes.
MS (APCI pos): m / z = 276 (MtH) *.
Example 2C, enantiomer A
<img file="MA32201B1_D0160.tif" />
<img file="MA32201B1_D0161.tif" />
32201Β1
192
POl-2363-ff
A solution of Example 2Α (2g, 7.26mmol) in tetrahydrofuran (10ml) was treated with 70% HSO4 in water (10ml) and allowed to reflux for 16 hours. The mixture was cooled, made basic to pH 14 with 32% NaOH in water, diluted with water (50 mL) and extracted with dichloromethane (2 x 50 mL). The resulting solution was acidified to pH 1 with 9Ν HCl, extracted with dichloromethane (3 x 50 mL) and the combined organic phases were dried. Evaporation of the solvent gave 0.84 g (74.1%) of a brown oil.
HPLC-MS (1Ε hydro): Tr: 1.73 minutes.
MS (APCI neg): m / z = 155 (Μ-Η) -.
Chiral HPLC (chiral method 2): Tr: 6.92 minutes ee:
%.
ر
MA 32201 Bl
193
POl-2363-ff
Example 2Ρ, enantiomer B
F— لح ٢ — QH
By analogy with the preparation of Example 2C, the title compound was obtained using Example 2Β as the starting compound. 1.4 g (8.96 mmol) were obtained.
Yield: 82.3%.
HPLC-MS (1Ε hydro): Tr: 1.30 minutes.
MS (APCI neg): m / z = 155 (Μ-Η) '.
Chiral HPLC (chiral method 2): Tr: 6.49 minutes ee:
98,6 %.
Example 3Α
2- (4-trifluoro-methyl-pvridin-2-vl) malonic acid diethyl ester
<img file="MA32201B1_D0162.tif" />
A suspension of 60% sodium hydride in mineral oil (1.65g, 41mmol) in dry dioxane (36ml) was treated with diethyl malonate (6.3ml, 41mmol) at 25 “c and heated to 60 ٠c for 30 minutes. Cuprous chloride (1.63 g, 17 mmol) was added, the mixture was heated to 80 ٥c and 2chloro-4_ (trifluoromethyl) -pyridine was added then the temperature was increased to 100 ° C for 16 hours.
After cooling to 20 ° C, the mixture was acidified with 37% HCl, diluted with water (120 ml) and /
MY
32201Β1
194
POl-2363-ff extracted with dichloromethane (2 X 60 ml). The organic phase was dried and evaporated to give a crude oil which was purified by flash chromatography eluting with 95/5 to 60/40 nhexane / ethyl acetate.
1.9 g (38%) was obtained as a colorless oil.
HPLC-MS (2F)
T: 12.24 minutes.
MS (ESI pos): m / z = 306 (MtH) '
Example 4Α
The following example was synthesized by analogy with the preparation of Example 5U, using the corresponding acid (Sinova Inc., Bethesda, MD 20814, USA) as the starting compound.
<img file="MA32201B1_D0163.tif" />
/٠١
HPLC-MS (method 1): Rp: 1.47 minutes.
MS (ESI pos): m / z = 194 (M ؛ H-EtOH) ٠.
Example 4Β
<img file="MA32201B1_D0164.tif" />
2.0 g (8.6 mmol) of Example 4Α was dissolved in 40 ml of ethanol, Pd (10% on charcoal) was added, and the mixture was hydrogenated at room temperature (2 hours , 50 psi). The reaction mixture was filtered and the residue was washed with
<img file="MA32201B1_D0165.tif" />
MY
32201Β1
195
POl-2363-ff
Ethanol. The solvent was evaporated under reduced pressure. 1.80 g (100%) of the product was obtained.
HPLC-MS (method 1): Rr: 0.91 minutes.
MS (ESI pos): m / z = 210 (M + H) ٠.
Example 5Α
3-Trifluoromethyl-pentanoic acid methyl ester, A-enantiomer
Enantiomer A and nitrogen methanol,
To a stirred solution of Example ID (250 mg, 1.47 mmol) in dichloromethane (10 ml) (0.25 ml), under a trimethylsilyldiazomethane atmosphere (2.0 M solution in diethyl ether) (2 , 1ml, 4.19mmol) was added dropwise at 0 ° C. The reaction mixture was allowed to stir keeping the temperature below 5 ° C for 1 hour. The solvent was removed (40 ٠c, 25 bar) to give 250 mg (75.4%) of a yellow oil which was used in the next step without further purification.
GC (3Α method): Tr: 3.29 minutes 25 MS (El): m / z: 165 (Μ-19) ٠, 155 (Μ-29) ٠, 153 (Μ-31) ٠.
The following examples were synthesized by analogy with the preparation of Example 5Α, using the corresponding acids as starting compounds:
<td></td><td>structure</td><td>composed of start: acid carboxylic</td><td>Tr [minutes]</td><td>SM m / z</td>
ΜΑ 32201Β1
196 POl-2363-ff
<td></td><td>structure</td><td>composed of start: acid carboxylic</td><td>Tr [minutes]</td><td>SM m / z</td>
<td>Example 5Β Enantio- mother A</td><td>F — r ا 0 ح</td><td>Example 2C</td><td>8.01 (method 3Α)</td><td>170 [El]</td>
<td>Example 5C Enantio- mother B</td><td>كجنبء</td><td>2D example</td><td>8.01 (method 3Α)</td><td>170 [El]</td>
<td>Example 5D Enantio- mother B</td><td>/ جئي</td><td>Example 1Ε</td><td>3.29 (method 3Α)</td><td>165 (Μ-19) ٠, 155 (Μ-29) ٠, 153 (Μ-31) ' [El]</td>
<td>Example 5Ε</td><td> ٦</td><td>ي به</td><td>7.82 (method 3Α)</td><td>252 [El]</td>
<td>Example 5F</td><td>زي</td><td> 0</td><td>9.53 (method 3Α)</td><td>202 [El]</td>
<td>Example 5G Enantio- mother s</td><td>ثم ٠ رل</td><td>ب 0 رر ١</td><td>3.92 (method</td><td>130 [El]</td>
<td>Example 5Η</td><td>دد</td><td>..- 1 ز</td><td>5.09 method 3Α</td><td>115 (Μ-29) ٠ [El]</td>
MY
32201Bl
197 POl-2363-ff
<td></td><td>structure</td><td>composed of start: acid carboxylic</td><td>Tr [minutes]</td><td>SM m / z</td>
<td>Example 5ΗΑ mixed racemic cis</td><td> -١٦٠</td><td>Example 18Α</td><td>1.22 (method 1)</td><td>264 [ESI, (MtH) د]</td>
MA 32201 Bl
198 POl-2363-ff
Example 51
[2- (1-Acetyl-piperidin-4-yloxy) phenyl] -acetic acid methyl ester
<img file="MA32201B1_D0166.tif" />
O
Di-tert-Butyl azodicarboxylate (305 mg, 1.32 mmol) was added dropwise to a solution of 1- (4-hydroxypiperidinlyl) -ethanone (259 mg, 1.8 mmol) in tetrahydrofuran (4 ml) under a nitrogen atmosphere. Then the methyl ester of (2-hydroxy-phenyl) -acetic acid (200 mg,
1.2 mmol) and triphenylphosphine (347 mg, 1.3 mmol) were added. The yellow mixture was stirred at 20 ° C for 16 hours. ؛
The solvent was evaporated and the residue was purified on silica using a mixture of hexane / ethyl acetate of polarity ؛ increasing (70% to 100% ethyl acetate) as the eluent to give 195 mg (55.6%) of a colorless oil.
HPLC-MS (GradCNHOOH method): Tr: 2.67 minutes.
MS (ESI pos): m / z = 292 (Μ + Η) '.
The following examples were synthesized by analogy with the preparation of Example 5G, using the corresponding alcohols as starting compounds:
<img file="MA32201B1_D0167.tif" />
ΜΑ 32201Β1
199 POl-2363-ff
<td>NOT ج ٠ S w</td><td>٦١ ٢٩ ب ٥٦ انح</td><td></td><td></td>
<td>or ي ٥ ق هع b</td><td>ل ٠٠٠ إب 0 κ ٩ م ة ع LO ا دب ٠ ٠٥ ن ١ ل ٢١ ê 3 ٠> ى</td><td></td><td></td>
<td>ببا ى</td><td></td><td>0.35 (hexane / acetate ethyl 8/2)</td><td>ن ١ ك دلج ٢٩ دآيم ١١ لل م رئإلآ ن Γϋ لام ح ٢ ن ٠ ع C لز ΰ) 0 'X ، ن Ό تع</td>
<td>composed of start: alcohol 1 ة</td><td>دب</td><td> '1</td><td>ه Ο</td>
<td>structure</td><td>عبك لآ ٠</td><td>هلاب لآ ١</td><td>ب ٠٠ ا لآه</td>
<td></td><td>Example 5 ل mixed racemic</td><td>Example 5Κ</td><td>Example 5L</td>
MA 32201 BI
POl-2363-ff
<td>NOT ي ٦ S حس</td><td></td><td></td><td></td>
<td>; له دد ة H B ته يح</td><td></td><td></td><td></td>
<td>صبلأ ى</td><td>0.2 (hexane / acetate ethyl 7/3)</td><td>ط ق د ي ؛ ٠<sup>ن</sup>ح ة لآ ع</td><td>له ة- ? 1 '٥ ٢٥ ة ع ب</td>
<td>composed of start: alcohol</td><td>7 ٠ ت</td><td> ٥٠</td><td>0 O</td>
<td>له بإ دم ن S للي لرأ</td><td>خي</td><td>ود. هئب</td><td> °-¾</td>
<td></td><td>Example 5Μ</td><td>Example 50</td><td>Example 5Ρ \ ١</td>
MA 32201 Bl
201 POl-2363-ff
Example 5Q
(3-methoxy-pyridin-2-yl) -acetic acid eterdemethyl
<img file="MA32201B1_D0168.tif" />
A mixture of (3-methoxy-2-pyridin-2-yl) acetonitrile (400 mg, 2.7 mmol) in 2 ml of methanol and 96% sulfuric acid (1.8 ml, 32 mmol) was been heated in a microwave oven at 120 ٥c for 1 hour. The mixture was cooled to 0 ° C, made basic with solid NaHO, diluted with water (2 ml) and extracted with dichloromethane - The separated organic phase was dried and evaporated to give 450 mg (92%) of a dark yellow oil which was used in the next step without further purification.
HPLC-MS (Grad method c NH OOH): Tr: 1.92 minutes.
MS (ESI pos): m / z = 182 (M ؛ H) ٠.
<img file="MA32201B1_D0169.tif" />
MA 32201 Bl
202
POl-2363-ff
Example 5R
(4-Trifluoromethyl-pyridin-2-yl) acetic acid ethyl ester
Anhydrous solution (8 ml) at 3.27mmol) and
<img file="MA32201B1_D0170.tif" />
of the example treated, the resulting mixture chloride was cooled until
3Α (1.0 g, with lithium
3.27 mmol) in DMSO! Water (60 microliters, (347 mg, 8.2 mmol). Heat to 120 ٠c for 16 hours. After 20 ٥c, the mixture was treated with brine (12 ml). ) and extracted with ethyl acetate (3 X 20 ml) The organic phase was dried and evaporated to give a crude oil which was purified by flash chromatography eluting with n-hexane / acetate. ethyl 8/2.
390 mg (51%) was obtained as a colorless oil.
HPLC-MS (method 2F): Tr: 11.09 minutes.
MS (ESI pos): m / z = 234 (M + H) ٠.
<img file="MA32201B1_D0171.tif" />
32201Β1
203
POl-2363-ff
Example 5S
Ethyl ester of 1 (6-trifluoromethyl-pyridin-2-yl) acetic acid
<img file="MA32201B1_D0172.tif" />
A mixture of cesium carbonate (1.87 g, 5.75 mmol) and tritbutylphosphine (107 µl, 0.44 mmol) in anhydrous 1,210 dimethoxyethane (10 ml) was treated with tris (dibenzylideneaketone) di-palladium (81 mg, 0.09 mmol), 2bromo-6- (tri-fluoromethyl) pyridine (1 g, 4.42 mmol) and diethyl malonate (0.8 ml, 5.3 mmol) under one atmosphere nitrogen. The mixture was heated at 150 ٥c for 30 minutes in a microwave oven. After cooling to 20 c, the mixture was treated with saturated ammonium chloride solution (120 ml) and extracted with ethyl ether (3 x 80 ml). The organic phase was dried and evaporated to give a crude oil which was purified by flash chromatography eluting with n20 hexane / ethyl ether 6/1.
460 mg (81%) was obtained as a colorless oil.
GC (3Α method): Tr: 8.28 minutes.
MS (El): m / z = 233 (M) ٠.
Example 5Τ, racemic mixture
<img file="MA32201B1_D0173.tif" />
<img file="MA32201B1_D0174.tif" />
MY
32201Β1
204 POl-2363-ff g (148 mmol) of Example IA were combined with 2 g of Pd / c (10%) and hydrogenated at room temperature (6 hours, إ psi). The reaction mixture was filtered and washed with ؛ diethyl ether. The solvent was evaporated off under reduced pressure ؛ (500 mbar, bath temperature 40 ° C). 27.6 g (94%) of the product was obtained as a colorless liquid. إ
HPLC-MS (method 1): Rr: 1.65 minutes. ؛
Example 5ΤΑ
؛ 10
كدم;
1.49 g (95%, 7.43 mmol) was dissolved in 20 ml of ethanol and hydrogenated over 150 mg of Pd / c (10%) at atmospheric pressure for 14 hours. The mixture was filtered and the solvent was removed to give 1.27 g (89%) of the product.
MY
32201Β1
205
POl-2363-ff
Example 5U
Br
<img file="MA32201B1_D0175.tif" />
A solution of 15 g (69.8 mmol) of (2-bromo-phenyl) acetic acid in 50 ml of ethanol was cooled to 0 ٠c and 8 ml (110 mmol) of thionyl chloride was added dropwise. drop The reaction mixture was heated to 50 ° C overnight. After cooling to room temperature, the solvent was removed under reduced pressure. The residue was mixed with ethyl acetate and filtered through 30 g of basic aluminum oxide. The filtrate was evaporated under reduced pressure. 18 g (92%) of the product was obtained.
HPLC-MS (method 1): Tr: 1.62 minutes.
MS (ESI pos): m / z = 243/45 (Br) (M + H) ٠.
The following examples were synthesized by analogy with the preparation of Example 5u, using the corresponding acids as starting compounds.
<img file="MA32201B1_D0176.tif" />
ΜΑ 32201Β1
206 Ρ01 2363-ff
<td>SM (ESI m / z)</td><td>هج ق جى 00 ا — ا</td><td>٢٩ ٧ اح in in</td><td>ق ة هب</td>
<td>Tr [minutes]</td><td></td><td>1, 56 (method 1)</td><td>لا</td>
<td>starting compound</td><td>زه ٠</td><td>أ</td><td>ا</td>
<td>له بز د دب U ة دب</td><td> <0</td><td><sup>ة</sup>زا ٧٦</td><td>عج دجع لما</td>
<td></td><td>< جى له ί له ة</td><td>جى له ΐ له ω</td><td>ج جى له ا له ئ</td>
ΜΑ 32201Β1
POl-2363-ff
<td>X ة ١٠٠٠٠٠٠ ٣٩ ٢١ ٢٩</td><td>نتإ ١ ع 1 ع ٢٦ همكا Ï ى يمية خ يم ليه <sup>ب</sup>يج جم ٢٩</td><td>K ة لمم ٩ م ٢٩</td><td>K ؛ ٢٩ ٠ ل ١ م</td>
<td></td><td>ا; له ١ g م ١٠</td><td></td><td></td>
<td>ة ο I</td><td>م</td><td>° fe</td><td>معؤ</td>
<td> ٠٦</td><td>> O ٠ = ( ٠ ا /> ق</td><td>٠ اً٠</td><td>دحؤ</td>
<td>X ٦ ى ده t له X مأ</td><td>لى له Ï وه لا</td><td>Example 5AA mixed racemic</td><td>حتاً > ١ ى له ا له X لا</td>
،
32201Β1
<img file="MA32201B1_D0177.tif" />
POl-2363-ff
<td>K ة ٧ oo دكا ٦ ى</td><td>K ؛ دى ٠١</td><td>W ة ص ٠ ٠ دى σ? لام</td><td>available in the trade</td>
<td>. \ 1.65 (method 1)</td><td>لا تميج</td><td>لا</td><td></td>
<td>٠ ^ α</td><td>له</td><td>٠٩-ρ مر</td><td></td>
<td> ٥٤</td><td>له</td><td>هه</td><td>ة</td>
<td>Example 5AC</td><td>Q < دى له Î له مآ</td><td>لا > دكا له g- لآ ω</td><td>ئ يع لآ (LT gi ره وع ri · الح ا— r ج ة به ر ١٠ Ü ؛ ح υ بم له له له ١ * ه ج لا</td>
<img file="MA32201B1_D0178.tif" />
ΜΑ 32201Β1
209 POl-2363-ff
<td></td><td></td><td>ج I لى 00 بم</td>
<td>I- 1.46 (method 1) \ \</td><td>. 1.63 (method 1)</td><td></td>
<td>لآه</td><td> ١</td><td>: لإم</td>
<td> ٥٩</td><td> ٠٩</td><td> :٦٢٦</td>
<td>وأ لكا له ï 0 X w</td><td>ة ملم له صيع له هنا ω</td><td>Η ه ما له ة Λ) X ئ</td>
MA 32201 Bl
POl-2363-ff
<td>ة ί ٩ م لجم</td><td></td><td>H ئ ة ٢٠٠ اة 00 ل ١ م</td>
<td>؛ 5 ن ١ ε ٧</td><td></td><td>1.58 (method 1)</td>
<td>\ ني</td><td> ٩</td><td>oo U. 0 أ ٠</td>
<td> ١٠٢٥٠١</td><td>۶ ي</td><td>-تم طا داداً ييب</td>
<td>٦ „؛ ؛ Ρ1 ؛ Ε</td><td>Example 5AK</td><td>Example 5AL \ ١ \ \ ا</td>
ΜΑ 32201Β1
POl-2363-ff
<td>ة ί ٠١ لاح ٣١</td><td>Ό £ ذ ة " ٢٩ لاح</td><td>£ ة م ١ ٢١ وكا ا — م</td>
<td>1.29 (method 1)</td><td>ؤ ج</td><td>ل ن ١ ج ص ١</td>
<td>> يق</td><td> ١#؛</td><td>ج ه 0</td>
<td>.... ر</td><td>ه</td><td>ر ٠٦١</td>
<td>ة تلع وى له بؤ له M</td><td>03 م يع وكا له & له ة</td><td>Example 5ALC أ i</td>
ΜΑ 32201Β1
POl-2363-ff
<img file="MA32201B1_D0179.tif" />
Μα 32201Β1
213
POl-2363-ff
Example 5AM
The following example was synthesized by analogy with the preparation of Example 5U, using the corresponding acid as the starting compound and methanol as the solvent.
<img file="MA32201B1_D0180.tif" />
HPLC-MS (method 1): Rr: 1.04 minutes.
MS (ESI pos): m / z = 167 (MtH) '.
The following examples were synthesized by analogy with the preparation of Example 5AM, using the corresponding acids as starting compounds.
<td></td><td>structure</td><td>starting compound</td><td>Tr [minutes)</td><td>SM (ESI, m / z)</td>
<td>Exp. 5ΑΜΑ</td><td>ألا</td><td>0 اقع لا</td><td>1.52 (method 1)</td><td>236 (MtH) '</td>
<img file="MA32201B1_D0181.tif" />
ΜΑ 32201Β1
214 POl-2363-ff
E ejnple 5AN
دبور
6.0 g (88.5 mmol) of pyrazole was dissolved in 60 ml of
DMSO and 10.4 g (93 mmol) of potassium tert-butoxide were added in portions, keeping the temperature between 20 ٠c and ؛ 'VS. The reaction mixture was stirred for 10 minutes at room temperature. 10.8 ml (98 mmol) of ethyl bromacetate was added dropwise, keeping the temperature ؛ between 25 "c and 35" c. The reaction mixture was stirred for 2 إ hours at room temperature. The reaction mixture was added إ to saturated aqueous NaCl solution and extracted with
Ethyl acetate. The organic phase was dried, filtered and the filtrate was evaporated under reduced pressure. The residue was purified by preparative CLMP (SiOz, eluent dichloromethane / methanol 95/5). 10.4 g (38%) of the product was obtained.
<img file="MA32201B1_D0182.tif" />
1.83 g (7.7 mmol) of Example 4Β was mixed with 60 ml of 4N HCl and cooled with an ice bath. A solution of 1.15 g (16.4 mmol) of sodium nitrite in 13.5 ml of water was added dropwise. After 10 minutes, a solution of 3.9 g (39.5 mmol) of copper (I) chloride in 20 ml of concentrated HCl was added dropwise. The reaction mixture was brought to
<img file="MA32201B1_D0183.tif" />
ΜΑ 32291Β1
215 POl-2363-ff room temperature and stirred for 30 minutes. The mixture was extracted with ethyl acetate. The organic phase was neutralized with potassium carbonate, filtered through Celite and the filtrate was extracted with water. The organic phase was dried, filtered and the filtrate was evaporated under reduced pressure. 1.24 g (62%) of the product was obtained.
HPLC-MS (method 1): Rr: 1.60 minutes.
MS (ESI pos): m / z = 229/231 (Cl) (MtH) ٠.
Example 5ΑΡ
<img file="MA32201B1_D0184.tif" />
Under argon, 1.00 g (4.11 mmol) of Example 5U, 540 mg (4.95 mmol) of 3-methylpyridone and 80 mg (0.42 mmol) of copper (I) iodide were mixtures with 5 ml of DMSO and 1.14 g (8.25 mmol) of potassium carbonate, and 120 mg (0.82 mmol) of 8hydroxyquinoline were added. The mixture was stirred for 48 hours at 120 ° C. After cooling to room temperature, the mixture was dissolved in ethyl acetate and washed with 1M HCl and saturated sodium chloride solution. The organic phase was separated, dried and evaporated. The residue was purified by HPLC (eluent A: water t 0.13% TFA, eluent B: acetonitrile). The acetonitrile was evaporated and the remainder was extracted with ethyl acetate. The organic phase was dried and evaporated to give 633 mg (57%) of the desired product.
HPLC-MS (method 1): Rr: 1.56 minutes.
MS (ESI pos): m / z = 272 (M ؛ H) ٠.
Example 6Α
32201Bl
216
POl-2363-ff
<img file="MA32201B1_D0185.tif" />
g (54 mmol) of Ι-Ν-Βοο-3-pyrrolidinone was dissolved in 50 ml of ethanol and 7.3 g (55.2 mmol) of tert-butyl carbazate was added. The reaction mixture was stirred at room temperature for 2 hours. The solvent was evaporated under reduced pressure. The residue was purified by preparative CLPM (Si0<sub>2</sub>, eluent dichloromethane / methanol 95/5). 18 g (89%) of the product was obtained as an oil.
HPLC-MS (method 1): Tr: 1.35 minutes.
MS (ESI neg.): M / z = 298 (Μ-Η) -.
Example 6Β
The following example was synthesized by analogy with the preparation of Example 6Α, using Ι-Ν-Βοο-3-piperidone as the starting material.
<img file="MA32201B1_D0186.tif" />
Example 7Α, racemic mixture
<img file="MA32201B1_D0187.tif" />
32201Bl
217
POl-2363-ff
<img file="MA32201B1_D0188.tif" />
g (48 mmol) of Example 6Α was dissolved in 300 ml of methanol, 2.5 g of Pd / c (10%) was added, and the mixture was hydrogenated at room temperature (8 hours, 50 psi ). The reaction mixture was filtered and the residue was washed with methanol. The solvent was evaporated under reduced pressure. 16 g of product were obtained in the form of a colorless oil and used without further purification.
HPLC-MS (method 1): Rr: 1.36 minutes.
Example 7Β, racemic mixture
The following example was synthesized by anaioqie with the preparation of! 'Example 7Α, using!' Example 6Β as the starting compound.
<img file="MA32201B1_D0189.tif" />
HPLC-MS (method 1): Tr: 1.42 minutes.
MS (ESI pos): m / z = 316 (MtH) '.
Example 7C
ΜΑ 32201Β1
218
POl-2363-ff
<img file="MA32201B1_D0190.tif" />
g (100 mmol) of tetrahydropyran-4-one was dissolved in 100 ml of methanol and 14.5 g (110 mmol) tertbutyl carbazate was added. The reaction mixture was stirred at room temperature for 2 hours. The solvent was evaporated under reduced pressure. The residue was mixed with 140 ml of acetic acid (50%), 6.9 g (110 mmol) of sodium cyanoborohydride was added and the mixture was stirred at room temperature overnight. The reaction mixture was neutralized with 4 Met NaOH extracted with dichloromethane. The organic phase was washed with a saturated aqueous solution of sodium hydrogencarbonate and a saturated aqueous solution of sodium chloride, The organic phase was dried over sodium sulfate, filtered and the filtrate was concentrated under reduced pressure. 19 g (88%) of the product was obtained as a white solid.
MS (ESI pos): m / z = 217 (MtH) ',
The following example was synthesized by analogy with the preparation of Example 7C using a ketone as the starting compound.
My 32201 bi
219 POl-2363-ff
<td>NOT ي ٦ ج مآ</td><td>d</td><td>ل ω</td><td>ί هع LO لج 5 ; ω</td>
<td>; له دب ة ٠٢١ 6 كع هب</td><td>تلع لآم 2 U H TJ ؤ ي ٠ ي ١</td><td>11.22 - (method 3Α)</td><td>0.99 (method 1)</td>
<td>I starting compound: cetone</td><td>حيه</td><td>حيه</td><td> 0=0</td>
<td>له يلم 5 ن د لد W</td><td>ز-</td><td>لإ ٠ = < ٦٩</td><td>اه ζ — ο ٠</td>
<td></td><td>Example 7CA cis, racemic mixture</td><td>Example 7CB trans, racemic mixture</td><td>Example 7CC</td>
<img file="MA32201B1_D0191.tif" />
32201Β1
220
POl-2363-ff
Example 7D
<img file="MA32201B1_D0192.tif" />
racemic mixture Cis
A solution of 2-methyl-tetrahydr0-pyran-4-0ne (2.2g,
19.7 mmol) in methanol (30 ml) was treated with tert-butyl carbazate (2.6 g, 19.7 mmol) and stirred for 3 hours at 20 ° C. Evaporation of the solvent gave a white solid which was mixed with 30 ml of acetic acid (50% in water), and treated with sodium cyanoborohydride (1.2 g, 19.7 mmol) per serving. . The mixture was stirred at 20٠c for 16 hours then neutralized with 5N NaOH and extracted with dichloromethane. The organic phase was washed with saturated NaHCO3 solution and brine, dried, filtered and evaporated to give a crude solid. The separation of the diastereoisomers was obtained by flash chromatography on SiOz eluting with a mixture of cyclohexane / ethyl acetate of increasing polarity (from 7/3 to 1/1) to give 1.85 g (41%) of a solid white.
Rf: 0.29 (hexane / ethyl acetate 1: 1).
HPLC-MS (Grad_90_l٥_C8_acide method): Tr: 1.79 minutes.
MS (ESI pos): m / z = 131 (Μ-100٠Η) '.
The cis configuration between methyl and the carbazyl group is assumed due to the ROESY correlation between Η-2 and Η-4.
Example 7Ε
<img file="MA32201B1_D0193.tif" />
32201Β1
221
POl-2363-ff
<img file="MA32201B1_D0194.tif" />
Racemic mixture Trans
0.7 g (16%) of a colorless oil was obtained as a second product by flash chromatography of Example 7D.
Rf: 0.29 (hexane / ethyl acetate 1: 1, staining with Pancaldi's reagent).
HPLC-MS (Grad_90 10_C8 acidic method): Rr: 1.96 minutes.
MS (ESI pos): m / z = 131 (Μ-100 + Η.
Example 8Α, racemic mixture
<img file="MA32201B1_D0195.tif" />
g (46.5 mmol) of Example 7Α were dissolved in 50 ml of dichloromethane, cooled with an ice bath and 25 ml (325 mmol) of trifluoroacetic acid were added. The reaction mixture was stirred 3 solvent was evaporated under purified by CLPM dichloromethane / methanol 8/2) obtained.
hours at room temperature. The reduced pressure. The residue was preparative (Sic> 2, eluent. 12 g (78%) of the product was
Example 8Β
MY
32201Β1
222 POl-2363-ff
The following example was synthesized by analogy with the preparation of Example 8Α, using Example 7c as the starting compound.
<img file="MA32201B1_D0196.tif" />
MS (ESI pos): m / z = 117 (M + H) ٠.
Example 8C, racemic mixture
<img file="MA32201B1_D0197.tif" />
13.0 g (37.1 mmol) of Example 7Β were dissolved in 5 ml of dioxane and 93 ml (371 mmol) of hydrochloric acid in dioxane (4 M) were added. The reaction mixture was stirred overnight at room temperature. 40 ml of diethyl ether were added and the mixture was stirred for 15 minutes at room temperature. The reaction mixture was filtered. 7.0 g (100%) of the product was obtained as a white solid.
The following examples were synthesized by analogy with the preparation of Example 8c using Boc-hydrazine as the starting compound.
<td></td><td>structure</td><td>composed of start: Boc- hydrazine</td><td>SM m / z</td>
<img file="MA32201B1_D0198.tif" />
ΜΑ 32201Β1
223
POl-2363-ff
<td></td><td>structure</td><td>composed of start: Boc- hydrazine</td><td>SM m / z</td>
<td>Example 8CA cis mixture racemic</td><td>HN H ملح</td><td>Example 7CA</td><td>131 (Μ + Η) '</td>
<td>Example 8CB trans mix racemic</td><td></td><td>Example 7CB</td><td>131 (MtH) '</td>
<td>Example 8CC</td><td></td><td>Example 7CC</td><td>133 (Μ + Η) '</td>
<img file="MA32201B1_D0199.tif" />
<img file="MA32201B1_D0200.tif" />
32201Β1
224
POl-2363-ff
Example 8D
ΗΝ'ΝΗ
<img file="MA32201B1_D0201.tif" />
trans racemic mixture
A solution of Example 7Ε (700 mg, 3 mmol) in dioxane (5 ml) was treated with 4 N HCl in dioxane.
<td>(15 ml.</td><td> 60</td><td>mmol),</td><td>and</td><td>the</td><td>mixed</td><td>has been</td><td>restless</td><td>at 20 ° c</td><td colspan="2">for 18</td>
<td>hours.</td><td>The</td><td>solvent</td><td>at</td><td>summer</td><td>evaporated</td><td>for</td><td>give</td><td>560 mg (</td><td> '91 %)</td><td>of a</td>
<td>solid</td><td colspan="2">pantyhose mistletoe</td><td>at</td><td>summer</td><td>used</td><td>in</td><td>!'step</td><td>next</td><td>without</td><td>more</td>
of purification.
HPLC-MS (Grad_C8_NH 00Η Lowmass): Tr: 0.67 minutes. MS (ESI pos): m / z = 131 (M ؛ H) ٠.
Example 8Ε 15
<img file="MA32201B1_D0202.tif" />
racemic mixture cis
By analogy with the preparation of Example 8D, the title compound was obtained using Example 7D as the starting compound.
Yield: 68.3%.
HPLC-MS (GradCH 00H_Lo١nnass method): Tr: 0.70 minutes. ؛
MS (ESI pos): m / z = 131 (MH). ؛
Example 9Α, racemigue mixture
<img file="MA32201B1_D0203.tif" />
MY
32201Β1
225
POl-2363-ff
<img file="MA32201B1_D0204.tif" />
32.0 g (77.8 mmol) of Example 8Α were mixed with 12.0 g (98.3 mmol) of ethoxymethylene-malonodinitrile in 250 ml of ethanol, and 40 ml (288 mmol) of triethylamine have been added. The reaction mixture was heated at 50 ٠c for 2 hours. After cooling to room temperature, the solvent was removed under reduced pressure. The residue was purified by preparative CLPM (Si٠2, eluent dichloromethane / methanol 8/2).
HPLC-MS (method 1): Tr: 0.29 minutes.
The following examples were synthesized by analogy with the preparation of Example 9Α, using corresponding hydrazines as starting compounds.
<img file="MA32201B1_D0205.tif" />
MY
32201Bl
226 POl-2363-ff
<td>٩ ج ي ٦ ثر w w S Ul</td><td>ته έ ب Μ ٠١ 1—,</td><td>ته ί ٧ ΓΌ σ١ لي</td>
<td>Tr [minutes]</td><td>SJ ب</td><td>إب ؛؛ ؤ '٠ ن ١ ε ب</td>
<td>starting compound</td><td>Example 8C</td><td>Example 8Β</td>
<td>(U M للي U ة للي W</td><td></td><td> ١</td>
<td></td><td>لآ d σ ٠٢٨ ε <ك 0Q (ϋ ليلم ٠١ ن ن ٠١ بم مو بم ن له ١ X ج ω</td><td>Example 9C</td>
٦ΐΖ1١
أ
<td>æ ة ب CN ٠١ ٢١</td><td>ة ٠٠٠٠٠٠ ها ٠ له</td>
<td>0.32 (method 1) ا</td><td>0.40 (method 1)</td>
<td>ت \ \ ر جعج</td><td>لالا -وه</td>
<td>حبك</td><td>حعبك</td>
<td>Q ٠١ له Ï (U ب ئ</td><td>Example 9Ε</td>
POl-2363-ff
ΜΑ 32201Β1
POl-2363-ff
أت
S د
(Ü
أ ه
ئ ي ٢
يد
&
ن
لا
نبر
١١١
Ζ
تم
Z
تمن
ؤ
ج
ي g
Q. G
Γϋ
لع 'X g لآ
MY
32201Β1
229 POl-2363-ff
Example 9F
<img file="MA32201B1_D0206.tif" />
A mixture of 4.4 g (38 mmol) of (tetrahydro-pyran-4-yl) hydrazine and 4.7 g (38 mmol) of ethoxy-methylene-malononitrile in 90 ml of ethanol and 10.5 ml ( 103 mmol) of triethylamine was stirred at 50 ° C for 30 minutes. After cooling to 20 ° C, the solvent was removed under reduced pressure and the residue was treated with a mixture of water / dichloromethane = 1/1. The resulting suspension was stirred for 15 minutes then filtered to give a yellow solid which was then washed with dichloromethane, water and dichloromethane. The solid was dried at 45 ٠c under reduced pressure. 2.7 g (37%) of the title compound was obtained as a yellow solid and used in the next step without further purification.
The following examples were synthesized by analogy with the preparation of Example 9F, using corresponding hydrazines as starting compounds.
<img file="MA32201B1_D0207.tif" />
ΜΑ 32201Β1
230 POl-2363-ff
<td>٦ ح X ٦ كآ</td><td>æ ة رج {3> ٢٩</td><td>K ٤ ٦ م ٠١ ٩</td>
<td>Tr [minutes]</td><td>اً ٠٣٩ U (ύ ن 03 Ό ن 0 Η I ع 00 Ο لفي ج بأ رع ١ بأ ا g ٠ ب ٠٦ ب S ى</td><td>4.97 (method 1Ε hydro)</td>
<td>starting compound: hydrazine</td><td>رم</td><td>م</td>
<td>له 5 υ at دلج لكآ</td><td>; V '</td><td>مم</td>
<td></td><td>Example 9G racemic mixture</td><td>Example 9Η racemic mixture</td>
ΜΑ 32201Β1
POl-2363-ff
<img file="MA32201B1_D0208.tif" />
ΜΑ 32201Β1
232
POl-2363-ff
Example 9GA (enantiomer A)
<img file="MA32201B1_D0209.tif" />
Enantiomer A
Example 9G was subjected to chiral separation to isolate its enantiomers. The brand A enantiomer, of unknown but unique stereochemistry, was isolated using the following conditions.
<td>Quantity supplied</td><td>5 g</td>
<td>Chiral column</td><td>Daicel Chiralpak AD 50 X 300 mm</td>
<td>Mobile phase</td><td>n-Hexane (60%) / methyl! -tert-butyl ether (40%) / ethanol (5%) v / v</td>
<td>Debit</td><td>20 ml / minute</td>
<td>Detection</td><td>UV at 254 nm</td>
<td>Injection mode</td><td>continued</td>
g of enantiomer A were obtained.
The enantiomeric excess is 99.3%; retention time of 27.83 minutes; (analytical method: chiral 3).
'MY
32201BI
233 POl-2363-ff
Example 9GB (enantiomer B)
<img file="MA32201B1_D0210.tif" />
Enantiomer B
Isolate using the same conditions as those used for enantiomer A, with 0.5 g obtained; The enantiomeric excess is 96.7%; Tr: 30.94 minutes; (analytical method: chiral 3).
Example 10Α, racemic mixture
<img file="MA32201B1_D0211.tif" />
4.0 g (22.6 mmol) of Example 9Α was mixed with ml of tetrahydrofuran, and 5.7 g (30 mmol) of di-tert-butyl dicarbamate was added. The reaction mixture was heated at 60 ° C for 5 hours. After cooling to room temperature, the solvent was removed under reduced pressure. The residue was purified by preparative CLPM (SO, eluent dichloromethane / methanol 9/1).
MA 32201 Bl
234
POl-2363-ff
HPLC-MS (method 1١: Tr: 1.28 minutes.
MS (ESI pos): m / z = 278 (MtH) '.
The following examples were synthesized by analogy with the preparation of Example 10Α, using corresponding pyrazoles as starting compounds.
<img file="MA32201B1_D0212.tif" />
MA 32201Β1
POl-2363-ff
<td>١ ج لآ Η < CO ω ة w</td><td>لأ g لام ٠٦ لام</td><td>ق لام ٠٦ لام</td>
<td>10 له لا VS ٠Η ج ع Β</td><td>لا ث</td><td>1.33 (method 1)</td>
<td>starting compound</td><td>Example 9D</td><td>QC ٠٦ له 1 له ω</td>
<td>له بط 5 ن ة لا</td><td>٩ م</td><td> .٦٦.</td>
<td></td><td>Example 10Β</td><td>LOC example racemic mixture</td>
ΜΑ 32201Β1
236 POl-2363-ff
Example 11Α, racemic ielange
<img file="MA32201B1_D0213.tif" />
<img file="MA32201B1_D0214.tif" />
2.4 g (8.96 mmol) of Example 10Α were dissolved in ml of ethanol. At room temperature, a solution of 10 ml ؛ (120 mmol) of hydrogen peroxide (35% in water) and 50 ml of ammonia (25% in water) were added slowly over a period of 10 minutes. The reaction mixture was stirred at room temperature for 2 hours. The solution was ؛ carefully concentrated to a volume of 50 ml under reduced pressure. A precipitate formed and was collected by ؛ filtration. 1.3 g (50%) of the product was obtained as a solid. ؛
HPLC-MS (method 1): Rr: 1.08 minutes. إ
MS (ESI pos): m / z = 296 (MtH) ٠.
The following examples were synthesized by analogy with the preparation of Example 11Α, using corresponding pyrazoles as starting compounds.
ΜΑ 32201Β1
P0i-2363-ff
<td>NOT ي ٦ ١ ى ن ١ نع s \ لمح Ü) 0 مه لمح م ١</td><td>X έ ٧ ٢١ ٢١ لجم</td><td>ج ' لج 00 O ω</td>
<td>Tr [minutes]</td><td>0.44 (method 1)</td><td>1.12 (method 1)</td>
<td>composed of departure</td><td>٧ in ن ï إه م ١</td><td>QC ٠ Γ, له ة ن ω</td>
<td>ده ١٩ دب υ ة دب مأ</td><td>اشم ؛</td><td>بعمبب</td>
<td></td><td>مآ له & ن يملآ ئ</td><td>لا ٢١ له Î له ة</td>
MA 32201 Bl
238 POl-2363-ff
<td>310/311 (Μ + Η) ب HPLC-MS</td><td>ة ة</td>
<td>I I 1.13 (method 1) ا ا</td><td>2.39 (method 2F)</td>
<td>دا ٠ ٢٩ ريم بيع ن لا</td><td>Example 9G</td>
<td> :؛؛:٠٢</td><td> : >؛ ،</td>
<td>ن ق ج Φ ن H Η Ο٦ £ ءلآ ن Η ن ة ٩ ن ١ X بط ح لا</td><td>نتأ ن ت ؤ Φ د ٠ H rf ء ء لآ ن ي ، ن لآ ٢ دم ١ X اط غ لا</td>
MA 32201 Bl
239 POl-2363-ff
<td>211 (MH) ا</td><td>ج O] ΓΟ م</td><td>K at لى لام Μ</td>
<td>ل m 0 w ة ع 0١ ا نب ، ١φ œ ٠ 'ة ع</td><td>8 " "P 0 K ح ة ع in ا دم ، هه ن ١ rl , لا غ fO بلم وع</td><td>. ! ء CM Ο لم ، ب ٢ له ١ ί— ا Ë I ٠ ٧ σι ρ πί ى</td>
<td>Example 9Η</td><td>٣ ق</td><td>Example 91</td>
<td>دمي</td><td>٠ لآي</td><td>مي</td>
<td>Example IIF mixed racemic</td><td>Example 11G mixed racemic</td><td>Example 11Η trans mix racemic ١</td>
MA 32201 BI
240 POl-2363-ff
<img file="MA32201B1_D0215.tif" />
ΜΑ 32201Β1
POl-2363-ff
MY
322٥1Β1
242
Example read, racemic mixture
POl-2363-ff
<img file="MA32201B1_D0216.tif" />
2.30 g (11.2 mmol) of Example 9Ε were dissolved in 6 ml of dimethylsulfoxide. While cooling with ice, 8 ml (77.6 mmol) of hydrogen peroxide and 1.7 g (12.3 mmol) of potassium carbonate were added. Then the reaction mixture was stirred for 15 minutes at room temperature. The reaction mixture was cooled with an ice bath, 100 ml of water was added and extraction with dichloromethane was performed. The aqueous phase was evaporated under reduced pressure. The residue was mixed with dichloromethane and filtered 2.8 g (52%) of the product was obtained as a white solid.
HPLC-MS (method 1): Tr: 0.24 minutes.
<img file="MA32201B1_D0217.tif" />
<img file="MA32201B1_D0218.tif" />
32291Β1
243
POl-2363-ff
Example 12Α
<img file="MA32201B1_D0219.tif" />
660 mg (2.13 mmol) of Example 1e were dissolved in ml of absolute ethanol. 1.85 g (10.7 mmol) of Example 5AC and 430 mg (10.7 mmol) of sodium hydride (60% suspension in mineral oil) were added. The reaction mixture was heated at 150 ° C for 30 minutes in a microwave oven.
After cooling to room temperature, the solvent was evaporated off under reduced pressure. The residue was purified by preparative HPLC (eluent A: water t 0.13% TFA, eluent B: acetonitrile). 320 mg (38%) of the product was obtained as a white solid.
HPLC-MS (method 1): Rr: 1.61 minutes.
MS (ESI pos): m / z = 402 (Μ + Η) '.
The following examples were synthesized by analogy with the preparation of Example 12A, using pyrazoles and corresponding esters as starting compounds.
MY
32201BI
244 POl-2363-ff
<td>NOT ج H مآ ω ٠ ، ٠١ ي ٠ ١ <υ S ة OT \ ل ٠ 0 Λ</td><td>at at ٠ ٣٩ r؟</td><td>492 (Μ-Η) -</td>
<td>Tr [minutes]</td><td>sf</td><td>1.66 (method 1)</td>
<td>composed of departure : ester</td><td></td><td>" < LO ده î لة ق</td>
<td>composed of departure : pyrazole</td><td>- Example binds Î 1</td><td>. UC example 1_</td>
<td>ن بخ s ن ح دب Μ</td><td>دمم ا ٠</td><td>م ١ LL—> O</td>
<td></td><td>Example 12Β</td><td>Example 12c</td>
MA 32201 Bl
245 POl-2363-ff
<td>SM (ESI pos / neg, m / z)</td><td>K ج لام co ω</td><td>æ ί ٧ ο ٠ ل؟ 00</td>
<td>Tr [minutes]</td><td>1.02 (method 1)</td><td>؛ 5 ~ ل</td>
<td>composed of departure : ester</td><td>I Example 5AC I</td><td>نه ،</td>
<td>composed of departure : pyrazole</td><td>ا . Example HJ 1</td><td>b ٢٩ له i له X ةل ١</td>
<td>ن U ة ن ة دم ω</td><td>رده ع</td><td>سمه هل ٠</td>
<td></td><td>mw لا لآ لا ' ج ه ل ٢١ O rf OT ن ن τ ' Ί Cr, 0 a C 'لا E Π5 U لا H 'لا X '(* لا ما ة ٦ ل ٦</td><td>Example 12Ε Mix of stereoisomers ا ا ١</td>
MY
32201Β1
246 POl-2363-ff
<td>NOT H) هاً * لا ٠٦ ٧ ن ١ لع s ١١ لآراً ها 0 به</td><td>ع ج ٢٩</td><td>m È لكا ٠١ ΓΟ</td>
<td>لآ له ده ة ٠٢١ ج لا ئ هج</td><td>1.12 (method 1)</td><td>1.49 (method 1)</td>
<td>composed of departure : ester</td><td>\ Example 5ΑΕ Î \ I</td><td>٦ ° Ό</td>
<td>composed of departure : pyrazole</td><td>١ \ Example 11 ل أ</td><td>1 ا Example 11Α</td>
<td>له يخ ده U ح ده w</td><td>عمثك ٩۶</td><td></td>
<td></td><td>Example 12F Mix of stereoisomers</td><td>ى CN له H ٠٩ ω ω laughed. ٠١ r — I ة c ح حة ١ rd ج ri U له fd ن ١ X wew</td>
MY
32201Bl
247 POl-2363-ff
<td>; Hey حكاً ، ٠ لا ٥١ ي ن ١ ة S \ لكاً م ١ 0 به</td><td>K έ ٠ 00 r؟</td><td>لمة ة معلآ VD M</td>
<td>Tr [minutes]</td><td>؛ s ؛ ١α ε</td><td>ه ب</td>
<td>composed of departure : ester ا</td><td>ملآ > لاى Φ t φ w</td><td>Q < fl ن ن لا</td>
<td>composed of departure : pyrazole</td><td>ا \ Example 11Α .. \ I</td><td>Example 11Α</td>
<td>Q) M ق ن ح ده W</td><td>; ... خ</td><td>ثم ١</td>
<td></td><td>ثت ٦ ل 0١ H (U ؤ ن ن بم ٠١ بم ج ه به ١φ ل ٩ ج U بم ل ٠ ل ٩ ن 'X ب we</td><td>Example 121 ؛ mixed racemic .</td>
<img file="MA32201B1_D0220.tif" />
32201Bl
248 POl-2363-ff
<td>; يلآ H W ، لا ٠١ ٧ له ' S \ لآرح لى 0 ه</td><td>K ٩١ نتاً</td><td>" غ ب ى له</td>
<td>Tr [minutes]</td><td>؛ ج</td><td>SJ إ ج</td>
<td>composed of departure : ester</td><td>م</td><td>Example 5Τ ا</td>
<td>composed of departure : pyrazole</td><td>Example 11Α ا ١ ا</td><td>ه له ا له ة</td>
<td>له لأ دفي ٧ ة لفي لئ</td><td>ثم ة</td><td>ثم لاخ '</td>
<td></td><td>Example 12 ل mixed racemic</td><td>Example 12Κ Mix of stereoisomers I ا .</td>
<img file="MA32201B1_D0221.tif" />
32201Β1
249 POl-2363-ff
<td>NOT ج ١ H دكح * لا ٠١ ٧ ن ١ ة S \ لكاً لالا 0 ع</td><td>K ة ٠٠٠٠٠٠٠ لام ٠ ٦٣</td><td>K ق CO ο</td><td>w ة ص ٠ d ٠١</td>
<td>Tr [minutes]</td><td>؛ ة</td><td>ؤ 5</td><td>ر ٧</td>
<td>composed of departure : ester</td><td>ن ٦ ى ن Î له ة</td><td></td><td>ة LO له Ï V X لا</td>
<td>composed of departure : pyrazole</td><td>ه t — 1 rf له Î له ئ</td><td>Q d له له ئ</td><td>O ت Î ن X لا</td>
<td>له بذ 3 دلم ة دلج هاً</td><td>ده مر ا</td><td>ده مر م °</td><td>ده مئ م طا</td>
<td></td><td>Example 12L mixed racemic</td><td>Example 12Μ melancholy racemic ا</td><td>Example 12Ν mixed racemic ا ١</td>
MY
32291BI
POl-2363-ff
<td>SM (ESI pos / neg, m / z)</td><td>K ة ص ١ ٣١ rl Γ؟</td><td>K بآ بآ</td><td>K at QC لاع</td>
<td>> n m لل ة ق ع Ε-ι</td><td>1.13 (method 1)</td><td>S ؤ</td><td>ا I 1.53 (method 1)</td>
<td>composed of departure : ester</td><td>نح ”</td><td>Example 5Τ</td><td>Example 5AG</td>
<td>composed of departure : pyrazole</td><td>I HD example .</td><td>HD example</td><td>HD example</td>
<td>له لأ لد υ ة لد w</td><td>نمده ثم ٠ ه</td><td>نمده ثم ٩</td><td>'؛ -٠٢ ثم لأ ٠</td>
<td></td><td>Example 120 mixed racemic</td><td>Example 12Ρ Mix of stereo-! someres</td><td>Οί لاع وه ب ٢ & له له ٠Η ٠١} —f ة تل ج له ١ ϋ> ح rl U له ل ٩ وه ١ نح بر ج لا</td>
ΜΑ 32201Β1
POl-2363-ff
<img file="MA32201B1_D0222.tif" />
<img file="MA32201B1_D0223.tif" />
<img file="MA32201B1_D0224.tif" />
32201Bl
POl-2363-ff
<td>SM (ESI p٥s / neg, m / z)</td><td>æ ة ب 00 ao جم</td><td>K ع 00 لم لم</td>
<td>not له دب ج تع ته E- ،</td><td>1.56 (method 1)</td><td>ئ ٢٩ لآ -r Γ- Ό 0 ، ع ل للج لآ ' ج</td>
<td>composed of departure : ester</td><td> ٢'</td><td>ئح “</td>
<td>composed of departure : pyrazole '' '' '</td><td>. HD example î i</td><td>ئخي</td>
<td>له بل دب υ ة للي w</td><td>ج '؛ ٩ مح ٠ ه</td><td>; -. ة '</td>
<td></td><td>Example 12U mixed racemic</td><td>12V example</td>
<img file="MA32201B1_D0225.tif" />
ΜΑ 32201Β1
POl-2363-ff
<td>SM (ESI pos / neg, m / z)</td><td>K î co ٠٦ ٣١</td><td>لأ ق سلأ ٠١ ٢١ CM</td>
<td>; له لا ة ٠Η ج لا this E-,</td><td>6.96 (method 2F)</td><td>8.28 (method 2F) I I</td>
<td>composed of departure : ester</td><td>تبه</td><td>Example 5AC</td>
<td>composed of departure : pyrazole</td><td>: ة |</td><td></td>
<td>\ structure ١</td><td> ٠٩</td><td>ع</td>
<td></td><td>جا CM ٢١ له î له ة</td><td>X CM له له ة</td>
ΜΑ 32201Β1
254 POl-2363-ff
<td>SM (ESI pos / neg, m / z)</td><td>لآ ج ما ٠١ لام</td><td>لآ ف ٦ ى ٠١ لام</td>
<td>Tr [minutes]</td><td>تة لا لاكا و ٦ ب 0 ' ع ٠١ لا ' ة '١</td><td>9.54 (method 2F) ١ I</td>
<td>composed of departure : ester ا</td><td>له 1 له ة</td><td>\ ١ I ا Example 5ΑΗ</td>
<td>composed of departure : pyrazole</td><td></td><td></td>
<td>ده M زلج U ة دلج V)</td><td> ;٦'</td><td>زي ؛؛ دجإحاب</td>
<td></td><td>Example 12Υ</td><td>Example 12Ζ</td>
MY
322٠1Β1
255 POl-2363-ff
<td>SM (ESI pos / neg, m / z)</td><td>K ة ي</td>
<td>Tr [minutes]</td><td>تة Μ له οο Ό بو ١ 0 ١ ع ١٥ ن ١ g</td>
<td>composed of departure : ester</td><td>ق جى له ا له ج</td>
<td>composed of departure : pyrazole</td><td></td>
<td>ن M B U B دلج ١π</td><td> ٦</td>
<td></td><td>Example Ι2ΑΑ</td>
ΜΑ 32201Β1
256 ا POl-2363-ff
Example 13Α, racemic mixture
<img file="MA32201B1_D0226.tif" />
4 00 mg (1.35 mmol) of example 11Α were dissolved in إ ml of absolute ethanol, 840 mg (5.4 mmol) of example 5AC and ٠ ؛
220 mg (5.5 mmol) sodium hydride (60% suspension in>
mineral oil) have been added. The reaction mixture was heated at 150 ٠c for 30 minutes in a microwave oven.
After cooling to room temperature, the mixture ؛ The reaction was acidified with 4N hydrochloric acid. The solvent was removed under reduced pressure. The residue was ؛ purified by preparative HPLC (eluent A: water + 0.13% TEA,
<td></td><td>eluent B: acetonitrile).</td><td>250 mg (46</td><td>%) of the product were obtained</td>
<td> 15</td><td>in the form of a solid</td><td>White.</td><td></td>
<td></td><td>HPLC-MS (method 1)</td><td>: Tr: 0.93</td><td>minute.</td>
<td></td><td>MS (ESI pos): m / z =</td><td>: 288 (M٠H) ٠</td><td></td>
<img file="MA32201B1_D0227.tif" />
ΜΑ 32201Β1
٦ ح 2
POl-2363-ff
Example 13Β
<img file="MA32201B1_D0228.tif" />
330 mg (0.82 mmol) of Example 12Α were dissolved in ml of dichloromethane and 1 ml of trifluoroacetic acid was added. The reaction mixture was stirred at room temperature overnight. The solvent was evaporated under reduced pressure. The remaining product was purified by preparative HPLC (eluent A:
water + 0.13% TFA, eluent B: acetonitrile). 240 mg (70%) of the product was obtained.
HPLC-MS (method 1): Rr: 0.96 minutes.
MS (ESI pos): m / z = 302 (MtH) ♦.
The following examples were synthesized by analogy with the preparation of Example 13Β, using corresponding Boc protected amines as starting compounds.
<img file="MA32201B1_D0229.tif" />
32201Bl
258 POl-2363-ff
<td>NOT ة H ، ما ω تة هآ</td><td>ئ ί لام ٠ <η</td>
<td>Tr [minutes]</td><td>أ 1.01 (method 1)</td>
<td>starting compound</td><td>Example 12L ١ \ ١ I I _1</td>
<td>له p ن p p ما</td><td>لأجر-</td>
<td></td><td>Example 13C racemic mixture</td>
ΜΑ 32201Β1
259 POl-2363-ff
<td>ع ٦ ق ر ٠ ل ٠ ٢١ 00</td><td>ع ١ ة ٧ ي ٠١ ٢١٦</td>
<td>\ ١ I I 0.93 (method 1)</td><td>1.09 (method 1)</td>
<td>Example 12Μ</td><td>Example 12Ν</td>
<td>لي ° مبج ٠ “لآة</td><td>؛ ح-</td>
<td>له ج ج ' له ١ ن O ةاً٢ ٢٣١ بإ ا-ا له له ٠٦ 1—1 ناً ظ ل ٩ ح ٢٩ د ٩ له ١ κ ح لا</td><td>له ؤ ٠٩ ج ن ١ ن لا حأاً لم ٢ صج ٩ له له ٠١ ٩ لع ag ni 4 0 0 ' WB</td>
MA 32201 Bl
260 POl-2363-ff
<td>X حكا ٠١ لام</td><td>X ؛ ٠ CO ٢١٦</td>
<td>. \ 0.92 (method 1)</td><td>1.08 (method 1)</td>
<td>O لام له î (U X ئ</td><td>Example 12Η</td>
<td>دريده</td><td>يرمل 'لآلأل</td>
<td>له ج B له ١ دأ هتآ ثم ٢٩ بخ يم له له ٠٦ ب ٠ ثاً ج H له له ١ X ح W</td><td>Example 13G racemic mixture</td>
<img file="MA32201B1_D0230.tif" />
32201Β1
261 POl-2363-ff
<td>ن ق ها له ٩ م</td><td>æ ق ٩١ له</td>
<td>ا ١ 0.96 (method 1)</td><td>0.89 (method 1)</td>
<td>Example 121</td><td>b له ٢١ له 1 له W</td>
<td>غر ٠١</td><td>٥ <k</td>
<td>له ؤح ٠٢١ S له ١ w U لأآ ٢ ٢٩ بط rf له له ٠١ بم تع ج له ح ا—> له له ١ κ ح لا</td><td>Example 131 racemic mixture</td>
<img file="MA32201B1_D0231.tif" />
32201Β1
262 POl-2363-ff
<td>w ة ب ٠ ٦ م م</td><td>X ة ضلآ ٠ ٢١ ١٦ م</td>
<td>١ تم ٢١ له ؤآ ٠ K 0 ع 8 P ن ١ ح ٧</td><td>0.92 (method 1)</td>
<td>١ \ ١ \ ١ Example 12Κ ١ ١ \ \</td><td>Example 12Β \ ا ١ ا ١ ا</td>
<td>عرا</td><td>ت-؟ نم ؛</td>
<td>ل 13 Example ، ؛؛, ؛, ؛؛؛ ،. ؛, اذلال</td><td>يئ ٩ م rl له له XJ W</td>
Μα 32201Β1
263 POl-2363-ff
<td>K 1 ب σ \ 00</td><td>X ة ب r؟ co</td>
<td>1.07 (method 1)</td><td>. . 1.04 (method 1) ا</td>
<td>O ل ٢١ ده î لآ ب w</td><td>I \ . . ١ ا I Example 12Ρ</td>
<td>-دن ان</td><td>.- ؛: ن ٩</td>
<td>ص ٠ co ٣٩ له & له ة</td><td>إ ئ 0 ؤآ H ة. ده ده O ٠١ H له 'ة ئ بل ίϋ ح له ١ بم له لب له ١ κ MSW</td>
ΜΑ 32201Β1
264 POl-2363-ff
<td>w ع σι ٢٠٩ <η</td><td>K ة رطلآ هع</td>
<td>ام ؤ لى ن ١ ح</td><td>0.89 (method 1) .</td>
<td>Example 120 ١</td><td>Example 12S</td>
<td>7 اً'لى</td><td>إ ٠> ٠</td>
<td>Example 13Ν racemic mixture</td><td>Example 130 racemic melanqe</td>
MY
32201Β1
265 POl-2363-ff
<td>نلج ؛ جى ٢٩</td><td>ة 00 00 لجم</td>
<td>. . 1.04 (method 1)</td><td>0.94 (method 1)</td>
<td>Example 12Τ</td><td>حت ل ١ م Ά لا Ï لا W</td>
<td>زه</td><td>ي ° أ ٠</td>
<td>زم بج ج ٠ دم ١ U بلع fü ٢٩ ri μ لا لا Γ-1 σ١ تاًلآ بم لا لا ١ X ح W</td><td>Example 13Q racemic mixture</td>
MA 32201 Bl
Ί
POl-2363-ff
Example 15Α
<img file="MA32201B1_D0232.tif" />
Enantiomer A
200 mg (1.12 mmol) of Example 9GA were mixed with 4.5 ml of an ammonia solution (30% in water). The reaction mixture was heated at 130 ° C for 30 minutes in a microwave oven. After cooling to room temperature.
<td>the solvent</td><td>has been evaporated</td><td>under pressure</td><td>scaled down. 180 mg (82%</td><td>) of</td>
<td>product have</td><td>been obtained.</td><td></td><td></td><td></td>
<td>GC-SM</td><td>(method 3Α. 1</td><td>): Tr: 12.62</td><td>minutes.</td><td></td>
<td>[M] * =</td><td> : 196.</td><td></td><td></td><td></td>
Example 16Α
عآح
حد ό
Enantiomer B
150 mg (0.84 mmol) of Example 9 GB were mixed with
2.10ml of an ammonia solution (30% in water). The reaction mixture was heated at 130 ٥c for 30 minutes in a microwave oven. After cooling to room temperature.
ΜΑ 32201Β1
267 POl-2363-ff the solvent was evaporated under reduced pressure. 100 mg (60%) of the product was obtained.
GC-SM (method 3Α. 2): Tr: 12.59 minutes.
[M] ٠ = 196.
Example IA, mixture of stereoisomers
<img file="MA32201B1_D0233.tif" />
A solution of 1.00 g (5.32 mmol) of 2-methoxy-5bromopyridine in 10 ml of anhydrous THF was cooled to -78 ° C and η-BuLi (3.66 ml, 5.85 mmol, 1, 6 M in hexane) was added. After 10 minutes at -78 ٠c, 1.18 g (6.38 mmol) of 2-oxo-cyclohexyl-acetic acid ethyl ester was added and the mixture was warmed to 25 c. Water was added (Iml) and the mixture was concentrated under reduced pressure. The ; residue was purified by preparative HPLC (eluent A: water t 0.13% f TFA, eluent B: acetonitrile). 370 mg (28%) of the product was obtained as an oil. ج
HPLC-MS (method 1): Rp: 1.23 minutes.
MS (ESI pos): m / z = 248 (MtH) '. إ
I ٠
Example 18Α, cis, racemic mixture
<img file="MA32201B1_D0234.tif" />
OH
<img file="MA32201B1_D0235.tif" />
32201Β1
268
POl-2363-ff
380 اً mg (1.54 mmol) of Example 17Α was mixed with 5 ml of methanol, 50 mg of Pd / c (10%) was added, and the إ mixture was hydrogenated at room temperature (8 hours , 50 psi).
؛ The reaction mixture was filtered and the residue was washed with methanol. The solvent was evaporated under reduced pressure.
340 mg (89%) of product was obtained as a colorless oil and used without further purification.
HPLC-MS (method 1): Rr: 1.01 minutes.
MS (ESI pos): m / z = 250 (M + H)<sup>+</sup>.
<img file="MA32201B1_D0236.tif" />
MA 32201 BI
<td></td><td> 269</td><td></td><td>POl-2363-ff</td>
<td>Examples of modes of</td><td>production</td><td></td><td></td>
<td>EXAMPLE 1</td><td></td><td></td><td></td>
<td></td><td>O H</td><td></td><td></td>
<td></td><td>HN ^</td><td> ٢١</td><td></td>
<td></td><td></td><td>را ن</td><td></td>
100 mg (0.48 mmol) of example 11Β were dissolved in 5 ml of absolute ethanol, 400 mg (2.17 mmol) of example 5v and 100 mg (2.5 mmol) of sodium hydride (60% suspension in mineral oil) were added. The reaction mixture was heated at 150 ° C for 30 minutes in a microwave oven. After cooling to room temperature. The solvent was evaporated under reduced pressure. The residue was purified by preparative HPLC (eluent A: water + 0.13% TFA, eluent B:
acetonitrile). 29 mg (18%) of the product was obtained as a white solid.
HPLC-MS (method 1): Rr: 1.08 min.
MS (ESI pos): m / z = 331 (MtH) *.
The following examples were synthesized by analogy with the preparation of Example 1, using pyrazoles and corresponding esters as starting compounds.
MA 32201 Bl
POl-2363-ff
<td>SM (ESI p٥s / neg, m / z)</td><td>ة ί س ٠ لاس لاح ، Η</td><td>لمة έ ٣٩ Ch لام</td>
<td>Tr [minutes]</td><td>1.27 (method 1)</td><td>1.22 (method 1)</td>
<td>starting compound: ester</td><td>لآ</td><td> '٠</td>
<td>composed of departure : pyrazole</td><td>Example 11Β</td><td>Example 11Β</td>
<td>ن M له U د M دب w</td><td>هت ٦ ه لآ</td><td> ٠٩</td>
<td></td><td>Example 2</td><td>Example 3</td>
MA 32201 Bl
POl-2363-ff
<td>NOT H) لكح W * ٠١ ب له ' s ة m '٠tn 0 Λ</td><td>j ج ج لا جى جم</td><td>بز به ل ج ح σ١ oo ٦ م</td>
<td>Tr [minutes]</td><td>- 1.23 ؛ 1 method)</td><td>1 ؟؛ ي ج ب</td>
<td>starting compound: ester 1- -</td><td>. . Example 5Υ</td><td>Example 5U</td>
<td>composed of departure : pyrazole</td><td>. Example 11Β</td><td>Example 11Β</td>
<td>له بز B υ بذ للي w</td><td>هحم</td><td>مع ١</td>
<td></td><td>Example 4</td><td>Example 5</td>
MY
32201BI
POl-2363-ff
<td>SM (ESI pos / neg, m / z)</td><td>h ج هع لمم هع CO</td><td>ة لج س ٠ LO ب co</td>
<td>Tr [minutes]</td><td>1.28 (method 1)</td><td>1.22 (method 1) \ L</td>
<td>starting compound ؛ ester ا</td><td>ت</td><td>Example 5W</td>
<td>composed of departure : pyrazole ا</td><td>\ \ Example 11Β</td><td>ï له w</td>
<td>له إلم ل 4 υ ت Μ دم in</td><td>حا ٢ ع ٠٥٩</td><td>مده ٦٩</td>
<td></td><td>Example 6</td><td>Example 7 i</td>
ΜΑ 32201Β1
POl-2363-ff
<td>ti H gm W *. ٠٦ ب s ة Ul ١ Ώ 0 ئ</td><td>K ة ع</td><td>ace ق ٣١ ٦ م</td>
<td>للا له دم ة ئ ٠ ع ب</td><td>1.14 (method 1)</td><td>1.37 (method 1)</td>
<td>starting compound: ester</td><td></td><td>Example 5Χ</td>
<td>composed of departure : pyrazole</td><td>Example 11Β</td><td>Example 11Β</td>
<td>structure</td><td>حكمة رحب</td><td>مئو لأ ؛</td>
<td></td><td>Example 8</td><td>Example 9</td>
.ΜΑ 32201Β1
274 POl-2363-ff
<td>SM (ESI p٠s / neg, m / z)</td><td>ج ': إهج هت 00</td><td>ق ٠ — ا (مم</td>
<td>; له دفي d ح ٠ تع ب</td><td>1.30 (method 1)</td><td>ل ق ر 0 ' ح ك ١٠</td>
<td>starting compound: ester \</td><td></td><td>خ</td>
<td>composed of departure : pyrazole</td><td>\ \ Example 11Β</td><td>Example 11Β</td>
<td>له بلم d لفي ن د بلم لفي م ٦</td><td>٥Ό ج<sup>أ</sup></td><td>ركمكل ٦ مت</td>
<td></td><td>٠ ٢٠٩ له ا له X مآ</td><td>rf ٢٩ له Î له ة</td>
MA 32201 BI
POl-2363-ff
<img file="MA32201B1_D0237.tif" />
MA 32201 Bl
276 POl-2363-ff
<td>SM (ESI pos / neg, m / z)</td><td>K ق ١ ئ CM لمم</td><td>ف هلم ٠١ ٢٠٦</td>
<td>W لة لا ة ؤ ته يع</td><td>. I 1.28 (method 1)</td><td>1.49 (method 1)</td>
<td>starting compound: ester . I \</td><td>ئ ri) Lf) d) i 0) w</td><td> %</td>
<td>composed of departure : pyrazole</td><td>Example 11Β ؛ \</td><td>< Z ï له M</td>
<td>له M لا لا U لا M لا ما</td><td>٥٦3٥ - نم '·</td><td></td>
<td></td><td>Example 14 mixed racemic</td><td>Example 15 mixed racemic</td>
MA 32201 BI
POl-2363-ff
<td>SM (ESI pos / neg, m / z)</td><td>œ ة ٧ ٦٣ ١</td><td>Κ ق لام ٠ ياً</td>
<td>; له دلج ة ٢١ * g II تع ب</td><td>I-1 1.49 (method 1)</td><td>1.65 (method 1)</td>
<td>starting compound: ester</td><td> ١٠٩</td><td>Example 5AC</td>
<td>composed of departure : pyrazole</td><td>\ Example 11Α</td><td>HD example</td>
<td>له بخ دب U د بخ للي مآ</td><td>يرم ع ٠</td><td>ده مبج</td>
<td></td><td>هلأ له بم ج ن ن ri · ٠٦ r — I ئ تع ه له'١ E f0 ٧ بم له Ü ؛ ده ١ بحن بخ ج لا</td><td>ل 0 تاً ب ٠ D) ده لم. ٠٦ بم خ تع به له ١ Ü) ج ن يم ن Γϋ له ١ بحن بخ ح لا</td>
32201Β1
POl-2363-ff
بى
<td>SM (ESI p٥s / neg, m / z)</td><td>ة رخ 00 ٠ ٦٣</td><td>K ة مع ١ ٦٣ ٠٦ ٦٣</td><td>ئ ج ٢٩ ٢٩ ٦٣</td>
<td>Tr [minutes] \</td><td>ق ج ص ٠</td><td>ؤ s ب</td><td>3 S ي Γ-î له ١ ح نمتجلآ</td>
<td>starting compound: ester</td><td>ا ٠</td><td>ئ > لآى (U i له ω</td><td> ٠٥</td>
<td>composed of departure : pyrazole</td><td>HD example</td><td>"F— ا ٢٩ له لآ لا</td><td>Q 1 1 له κ عآ</td>
<td>له بلخ ت ؛ دلج υ ة دلج لب</td><td>؛ ٠١ ص وا</td><td>د مو ا</td><td>ده مئ ة</td>
<td></td><td>Example 18 mixed racemic</td><td>σι له ب ٢ ج له له ٠٩ ٠٦ ٩ ج C ج له ١ لأ> Ε ٧ ٩ له Π5 له> κ بلخ ج W</td><td>Example 20 mixed racemic</td>
MA 32201 Bl
279 POl-2363-ff
<td>SM (ESI p٥s / neg, m / z)</td><td>K ج ك ٠ لآ ٩٠ ٩٠ ٩٠</td><td>T ؛ CO ٩٠</td><td>K ة ب 00 له ٩٠</td>
<td>Tr [minutes]</td><td>1.63 (method 1)</td><td>1 ة ؤج</td><td>1 ة ٧</td>
<td>starting compound: ester</td><td>Example 5Τ</td><td>ة ٦ لغ له Î له ة</td><td></td>
<td>composed of departure : pyrazole</td><td>-1 ا I HD example 1</td><td>Example 11D</td><td>Example 11D</td>
<td>له u لفي 0 بز لفي HE</td><td>م مئ ا</td><td>؛ ٠١ دبؤ م ااي ٦ ،؟ ١٩</td><td>٥۴٢ ص لآيي ٠ م</td>
<td></td><td>Example 21 mixed racemic</td><td>Example 22 mixed racemic</td><td>Example 23 mixed racemic</td>
MA 32201 Bl
POl-2363-ff
<img file="MA32201B1_D0238.tif" />
MA 32201 BI
POl-2363-ff
<td>SM (ESI pos / neg, m / z)</td><td>301 (MtH) '</td><td>" ق ٠٦ لى جم</td>
<td>; d) دلج ة ج ته b</td><td>0.87 (method 1)</td><td>1.17 (method 1) \ I ١ ا ١</td>
<td>\ starting compound: ester</td><td>Example 5ΑΝ</td><td>Example 5AJ</td>
<td>composed of departure : pyrazole</td><td>S له ة له w</td><td>ω & له عآ</td>
<td>له M للي υ ب للي لكاً</td><td>متم</td><td>مئ ١ اه</td>
<td></td><td>Example 26</td><td>Example 27</td>
<img file="MA32201B1_D0239.tif" />
32201Bl
282 POl-2363-ff
<img file="MA32201B1_D0240.tif" />
<img file="MA32201B1_D0241.tif" />
32201Bl
POl-2363-ff
<td>SM (ESI p٥s / neg, m / z)</td><td>X ة ها ٦ م</td><td>X S '١ co oo co</td><td>٧ ٠ م χ Γ0 X LD م</td>
<td>Tr [minutes]</td><td>ا g</td><td>1.56 (method 1)</td><td>s ί</td>
<td>starting compound: ester</td><td>اه</td><td>مي ٠</td><td>Example 5ΑΟ</td>
<td>composed of departure : pyrazole</td><td>HD example</td><td>HD example : !</td><td>X ٣١ له ا له W</td>
<td>له p لآ p ن لآ p p w</td><td>٠۴ ص ٥٩</td><td>د ٠ محو ه</td><td>مع ٠٩</td>
<td></td><td>Example 31 mixed racemic</td><td>Example 32 mixed racemic</td><td>Example 33 ا</td>
<img file="MA32201B1_D0242.tif" />
MY
32201Β1
<td>٩ ج. أ H مأ ٠٠٠ لا ٠١ - له ١ ة ة \ لتآ لكاً 0 ع</td><td>X ة ٢٩ ٩ م</td><td>X ة ٧ ها ها ٢٩</td>
<td>له لي ء ٠٩ g I -, ى b</td><td>ات ع ع ٠ΛΙ g</td><td>1.17 (method 1)</td>
<td>starting compound: ester</td><td></td><td></td>
<td>composed of departure : pyrazole ١</td><td>ا ١ Example 11Β ! -</td><td>Example 11Β</td>
<td>له لت دلي U بخ دفي م ٦</td><td>رص ٦٦- '</td><td>ص ٠٩٢</td>
<td></td><td>ب ٢٩ له ΐ له ق</td><td>لكا ٢٩ له ΐ له لح لا</td>
ببا
يبا
د
لام
ئ
MY
32201Β1
POl-2363-ff
<td>NOT يع ١ H لكع M k ٠١ ب لا ١ ة ة ١ لكع W 0 ى</td><td>K έ '١ σ١ ٩ م Οϋ</td><td>٢٩ ο η κ 03 + ω S laughed 00 ٢٩</td>
<td>Tr [minutes] \</td><td>1.36 (method 1)</td><td>; (d Ό ٢٩ ع بم للج لآ ' ح ٧</td>
<td>starting compound: ester</td><td>ب.</td><td>Example 5AL</td>
<td>composed of departure : pyrazole</td><td>Example 11Β</td><td>Example 11Β</td>
<td>لا μ U 0 μ حج مأ</td><td>مع ٩</td><td>مكل اه</td>
<td></td><td>Example 36</td><td>Example 37</td>
Μα 32201Β1
286 POl-2363-ff
<td>٦ ج ح ١ H مآ ١ لا ٠١ ٧ ن ١ ة S \ لكح W 0 به</td><td>co * 00 تج co ي H 00 co لاح ١٠١ بم ٠١ ٧ ١] co s—</td><td>بى دا : 's ق م ماً co</td>
<td>Tr [minutes] I ١</td><td>-1 1.44 (method 1)</td><td>1.28 (method 1)</td>
<td>starting compound: ester</td><td>Example 5Ζ</td><td>.ة</td>
<td>composed of departure : pyrazole</td><td>١ ١ Example 11Β \ \</td><td>I Example 11Β</td>
<td>structure I</td><td>مك ٥٩</td><td>مة ٠٩</td>
<td></td><td>Example 38</td><td>Example 39</td>
MY
32201BI
لالم
<td>SM (ESI pos / neg, m / z)</td><td>æ ت ٩ م</td><td>K ق م ٠ ٦ م</td>
<td>ω (1) P ة ق تع يع</td><td>ل ي e * ١٠٠٠٠٠</td><td>ؤ؟ غ د له ١ يير</td>
<td>starting compound: ester</td><td> 5</td><td>(] ص < 1Ο غ ب لا</td>
<td>composed of departure : pyrazole</td><td>Example 11Β</td><td>Example 11Β</td>
<td>ن M ة υ ة لد ل ٧</td><td>مح</td><td>وحبره ح</td>
<td></td><td>O لة لة ة</td><td>ه ٣ ا ٠ ٢٣ لة بيع لة ة</td>
287 POl-2363-ff
MY
32201Β1
POl-2363-ff
<td>SM (ESI pos / neg, m / z)</td><td>s لكا ω</td><td>K έ س ١ ١ ى LO co</td>
<td>\ I Tr [minutes]</td><td>ا . ا 1.31 (method 1)</td><td>1.25 (method 1)</td>
<td>-1 ا starting compound: ester</td><td>" P < LD 0 ï لآ ئ</td><td>Q بى < LO لآ Î ω X w</td>
<td>composed of departure : pyrazole</td><td>ا . Example 11Β</td><td>ه : ï له w</td>
<td>له M B ٧ ى لا (/}</td><td> .٦/٦'</td><td></td>
<td></td><td>Example 40-2</td><td>Example 40-3</td>
T?
ΜΑ 32201Β1
289 POl-2363-ff
<td>SM (ESI pos / neg, m / z)</td><td>X ج لجم ٩١</td><td>X ة رلآ ب ٠١ ٢٩</td>
<td>Tr [minutes]</td><td>I- 1.18 (method 1)</td><td>1.24 (method 1)</td>
<td>starting compound: ester</td><td>g ١ ى له ا ره لا</td><td>ق لكا له & لآ ئ</td>
<td>composed of departure : pyrazole I</td><td>Example 11Β Î</td><td>" له لا</td>
<td>له M د حلب ن د ب لب</td><td>محي ج</td><td>مع ></td>
<td></td><td>Example 40-4 cis mixture racemic</td><td>Example 40-5</td>
MY
32201Β1
290 POl-2363-ff
<td>SM (ESI pos / neg, m / z)</td><td>æ ة لم لكا لم</td><td>" ع 03 ب — ا ٣٣</td>
<td>Tr [minutes]</td><td>1.22 (method 1)</td><td>1.35 (method 1)</td>
<td>1 starting compound: ester</td><td>تلع هج ٦ ى (1) لا لا</td><td>لا > لكا لا ؤ له عآ</td>
<td>composed of departure : pyrazole I</td><td>لآ لا بيع له ω</td><td>I Example 11Β</td>
<td>له M للي υ Μ للي لكاً</td><td>مم ا</td><td>مع ¾- ۶٥</td>
<td></td><td>Example 40-6</td><td>م \ O ٢٣ لا باً لآ ! X! W</td>
ΜΑ 32201Β1
291 POl-2363-ff
E ample 41
<img file="MA32201B1_D0243.tif" />
80 mg (0.38 mmol) of example 11Β were dissolved in 1 ml of absolute ethanol, 262 mg (1.52 mmol) of ethyl tetrahydropyran-4-ylacetate and 45.1 mg (1.10 mmol) d Sodium hydride (60% suspension in mineral oil) was added. The reaction mixture was heated at 150 ° C for 40 minutes in a microwave oven. After cooling to 20 ° C, the solvent was evaporated under reduced pressure. The residue was treated with water (10ml), acidified with HCl (10% in water) and extracted twice with dichloromethane (2ml). The organic phase was dried over sodium sulfate, filtered and the filtrate was concentrated under reduced pressure. The residue was triturated with ether to give 65 mg (53.7%) of the product as a white solid.
HPLC-MS (Grad_C8_H OOH method): Tr: 1.89 minutes.
MS (ESI pos): m / z = 319 (M٠H) ٠.
The following examples were synthesized by analogy with the preparation of Example 41, using pyrazolylcarboxamides and corresponding esters as starting compounds.
ΜΑ 32201Β1 ؛
292 POl-2363-ff
<td>NOT هم K هاً H W مل</td><td>ب رس ي ن ق ٢٩</td><td>ع ٠١ ب 03 ج ل ٢١</td>
<td>M له دفي ة ï .ى Ε-ί</td><td>ل ب لآ ٠ ؛ Μ 0 X ٠ ة ع Ο ده له ١ CN ؤ</td><td>"I ٠ يب »0 0 ί» ع ٠ لل ل ٠ ١Μ Ν ؤف</td>
<td>ب له دلج ω</td><td>نمع ي</td><td>١٥ وم</td>
<td>s د § 'و ة 0 h ة</td><td>ع ن بتع V ة</td><td>ω AT له له ة</td>
<td>له Μ ة U Μ دلج للا</td><td>مع همه</td><td>همتربم ٢ ه م</td>
<td></td><td>CN له ب ج له له ٠١ ب ٢ Γ, ء ٠ ج Η ح ÎÜ 'ن ب ٢ له U X له ١ (Q ح لا Μ</td><td>٦ م ، 1 له ا له ة</td>
ΜΑ 32201Β1
293 POl-2363-ff
<td>NOT م ٠٠ لآن ١٣١ ٦ لآ ئ</td><td>E ٠١ لا</td><td>ب ٦ ن ؤم</td><td>ع بم</td>
<td>Tr [minutes] ا</td><td>Π , -لا 00 ي ٠ 'ة ؤ بع</td><td>لا ب ٦٦ تتأ 0 \ Z ئ ٠ CO ره ١ ٩ م | لا ة ") ب ى</td><td>ί! Î ا ٠ ة ب ع ئ بم</td>
<td>هز ن دفي م ٦ W</td><td>ب ة</td><td>بي لات<sup>1</sup></td><td>١٠ ك ٦ بظ طا</td>
<td>؛ I ة</td><td>" ٢١ ن متع له ق</td><td>03 : Î له H</td><td>ه ; Ϊ له ة</td>
<td>structure</td><td>لاجلاه ..</td><td>٥Ϊ٧Ό ؛ ة</td><td>مع ب ٦٩</td>
<td></td><td>مأ إهم ميع له لا</td><td>ύ ٦٣ له له ب لا</td><td>ها زه ٦٣ ؤ ن ن d Ο٦ Γ, ج £ لآ ن d ن Π5 ده ١ X M ج لا</td>
ί '
ΜΑ 32201Β1
294 POl-2363-ff
<img file="MA32201B1_D0244.tif" />
Μα 32201Β1
295 POl-2363-ff
<td>لا ر k لس H ثس لا</td><td>ب ٢٩ ج ماً</td><td>æ لام ة م</td><td>ب رى ي بى</td>
<td>Tr [minutes]</td><td>3.02 (method GradC8NH OOH)</td><td> - ----- ٢ 5.97 (method 1Ε hydro)</td><td>-٠٠ ٢٥ تت ٦ 0 ٦ ى | د ة ٦ 00 ن ١ 1 \ C 'ه</td>
<td>ب له لد مأ لا</td><td>لا لآى له Ï له نح لا</td><td>مد</td><td>Example 5AK</td>
<td>pyrazolyl- carboxamide</td><td>نكاً : ا ره لا</td><td>Example 11Β ا \</td><td>لكاً : ا له ω</td>
<td>له ب ي لد 0 ة لد W</td><td>مئ ٩</td><td>ممح هجي</td><td>ممح ج ٩</td>
<td></td><td>٠ لكا له Î له ة</td><td>٣١ لكا له بؤ له ω</td><td>٢٩ لكا له ا له نح لا</td>
ΜΑ 32201Β1
296 POl-2363-ff
<td>٦ ج ر مآ Η لكح لا</td><td>ع ها بي م غ ٢٩</td><td>ع ٠١ ج ها ج ٢٩</td><td>؟ ي ق ٢٩</td>
<td>ت ٠ ره دلج ة Î ع &</td><td>"I ٠ ل ٦ ته 0 (ص ا<sup>ة</sup> غ ٢٦ CO له 'بم ب ة</td><td>I " 0 X (ى } X تء ٢ ب ٢ ت ٠ Ό ٢٩ د ؤ " بخ ى</td><td>1. ي إب يتب 0 rl \ ة ٠ ء ٢٩ 33> له ١ ٦ م | ي ج d ب تع</td>
<td>هلآ له لفي W لا</td><td>مؤ ي</td><td>٠ مق _ ؛ Σ</td><td>" ١ ى ج له ω</td>
<td>pyrazol د- carboxamide</td><td>ffl ٣١ له t ده H</td><td>m ; î ره لا</td><td>ه : ا له ة</td>
<td>له M 5 ن ح لل W</td><td>ئثمئو ب ٦</td><td>مو</td><td>مج ٩</td>
<td></td><td>(Ï) لى له له ة</td><td>ب لكا له & ره ئ</td><td>لكا لى له بيع له X لا</td>
Μα 32201Β1
297 POl-2363-ff
<img file="MA32201B1_D0245.tif" />
ΜΑ 32201Β1
لا
<img file="MA32201B1_D0246.tif" />
298 POl-2363-ff
MA 32201 BI
299 POl-2363-ff
<img file="MA32201B1_D0247.tif" />
ΜΑ 32201Β1 ؛
300 POl-2363-ff
<img file="MA32201B1_D0248.tif" />
ΜΑ 32201Β1
POl-2363-ff
<img file="MA32201B1_D0249.tif" />
MA 32201 BI
302 POl-2363-ff
<td>NOT ر ٦٢٦ K H CO ئ</td><td>5 تي ق لن</td><td>يه m ب هج ف ٢١٠</td><td>303 (MtH) *</td>
<td>Tr [minutes]</td><td>ئ ه ٠ (tt ب Ό سماً 0 ، ع ٠١ 'tt) fi</td><td>ئ لح tt) ٠١ لآ œ 0 ع 00 0 ' ج</td><td>هل ١ لجم يب ة ع ة له ١ g</td>
<td>ب لة لد w لا</td><td>٠ ء ١ وتع</td><td>مجا 7</td><td>مع ض</td>
<td>يأن اق 1 ؛</td><td>لآ ٣١ لة i لة ج</td><td>لآ لة 1 له ة</td><td>لآ " Ï له ئ</td>
<td>structure I</td><td>ص ع</td><td>مع / ٠٩</td><td>ردؤ ح ;؛؛</td>
<td></td><td>00 لة لآم ج لة لة ياً٠ ة ا ن ج b fd ن H لة fd لة ١ X صخ ح لا</td><td>Example 74 mixed racemic</td><td>٦ ى ل 0 ٢١ ؤ ن رة ٠γ | ا 0 H ة ة Œ d <φ ج ن rl ن fd له ١ بط ة لا</td>
-MA 32201 BI
POl-2363-ff
<img file="MA32201B1_D0250.tif" />
32201Bl
304 POl-2363-ff
<td>SM (ESI, m / z)</td><td>ΐ تح ق لم</td><td>ى rf ب ها ق دم</td><td>? لة ق ليم</td>
<td>m له لا ة ؤ لمآ يع</td><td>7.10 (method 1Ε fusion)</td><td>5.97 (method 1Ε fusion)</td><td>4.73 (method 1Ε hydro)</td>
<td>هلأ له لا W ئ</td><td>ر</td><td>١٠ رج</td><td>١٣٥ ول</td>
<td>1 د g ي ة 0 I S ؛</td><td>١ ١ Example 11Ε !</td><td>لآ ١—٢ له له لا</td><td>Example 11Ε . . _I</td>
<td>له بز د υ بخ لا</td><td>ردؤ ؛ ب</td><td>مج ةب ٠</td><td>ز ٦ خ ٠١</td>
<td></td><td>Example 79 mixed racemic</td><td>Example 80 mixed racemic</td><td>Example 81 I Mix of stereo- isomers ١</td>
MA 32201 Bl
نتع ة
>1
لآ
Ό
نع
Ë
١٥
> ر
لا
ت
ة
ره
لا
ردع
لآ
٠١
ة
ياً
ة
لا
ج
لآ
1<
لا
ة
ء لا:
"ة
رثمتم
لا
اه 'β
له ه
ع
POl-2363-ff
لآ
1<
ء
لا
ؤ
ء (Ό
لا
>
ة
X
لآ:
ί ω
لا tm
ج ة
لعد ج '
ق
ثع "٠
I
5 ة
د
دلج
لا
ة '
M
<img file="MA32201B1_D0251.tif" />
32201Β1
306 POl-2363-ff
<img file="MA32201B1_D0252.tif" />
<img file="MA32201B1_D0253.tif" />
32201Β1
<img file="MA32201B1_D0254.tif" />
307 POl-2363-ff
<img file="MA32201B1_D0255.tif" />
My
32201Bl
<img file="MA32201B1_D0256.tif" />
ة 'g
Ε-Ι
308 POl-2363-ff
بيع
إه ïï ة
لا
لاً g
ع
U
<img file="MA32201B1_D0257.tif" />
<img file="MA32201B1_D0258.tif" />
مر
اه
<td>لام</td><td></td><td></td><td> ٠٩</td><td></td><td></td><td>١ ذ؟</td><td></td><td></td>
<td> ٠١</td><td></td><td>له</td><td> ٠٦</td><td></td><td>له</td><td>σ١</td><td></td><td>له</td>
<td></td><td></td><td>ي</td><td></td><td></td><td>د</td><td></td><td></td><td>د</td>
<td>له</td><td>له</td><td>σ</td><td>له</td><td>له</td><td></td><td>له</td><td>له</td><td>يرا</td>
<td>I</td><td> ٠١</td><td> ٢٩</td><td> ٩</td><td> ٠١</td><td> ٩</td><td> ٢٩</td><td> ٠١</td><td> ٠٩</td>
<td>(ه</td><td>تع</td><td>g</td><td>ئ</td><td>تع</td><td>g</td><td>ئ</td><td>تع</td><td>g</td>
<td> &</td><td>Irt</td><td>له ١</td><td>'g</td><td> ٠</td><td>له ١</td><td>g</td><td>rt</td><td>له ١</td>
<td> 0</td><td> ;</td><td>U</td><td>له</td><td> ٢٩</td><td>ن</td><td>له</td><td> ٩</td><td>ن</td>
<td>ب</td><td>له ١</td><td>fü</td><td>ب</td><td>له ١</td><td> ٠</td><td>يمج</td><td>له ١</td><td>rt</td>
<td>ئ</td><td>g</td><td>Μ</td><td>هآ</td><td>g</td><td></td><td>W</td><td>g</td><td> ٩</td>
<img file="MA32201B1_D0259.tif" />
MA 32201 BI
309 POl-2363-ff
<td>NOT ر . * ٦ لآ حكح م ١</td><td>? ة ج لا ٢</td><td>٥٩ ٠١ 00 5 OJ لج</td><td>ب ٠١ ة م</td>
<td>Tr [minutes]</td><td>0 ملآ 1 < ع لا ٠ ده م تآ 0 ء دب ن ١ ح ب</td><td>0 بلم Ό > 1 ع لا لمم ٩ ٩ م ده م ت ٦ 0 م دلج له ١ ح با</td><td>8.17 (IE hydro method)</td>
<td>بخ ده دلج ها لا</td><td>كم</td><td>هلأ</td><td>ب ه</td>
<td>ؤد ج ة ج 0 ؛؛</td><td>ئ ٢٩ له له لا</td><td>لا r) ٩ لا بؤ لا لا</td><td>لا " 1 لا X لآ</td>
<td>structure</td><td> , ٦</td><td>صي ة</td><td>ه ٠ م ٠ لا</td>
<td></td><td>Example 95 Mix of stereo- isomers</td><td>Example 96 mixed racemic</td><td>نه ١ ة ج وه ده ٢٠. لى بم ج ة بج ره ١ Ü) ح υ ٩ له ϋ) ره ١ κ بز ح لا</td>
<img file="MA32201B1_D0260.tif" />
32201BI
POl-2363-ff
<img file="MA32201B1_D0261.tif" />
<img file="MA32201B1_D0262.tif" />
32291Β1
POl-2363-ff
<td>SM (ESI, m / z)</td><td>ع ٠١ ب نباً ع ٢٩</td><td>η HH ΰ τ ج لم</td><td>ω ق</td>
<td>M له دلج د ة ج لا ئ &</td><td>0 بط لآ ح ع لا rl لى ده حم لآ 0 ع لا له ١ ح '٦</td><td>جثم 0 لآ 00 CM> 1 ع ٠ 00 متآ ٢٩ رلأ</td><td>Ο بلآ لا ع لأ ٠ لآ αο أاً 0 ع رفي لآ ' غ</td>
<td>بط له لا لكع لا</td><td>ئ ى ،</td><td>لا لكا له Î لآ X "</td><td>٠ ا at</td>
<td>pyrazolyl- carboxamide</td><td>متأ لا له له</td><td>لأ ٣١ له ا لآ X ئ</td><td>لا ب ٢ ٢١ له إه لا</td>
<td>له هلآ لا ن ة لا لكع</td><td>صني</td><td>ثم ، ١</td><td>ثم</td>
<td></td><td>Example 101 mixed racemic</td><td>٢٩ ده ه بج ن وه | ٠γ 0١ لم Η ة & ذة ١ له ح HU له له له ١ Κ لا ح لا</td><td>, 0 § بج ن ن لا ٠١ ي— Γ ة ة لا له ١ له ج υ لا له له ١ لا ح لا</td>
32201Β1
POl-2363-ff
<img file="MA32201B1_D0263.tif" />
<img file="MA32201B1_D0264.tif" />
32201Bl
POl-2363-ff
<img file="MA32201B1_D0265.tif" />
MY
32201Bl
314 POl-2363-ff
<td>٦ ج م خ ٦ لآ H ٦ لآ تآ</td><td>هب ٢٩ ي ت ج لثن</td><td>لب rl ب ٠١ ق لح</td><td>s! ï م s</td>
<td>Tr [minutes]</td><td>8.42 (IE hydro method)</td><td>7.15 (IE hydro method)</td><td>9.90 (method 2F)</td>
<td>Ester</td><td>٠ لأ ي</td><td>S موه Y</td><td>٠ و</td>
<td>pyrazolyl- carboxamide</td><td>Example 11Η</td><td>K هم * —J لا î لا ω</td><td>-1 Example 111</td>
<td>لا بلم 5 U بخ للي w</td><td>ردم اه</td><td>ريه ٠γ</td><td>٧ بر “Y</td>
<td></td><td>٩ م ن ي اج ن ع ٠ ن awa 'g لا ١ ΰ) تع É ن ίϋ Η لا ΰ) لا ١ X Μ اط ح للي لا</td><td>Example 114 trans; mixed racemic</td><td>Example 115 cis; mixed racemic</td>
MY
32201Bl
٠١
ي
<
لآ
لأ
له œ
ع
دفئ
<img file="MA32201B1_D0266.tif" />
ة
G
Ό> 1
تع
لآ
<img file="MA32201B1_D0267.tif" />
Ό
لا
لآ
POl-2363-ff
Ό
نع
لا
Ό
لا
لا
<img file="MA32201B1_D0268.tif" />
m
٩ م
<img file="MA32201B1_D0269.tif" />
<img file="MA32201B1_D0270.tif" />
<img file="MA32201B1_D0271.tif" />
<td></td><td>له</td><td></td><td></td><td>لا</td><td></td>
<td></td><td>σ '</td><td></td><td></td><td> ٠١</td><td></td>
<td>هت</td><td>تع</td><td></td><td>ج</td><td>ة</td><td></td>
<td> ٩</td><td>له</td><td></td><td>, —I</td><td>لا</td><td></td>
<td> ٩</td><td>Γ-Η</td><td>لا</td><td>laughed</td><td>laughed</td><td>لا</td>
<td></td><td></td><td>لذ</td><td></td><td>لاج</td><td>د</td>
<td>لا</td><td>ί</td><td>ب ٠</td><td>لا</td><td>ε</td><td>ب ٠</td>
<td> ٩</td><td></td><td> ٠٢٩</td><td> ٩</td><td></td><td>· Η</td>
<td>ة</td><td> .*٠</td><td>ε</td><td> 0،</td><td> ٠٠</td><td>ε</td>
<td>ε</td><td></td><td>لاج</td><td>g</td><td></td><td>لاج</td>
<td>لا</td><td>لكاً</td><td>ن</td><td>له</td><td>لكاً</td><td>υ</td>
<td>X</td><td>ه ٠٢</td><td>لا</td><td>X</td><td> ٩.</td><td>لام</td>
<td>ω</td><td> ٧</td><td>μ</td><td>لآ</td><td>ن</td><td>μ</td>
<td> 00</td><td></td><td></td><td></td><td> ٠١</td><td></td><td></td><td></td>
<td> ٢٩</td><td></td><td></td><td></td><td>AT</td><td></td><td></td><td></td>
<td> ٣٩</td><td></td><td></td><td>لا</td><td> ٢٩</td><td></td><td></td><td>لا</td>
<td></td><td></td><td></td><td>ى</td><td></td><td></td><td></td><td>لإ ٠</td>
<td>لا</td><td></td><td>لا</td><td>ب ٠</td><td>لا</td><td></td><td>لا</td><td>ب ٠</td>
<td>ا — ا</td><td></td><td> ٠١</td><td> ٠٢٩</td><td>ا — ا</td><td></td><td> 0٦</td><td>يم ٠</td>
<td>ئ</td><td>ظ.</td><td>ة</td><td>ε</td><td>ئ</td><td>ج ٠</td><td>ة</td><td>ε</td>
<td>e</td><td></td><td>لا</td><td>لاج</td><td>ε</td><td></td><td>لا</td><td>لاج</td>
<td>لا</td><td>لكح</td><td> ٢٩</td><td> 0</td><td>لا</td><td>لكاً</td><td> ٢٩</td><td>U</td>
<td>X</td><td>Ή</td><td>لا ١</td><td>لا</td><td>X</td><td></td><td>لاج</td><td>لام</td>
<td>W</td><td>ن</td><td>ε</td><td>μ</td><td>مأ</td><td>U</td><td>ε</td><td>هلآ</td>
32201Β1
316 POl-2363-ff
<td>SM (ESI, m / z)</td><td>ته م ؛ م</td><td>ب o ي LD ة م</td><td>ب لاع ± ب ق Γ0</td>
<td>Tr [minutes]</td><td>0 p > 1 ع ٩ م W <η rl ن دم TJ ο ء ρ له ١ Η ٧</td><td>9.91 (method 2F)</td><td>6.95 (method 2F)</td>
<td>Ester</td><td>ح</td><td>۶ at</td><td>لآم</td>
<td> ؛ ؛؛</td><td>Η ٢١ ٣٩ له ة إه ω</td><td>H rl له ا له ة</td><td>لأ ة " إه لا</td>
<td>له p لآ p U p p w</td><td>ص لآه</td><td>ده i</td><td>مو ا ٠</td>
<td></td><td>Example 120 cis; mixed racemic</td><td>لام له rl ج D ن rl الح (r ة ٠ ج ن ١ ΰ> ج لا rl لئ له لآ له ١ tt .rl P ج U ثئ</td><td>Example 122 mixed racemate</td>
<img file="MA32201B1_D0272.tif" />
32201Β1
POl-2363-ff
<td>SM (ESI, m / z)</td><td>ته لام ق م</td><td>" ة 00 ٠١ لام</td><td>ة ق ** لى ٠١ زمم</td>
<td>ü) له لؤ تع ج ' Ι -— I ى ب</td><td>ل Ol O " ١ ة ب ته ن 'دن ا ٩ ة</td><td>ة M ة ع 00 W بم ٠٦ ن ص Ό 0 تع لز '(L) Ë</td><td>0 بز ل ٦ لا تع لا OJ 00 Φ ت ٦ 0 تع ل * ن ' ج</td>
<td>بر له لم مل حآ</td><td> ٠٦٥</td><td> ٠٩'</td><td>لا لكا له Ï ن X ئ</td>
<td>دد ج أ ؛</td><td>٩ بم له له * ا لا</td><td>هاً ه ٣ له Î ن لا</td><td>" : ة ره مآ</td>
<td>له ب دب U ة دب للا</td><td>مح ا ٠</td><td>ص ٠١</td><td>مم</td>
<td></td><td>تاً له ا له ق</td><td>Example 124 mixed racemate</td><td>١ ى بم H له بؤ له ئ</td>
MY
32201Bl
POl-2363-ff
<img file="MA32201B1_D0273.tif" />
MY
32201Bl
319 POl-2363-ff
<img file="MA32201B1_D0274.tif" />
MA 32201 Bl
POl-2363-ff
<img file="MA32201B1_D0275.tif" />
MA 32201Β1
POl-2363-ff
<img file="MA32201B1_D0276.tif" />
<img file="MA32201B1_D0277.tif" />
MA 32201 Bl
ني
<td>SM (ESI, m / z)</td><td>Κ ؛ لاى CM</td><td>K ؛ 00 in</td><td>ج ٢١ ٠٦ لاع</td>
<td>Tr [minutes]</td><td>0 بلم TJ > 1 لا لا لاى وه ر ٢ b 0 ع للج ن ١ ج</td><td>٨ ο بلم TJ لا لا 00 بم ها نم ٦ لا 0 تعم لز ن ١ ح ٧</td><td>9.23 (method 2F)</td>
<td>M له دلج لكاً لا</td><td>ه ١٠</td><td>لايي</td><td> ٩</td>
<td>s اة I 5 ة</td><td>> هع له ا له ق</td><td>> ها ن عتع ن W</td><td>m i ن لا</td>
<td>له بلم د لد U ة لد مآ</td><td>ردمتو</td><td> -</td><td>لص ٩</td>
<td></td><td>Example 132-6 Enantiomer B</td><td>Example 132-7 Enantiomer B</td><td>Example 132-8 trans, mixed racemigue</td>
322 POl-2363-ff
MA 32201 Bl
POl-2363-ff
<td>ض . * هآ H ماً م ٦</td><td>" ق لى مم</td>
<td>Tr [minutes] ا ١</td><td>8.83 (2L method)</td>
<td>Μ له لد لى لا</td><td></td>
<td>: ٠ غ 3 ة 1 ة</td><td>Example 15Α</td>
<td>له بز ة لا دب لى</td><td>مع هغي ٠</td>
<td></td><td>ه <σ لآ لن بز Π له 'rf 0 ن دفي ئلآ ة E 0) لآ ة X لا لا</td>
<img file="MA32201B1_D0278.tif" />
ΜΑ 32201Β1
1 (tt ahydro-py an-4-yl) -1,5-dihydropyrazolo [3,4-d] pyrimidin-4-one
324
POl-2363-ff
Example 133
<img file="MA32201B1_D0279.tif" />
Example 11Β (0.1 g, 0.48 mmol) was mixed with
Polyphosphoric acid (1.0 g) and 2- (trifluoro methoxy) phenylacetic acid (248 mg, 1.9 mmol) were added. The mixture was heated at 120 ٠c for 16 hours. The temperature was lowered to 20 ° C and the pH value was adjusted to 7 by adding ammonia (30% solution in water). The aqueous phase was extracted with dichloromethane (2 X 20 ml) and the organic phase was dried over sodium sulfate. The crude mixture was purified by flash chromatography. Eluent: hexane / ethyl acetate 40/60.
23.5 mg (16%) was obtained as a white solid.
HPLC-MS (1Ε) Tr: 6.77 minutes.
MS (APCI pos): m / z = 305 (M + H) ٠.
The following examples were synthesized by analogy with the preparation of Example 133, using the corresponding carboxylic acids as starting compounds.
ΜΑ 32201Β1
POl-2363-ff
<img file="MA32201B1_D0280.tif" />
ΜΑ 32201Β1
326 POl-2363-ff
<td>MS (ESI, m / z)</td><td>لآ ٦ م ي دكاً 5 م</td><td>ب ٦ د ١ ي ٠١ ع لم</td><td>ع ٠١ CM + ع ١ م</td>
<td>Tr [minutes]</td><td>W له 00 وآ ٦٣ 0 ٠٠ جد ١٠۵ له ١ g ب</td><td>ω لآ ل ٢١ اً حآ 0 ج ع ها لآ ' g ب</td><td>ل HOK اح ة ٦ 00 ن ١ له ا</td>
<td>starting compound</td><td>مدز رم:</td><td>هلق ه</td><td>١٦٦٣٥ رج</td>
<td>له بلخ 3- ن د بلخ للي لأكأ</td><td>اير ٠٥</td><td>ئه ١ ي ٠</td><td>٥٢۶٠ مي</td>
<td></td><td>Example 137</td><td>00 زم ٣٩ له له ة</td><td>Example 139</td>
<img file="MA32201B1_D0281.tif" />
MA 32201 Bl
P0i-2363-ff
<td>هج H لماً لا ة co</td><td>ع ٠١ ي CM ج ٩ م</td><td>ع ٠١ ب CM ة م</td><td>Ï ؛ ذم</td>
<td>Tr [minutes]</td><td>8 " -Μ هم بت► 0 ٢١ ί Ν 00 وها â, ن بز ى</td><td>"8 لآ" O 0 لا O, ا 2 ؤ CMI Ό ® S, لا له بط ى</td><td>٠٠ ب وحم لا Q ٢١ \ رخك ٠ O CO زه ١ ٩ م اة ؤ S O</td>
<td>starting compound</td><td>ه ٣ ة ؤ</td><td>هلاق</td><td>متأ د؟</td>
<td>structure</td><td>متى.</td><td>نور ا</td><td>نوو لاه</td>
<td></td><td>٠ ب ٩ ٣١ له i له ω</td><td>لل ٠ بم له Ï له لا</td><td>له ٢۴ ٢٩ له " له ة</td>
ΜΑ 32201Β1
POl-2363-ff
<td>MS (ESI, m / z)</td><td>X جح ج ١ ء</td><td>م ٩</td>
<td>Tr [minutes]</td><td>"I ٠ راً rf 0 X ٦ ة ٦ ده ن ١ لجم غ ج (Ü M ى</td><td>1 " X لآ ٠٥ ، تة ي لام 00 لالا ٦ م , ن ج (ύ لأ ى</td>
<td>starting compound</td><td>نص 1</td><td>هم ١ ق</td>
<td>ن إلم رب υ ح لفي tfl</td><td>0 ل'د ٠ ج</td><td>٠ له ٦ ي ٠ م</td>
<td></td><td>Example 143</td><td>Example 144 I ١ ا</td>
MA 32201 BI
Example 145, racemic mixture
329 POl-2363-ff
<img file="MA32201B1_D0282.tif" />
106 mg (0.47 mmol) of Example 12V were mixed with ml of ethyl acetate and 0.5 ml of dimethylformamide, then 51 mg (0.61 mmol) of 3,4-dihydro-2H-pyrane and 88.4 mg (0.51 mmol) إ of p-toluenesulfonic acid was added. The reaction mixture was heated to 60 ° C and stirred for 2 hours. After cooling to room temperature, ethyl acetate was added and the mixture was washed with saturated sodium hydrogencarbonate and with saturated sodium chloride. The organic phase was evaporated under reduced pressure. The residue was purified by preparative HPLC-MS. 31.5 mg ؛ (21.7%) were obtained.
MS (APCI pos): m / z = 312 (MtH) '.
HPLC-MS (2F method) Rr: 8.26 minutes.
The following examples were synthesized by analogy with the preparation of Example 145, using corresponding pyrazolopyrimidinones as starting compounds.
<img file="MA32201B1_D0283.tif" />
ΜΑ 32201Β1
POl-2363-ff
<td>MS (ESI, m / z)</td><td>K ί s</td><td>X ؛ 00 ٠ oo</td><td>" ج - - 00 ٠ 00</td>
<td>Tr [minutes]</td><td>ء لن <η ن in p K 0 in ع ة '</td><td>10.98 (method 2F)</td><td>ئ ل ٢١١ أل ة S لد H له ١ ح</td>
<td>starting compound</td><td>Example 12W</td><td>Example 1</td><td>Example 12Υ I I ١ _I</td>
<td>له بز B 0 تاً صل لد w</td><td>مع > ٠</td><td>زمتم V</td><td>مج لا</td>
<td></td><td>Example 146 racemic mixture</td><td>Example 147 racemic mixture</td><td>Example 147-1 racemic mixture . _I</td>
<img file="MA32201B1_D0284.tif" />
32201Β1
POl-2363-ff
<img file="MA32201B1_D0285.tif" />
MY
32201Bl
332 POl-2363-ff
Example 148
<img file="MA32201B1_D0286.tif" />
160 mg (470 mmol) of Example 12Ε was dissolved in ml of methanol and 350 mg of Raney nickel was added. The reaction mixture was hydrogenated at room temperature for 6 hours, filtered and the solvent was evaporated under reduced pressure. ؛
100 mg (65%) of the product were obtained.
HPLC-MS (method 1): Rr: 0.95 minutes.
MS (ESI pos): m / z = 324 (MtH).
The following examples have been synthesized by analogy with ؛ the preparation of Example 148, using corresponding N-oxides as starting compounds.
<img file="MA32201B1_D0287.tif" />
32201Bl
333 POl-2363-ff
<td>; يلآ H ، ١ ئأ لا ة هآ</td><td>نلج at هع ٢٩ ٢٩</td><td>K ق 00 ٠ r؟</td>
<td>Tr [minutes] .</td><td>0.95 (method 1)</td><td>1.11 (method 1)</td>
<td>starting compound</td><td>. Example 12D</td><td>Example 12F</td>
<td>لا μ أتم U د μ دب w</td><td>٦ مك ؛</td><td> '۶٢٠ ...</td>
<td></td><td>Example 149</td><td>Example 150 I ا ١</td>
MY
32201Β1
334 POl-2363-ff
Example 151
<img file="MA32201B1_D0288.tif" />
62 mg (150 mmol) of Example 13Β were dissolved in 4 ml of dichloromethane, then 22.5 µl (300 mmol) of acetyl chloride and 42 µl (300 mmol) of triethylamine were added. The reaction mixture was stirred at room temperature overnight. ي
The solvent was removed under reduced pressure. The residue was purified by preparative HPLC (eluent A: water t 0.13% TFA, eluent B: acetonitrile). 28 mg (55%) of the product was obtained.
HPLC-MS (method 1): Tr: 1.18 minutes. ؛
MS (ESI pos): m / z = 344 (M + H) ٠.
The following examples were synthesized by analogy with the preparation of Example 151, using the corresponding starting compounds. It will be obvious that acetyl chloride has been introduced as an acylating agent, but not for all the compounds, and other acylating agents such as a methoxychloroformate, a substituted or non-substituted aminocarbonyl chloride, a phenoxycarbonyl chloride substituted or not ؛ substitute, a substituted or unsubstituted benzoyl chloride, available commercially, have been used.
<img file="MA32201B1_D0289.tif" />
32291BI
335 POl-2363-ff
<img file="MA32201B1_D0290.tif" />
<img file="MA32201B1_D0291.tif" />
32291BI
336 POl-2363-ff
<img file="MA32201B1_D0292.tif" />
MA 32201 Bl
وه
<td>تاً هم ج هاً ١٢١ لكح ئ</td><td>K i ٥ م</td><td>" ؛ لمم <η</td><td>" ة رع ١ لاى ها ا 3 ؛ ٠</td>
<td>Tr [minutes]</td><td>if يي ١ ج</td><td>if ة د له ١ Ë</td><td>S ؤ</td>
<td>starting compound</td><td>at ٠٦ ٣١ d) î لآ w</td><td>٧ هم AT له Ï له ق</td><td>ح ٦ هاً له i له ج</td>
<td>structure</td><td>١ ل ٠٢ ص ٠٥</td><td>\ ل ٠٢ لآور ع</td><td>\ له ٠٢ همتم ٠٥ وثد</td>
<td></td><td>ده σ ج ٠ له ١ ن σ١ m لاى بد ا-ا له له ٠٦ بم ء ه ٠ له ئ ب له له ١ X M e</td><td>Example 160 racemic mixture</td><td>ا ؛ 16 Example racemic mixture</td>
337 POl-2363-ff
MY
32201Bl
338 POl-2363-ff
<td>SM (ESI, m / z)</td><td>K ع ٠ ٦٣</td><td>K s oo ٠١ ٦٣</td><td>K ج ٧ لام لام</td>
<td>\ I Tr [minutes] ١</td><td>1.62 (method 1) \</td><td>1.48 (method 1)</td><td>؛ ج ث</td>
<td>starting compound</td><td>u ٢١٦ AT لا & لا w</td><td>لا لمم ٢٠٩ لا î لا ة</td><td>وع (Ï) لا Î لا ة</td>
<td>لا 5 u 3 لفي w</td><td>“٥٢٥٠٠ هدور</td><td>م ٠ مبج ١ • II</td><td>د٢٠'تم ز</td>
<td></td><td>Example 162 racemic mixture</td><td>Example 163 racemic mixture</td><td>لا بج ح ٠ لا ١ ن ٦٣ لاًك عا d M لا لا d ٠١ ثاً لآ d لا لا ١ X β لا</td>
MY
32201BI
339 POl-2363-ff
<td>NOT ر k ت تأ H لكح ئ</td><td>K X ٠ ٢٣١ م</td><td>لآ ة ٧ ٠ ٠ ٣۴</td>
<td>لى ده لل ة e • · ته بأ</td><td>ت له ١ ؤ</td><td>I- I 1.28 (method 1)</td>
<td>starting compound</td><td>> ٢١٦ ٢١ له Î لا X ω</td><td>Example 13F .</td>
<td>له الم د دفي 0 M دفي لى</td><td>ثمي ع</td><td>مؤ ٥٥٩</td>
<td></td><td>Example 165 racemic mixture</td><td>Example 166 racemic mixture</td>
MA 32201 BI
340 POl-2363-ff
<td>NOT ر K لكآ H لس لا</td><td>" ί لخم ٠١ (نمم</td><td>K ة ب 00 ها لم</td>
<td>Tr [minutes]</td><td>1.36 (method 1)</td><td>1.1 (method 1)</td>
<td>starting compound</td><td>ا Example 13Α</td><td>- Example 13Η . ا ا I</td>
<td>له بلم 5 U ة لد w</td><td>لآمع ع</td><td>// ا</td>
<td></td><td>له ي g له ١ υ ٢٠٠ rt حكآ بر rl له له rl ٠١ ء ج H له له ١: < ج لا</td><td>Example 168 racemic mixture</td>
<img file="MA32201B1_D0293.tif" />
32201Β1
341 POl-2363-ff
<td>NOT هم ο ٠ ، ١٩ لكح لا</td><td>X g بلا co الا</td><td>1 ٠ ٢٩ ب</td>
<td>. Tr [minutes] . .</td><td>(method 1)</td><td>٢٩ ام ي ة</td>
<td>starting compound</td><td>Example 13G</td><td>Example 13Η</td>
<td>له ها لآ p U p p w</td><td>هعمبج</td><td>لآ</td>
<td></td><td>Example 169 racemic mixture</td><td>Example 170 racemic mixture</td>
<img file="MA32201B1_D0294.tif" />
32201BI
342 POl-2363-ff
<td>مج ر co ٠ ، H co ئ</td><td>K ق ٧ GO ٩ لآ</td><td>ج ب 00 م م</td>
<td>Tr [minutes]</td><td>if له ١ ة يا</td><td>٣٩ اة ع د له ١ ج</td>
<td>starting compound</td><td>Example 131</td><td>Example 13F ا</td>
<td>ن M د لل υ ة لد σι</td><td>هريتم ه</td><td>تدجو ادت</td>
<td></td><td>له 3 σ ج ٠ له ١ ن I— ا fd ٢١ بد بأ له له 1—1 σ١ ء هفاً fd ج يم له له ١ X خ W</td><td>Example 172 racemic mixture</td>
ΜΑ 32201Β1
343 POl-2363-ff
<td>تاً ر ج لى H لى مآ</td><td>ة ب ها 00 00</td><td>K ع οο ب ٩١</td>
<td>Tr [minutes]</td><td>ه ي ع 1</td><td>1.44 (method 1)</td>
<td>starting compound</td><td>I Example 13Μ I ا</td><td>S οο H له ة له X W</td>
<td>له صل s ن صل لب م ٦</td><td>Y مز. ".1</td><td>تمه مز .٥ طا لما</td>
<td></td><td>Example 173 Mix of stereoisomers</td><td>لى له له '٩ ح له ٢٠٠ d Τ5 0 تن. وه ل 0 0 ٠١ rl له ١ تع به بإ C) غ له ١ ب له دب ن 'X ω s W</td>
<img file="MA32201B1_D0295.tif" />
MA 32201 Bl
344 POl-2363-ff
<td>; ض . * هآ H ١ لآ لا</td><td>K ق ب لكا ٢١</td><td>K ؛ ٩ م لكا لمم</td>
<td>له دي VS ؤ ى ب</td><td>I 1.04 (method 1)</td><td>0.84 (method 1)</td>
<td>ا starting compound ا ١</td><td>Example 13Ν</td><td>Example 13Ν</td>
<td>له d ح U ة لفي ل ٧</td><td>0٢٥ مبج ٠ ه</td><td></td>
<td></td><td>Example 175 racemic mixture</td><td>Example 176 racemigue mix</td>
MA 32201 Bl
345 POl-2363-ff
<td>هج مئ w K H لكح ω</td><td>K ج ٠ CO لم</td><td>æ ة ب CO لى</td>
<td>I- Tr [minutes] I</td><td>اي دب ن لآ ' ε ب</td><td>ل ؤ</td>
<td>1- starting compound</td><td>Ο لم ٢٩ لآ & لا ة</td><td>هدآ لم لا & لا ق</td>
<td>ن ب 3 u ة للي لكاً</td><td>Ογ٠ متم دب</td><td>ب 0 مثر ٩ρ</td>
<td></td><td>لا ج ح ٠ لا ١ 0 ٢١ Π5 م يز يم لا لا 0٦ يم تع ؤ ل ٩ ج بم لا لا ١ X ε لا</td><td>لا ج ٩ ' ح لا ١ 00 υ ίϋ ٢١ بز ب لا لا Η ٥١ تع لمع ίΰ ح Η لآ لآ 'يح ω ε</td>
<img file="MA32201B1_D0296.tif" />
ΜΑ 32201Β1
346 POl-2363-ff
<img file="MA32201B1_D0297.tif" />
MA 32201 Bl
347 POl-2363-ff
<td>; ر . * حكآ H لمئاً م ٦</td><td>لا ع ل ١ م in لام</td><td>K ί r؟ rl ب</td>
<td>Tr [minutes] I .</td><td>1.34 (method 1) I</td><td>s إ</td>
<td>starting compound 1</td><td>vs# لام ٢١ 0) m ة</td><td>Example 13D</td>
<td>ن M تن لد U ة لد to</td><td>متم ع</td><td>٥٣٠ مم i</td>
<td></td><td>Example 181 racemic mixture</td><td>Example 182 racemic mixture</td>
ΜΑ 32201Β1
لآ
<td>NOT ر ج حآ H لكع لا</td><td>ج ج ٧ ها ٠ ي</td><td>لا ί ٠ CM ي</td>
<td>Tr [minutes]</td><td>ق ي ٧</td><td>1.30 (method 1)</td>
<td>starting compound</td><td>I I Example 13C</td><td>Example 205</td>
<td>له لا ق U ة لز لكع</td><td>بن متو [></td><td>٧٠ متم</td>
<td></td><td>Example 183 racemic mixture</td><td>Example 184 racemic mixture</td>
348 POl-2363-ff
ΜΑ 32201Β1
349 POl-2363-ff
<td>Μ ر ٠٠ ها Η W W</td><td>" ة ٧ 00 ماً ي</td><td>K 1 CN CO ماً</td>
<td>Tr [minutes]</td><td>1.53 (method 1)</td><td>sj ص ١</td>
<td>starting compound ا</td><td>Example 13D ا ί .</td><td>Example 204</td>
<td>لا بخ 5 U H للي w</td><td>٥٢o {l رده Y</td><td>٠٨٠٥ لأ ٠</td>
<td></td><td>Example 185 racemic mixture</td><td>لا ؤ g لا ١ υ هع οο (ΰ بخ با لا لا ٠١ ب ٢ ة هداً ε Η ن 0 'X ε لا</td>
MA 32201 Bl
350 POl-2363-ff
<td>; ر . * ٢٦ آ H لكع ملآ</td><td>Sd ق ح ٠ لا ٠ م</td><td>" £ هما عا ٩ م لا</td>
<td>م ١ لا ج ة ج - ' ى هج</td><td>؛ 5 ن ' ح هم ١٠</td><td>1.29 (method 1)</td>
<td>starting compound</td><td>٦۴ ٠ ٢٩ لا & لؤ ω</td><td>Example 13Ε . ١ ؛</td>
<td>لا μ د لل υ μ دفي لكاً</td><td>متم اه</td><td>ج</td>
<td></td><td>لا ج ج لاج دع ٢١ لا 00 μ ا — ا لا لا ٠٦ ب ٠ ثاً هثاً لا ة بم لا لا ١ X g لا</td><td>Example 188 racemic mixture</td>
<img file="MA32201B1_D0298.tif" />
32201BI
351 POl-2363-ff
<td>; ر ١٠ ٦ ل ٦ H هآ W</td><td>κ ج ص —٠٠ 00 ه ٢ ٦ م</td><td>¥ ج ة <η</td>
<td>Tr [minutes]</td><td>I 1.08 (method 1)</td><td>1.18 (method 1)</td>
<td>starting compound</td><td>O ٦ م لهم & ن ق</td><td>Example 13F</td>
<td>له M 3 U 3 M دلج مآ</td><td>۴ مثو ة</td><td>ثمتم ١</td>
<td></td><td>Example 189 racemic mixture</td><td>Example 190 racemic mixture ا</td>
<img file="MA32201B1_D0299.tif" />
MA 32201 Bl
352
POl-2363-ff
Example 191, racemic mixture
O
<img file="MA32201B1_D0300.tif" />
60 mg (0.2 mmol) of Example 13c was dissolved in 5 ml of xylene and 57 mg (0.2 mmol) of 2,2,2-trifluoroethyl trichloromethanesulfonate was added dropwise. The reaction mixture was heated to 140 ٠c and stirred for 5 hours. The solvent was removed under reduced pressure. The residue was purified by preparative HPLC (eluent A: water 0.13 ا% TFA, eluent B: acetonitrile). 24.8 mg (32%) of the product was obtained.
HPLC-MS (method 1): Rp: 1.45 minutes.
MS (ESI pos): m / z = 384 (Μ + Η) '.
The following examples were synthesized by analogy with the preparation of Example 191, using the corresponding starting compounds.
ΜΑ 32201Β1
353 POl-2363-ff
<img file="MA32201B1_D0301.tif" />
MY
32201Β1
354
POl-2363-ff
Example 194, racemic mixture
<img file="MA32201B1_D0302.tif" />
400 mg (1.35 mmol) of example 11Α were dissolved in ml of absolute ethanol, then 840 mg (5.4 mmol) of example 5AC and 220 mg (5.5 mmol) of sodium hydride (60% suspension in mineral oil) were added. The reaction mixture was heated to 150 ٠c for 30 minutes in a microwave oven. إ
After cooling to room temperature, the reaction mixture was acidified with 4 N hydrochloric acid. The solvent was removed under reduced pressure. The residue was إ, purified by preparative HPLC (eluent A: water 0.13 ا% TFA, \ eluent B: acetonitrile). 250 mg (46%) of the product was obtained in the form of a white solid. إ
HPLC-MS (method 1): Rr: 0.93 minutes.
MS (ESI pos): m / z = 288 (MtH) '.
<img file="MA32201B1_D0303.tif" />
MA 32201Β1
355
POl-2363-ff
Example 195
<img file="MA32201B1_D0304.tif" />
330 mg (0.82 mmol) of Example 12Α was dissolved in ml of dichloromethane and 1 ml of trifluoroacetic acid was added. The reaction mixture was stirred at room temperature overnight. The solvent was evaporated under reduced pressure. The residue was purified by preparative HPLC (eluent A: water ا
0.13% TFA, eluent B: acetonitrile). 240 mg (70%) of the product was obtained.
HPLC-MS (method 1): Rr: 0.96 minutes.
MS (ESI pos): m / z = 302 (MtH) *.
The following examples were synthesized by analogy with the preparation of Example 195, using the corresponding Boc protected amines as starting compounds.
<img file="MA32201B1_D0305.tif" />
MA 32201 bi
356 POl-2363-ff
<td>MS (ESI, m / z)</td><td>X ؛ لام ٠ ٢٩</td><td>X ة / لآ ٠ ٩ م</td>
<td>Tr [minutes]</td><td>H يه د لآه 5 د 1</td><td> ؛5</td>
<td>starting compound</td><td>م ١ لام له i Œ) X ئ</td><td>X لام له له W</td>
<td>له p لآ p ن لآ p p لن</td><td>إه</td><td></td>
<td></td><td>Example 196 racemic mixture</td><td>له لآ م ٠ 'P ح له ١ ٢١ υ ٠١ ίΰ rl P له له H ٠١ ئاً ج لآ ج ا-ا له له ١ X ة لا</td>
MY
32201Β1
357 POl-2363-ff
<td>ى ق ٦٣ ٠١ لآم</td><td>K ه ها σ١ لن</td>
<td>if غ ٢٣ (0 ' ج ملآ</td><td>0.92 (method 1)</td>
<td>ة فين ٣١ له ة لآ X W</td><td>Example 12G</td>
<td>'' خ- '</td><td>ج</td>
<td>Example 198 racemic mixture</td><td>Example 199 racemic melanqe</td>
<img file="MA32201B1_D0306.tif" />
MY
32201Β1
كا
<td>ÜJ ί ٠ 00 <η</td><td>ع ة ص ١ لخ</td>
<td>لا رأ ٠٦</td><td>0.89 (method 1)</td>
<td>ا Example 12Η !</td><td>١ I Example 12 ل</td>
<td>ي ٠</td><td>حي</td>
<td>Example 200 racemic mixture</td><td>Example 201 racemic mixture</td>
358 POl-2363-ff
<img file="MA32201B1_D0307.tif" />
32201Β1
359 POl-2363-ff
<td>لآ ة ٠ بم</td><td>لآ ل ٢ ء لم</td>
<td>\ I \ I \ \ 0.92 (method 1)</td><td>1.07 (method 1)</td>
<td>QC عب له بج ع ١</td><td>I- أ Example 12C \</td>
<td>-٦ لإب</td><td> ..:.'5</td>
<td>Example 202</td><td>Example 203</td>
MA 32201 Bl
360 POl-2363-ff
<td>X ق 00 لام ٩ م</td><td>ع ق CD ٩ م</td>
<td>0.95 (method 1) ١</td><td>1.13 (method 1) ١ ا I ا</td>
<td>ل ٠ لام بم لة ا دج W</td><td>I --- I \ \ Example 12R</td>
<td></td><td>..: · ..اً</td>
<td>لة ٠١ ٠ε , ١α r U؟ rt ٠ M لام له له ٠٦ H C ج rt ح بم له له ١ X g لآ</td><td>له ٠١ ح له ١ υ ٦ لا m ٠ بذ لام له له H ٠١ هه rt ح H له له ١ X ح W</td>
MY
32201Β1
361 POl-2363-ff
<img file="MA32201B1_D0308.tif" />
ΜΑ 32201Β1
362 POl-2363-ff
Example 207, racemic mixture
<img file="MA32201B1_D0309.tif" />
50 mq (120 mmol) of Example 13Α were dissolved in 5 ml of dichloromethane and 15 mg (500 mmol) of formaldehyde were added. The reaction mixture was stirred at room temperature for 1 hour. 15 µl (260 mmol) of acetic acid and 35 mg (160 mmol) of sodium triacetoxyborohydride were added. The reaction mixture was stirred for 2 hours at room temperature. The solvent was removed under reduced pressure. The residue was purified by preparative HPLC (eluent A: water + 0.13% TFA, eluent B: acetonitrile). 34 mg (65%) of the product was obtained.
HPLC-MS (method 1): Rp: 0.99 min.
MS (ESI pos): m / z = 302 (M + H) ٠.
The following examples were synthesized by analogy with the preparation of Example 207 using the corresponding amines as starting compounds.
MA 32201 Bl
363 POl-2363-ff
<td>مج لآ H ١ تآ لا S m</td><td>" È هلم laughed هم</td><td>ق لكاً ٠ ب</td>
<td>Tr [minutes]</td><td>٢ ١ ا 1.02 (method 1) \</td><td>ؤ ة</td>
<td>starting compound</td><td>راً هم له Ï ن لا</td><td>Example 13Ε I</td>
<td>له بز ي ن ة لا (0</td><td></td><td> ;</td>
<td></td><td>له ج ح ٠ له ١ داً ته d ٠ بز ل ١ م له له r — I ٠١ ة بثع rt ج بم له له- X ج "</td><td>Example 209 racemic mixture</td>
<img file="MA32201B1_D0310.tif" />
32201Bl
364 POl-2363-ff
<td>NOT لآ H٠ حكح Μ تة مآ</td><td>K ة ر_ا ١ ٠ ٩ m</td><td>X ج ب لا σι م</td>
<td>Tr [minutes]</td><td>if وف ح ٧</td><td>I- 1.11 (method 1)</td>
<td>starting compound</td><td>Example 13F .</td><td>I- ί . . : Example 13G . .</td>
<td>ن μ ص ن μ دفي ω</td><td><sup>ئ</sup>ةه</td><td>ح ؛</td>
<td></td><td>لا بج ج لاج ن ٠ لا ي ٢ eq μ لا لا ٠١ بم ء ع 0 g H لآ لآ 'X ج لا</td><td>Example 211 racemic mixture</td>
MY
32201BI
365 POl-2363-ff
<td>H ٦ لآ ω ة co</td><td> « ٠ ٢٣ 00</td><td>X r؟ ٢٣ co</td>
<td>w له لد ة ج لا كه ب</td><td>0.98 (method 1)</td><td>1.02 (method 1)</td>
<td>starting compound</td><td>Example 13Η</td><td>Example 13J</td>
<td>له ب 3 لد ن ح لد 0)</td><td>هه</td><td>ييب</td>
<td></td><td>Example 212 Jnèllrlyr- lyçÎr.Lçuc</td><td>w (L) له 'co ح له rl d Q ل ٢١ مأ H. له له 0 ٠١ H لآ 'a ة ب d) ح ده ١ H ده لد له ١ X لكأ تج W</td>
MY
32201BI
366 POl-2363-ff
<td>NOT لكآ لا ة لكآ</td><td>æ ف CO QO CN</td><td>X ة رلآ بأ ل ٢١ لم</td>
<td>للا له لد ثآ at H ج ته يج</td><td>ل غ '٠ '41 e ٧</td><td>ؤ ج</td>
<td>starting compound</td><td>١ م ١ لم ٣١ له Ï له ω</td><td>Q (م ٣٩ زعم & له W</td>
<td>له بل ق 0 ة لد للا</td><td>تثم ٠</td><td>اً</td>
<td></td><td>Example 214 . Îaf.j</td><td>له & ج له ١ دآ ١ كا rt ا r بلم لام له له ٠١ ب بى نه له ١ X ح ئ</td>
MA 32201 Bl
367 POl-2363-ff
<img file="MA32201B1_D0311.tif" />
MY
32291Β1
368 POl-2363-ff
Example 219
<img file="MA32201B1_D0312.tif" />
Under an argon atmosphere, 100 mg (0.26 mmol) of Example 5, 95 mg (0.77 mmol) of pyridine-3-boronic acid, 310 μΐ (2.41 mmol) of a solution aqueous sodium carbonate (2 M), ml dioxane and mg (0.02 mmol) tetrakis (triphenylphosphine) palladium (0) were combined. The reaction mixture was heated at 140 ٥c for 35 minutes in a microwave oven. After cooling to room temperature, the reaction mixture was filtered through celite. The filtrate was evaporated under reduced pressure. The residue was purified by preparative HPLC. 82 mg (83%) of the product was obtained.
HPLC-MS (method 1); Tr: 1.00 minutes.
MS (ESI pos): m / z = 388 (MtH) '.
The following examples were synthesized by analogy with the preparation of Example 219 using corresponding boronic acids as starting compounds.
32201Β1
بي read
خ
CM
ئ σι
<td>MS (ESI, m / z)</td><td>ج ٠ ج ثميلآ 00 ي</td><td>K ج م ٩ r؟</td>
<td>Tr [minutes]</td><td>ا 1.01 (method 1) 1 \</td><td>1.24 (method 1) ١</td>
<td>starting compound</td><td>م - o — CQ رج</td><td>لم ٠ ؤ</td>
<td>ن ب لد U ة لد w</td><td>ب ؛</td><td>نجو ا بم</td>
<td></td><td>Example 220</td><td>٢ — t ٢٩ لام ن ί ن ب حلأ</td>
MY
32201Bl
ا
POl-2363-ff
<td>MS (ESI, m / z)</td><td>ع ٦ ة لام ا— f ب ١</td><td>K ة ص ١ ه ٢ ٦٣</td>
<td>W له دلج ة ٠٣٩ ج تلع</td><td>1.34 (method 1)</td><td>1.03 (method 1) I</td>
<td>starting compound</td><td>يمر</td><td>نموث</td>
<td>structure</td><td>حلن مخب كنج</td><td>مؤ ه</td>
<td></td><td>Example 222</td><td>Example 223 . . I .</td>
ΜΑ 32201Β1
وجا
<td>MS (ESI, m / z)</td><td>" ق ٠٠٠٠٠٠٠ 00 00 حمم</td><td>K ة ب 00 I— ا مأ</td><td>ة ع ٢٦٠ σ١ ميا</td>
<td>لن لا دد ة 'g CC ε</td><td>0.96 (method 1) I</td><td>1.18 (method 1)</td><td>I 1.57 (method 1)</td>
<td>starting compound</td><td>κ></td><td>هج</td><td></td>
<td>لا بز ة لا بخ لد لن</td><td>مى مدك ٠٧: Ο</td><td>نلح ، لآ : ٧٧</td><td>مئ ?</td>
<td></td><td>Example 224</td><td>Example 225</td><td>Example 226 . . . \</td>
POl-2363-ff
<img file="MA32201B1_D0313.tif" />
32201BI
372 POl-2363-ff
<td>NOT ) H ، at W S ئ ٢ آ</td><td>κ ؛ σ١ ب ٢ ب</td><td>at ة ص ١ هع ٠ مل ٦</td><td>at ة ٧ ٢٩ ب</td><td>at ج ٧ ٠١ 0Ο ٦ م</td>
<td>Tr [minutes]</td><td>إ ؛ ع ر 0 ' ح * ٠٠٠٠٠٠٠</td><td>ؤ ة</td><td>ه تي ر 1</td><td>اق 'Φ β —— "</td>
<td>starting compound</td><td>٩ مر</td><td></td><td>١ همر</td><td> ٠-</td>
<td>له ب للي υ 3 بخ ل + w</td><td>برحمتمت د</td><td>مبج ب '</td><td>مبج</td><td>.ى</td>
<td></td><td>مم دحا (1) ه وج ع ١</td><td>00 بم بم له بؤ له ق</td><td>٠١ بم بم له Î له ق</td><td>٠ Γ0 بم له ؤ له ق</td>
ΜΑ 32201Β1
POl-2363-ff
<td>MS (ESI, m / z)</td><td>æ ف ٦٣ ٦٣</td><td>" ق T — ١ σ١ لآم</td><td>ة ج هملآ ٦٣ ٠ ٦٣</td>
<td>اً له د تع ج ى ته ب</td><td>لا</td><td>1.16 (method 1)</td><td>if ي م له ١ ج ٧</td>
<td>starting compound</td><td>لآ؟ ٠-هأ رز ٠</td><td>ذبج ... 'خ</td><td>, ٠ CQ-O 0</td>
<td>له ب لم لا ة دم للآ</td><td>٥Ό م .؛ ''</td><td> :</td><td>ه ٠ م</td>
<td></td><td>Example 230-1</td><td>Example 230-2</td><td>لم ن لآم لن له Ï لة W</td>
ΜΑ 32201Β1
374 POl-2363-ff
<img file="MA32201B1_D0314.tif" />
UK
32201Β1
375
POl-2363-ff
Example 231
<img file="MA32201B1_D0315.tif" />
A vial was charged under an inert atmosphere with the example (175 mg, 0.45 mmol), and pyrazole (306 mg, 4.49 mmol), copper iodide (85 mg, 0.45 mmol). ) and cesium carbonate (439 mg, 1.35 mmol) were added. Dimethylformamide (5 ml), ئ degassed beforehand, was then added, then N, N'10 dimethyl-ethylenediamine (47.87 μΐ; 0.45 mmol). The reaction mixture was heated at 120 ٠c for three hours. The suspension was then filtered through a pad of celite; the celite was washed with DMF. The volume of the organic phase was reduced under reduced pressure and then saturated solution;
ammonium chloride was added, followed by ethyl acetate. إ
The phases were separated and the organic phase was washed with إ brine and then dried. The crude product was purified using ؛ of an SPE cartridge and the product obtained was further purified by SPE Stratosphere "PL-THIOL MP" to completely eliminate ؛
0 copper salts. The solid obtained was triturated with diethyl ether. 15.5 mg of the desired compound were obtained (yield = 9.2%). ح
HPLC-MS (1Ε hydro method): Tr: 7.80 minutes.
MS (ESI pos): m / z = 377 (MtH) '.
Example 232
<img file="MA32201B1_D0316.tif" />
,./
MY
32201Β1
POl-2363-ff
Example 53 (100 mg, 0.298 mmol) and hydroxylamine (0.073 ml, 1.19 mmol) were mixed together in absolute ethanol (4 ml) in a 50 ml flask. The reaction mixture was allowed to reflux for 3 hours before being subjected to a final work-up. The solvent was then removed under reduced pressure to obtain 120 mg (70% content, 0.228 mmol) of Nhydroxy-2- [4-ΟΧΟ-1- (tetrahydro-pyran-4-yl) -4,5-dihydro- Hpyrazolo [3,4-d] pyrimidin-6-ylmethyl] -benzamidine as a solid which was used as is in the next step.
N_hydroxy-2_ [4-ΟΧΟ-1- (tetrahydro-pyran-4-yl) -4,5-dihydrolH-pyraz0l0 [3,4-d] pyrimidin-6-ylmethyl -benzamidine (120 mg, content 70% ; 0.228 mmol) was suspended in
Trimethyl orthoacetate (5 ml) and acetic acid was then added (1 ml); the mixture was heated at 100 ٠c for one hour. The mixture was cooled to room temperature and the precipitation of a solid was observed. The filtrate was evaporated under reduced pressure; the crude product was purified by flash chromatography. The product was then triturated with diethyl ether. 24 mg of the desired compound were obtained (yield: 26.6%).
HPLC / MS (method 1Ε hydro)
MS (ESI pos): m / z = 393 (MH) *.
Example 233
<img file="MA32201B1_D0317.tif" />
Example 12Χ (25 0 mg, 1.14 mmol) was dissolved in 20 ml of hot methanol. Alumina (neutral) was added and the solvent was then removed to give a white powder which was transferred to a 2 ml flask of wheaton; 5,6-dihydro
ΜΑ 32201Β1
٦ΊΊ
POl-2363-ff
2H-pyran-2-oxo was added followed by DMFe (1 mL) and the vial was sealed. The suspension was heated to 80 ° C with orbital stirring for 4 days. The reaction was then filtered and the alumina was washed with methanol, ethyl acetate and dichloromethane; the organic solutions were combined and the solvents were removed under reduced pressure. The crude product was purified by flash chromatography.
Eluent: (gradient from a mixture of n-hexane / ethyl acetate 9/1 to ethyl acetate (100%) then ethyl acetate / methanol 99/1 to 94/6). 70 mg of the desired compound was obtained as a solid (19.3%).
HPLC-MS (method 2F): Tr: 9.06 minutes.
MS (ESI pos): m / z = 317 (M٠H) ٠.
Example 234
<img file="MA32201B1_D0318.tif" />
Example 53 (160 mg, 80% content, 0.38 mmol) and hydrazine hydrate (0.186 ml, 3.81 mmol) were mixed together in absolute ethanol (4 ml) in a mixture. 25 ml flask. The reaction mixture was allowed to reflux for 6 hours before being subjected to a final work-up. The solvent was removed under reduced pressure to obtain 200 mg (70% content, 0.38 mmol) of the desired substance used as it is in the next step. The substance (200 mg, content 70%, 0.38 mmol) was suspended in trimethyl orthoacetate (6 ml). Acetic acid was added (0.6ml) and the solution was heated to 80 ° C for 30 minutes. Trimethyl ortoacetate and acetic acid were removed under reduced pressure and the crude product was partitioned between water and dichloromethane. The organic phase was dried and the crude product was purified by flash chromatography. (gradient: from the mixture
ΜΑ 32201Β1
378 ا POl-2363-ff dichloromethane / methanol 98/2 and with the dichloromethane / methanol mixture 90/10 to finish). The product was further purified by trituration with diethyl ether. 8 mg of the desired compound were obtained (4%).
HPLC-MS (IE hydro method): Tr: 6.82 minutes.
MS (ESI pos): m / z = 392 (MtH) ٠.
Example 235
<img file="MA32201B1_D0319.tif" />
mg (0.06 mmol) of Example 230-4 in 3 ml of methanol were hydrogenated over Pd / C (10%) under atmospheric pressure. The catalyst has been removed. The solvent was evaporated and the residue was chromatographed by HPLC (eluent A: water t 0.13% TFA, eluent B: acetonitrile) to give 15.7 mg (71%) of the product.
HPLC-MS (method 1): Tr: 1.35 minutes.
MS (ESI pos): m / z = 369 (MtH) '.
<img file="MA32201B1_D0320.tif" />
ΜΑ 32201Β1
379
POl-2363-ff
Example 236
<img file="MA32201B1_D0321.tif" />
100 mg (73%, 0.251 mmol) of Example 40-5 were dissolved in 2 ml of acetic acid and 30 μΐ (0.35 mmol) of a solution of hydrogen peroxide in water (35%) ) have been added. The mixture was stirred for 3 hours and the acetonitrile / water mixture was added. The mixture was chromatographed by HPLC (eluent A: water 0.13 ا% TFA, eluent B: acetonitrile) to give 50.3 mg (65%) of the product.
HPLC-MS (method 1): Rp: 0.88 min.
MS (ESI pos): m / z: 307 (M-tH) ٠.
Example 237
<img file="MA32201B1_D0322.tif" />
100 mg (73%, 0.251 mmol) of Example 40-5 were dissolved in 2 ml of acetic acid and 200 μΐ (2.33 mmol) of a solution of hydrogen peroxide in water (35%) ) have been added. The mixture was stirred for 3 days and the acetonitrile / water mixture was
<img file="MA32201B1_D0323.tif" />
MY
322٠1Β1
380
POl-2363-ff adds. The mixture was chromatographed by HPLC (eluent A: water
<td></td><td>0.13% ا</td><td>of TFA, eluent B:</td><td>acetonitrile) to give 21.5 mg</td>
<td></td><td>(27%) of</td><td>product.</td><td></td>
<td></td><td>HPLC</td><td>'-SM (method 1): Tr</td><td>: 0.93 minutes.</td>
<td> 5</td><td>SK V</td><td>ESI pos): m / z = 323</td><td>(MH *.</td>
<img file="MA32201B1_D0324.tif" />
ΜΑ 32201Β1
381
POl-2363-ff
Contents158
324 sheets
Sheet 1 Sheet 2 Sheet 3 Sheet 4 Sheet 5 Sheet 6 Sheet 7 Sheet 8 Sheet 9 Sheet 10 Sheet 11 Sheet 12 Sheet 13 Sheet 14 Sheet 15 Sheet 16 Sheet 17 Sheet 18 Sheet 19 Sheet 20 Sheet 21 Sheet 22 Sheet 23 Sheet 24 Sheet 25 Sheet 26 Sheet 27 Sheet 28 Sheet 29 Sheet 30 Sheet 31 Sheet 32 Sheet 33 Sheet 34 Sheet 35 Sheet 36 Sheet 37 Sheet 38 Sheet 39 Sheet 40 Sheet 41 Sheet 42 Sheet 43 Sheet 44 Sheet 45 Sheet 46 Sheet 47 Sheet 48 Sheet 49 Sheet 50 Sheet 51 Sheet 52 Sheet 53 Sheet 54 Sheet 55 Sheet 56 Sheet 57 Sheet 58 Sheet 59 Sheet 60 Sheet 61 Sheet 62 Sheet 63 Sheet 64 Sheet 65 Sheet 66 Sheet 67 Sheet 68 Sheet 69 Sheet 70 Sheet 71 Sheet 72 Sheet 73 Sheet 74 Sheet 75 Sheet 76 Sheet 77 Sheet 78 Sheet 79 Sheet 80 Sheet 81 Sheet 82 Sheet 83 Sheet 84 Sheet 85 Sheet 86 Sheet 87 Sheet 88 Sheet 89 Sheet 90 Sheet 91 Sheet 92 Sheet 93 Sheet 94 Sheet 95 Sheet 96 Sheet 97 Sheet 98 Sheet 99 Sheet 100 Sheet 101 Sheet 102 Sheet 103 Sheet 104 Sheet 105 Sheet 106 Sheet 107 Sheet 108 Sheet 109 Sheet 110 Sheet 111 Sheet 112 Sheet 113 Sheet 114 Sheet 115 Sheet 116 Sheet 117 Sheet 118 Sheet 119 Sheet 120 Sheet 121 Sheet 122 Sheet 123 Sheet 124 Sheet 125 Sheet 126 Sheet 127 Sheet 128 Sheet 129 Sheet 130 Sheet 131 Sheet 132 Sheet 133 Sheet 134 Sheet 135 Sheet 136 Sheet 137 Sheet 138 Sheet 139 Sheet 140 Sheet 141 Sheet 142 Sheet 143 Sheet 144 Sheet 145 Sheet 146 Sheet 147 Sheet 148 Sheet 149 Sheet 150 Sheet 151 Sheet 152 Sheet 153 Sheet 154 Sheet 155 Sheet 156 Sheet 157 Sheet 158 Sheet 159 Sheet 160 Sheet 161 Sheet 162 Sheet 163 Sheet 164 Sheet 165 Sheet 166 Sheet 167 Sheet 168 Sheet 169 Sheet 170 Sheet 171 Sheet 172 Sheet 173 Sheet 174 Sheet 175 Sheet 176 Sheet 177 Sheet 178 Sheet 179 Sheet 180 Sheet 181 Sheet 182 Sheet 183 Sheet 184 Sheet 185 Sheet 186 Sheet 187 Sheet 188 Sheet 189 Sheet 190 Sheet 191 Sheet 192 Sheet 193 Sheet 194 Sheet 195 Sheet 196 Sheet 197 Sheet 198 Sheet 199 Sheet 200 Sheet 201 Sheet 202 Sheet 203 Sheet 204 Sheet 205 Sheet 206 Sheet 207 Sheet 208 Sheet 209 Sheet 210 Sheet 211 Sheet 212 Sheet 213 Sheet 214 Sheet 215 Sheet 216 Sheet 217 Sheet 218 Sheet 219 Sheet 220 Sheet 221 Sheet 222 Sheet 223 Sheet 224 Sheet 225 Sheet 226 Sheet 227 Sheet 228 Sheet 229 Sheet 230 Sheet 231 Sheet 232 Sheet 233 Sheet 234 Sheet 235 Sheet 236 Sheet 237 Sheet 238 Sheet 239 Sheet 240 Sheet 241 Sheet 242 Sheet 243 Sheet 244 Sheet 245 Sheet 246 Sheet 247 Sheet 248 Sheet 249 Sheet 250 Sheet 251 Sheet 252 Sheet 253 Sheet 254 Sheet 255 Sheet 256 Sheet 257 Sheet 258 Sheet 259 Sheet 260 Sheet 261 Sheet 262 Sheet 263 Sheet 264 Sheet 265 Sheet 266 Sheet 267 Sheet 268 Sheet 269 Sheet 270 Sheet 271 Sheet 272 Sheet 273 Sheet 274 Sheet 275 Sheet 276 Sheet 277 Sheet 278 Sheet 279 Sheet 280 Sheet 281 Sheet 282 Sheet 283 Sheet 284 Sheet 285 Sheet 286 Sheet 287 Sheet 288 Sheet 289 Sheet 290 Sheet 291 Sheet 292 Sheet 293 Sheet 294 Sheet 295 Sheet 296 Sheet 297 Sheet 298 Sheet 299 Sheet 300 Sheet 301 Sheet 302 Sheet 303 Sheet 304 Sheet 305 Sheet 306 Sheet 307 Sheet 308 Sheet 309 Sheet 310 Sheet 311 Sheet 312 Sheet 313 Sheet 314 Sheet 315 Sheet 316 Sheet 317 Sheet 318 Sheet 319 Sheet 320 Sheet 321 Sheet 322 Sheet 323 Sheet 324
93 members in 37 offices
Priority claims8
| Document | Office | Kind | Date |
|---|---|---|---|
| 08153987 | European Patent Office (EPO) | A | |
| 08153987 | European Patent Office (EPO) | A | |
| 2009053907 | European Patent Office (EPO) | W | |
| 2009053907 | European Patent Office (EPO) | W | |
| 081539876 | – | – | – |
| EP20080153987 | – | – | – |
| PCTEP2009053907 | – | – | – |
| WO2009EP53907 | – | – | – |
Members93
| Document | Office | Kind | |
|---|---|---|---|
| AU2009232017A1 | Australia | A1 | |
| CA2716410A1 | Canada | A1 | |
| WO2009121919A1 | World Intellectual Property Organization (WIPO) | A1 | |
| UY31748A | Uruguay | A | |
| PE20091756A1 | Peru | A1 | |
| TW201002712A | Taiwan Province of China | A | |
| CL2009000800A1 | Chile | A1 | |
| AR071577A1 | Argentina | A1 | |
| CA2757231A1 | Canada | A1 | |
| WO2010112437A1 | World Intellectual Property Organization (WIPO) | A1 | |
| UY32531A | Uruguay | A | |
| ECSP10010506A | Ecuador | A | |
| MX2010010821A | Mexico | A | |
| IL207710D0 | Israel | D0 | |
| KR20100138991A | Republic of Korea | A | |
| TW201100426A | Taiwan Province of China | A | |
| CN101983199A | China | A | |
| EP2300478A1 | European Patent Office (EPO) | A1 | |
| MA32201B1This record | Morocco | B1 | |
| US2011082137A1 | United States of America | A1 | |
| AR076171A1 | Argentina | A1 | |
| JP2011516454A | Japan | A | |
| EA201001518A1 | Eurasian Patent Organization (EAPO) | A1 | |
| US2011184000A1 | United States of America | A1 | |
| AU2010230290A1 | Australia | A1 | |
| CO6321264A2 | Colombia | A2 | |
| IL214436D0 | Israel | D0 | |
| HK1149549A1 | Hong Kong, China | A1 | |
| MX2011010184A | Mexico | A | |
| SG174964A1 | Singapore | A1 | |
| ECSP11011386A | Ecuador | A | |
| TN2010000432A1 | Tunisia | A1 | |
| KR20120003868A | Republic of Korea | A | |
| EP2414363A1 | European Patent Office (EPO) | A1 | |
| CL2011002454A1 | Chile | A1 | |
| CN102365285A | China | A | |
| MA33152B1 | Morocco | B1 | |
| PE20120505A1 | Peru | A1 | |
| EA201101395A1 | Eurasian Patent Organization (EAPO) | A1 | |
| CO6501182A2 | Colombia | A2 | |
| HK1163105A1 | Hong Kong, China | A1 | |
| JP2012522027A | Japan | A | |
| NZ588245A | New Zealand | A | |
| AU2010230290B2 | Australia | B2 | |
| TN2011000493A1 | Tunisia | A1 | |
| SG189706A1 | Singapore | A1 | |
| NZ594567A | New Zealand | A | |
| US8623879B2 | United States of America | B2 | |
| US8623901B2 | United States of America | B2 | |
| EP2414363B1 | European Patent Office (EPO) | B1 | |
| JP5391264B2 | Japan | B2 | |
| DK2414363T3 | Denmark | T3 | |
| PT2414363E | Portugal | E | |
| AU2009232017B2 | Australia | B2 | |
| US2014073641A1 | United States of America | A1 | |
| TWI433850B | Taiwan Province of China | B | |
| SI2414363T1 | Slovenia | T1 | |
| HRP20140312T1 | Croatia | T1 | |
| UA105362C2 | Ukraine | C2 | |
| ES2460019T3 | Spain | T3 | |
| GEP20146098B | Georgia | B | |
| PL2414363T3 | Poland | T3 | |
| RS53167B | Serbia | B | |
| JP5542196B2 | Japan | B2 | |
| CN102365285B | China | B | |
| UA106368C2 | Ukraine | C2 | |
| CN101983199B | China | B | |
| US2014350025A1 | United States of America | A1 | |
| IL207710A | Israel | A | |
| EA021504B1 | Eurasian Patent Organization (EAPO) | B1 | |
| US9096603B2 | United States of America | B2 | |
| US9102679B2 | United States of America | B2 | |
| MY156377A | Malaysia | A | |
| EP2300478B1 | European Patent Office (EPO) | B1 | |
| BRPI1011533A2 | Brazil | A2 | |
| KR101623762B1 | Republic of Korea | B1 | |
| ES2573330T3 | Spain | T3 | |
| DK2300478T3 | Denmark | T3 | |
| HRP20160683T1 | Croatia | T1 | |
| SI2300478T1 | Slovenia | T1 | |
| HRP20160683T2 | Croatia | T2 | |
| RS54724B1 | Serbia | B1 | |
| ME02427B | Montenegro | B | |
| PL2300478T3 | Poland | T3 | |
| HUE027771T2 | Hungary | T2 | |
| CY1115155T1 | Cyprus | T1 | |
| CA2716410C | Canada | C | |
| CY1117626T1 | Cyprus | T1 | |
| BRPI0910690A2 | Brazil | A2 | |
| MY169766A | Malaysia | A | |
| BRPI0910690B1 | Brazil | B1 | |
| MY182670A | Malaysia | A | |
| BRPI0910690B8 | Brazil | B8 |
Numbers
- Publication
- 32201
- Publication, DOCDB
- 32201
- Publication, EPODOC
- MA32201
- Application
- 33216
- Application, DOCDB
- 33216
- Application, EPODOC
- MA20100033216
Titles3
- Arabic
- مشتقات 1- حلقية غير متجانسة -1،5-ثنائي هيدرو-بيرازولو [3،4-d] بيريميدين-4-أون واستخدامهم كمغير ل pde9a
- French
- Derives de 1-heterocyclyl-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-one et leurs utilisations a titre de modulateurs de pde9a
- English
- Derivatives of 1-heterocyclyl-1,5-dihydro-pyrazolo [3,4-d] pyrimidin-4-one and their use as modulators has PDE9A
Classification
- CPC, 16
- C07D487/04
- A61K31/519
- A61P1/04
- A61P11/00
- A61P15/08
- A61P21/00
- A61P25/00
- A61P25/16
- A61P25/18
- A61P25/20
- A61P25/28
- A61P3/04
- A61P3/06
- A61P43/00
- A61P9/00
- A61P3/10
- IPC, 2
- C07D487 04
- A61K31 519